<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006009.pub2" GROUP_ID="MOVEMENT" ID="419205021509503983" MERGED_FROM="" MODIFIED="2011-03-25 17:28:45 +0100" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-03-25 16:14:31 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-03-25 17:28:45 +0100" MODIFIED_BY="Ema Roque">
<TITLE MODIFIED="2011-03-25 16:11:09 +0000" MODIFIED_BY="Ema Roque">Dopamine agonists for the treatment of restless legs syndrome</TITLE>
<CONTACT MODIFIED="2011-03-25 17:28:45 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="C55B950C82E26AA20130726FC83DC6A4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Magdolna</FIRST_NAME><LAST_NAME>Hornyak</LAST_NAME><EMAIL_1>magdolna.hornyak@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49761270 5020</PHONE_1><FAX_1>+ 49 40 7612705013</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-03-25 17:28:45 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="BF1BEF6F82E26AA200AED564B62CA8A8" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Scholz</LAST_NAME><EMAIL_1>hanna.scholz@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761270 5357</PHONE_1></ADDRESS></PERSON><PERSON ID="04300295689766803046110120023521" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Claudia</FIRST_NAME><LAST_NAME>Trenkwalder</LAST_NAME><EMAIL_1>trenkwalder@pk-mx.de</EMAIL_1><ADDRESS><ORGANISATION>Paracelsus - Elena Hospital, Centre of Parkinson and Movement Disorders</ORGANISATION><ADDRESS_1>Klinikstrasse 16</ADDRESS_1><CITY>Kassel</CITY><ZIP>34128</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="67466654987436394892110120023942" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ralf</FIRST_NAME><LAST_NAME>Kohnen</LAST_NAME><EMAIL_1>rkohnen@rpsweb.com</EMAIL_1><ADDRESS><ORGANISATION>RPS Research Germany GmbH, Nuremberg and University Erlangen-Nuremberg</ORGANISATION><ADDRESS_1>Scheurlstrasse 21</ADDRESS_1><CITY>Nürnberg</CITY><ZIP>90478</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="C55EFE5082E26AA20130726F0964539D" ROLE="AUTHOR"><FIRST_NAME>Levente</FIRST_NAME><LAST_NAME>Kriston</LAST_NAME><EMAIL_1>l.kriston@uke.uni-hamburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Psychology</DEPARTMENT><ORGANISATION>University Medical Center, Hamburg - Eppendorf</ORGANISATION><ADDRESS_1>Martinistrasse 52</ADDRESS_1><CITY>Hamburg</CITY><ZIP>20246</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><FAX_1>+ 49 40 7410 54965</FAX_1></ADDRESS></PERSON><PERSON ID="C5538C8982E26AA20130726F753B6574" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dieter</FIRST_NAME><LAST_NAME>Riemann</LAST_NAME><EMAIL_1>Dieter_Riemann@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Hauptstrasse 5</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+497612706919</PHONE_1><FAX_1>+497612706619</FAX_1></ADDRESS></PERSON><PERSON ID="C55B950C82E26AA20130726FC83DC6A4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Magdolna</FIRST_NAME><LAST_NAME>Hornyak</LAST_NAME><EMAIL_1>magdolna.hornyak@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49761270 5020</PHONE_1><FAX_1>+ 49 40 7612705013</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-25 16:11:09 +0000" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Minor update: 11/16/06&lt;/p&gt;" NOTES_MODIFIED="2011-03-25 16:11:09 +0000" NOTES_MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="19" MONTH="1" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="12" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-13 23:48:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-13 23:48:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2011-01-11 09:09:54 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Psychiatry and Psychotherapy, University Hospital Freiburg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-01-11 09:09:54 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-01-11 09:09:54 +0000" MODIFIED_BY="[Empty name]">
<NAME>German Ministry for Education and Research</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>(Bundesministerium für Bildung und Forschung - BMBF, Project number DLR 01KG0723).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-01-12 15:33:19 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-01-12 15:20:11 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-05-18 15:08:50 +0100" MODIFIED_BY="[Empty name]">Dopamine agonists for restless legs syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2011-01-12 15:20:11 +0000" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a sensorimotor disorder characterised by an urge to move the limbs which is usually associated with unpleasant sensations. Symptoms are worse during rest, in the evening, and at night and improve by movement. The course of the disorder is usually chronic. Dopamine agonists are recommended as first-line treatment for RLS. </P>
<P>We could include 38 trials in the meta-analyses which investigated the efficacy and safety of dopamine agonist treatment compared to placebo or to other treatments for RLS. The studies were performed mostly in European and Northern American countries. Treatment durations varied from one week to seven months, but most treatments had durations of one to 12 weeks. Patients suffered from moderate to severe RLS and were treated with the dopamine agonists cabergoline, lisuride, pergolide, pramipexole, ropinirole, rotigotine, and sumanirole.</P>
<P>Dopamine agonists lead to a larger improvement on the International RLS Severity Rating Scale (IRLS) compared to placebo. Clinicians rated RLS symptoms as more improved with dopamine agonists compared to placebo (CGI-I). Also periodic limb movements in sleep were significantly reduced by dopamine agonists compared to placebo. Sleep efficiency was also slightly improved. Patients rated their quality of sleep and quality of life as markedly improved. Patients were, however, more likely to discontinue dopamine agonist treatment and experienced more adverse events when treated with dopamine agonists compared to placebo. All dopamine agonists were superior to placebo except sumanirole. Indirect descriptive comparisons revealed the highest efficacy for the ergoline dopamine agonists cabergoline and pergolide, which has to be weighed against potentially serious side effects such as cardiac valve fibrosis. The non-ergoline dopamine agonists lisuride, pramipexole, rotigotine, and ropinirole showed adequate efficacy.</P>
<P>Augmentation, a serious adverse event in dopaminergic treatment, has not been sufficiently assessed. Future studies need to investigate long-term efficacy of dopamine agonists against placebo or other active treatment and the frequency and the impact of augmentation on treatment outcome during dopaminergic treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-01-12 14:16:33 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-05-10 15:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-11-30 10:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate efficacy and safety of dopamine agonists for RLS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-30 15:02:50 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library </I>2008, Issue 4), MEDLINE, EMBASE, PsycINFO and CINAHL, from January 1985 to December 2008, plus reference lists of articles. We contacted pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-30 10:26:23 +0000" MODIFIED_BY="[Empty name]">
<P>We included double-blind randomised controlled trials (RCTs) of dopamine agonist treatment versus placebo or other treatment for a period of at least seven days in patients with RLS (&#8805; 18 years). Outcomes included the International RLS Severity Rating Scale (IRLS), Clinical Global Impressions (CGI-I), polysomnography and self rated sleep quality, quality of life, daytime functioning, and safety parameters.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-05-10 15:32:42 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers extracted data separately; assessed risk of bias; and contacted pharmaceutical companies and authors for additional information. We collected dropout rates due to adverse events and experience of adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-01-12 14:16:33 +0000" MODIFIED_BY="[Empty name]">
<P>We included 35 placebo controlled and three active controlled RCTs (N = 7365). The mean reduction on the IRLS was &#8722;5.7 points lower in dopamine agonist treatment compared to placebo (95% confidence interval (CI) &#8722;6.7 to &#8722;4.7). Periodic limb movements in sleep per hour of sleep (PLMS-Index; PLMSI) were &#8722;22.4/h lower than in placebo (95% CI &#8722;27.8 to &#8722;16.9). Self rated quality of sleep and disease specific quality of life were improved by a standardised mean difference (SMD) of 0.40 (95% CI 0.33 to 0.47) and 0.34 (95% CI 0.23 to 0.44), respectively. Patients were more likely to drop out (odds ratio (OR) 1.82, 95% CI 1.35 to 2.45) and experienced more adverse events under dopamine agonist treatment than with placebo (OR 1.82, 95% CI 1.59 to 2.08). Visual inspection of forest plots showed the highest efficacy in three studies investigating cabergoline and pergolide (N = 3). Active controlled trials investigated effects of cabergoline, pergolide, and pramipexole in a number of outcomes. The IRLS score was lower with cabergoline and pramipexole compared to levodopa (MD &#8722;5.3, 95% CI &#8722;8.4 to &#8722;2.1). Only four studies investigated treatment efficacy up to seven months. The most severe side effect, augmentation, was not assessed reliably.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-01-12 14:05:48 +0000" MODIFIED_BY="[Empty name]">
<P>The meta-analyses show the superiority of dopamine agonists over placebo in RCTs up to seven months. Cabergoline and pramipexole showed larger efficacy compared to levodopa in some but not all outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-01-12 15:33:19 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-01-12 15:22:51 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-01-12 15:22:51 +0000" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) - previously called 'the most common disorder you never heard of' - is a frequent, though often under-diagnosed, disorder with a high impact on sleep. The syndrome was first described in detail by <LINK REF="REF-Ekbom-1945" TYPE="REFERENCE">Ekbom 1945</LINK>. Obligatory diagnostic criteria were established half a century later by the International Restless Legs Syndrome Study Group (IRLSSG, <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>). These criteria were revised at a consensus conference held at the National Institute of Health (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). The essential criteria, supportive criteria, and associated features of the disease are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Table 1: Diagnosis criteria of restless legs syndrome</P>
<TABLE COLS="1" ROWS="4">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Essential criteria</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).</P>
<P>2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.</P>
<P>3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</P>
<P>4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been present previously).</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Supportive criteria and associated features of RLS</B>
</P>
</TH>
</TR>
<TR>
<TD>
<UL>
<LI>Positive family history</LI>
<LI>Response to dopaminergic therapy</LI>
<LI>Periodic limb movements (during wakefulness or sleep)</LI>
<LI>Natural clinical course</LI>
<LI>Sleep disturbance</LI>
</UL>
</TD>
</TR>
</TABLE>
<P>Epidemiological surveys in Western Europe and in the USA indicate that up to 10% of the population are afflicted with RLS. In females the prevalence is twice as high as in males and increases with age (<LINK REF="REF-Berger-2004" TYPE="REFERENCE">Berger 2004</LINK>; <LINK REF="REF-Berger-2007" TYPE="REFERENCE">Berger 2007</LINK>; <LINK REF="REF-H_x00f6_gl-2003" TYPE="REFERENCE">Högl 2003</LINK>; <LINK REF="REF-Phillips-2000" TYPE="REFERENCE">Phillips 2000</LINK>; <LINK REF="REF-Rothdach-2000" TYPE="REFERENCE">Rothdach 2000</LINK>; <LINK REF="REF-Ulfberg-2001" TYPE="REFERENCE">Ulfberg 2001</LINK>). According to recent surveys, one third of the people reporting RLS symptoms (i.e. 2% to 3% of the population) are impaired by the symptoms and their sequelae and may be in need of medical treatment (<LINK REF="REF-Hening-2004a" TYPE="REFERENCE">Hening 2004a</LINK>; <LINK REF="REF-Tison-2005" TYPE="REFERENCE">Tison 2005</LINK>).</P>
<P>Periodic limb movements while awake (PLMW) and during sleep (PLMS) are supporting features of the syndrome. PLMS are motor phenomena monitored during polysomnography and occur in approximately 80% of RLS patients (<LINK REF="REF-Montplaisir-1997" TYPE="REFERENCE">Montplaisir 1997</LINK>). PLMS monitoring is routinely performed in polysomnography where a bilateral surface electromyogram of the anterior tibial muscles is recorded. Scoring of PLMS is carried out according to standard criteria (<LINK REF="REF-Bonnet-1993" TYPE="REFERENCE">Bonnet 1993</LINK>; <LINK REF="REF-Iber-2007" TYPE="REFERENCE">Iber 2007</LINK>; <LINK REF="REF-Zucconi-2006" TYPE="REFERENCE">Zucconi 2006</LINK>). PLMS also occur frequently in several other sleep disorders and may be present in subjects who do not complain of sleep disturbance. PLMS are also common in the elderly, but are seen more frequently in patients with RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; for an overview see <LINK REF="REF-Hornyak-2004" TYPE="REFERENCE">Hornyak 2004</LINK>). Although the presence of PLMS is not specific to RLS, an elevated (&gt; 15/h) PLMS index (number of PLMS per hour of sleep, PLMSI; <LINK REF="REF-American-Academy-of-Sleep-Medicine-2005" TYPE="REFERENCE">American Academy of Sleep Medicine 2005</LINK>) is supportive of the diagnosis of RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). In 40% to 60% of cases there is a family history of the disorder, which suggests a genetic predisposition for RLS (<LINK REF="REF-Stefansson-2007" TYPE="REFERENCE">Stefansson 2007</LINK>; <LINK REF="REF-Winkelmann-2007" TYPE="REFERENCE">Winkelmann 2007</LINK>). Generally, patients with positive family history experience an earlier onset of symptoms (before the age of 30 to 45 years) than patients without afflicted relatives. A positive response to levodopa also supports the diagnosis of RLS, with almost 90% of patients showing a 50% relief of symptoms when treated with this agent (<LINK REF="REF-Stiasny_x002d_Kolster-2006" TYPE="REFERENCE">Stiasny-Kolster 2006</LINK>).</P>
<P>Sleep disturbances are commonly associated with RLS and are usually the reason why patients seek medical advice (<LINK REF="REF-Hening-2004a" TYPE="REFERENCE">Hening 2004a</LINK>). Sleep disturbances are also considered to be a feature of the full expression of the disorder. However, due to the frequent occurrence of sleep problems in other disorders and their limited occurrence in patients with milder RLS, they are not considered to be necessary for, or supportive of the diagnosis of RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). The natural course of the disorder varies greatly for those with milder RLS. For patients whose symptoms start early in adult life and who eventually seek treatment, typically, the severity and frequency of symptoms increase over time. Thus, the disorder is generally considered to be a chronic condition. Physical examinations usually do not result in pathological findings for patients with idiopathic (primary) RLS (i.e. of unknown cause). However, it is important for clinicians to look for factors that may exacerbate or trigger symptoms (secondary RLS). Beside the established causes of secondary RLS (e.g. end-stage renal disease, pregnancy, and iron deficiency), an increasing number of conditions including several neurological diseases such as multiple sclerosis, polyneuropathy, and cerebellar ataxias seem to be associated with the disorder (<LINK REF="REF-Allen-2007" TYPE="REFERENCE">Allen 2007</LINK>; <LINK REF="REF-Connor-2008" TYPE="REFERENCE">Connor 2008</LINK>; <LINK REF="REF-Manconi-2004" TYPE="REFERENCE">Manconi 2004</LINK>; <LINK REF="REF-Sch_x00f6_ls-1998" TYPE="REFERENCE">Schöls 1998</LINK>; <LINK REF="REF-Walters-2007" TYPE="REFERENCE">Walters 2007</LINK>).</P>
<P>Previous and current treatments aim for symptomatic relief of both the unpleasant sensations and the urge to move and thereby aim to improve sleep disturbance. Restless legs syndrome-associated curtailment of sleep may result in daytime problems such as fatigue, tiredness, and impaired functioning, as well as impaired quality of life (<LINK REF="REF-Kushida-2007" TYPE="REFERENCE">Kushida 2007</LINK>; <LINK REF="REF-Talati-2009" TYPE="REFERENCE">Talati 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-01-12 15:20:25 +0000" MODIFIED_BY="[Empty name]">
<P>Since the 1980s, therapy has focused on levodopa and dopamine agonists (<LINK REF="REF-Stiasny_x002d_Kolster-2009" TYPE="REFERENCE">Stiasny-Kolster 2009</LINK>; <LINK REF="REF-Trenkwalder-2008" TYPE="REFERENCE">Trenkwalder 2008</LINK>). In the past few years, several studies examining a variety of dopaminergic substances have been published. However, no controlled studies have yet investigated long-term treatment effects (i.e. for more than a year). A few meta-analyses have recently been undertaken and examined effects of dopaminergic medication such as levodopa and dopamine agonists on RLS (<LINK REF="REF-Baker-2008" TYPE="REFERENCE">Baker 2008</LINK>; <LINK REF="REF-Conti-2007" TYPE="REFERENCE">Conti 2007</LINK>; <LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>; <LINK REF="REF-Quilici-2008" TYPE="REFERENCE">Quilici 2008</LINK>; <LINK REF="REF-Talati-2009" TYPE="REFERENCE">Talati 2009</LINK>; <LINK REF="REF-Zintzaras-2010" TYPE="REFERENCE">Zintzaras 2010</LINK>). Second-line treatment options include antiepileptic drugs such as gabapentin, gabapentin enacarbil, and valproic acid as well as pregabalin and opioids (<LINK REF="REF-Eisensehr-2004" TYPE="REFERENCE">Eisensehr 2004</LINK>; <LINK REF="REF-Garcia_x002d_Borreguero-2002" TYPE="REFERENCE">Garcia-Borreguero 2002</LINK>; <LINK REF="REF-Kushida-2009" TYPE="REFERENCE">Kushida 2009</LINK>; <LINK REF="REF-Walters-1993" TYPE="REFERENCE">Walters 1993</LINK>; for overview see <LINK REF="REF-Conti-2008" TYPE="REFERENCE">Conti 2008</LINK>; <LINK REF="REF-Silber-2004" TYPE="REFERENCE">Silber 2004</LINK>). Although some of these agents are often used in the treatment of RLS (e.g. opioids), the number of studies investigating substances other than dopaminergic drugs is still limited.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-30 15:03:17 +0000" MODIFIED_BY="[Empty name]">
<P>The aetiology of the disorder is not sufficiently understood, but comprises a complex network system reflected in the many different topographical, genetic, and biochemical causes of RLS, either in isolation or in combination (<LINK REF="REF-Trenkwalder-2010" TYPE="REFERENCE">Trenkwalder 2010</LINK>). It is generally accepted that a dysfunction of the central nervous dopaminergic system may play a major role in those phenotypes with response to dopaminergic agents (<LINK REF="REF-Hening-2004b" TYPE="REFERENCE">Hening 2004b</LINK>; <LINK REF="REF-Trenkwalder-2004" TYPE="REFERENCE">Trenkwalder 2004</LINK>). Dopaminergic neurotransmission can modulate neuronal interactions at very low doses, contributing to cortical plasticity. Neuromodulators such as norepinephrine, dopamine, and 5-hydroxytryptamine (5-HT) can also modulate spinal motor neuron excitability at least fivefold (<LINK REF="REF-Heckman-2009" TYPE="REFERENCE">Heckman 2009</LINK>) interacting with both the motor and sensory system causing RLS symptoms. Differential responses of early and late flexor reflexes to dopaminergic agents and opioids combined with plasticity changes might explain why dopaminergic-induced hyperexcitability can occur during augmentation in RLS (<LINK REF="REF-Paulus-2006" TYPE="REFERENCE">Paulus 2006</LINK>). Brain iron storage may be involved in many phenotypes of RLS and also may interact with augmentation induced by dopaminergic therapy. Currently, it seems, that supplying iron is both a symptomatic and in some cases, i.e. pregnancy and iron deficiency anaemia, a curative way of treating RLS, although the mechanism of low brain iron in RLS is not yet understood. Other curative treatments for idiopathic RLS are not known.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-01-12 13:22:54 +0000" MODIFIED_BY="[Empty name]">
<P>Recent reviews have described the efficacy and safety of dopaminergic treatment for RLS. However, these meta-analyses investigated either a selection of dopaminergic drugs or only a limited number of outcome parameters (<LINK REF="REF-Baker-2008" TYPE="REFERENCE">Baker 2008</LINK>; <LINK REF="REF-Conti-2007" TYPE="REFERENCE">Conti 2007</LINK>; <LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>; <LINK REF="REF-Quilici-2008" TYPE="REFERENCE">Quilici 2008</LINK>; <LINK REF="REF-Zintzaras-2010" TYPE="REFERENCE">Zintzaras 2010</LINK>).</P>
<P>We undertook the present evaluation in order to systematically assess the therapeutic efficacy of all dopamine agonists investigated in RLS. Therefore, we used a pre-reviewed study protocol which included searching several databases; assessing quality of all included studies; and the evaluation of a wide range of clinically relevant aspects of treatment effects.</P>
<P>Compared to previous reviews we included a higher number of studies and additional clinically relevant outcome parameters. We investigated the effects on symptom severity using the IRLS (International RLS Severity Rating Scale) and the CGI (Clinical Global Impressions). Furthermore, we thoroughly analysed effects of dopamine agonist treatment on polysomnography parameters. To assess treatment effects we evaluated changes in the PLMS index (PLMSI, see above) as well as sleep efficiency. Further comprehensive analyses included questionnaires on quality of sleep, daytime functioning, quality of life, and the patients&#8217; global impression of change of the disorder (for description of the questionnaires see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Safety parameters such as dropout rates and major adverse events were recorded.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-05-10 09:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of dopamine agonists for the treatment of RLS compared to placebo and other active treatments.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-01-12 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-01-12 13:23:18 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-05-10 09:04:52 +0100" MODIFIED_BY="[Empty name]">
<P>We included all double-blind and randomised controlled trials (RCTs) investigating the treatment of RLS with a dopamine agonist versus placebo or another drug, enclosing trial designs with parallel groups as well as cross-over trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-30 15:03:19 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients (18 years or older) had to have a diagnosis of primary or secondary RLS according to diagnostic criteria defined by the IRLSSG (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-05-10 09:05:01 +0100" MODIFIED_BY="[Empty name]">
<P>The experimental intervention consisted of any dose or regimen of a dopamine agonist (DA) by any route (oral, intravenous, or transdermal) for a minimum of seven days. In the control intervention, either placebo or other comparative drugs were used.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-01-12 13:23:18 +0000" MODIFIED_BY="[Empty name]">
<P>Endpoints had to be validated instruments. Divided into primary and secondary endpoints, studies had to present at least one of the following endpoints:</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-11-30 15:03:22 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>International RLS Severity Rating Scale (IRLS).</LI>
<LI>PLMSI (number of PLM per total sleep time or time in bed).</LI>
<LI>Sleep efficiency (total sleep time during time in bed).</LI>
<LI>Number of dropouts due to adverse events (safety parameter).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-01-12 13:23:18 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Clinical Global Impressions - Improvement (CGI-I).</LI>
<LI>Self rated quality of sleep (description of the included questionnaires see below).</LI>
<LI>Disease-specific quality of life (description of the included questionnaires see below).</LI>
</OL>
<P>Additional outcomes which were expected to be useful for explaining effects:</P>
<OL>
<LI>Patient Global Impressions (PGI).</LI>
<LI>Number of patients experiencing adverse events (safety parameter).</LI>
<LI>Number of patients with augmentation (according to the definition of <LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; safety parameter).</LI>
<LI>Daytime tiredness (description of the included questionnaires see below).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-01-12 13:23:38 +0000" MODIFIED_BY="[Empty name]">
<P>The following resources were used for identification of relevant studies in any language.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-12-01 09:14:46 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library </I>2008, Issue 4), MEDLINE (January 1985 to December 2008), EMBASE (January 1985 to December 2008), PsycINFO (January 1985 to December 2008), and CINAHL (January 1985 to December 2008) to obtain all possibly relevant trials. As specified in the protocol, we excluded studies not using recently accepted diagnosis criteria from the meta-analyses. We did not search the Cochrane Movement Disorders Group's Trials Register as this database had not been updated by the Cochrane Movement Disorders Group. The respective search strategies are displayed in the <LINK TAG="APPENDICES" TYPE="SECTION">Appendices</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-01-12 13:23:38 +0000" MODIFIED_BY="[Empty name]">
<P>We searched online databases for additional unpublished studies. We accessed the Internet sites www.clinicaltrials.gov, www.clinicalstudyresults.org, and those trial registers that were offered online by relevant pharmaceutical companies. These were the trial sites of Boehringer Ingelheim, GlaxoSmithKline, and Lilly. <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> lists numbers of studies retrieved in these searches. We checked recent reviews and the reference lists of all included studies for additional publications in any language. We contacted the first authors of the following trials: <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>; <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>; <LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>. We also contacted the following pharmaceutical companies for information regarding additional data and not yet published trials: Boehringer Ingelheim, GlaxoSmithKline, Hoffmann La-Roche, Lilly, Pfizer, Axxonis, and Schwarz Pharma (UCB Group). We received information on studies until November 2009 and closed the database in December 2009.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-01-12 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-05-18 14:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers (HS and MH, the latter with support of CL, see acknowledgments) reviewed independently all obtained references to assess their potential relevance. Subsequently, the selected studies were assessed for inclusion from the full text. Authorship and results were not blinded. In both steps, any disagreements were resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-01-12 13:24:43 +0000" MODIFIED_BY="[Empty name]">
<P>Two reviewers (HS and MH, the latter with support of CL) independently extracted data using a prepared form, and afterwards they cross-checked resulting data files to resolve any disagreements and errors.</P>
<P>Extracted data included diagnosis criteria, study type, numbers of patients in treatment groups, doses given and process of titration, age, gender, ethnicity, country of trial, duration of symptoms, duration of treatment, occurrence of adverse events, and dropouts due to adverse events.</P>
<P>All questionnaires which were used in any of the included studies are presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>In the majority of studies, RLS severity was assessed by the International RLS Severity Rating Scale (IRLS; <LINK REF="REF-Walters-2003" TYPE="REFERENCE">Walters 2003</LINK>), which is a validated severity rating scale with 10 items rated from 0 to 4 and a total score of 0 to 40. Scores of 1 to 10 represent mild, 11 to 20 moderate, 21 to 30 severe, and 31 to 40 points indicate very severe symptoms. Symptom improvement was furthermore investigated by assessing responder rates of the Patient Global Impressions scale (PGI; <LINK REF="REF-National-Institute-of-Mental-Health-1976" TYPE="REFERENCE">National Institute of Mental Health 1976</LINK>) and responder rates of the Clinical Global Impressions &#8211; Improvement scale (CGI-I; <LINK REF="REF-National-Institute-of-Mental-Health-1976" TYPE="REFERENCE">National Institute of Mental Health 1976</LINK>). Self rated quality of sleep was assessed by the Sleep Problems Index II of the Medical Study Outcomes Sleep Questionnaire (MOS; <LINK REF="REF-Hays-2005" TYPE="REFERENCE">Hays 2005</LINK>), the scale &#8220;satisfaction with sleep&#8221; of the RLS-6 Scales (<LINK REF="REF-Kohnen-2004" TYPE="REFERENCE">Kohnen 2004</LINK>), the scale &#8220;sleep quality&#8221; of the questionnaire Schlaffragebogen-A (SF-A; <LINK REF="REF-Goertelmeyer-1985" TYPE="REFERENCE">Goertelmeyer 1985</LINK>), the Pittsburgh Sleep Quality Index (PSQI; <LINK REF="REF-Buysse-1989" TYPE="REFERENCE">Buysse 1989</LINK>), and Visual Analogue Scales (VAS) assessing sleep quality. In a few studies, self rated quality of sleep was assessed by two questionnaires. We extracted data of the more frequently used scale. Polysomnography data assessing PLMSI and sleep efficiency were also evaluated. When the PLMSI was not assessed, number of periodic limb movements (PLM), including PLM during sleep and during wake, divided per hour of time in bed were extracted (PLMI). We extracted data from restless legs-specific instruments assessing disease-specific quality of life (Hopkins RLS-QoL by <LINK REF="REF-Abetz-2005" TYPE="REFERENCE">Abetz 2005</LINK> and QoL-RLS by <LINK REF="REF-Kohnen-2002" TYPE="REFERENCE">Kohnen 2002</LINK>). We assessed daytime tiredness based on the scales &#8220;somnolence&#8221; of the MOS, &#8220;daytime tiredness&#8221; of the RLS-6 scales, and item 5 of the IRLS (tiredness or sleepiness related to RLS symptoms). Safety parameters such as dropout rates due to adverse events and number of patients experiencing adverse events were extracted.</P>
<P>Dichotomous data comprised the endpoints CGI-I and PGI, dropout rates due to adverse events and number of patients experiencing adverse events. Continuous (interval-scaled) data included baseline as well as end-of-treatment data and change from baseline means if available, together with respective standard deviations or standard errors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-30 11:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>Two reviewers (HS, MH, the latter with support of CL) independently performed assessment of methodological quality using the Cochrane Collaboration's tool for assessing bias (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 8). Resulting disagreements were resolved by discussion. Criteria such as randomisation, allocation concealment, and blinding were classified in each trial. Low to high risk of bias was assigned (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>). The results of each trial are displayed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section and are also presented together in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
<U>.</U> By consensus, CT, RK, MH, and HS decided upon the quality of the evidence of each outcome (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> for results).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-30 15:03:56 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We converted responder rates on the PGI and CGI-I scales into risk ratios with 95% confidence intervals. Risk ratios above 1 indicate a better response with treatment than placebo or other active drug.</P>
<P>We analysed safety parameters such as the number of dropouts due to adverse events and the number of patients experiencing adverse events using odds ratios (OR) with 95% confidence intervals. Odds ratios above 1 indicate more frequent negative events in the treatment group compared to negative events in the placebo or other active group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We analysed continuous (interval-scaled) data of questionnaires using mean differences with 95% confidence intervals for the primary outcomes IRLS score, PLMSI, and sleep efficiency. Negative mean differences indicate a better response in the treatment group for IRLS and PLMSI, positive mean differences indicate a better response in the treatment group for sleep efficiency. In trials with multiple treatment arms, we pooled results of all treatment arms in order to compare the overall treatment effect to the placebo effect.</P>
<P>We computed standard errors of mean differences from reported analysis (paired t-tests) in the cross-over trials when feasible (in trials <LINK REF="STD-Adler-2004" TYPE="STUDY">Adler 2004</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>; <LINK REF="STD-Wetter-1999" TYPE="STUDY">Wetter 1999</LINK>).</P>
<P>The secondary outcomes quality of sleep, quality of life, and daytime tiredness were assessed with different questionnaires in the included trials. Therefore, we calculated standardised mean differences (SMD) for these outcomes, i.e. Hedges' adjusted g, with a confidence interval of 95%. Standardised mean differences include values of 0.2 representing a small effect, 0.5 representing a moderate effect, and 0.8 indicating a large effect (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). Positive values for quality of sleep and quality of life and negative values for daytime tiredness indicate superiority of treatment over placebo.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-11-30 15:04:00 +0000" MODIFIED_BY="[Empty name]">
<P>Six of the included studies were double-blind randomised cross-over trials. Nine of the included studies used also minimum treatment doses, i.e. doses that fell out of the range of usually administered doses in routine care. Minimum doses were excluded from meta-analyses and only recommended doses were pooled. The minimum doses were defined by consensus (CT, MH, RK, HS) for lisuride (2.5 mg/24 h), pramipexole (0.125 mg), and rotigotine (0.5 mg/24 h and 1.0 mg/24 h). In three studies, the dopamine agonists cabergoline, pergolide, and pramipexole were compared to levodopa treatment, respectively.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-11-30 15:04:08 +0000" MODIFIED_BY="[Empty name]">
<P>When available, we extracted data from intention-to-treat analysis including the last observation carried forward (LOCF). In seven, mainly cross-over trials, we had to revert to the reported per protocol data.</P>
<P>We aimed to obtain additional information for 37 of 38 included trials. Therefore, we contacted pharmaceutical companies (Axxonis, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Pfizer, and Schwarz Pharma) and authors of the following trials: <LINK REF="STD-Adler-2004" TYPE="STUDY">Adler 2004</LINK>; <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>; <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>; <LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-11-30 11:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>We used Chi² tests to measure statistical heterogeneity of study results. The implemented I² statistics give an estimate of the degree of this heterogeneity. Values of 0% to 40% represent low heterogeneity; values of 30% to 60% represent moderate heterogeneity, whereas values of 50% to 90% may indicate substantial, and 75% to 100% considerable heterogeneity according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 9).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-05-10 12:52:38 +0100" MODIFIED_BY="[Empty name]">
<P>We examined funnel plots and investigated asymmetry coefficients to identify possible publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-01-12 13:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>We chose random-effects models to pool the data, as we could not expect any common underlying effect due to the diversity of study populations and medications. As analyses of covariance were used in most trials, we applied the generic inverse variance method for continuous outcomes. As we could obtain means and standard deviations for the calculation of SMDs, we used the inverse variance method for SMDs. For dichotomous outcomes, we applied odds ratios with the Mantel-Haenszel method for safety parameters and risk ratios with the Mantel-Haenszel method for the two responder outcomes.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-01-12 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<P>We performed subgroup analyses with each dopamine agonist in order to investigate efficacy and safety of each dopamine agonist treatment separately, and to identify sources of heterogeneity of treatment effects. We visually inspected treatment effects and their confidence intervals in indirect comparisons in order to observe this heterogeneity between the dopamine agonist subgroups. In order to investigate methodological heterogeneity, we also assessed the influence of study type on treatment effects by visual inspection (cross-over trial versus parallel group trial). Separate meta-analyses were performed for trials with active comparator treatments.</P>
<P>We assessed the influence of study quality on the heterogeneity of IRLS treatment effects by comparing treatment effects of studies with low risk of bias to those with unclear risk of bias (bias category &#8216;randomisation&#8217;, see above). The comparison was only made for this bias category, as in other bias categories, possible risk of bias was present in very few studies.</P>
<P>We exploratively investigated the influence of treatment duration on the IRLS treatment effect in a meta-regression analysis, since dopamine agonist treatment is a symptomatic and long-term treatment for RLS. To analyse the possible reasons for heterogeneous treatment effects, we performed an additional meta-regression to investigate the effect of number of study sites on IRLS treatment effect. We performed this explorative analysis as we were under the impression that small studies may show higher treatment effects. We hypothesized that with increasing number of study sites, patient populations become more heterogeneous. Lastly, we assessed the influence of the mean baseline IRLS score on IRLS treatment effect. To this end we performed univariable meta-regressions with each possible predictor separately as well as a multivariable meta-regression including all three predictors (treatment duration, number of study sites, and mean baseline IRLS).</P>
<P>In order to investigate heterogeneous IRLS treatment effects, an additional explorative subgroup analysis was performed. As over half of the included studies were performed predominantly in European countries, the influence of predominantly European versus other study origin on IRLS treatment effect was evaluated.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-01-12 15:33:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-01-12 14:16:47 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-11-30 11:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, we obtained 501 English and non-English publications searching the electronic databases. Sixty-four of these publications were potentially eligible after screening of titles and abstracts. Twenty-three fulfilled eligibility criteria after inspection of full texts and were included. The search in additional online databases yielded eight additional and unpublished trials and five trials which were listed in online databases and presented at scientific meetings. Two more trials were retrieved by checking reference lists. Thus, 38 trials were identified with 23 fully published trials, seven trials published as abstracts and partly online, and eight trials presented online. Information regarding additional trials and data was provided by Axxonis, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Schwarz Pharma. </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-01-12 14:16:47 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design and sample sizes     </HEADING>
<P>Overall, 38 randomised and double-blind studies were included for this review comprising 7365 participants (ranging from eight to 402 per study). Thirty-two of these studies were randomised parallel group trials (<LINK REF="STD-Allen-2004" TYPE="STUDY">Allen 2004</LINK>; <LINK REF="STD-Axxonis-2005" TYPE="STUDY">Axxonis 2005</LINK>; <LINK REF="STD-Axxonis-2008" TYPE="STUDY">Axxonis 2008</LINK>; <LINK REF="STD-Benes-2010" TYPE="STUDY">Benes 2010</LINK>; <LINK REF="STD-BI-2008" TYPE="STUDY">BI 2008</LINK>; <LINK REF="STD-BI-2009" TYPE="STUDY">BI 2009</LINK>; <LINK REF="STD-Bogan-2006" TYPE="STUDY">Bogan 2006</LINK>; <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>; <LINK REF="STD-Ferini_x002d_Strambi-2008" TYPE="STUDY">Ferini-Strambi 2008</LINK>; <LINK REF="STD-Garcia_x002d_Borreguero-2007" TYPE="STUDY">Garcia-Borreguero 2007</LINK>; <LINK REF="STD-GSK-2005" TYPE="STUDY">GSK 2005</LINK>; <LINK REF="STD-GSK-2006" TYPE="STUDY">GSK 2006</LINK>; <LINK REF="STD-GSK-2007" TYPE="STUDY">GSK 2007</LINK>; <LINK REF="STD-GSK-2008" TYPE="STUDY">GSK 2008</LINK>; <LINK REF="STD-GSK-2009" TYPE="STUDY">GSK 2009</LINK>; <LINK REF="STD-Hening-2010" TYPE="STUDY">Hening 2010</LINK>; <LINK REF="STD-Inoue-2010" TYPE="STUDY">Inoue 2010</LINK>; <LINK REF="STD-Kushida-2008" TYPE="STUDY">Kushida 2008</LINK>; <LINK REF="STD-Montagna-2010" TYPE="STUDY">Montagna 2010</LINK>; <LINK REF="STD-Oertel-2006" TYPE="STUDY">Oertel 2006</LINK>; <LINK REF="STD-Oertel-2007" TYPE="STUDY">Oertel 2007</LINK>; <LINK REF="STD-Oertel-2008" TYPE="STUDY">Oertel 2008</LINK>; <LINK REF="STD-Oertel-2010" TYPE="STUDY">Oertel 2010</LINK>; <LINK REF="STD-Partinen-2006" TYPE="STUDY">Partinen 2006</LINK>; <LINK REF="STD-Stiasny_x002d_Kolster-2004a" TYPE="STUDY">Stiasny-Kolster 2004a</LINK>; <LINK REF="STD-Stiasny_x002d_Kolster-2004b" TYPE="STUDY">Stiasny-Kolster 2004b</LINK>; <LINK REF="STD-Trenkwalder-2004a" TYPE="STUDY">Trenkwalder 2004a</LINK>; <LINK REF="STD-Trenkwalder-2004b" TYPE="STUDY">Trenkwalder 2004b</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>; <LINK REF="STD-Trenkwalder-2008" TYPE="STUDY">Trenkwalder 2008</LINK>; <LINK REF="STD-Walters-2004" TYPE="STUDY">Walters 2004</LINK>; <LINK REF="STD-Winkelman-2006" TYPE="STUDY">Winkelman 2006</LINK>). The other six trials were randomised cross-over trials (<LINK REF="STD-Adler-2004" TYPE="STUDY">Adler 2004</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>; <LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Wetter-1999" TYPE="STUDY">Wetter 1999</LINK>). Twenty-seven of the studies were published in peer reviewed journals; the remaining 11 studies were obtained from conference abstracts and partly from online registers. In the present review, these are referred to by the pharmaceutical company who initiated the study (Axxonis: <LINK REF="STD-Axxonis-2005" TYPE="STUDY">Axxonis 2005</LINK>; <LINK REF="STD-Axxonis-2008" TYPE="STUDY">Axxonis 2008</LINK>; Boehringer Ingelheim: <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-BI-2008" TYPE="STUDY">BI 2008</LINK>; <LINK REF="STD-BI-2009" TYPE="STUDY">BI 2009</LINK>; GlaxoSmithKline: <LINK REF="STD-GSK-2005" TYPE="STUDY">GSK 2005</LINK>; <LINK REF="STD-GSK-2006" TYPE="STUDY">GSK 2006</LINK>; <LINK REF="STD-GSK-2007" TYPE="STUDY">GSK 2007</LINK>; <LINK REF="STD-GSK-2008" TYPE="STUDY">GSK 2008</LINK>; <LINK REF="STD-GSK-2009" TYPE="STUDY">GSK 2009</LINK>).</P>
<P>Patients received cabergoline in three studies, lisuride in two, and pergolide in five studies. Pramipexole was used in 10 trials, ropinirole in 12, and rotigotine in five trials. One trial investigated sumanirole, a dopamine agonist which has not been licensed. One of the lisuride trials compared treatment with lisuride to treatment with ropinirole and placebo.</P>
<P>Three of the 38 trials investigated dopamine agonist treatment against levodopa (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>).</P>
<P>Methods, patients, interventions, and relevant outcomes of all included trials are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting and location</HEADING>
<P>Five studies (<LINK REF="STD-Adler-2004" TYPE="STUDY">Adler 2004</LINK>; <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>; <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>; <LINK REF="STD-Partinen-2006" TYPE="STUDY">Partinen 2006</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>) were conducted in one centre; all other studies were multi-centre studies. Patients were recruited from outpatient clinic settings and private practices.</P>
<P>Studies were conducted in the USA (N = 11), Germany (N = 6), Canada (N = 1), Finland (N = 1), Japan (N = 1), Switzerland (N = 1), and the United Kingdom (N = 1). Multinational studies were conducted in European countries (N = 10), Northern American and European countries (N = 1) and Northern American countries (N = 1). A further four studies were conducted in Europe with additional study sites in Australia (N = 3) and Korea (N = 1).</P>
<P>Treatment duration in cabergoline studies varied from five to eight weeks. Both lisuride trials were conducted over a period of 12 weeks. Pergolide studies ranged from 10 days to six weeks and pramipexole studies from three to 12 weeks with one further trial lasting 26 weeks. Ropinirole trials had treatment durations of 12 weeks, with the exception of two studies with durations of four and 26 weeks, respectively. Rotigotine studies had treatment durations of seven days to seven weeks with two studies having durations of seven months. In the sumanirole trial, patients were treated for eight weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Diagnosis of RLS was made according to the criteria defined by the International Restless Legs Study Group (IRLSSG; <LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>) with exception of one study, in which diagnosis was not explicitly made according to valid criteria but used acceptable diagnostic criteria (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>).</P>
<P>All studies but one (<LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>, N = 8 uremic patients) included almost entirely patients with primary RLS. Symptom severity at baseline was moderate to very severe (mean baseline IRLS score ranging from a score of 21 (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>) to 31.5 (<LINK REF="STD-Oertel-2006" TYPE="STUDY">Oertel 2006</LINK>)). </P>
<P>Patients were 55.1 years old (mean), ranging from a mean of 42.5 years (<LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>) to 60.5 years (<LINK REF="STD-Axxonis-2005" TYPE="STUDY">Axxonis 2005</LINK>). A mean percentage of 64.4 female patients participated in the trials, ranging from 45.5% (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>) to 84% (<LINK REF="STD-GSK-2008" TYPE="STUDY">GSK 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Study drugs were given orally with the exception of lisuride and rotigotine, which were applied transdermally using skin patches.</P>
<P>Flexible up-titration to optimised dose was used in 21 trials. Forced up-titration was performed either to one fixed level (<LINK REF="STD-Oertel-2006" TYPE="STUDY">Oertel 2006</LINK>; <LINK REF="STD-Pieta-1998" TYPE="STUDY">Pieta 1998</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), to the highest tolerated level (<LINK REF="STD-Adler-2004" TYPE="STUDY">Adler 2004</LINK>; <LINK REF="STD-GSK-2005" TYPE="STUDY">GSK 2005</LINK>; <LINK REF="STD-Inoue-2010" TYPE="STUDY">Inoue 2010</LINK>; <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>), or to multiple doses investigated in multiple study arms (<LINK REF="STD-Axxonis-2005" TYPE="STUDY">Axxonis 2005</LINK>; <LINK REF="STD-BI-2008" TYPE="STUDY">BI 2008</LINK>; <LINK REF="STD-Garcia_x002d_Borreguero-2007" TYPE="STUDY">Garcia-Borreguero 2007</LINK>; <LINK REF="STD-Oertel-2008" TYPE="STUDY">Oertel 2008</LINK>; <LINK REF="STD-Partinen-2006" TYPE="STUDY">Partinen 2006</LINK>; <LINK REF="STD-Stiasny_x002d_Kolster-2004a" TYPE="STUDY">Stiasny-Kolster 2004a</LINK>; <LINK REF="STD-Stiasny_x002d_Kolster-2004b" TYPE="STUDY">Stiasny-Kolster 2004b</LINK>; <LINK REF="STD-Trenkwalder-2008" TYPE="STUDY">Trenkwalder 2008</LINK>; <LINK REF="STD-Hening-2010" TYPE="STUDY">Hening 2010</LINK>; <LINK REF="STD-Winkelman-2006" TYPE="STUDY">Winkelman 2006</LINK>).</P>
<P>Maximum doses included 2.0 mg cabergoline in two studies. In the active controlled cabergoline study a maximum dose of 3.0 mg was used. Lisuride studies implemented 7.5 and 10.0 mg/48 h at the maximum. In pergolide studies a maximum dose of 0.25 mg was used in two studies, 0.65 mg in one, and 0.75 mg in two studies. In pramipexole trials, 0.25 mg was used in one study, 0.75 mg in eight, and 1.5 mg in one study at the maximum. In ropinirole studies, the maximum dose was 2.0 mg in one study, 4.0 mg in seven studies, and 6.0 mg in four studies. In rotigotine studies, maximum doses ranged from 2.0 mg/24 h (one study) over 3.0 mg/24 h (three studies) to 4.0 mg/24 h (one study). In the sumanirole study, 4.0 mg was used as the maximum dose. We excluded doses which are not recommended in practice, but which were included in dose-finding studies using multiple treatment arms (see also methods).</P>
<P>Doses of the comparator drug levodopa in the three active controlled studies were 300 mg/75 mg levodopa/benserazide (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), 300 mg/75 mg levodopa/benserazide dual release formulation (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>), and 400 mg/100 mg levodopa/carbidopa (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The IRLS was widely used to assess severity of symptoms and therapeutic effect. Other scales were used for symptom assessment and evaluation of secondary outcomes as well as safety parameters. Polysomnography parameters included the PLMSI and sleep efficiency.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-11-30 11:43:29 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 41 publications while checking the full text copies for eligibility. Nineteen reports were of trials which were published in full elsewhere. Four trials had a withdrawal design. Thirteen studies did not investigate patients in a randomised controlled design, four other publications were overviews on RLS and one study was not completed. <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and reasons for exclusion are presented separately.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-30 15:04:39 +0000" MODIFIED_BY="[Empty name]">
<P>We primarily report on quality of assessment of the primary outcomes IRLS, PLMSI, sleep efficiency, and dropout rates due to adverse events. All other outcomes included questionnaires and ratings and were, therefore, similar to the IRLS regarding the method of assessment.</P>
<ALLOCATION MODIFIED="2010-11-30 15:04:39 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation included computer-generated randomisation lists in 26 trials as stated in the study protocol or confirmed on request. Allocation of treatment was mostly performed with numbered packages and was partly based on an Interactive Voice Response System. Nine studies investigating PLMSI reported on randomisation procedure whereas six studies did not report sufficiently on that issue. In the majority of studies, allocation concealment was performed by dispensing numbered packages as described above. Adequate performance of randomisation could be assured in seven of 12 trials investigating sleep efficiency with reports of numbered packages in the majority of trials. The majority of studies contributing safety data reported adequately on randomisation and allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-05-10 12:55:17 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding of participants, investigators, and data analysts was sufficiently described in most trial reports for the IRLS and for dropout analysis. Blinded polysomnography rating was performed in 13 studies with insufficient information of blinding of polysomnography scoring in two more trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-05-10 13:52:36 +0100" MODIFIED_BY="[Empty name]">
<P>In most studies, the method of the last observation carried forward (LOCF) was used for inclusion of incomplete outcome data. Seven of the polysomnography studies reported per protocol data. In the majority of studies, the dropout rate from placebo and dopamine agonist treatment was not different. As all studies with high dropout rates (i.e. 20% to 25%) used the LOCF method, the likelihood of bias due to high numbers of dropouts can be considered low.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-05-10 12:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>The majority of studies investigated a wide range of questionnaire assessments regarding symptom severity, quality of sleep, daytime functioning, and disease-specific quality of life as well as polysomnography parameters. In a few trials, not all implemented measures were reported in the final study report although they had been mentioned either in the protocol or in result reports accessible online.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-10 12:55:34 +0100" MODIFIED_BY="[Empty name]">
<P>Seven studies were supported by governmental and pharmaceutical grants, 30 studies were fully sponsored by pharmaceutical companies, and one study did not report on funding. We could not ascertain any other major source of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-01-12 15:33:19 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison I: Dopamine agonists versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1a) Change on the severity scale IRLS</HEADING>
<P>Thirty trials assessed change from baseline as measured by the IRLS. The mean difference (MD) was &#8722;5.74 points in favour of dopamine agonist treatment compared to placebo treatment (95% confidence interval (CI) &#8722;6.74 to &#8722;4.74). This comparison showed considerable heterogeneity (I² = 75%). Results of the only cross-over trial overlapped with the overall mean difference (see comparison 1.1 and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1b) Medication subgroup analysis of change on IRLS</HEADING>
<P>The analysis of change from baseline on the IRLS revealed the following results in the medication subgroups (see also <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for all medication subgroups and <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>
<U>)</U>: One pergolide and two cabergoline trials showed similarly high treatment differences between treatment and placebo with a MD of &#8722;11.70 for one pergolide trial (95% CI &#8722;14.8 to &#8722;8.6) and &#8722;11.49 points for the cabergoline trials (95% CI &#8722;15.14 to &#8722;7.84, I² = 0%). Trials using transdermal systems such as the lisuride (MD &#8722;8.0, 95% CI &#8722;10.28 to &#8722;5.72, I² = 0) and rotigotine trials also showed high treatment effects (MD &#8722;6.98, 95% CI &#8722;8.99 to &#8722;4.96, I² = 44%). Somewhat lower effects were found in pramipexole studies (MD &#8722;5.16, 95% CI &#8722;6.88 to &#8722;3.43, I² = 76%), followed by ropinirole studies (MD &#8722;4.19, 95% CI &#8722;5.4 to &#8722;2.97, I² = 58%). The sumanirole study showed a treatment difference of &#8722;1.83 points (95% CI &#8722;4.71 to 1.05).</P>
<P>Visual inspection of confidence intervals revealed that those of the subgroups cabergoline and pergolide showed the highest effects, those of pramipexole and ropinirole showed lower effects. No significant treatment effect was observed with sumanirole. The confidence interval of lisuride overlapped with those of cabergoline, pergolide, pramipexole, and rotigotine and was higher than that of ropinirole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2a) Change in periodic limb movements in sleep index (PLMSI)</HEADING>
<P>Data from 15 trials were analysed regarding the treatment effect of dopamine agonists on the PLMSI. Data of eight trials contributing PLM data per hour of total sleep time and seven trials including PLM data per hour of time in bed were pooled. Mean difference in reductions of PLMSI was &#8722;22.38 per hour of sleep (or hour in bed) when compared to placebo (95% CI &#8722;27.82 to &#8722;16.94, I² = 73%). Cross-over trials were analysed separately and showed higher treatment effects over placebo than parallel group trials but confidence intervals overlapped slightly (see comparison 1.3 and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2b) Medication subgroup analysis of change in periodic limb movements in sleep index (PLMSI)</HEADING>
<P>Treatment difference was high with a wide confidence interval in one cabergoline trial (MD &#8722;32.76/h, 95% CI &#8722;56.79 to &#8722;8.73). In the other medication subgroups, larger effects resulted in pergolide (MD &#8722;35.08/h, 95% CI &#8722;44.88 to &#8722;25.29, I² = 11%), pramipexole (MD &#8722;30.47/h, 95% CI &#8722;51.58 to &#8722;9.35, I² = 85%), and in one rotigotine trial (MD &#8722;30.35/h, 95% CI &#8722;43.74 to &#8722;16.96). Somewhat lower effects resulted in the sumanirole trial (MD &#8722;18.90/h, 95% CI &#8722;27.41 to &#8722;10.39) and in ropinirole trials (MD &#8722;14.11/h, 95% CI &#8722;18.79 to &#8722;9.43, I² = 52%; see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> for all subgroups).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3a) Change in sleep efficiency</HEADING>
<P>Eleven trials investigated sleep efficiency assessed in polysomnography. Mean difference of improvement in sleep efficiency was 4.53% favouring dopamine agonists (95% CI 2.00 to 7.06, I² = 48%) including heterogeneous effects in cross-over trials (see comparison 1.5 and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3b) Medication subgroup analysis of change in sleep efficiency</HEADING>
<P>Pergolide trials were heterogeneous (I² = 73%) with a mean difference of 8.7% (95% CI 1.85 to 15.86). Effects did not differ from placebo in the following medication subgroups: sumanirole (MD 4.1%), cabergoline (MD 2.9%), rotigotine (MD 2.71%), pramipexole (MD 2.47%), and ropinirole (MD 2.19%; see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4a) Number of dropouts due to adverse events</HEADING>
<P>Thirty-four trials assessed dropout rates due to adverse events. Patients were more likely to drop out of dopamine agonist treatment compared to placebo treatment ( OR 1.82, 95% CI 1.35 to 2.45, I² = 41%, see <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The assumed control group risk (median of dropouts in placebo treatments) of 38 dropouts in 1000 patients increases to 66 of 1000 patients dropping out of treatment when treated with dopamine agonists. This corresponds with a risk difference of 28 out of 1000 patients who would drop out of treatment due to adverse events when treated with a dopamine agonist compared to placebo treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4b) Medication subgroup analysis of dropouts due to adverse events</HEADING>
<P>In the medication subgroups cabergoline, pergolide, pramipexole, rotigotine, and the only sumanirole trial, there were no differences regarding dropout rates compared to placebo (see comparison 1.8 and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). Differences resulted in lisuride (OR 3.6, 95% CI 1.79 to 7.26) and ropinirole trials (OR 1.76, 95% CI 1.31 to 2.38) indicating elevated dropouts due to adverse events in active treatment compared to placebo treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5a) Responder rates on CGI-I</HEADING>
<P>Twenty-seven trials reported on CGI-I. Patients treated with dopamine agonists responded to a greater extent on the CGI-I than those on placebo treatment (Risk Ratio (RR) 1.44, 95% CI 1.34 to 1.54, I² = 49%, see <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5b) Medication subgroup analysis of responder rates on CGI-I</HEADING>
<P>Risk ratios of the subgroups ropinirole (RR 1.36), rotigotine (RR 1.48), pramipexole (RR 1.53, I² = 71%), and lisuride (RR 1.75) differed only slightly with the exception of one cabergoline trial showing a higher RR of 2.32 (95% CI 1.13 to 4.77) and the sumanirole trial showing no effect (see comparison 1.10 and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> for details).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6a) Change in self rated quality of sleep</HEADING>
<P>Quality of sleep was investigated in 22 trials and improved more with dopamine agonists compared to placebo (standardised mean difference (SMD) 0.40, 95% CI 0.33 to 0.47, I² = 16%, see <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6b) Medication subgroup analysis of change in self rated quality of sleep</HEADING>
<P>When looking at medication subgroups, cabergoline, lisuride, pramipexole, rotigotine, and ropinirole trials showed larger treatment effects compared to placebo in descending order (see comparison 1.12, see <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7a) Change in disease-specific quality of life</HEADING>
<P>Disease-specific quality of life (QoL) was assessed in 17 trials by the QoL-RLS (<LINK REF="REF-Kohnen-2002" TYPE="REFERENCE">Kohnen 2002</LINK>; N = 7) and the Hopkins RLS-QoL (<LINK REF="REF-Abetz-2005" TYPE="REFERENCE">Abetz 2005</LINK>; N = 10). The results showed a small effect of dopamine agonists over placebo (SMD 0.34, 95% CI 0.23 to 0.44, I² = 61%, see <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7b) Medication subgroup analysis of disease-specific change in quality of life</HEADING>
<P>One cabergoline study investigating QoL revealed a large treatment effect over placebo (SMD 0.75, 95% CI 0.10 to 1.39). Moderate effects resulted in two lisuride trials (SMD 0.60, 95% CI 0.38 to 0.82) and in rotigotine trials (SMD 0.50, 95% CI 0.23 to 0.76, I² = 47%). Pramipexole and ropinirole studies showed smaller effects on QoL with SMDs of 0.30 and 0.23 with substantial to moderate heterogeneity (I² = 60% and 52%, respectively; see comparison 1.14 and <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8a) Responder rates on PGI</HEADING>
<P>In 13 trials investigating PGI, patients were more likely to respond when treated with dopamine agonists (RR 1.53, 95% CI 1.34 to 1.75) but study results showed substantial heterogeneity (I² = 73%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8b) Medication subgroup analysis of responder rates on PGI</HEADING>
<P>One pergolide trial with PGI assessment obtained the highest RR (4.51) followed by a lower RR for pramipexole (1.57; I² = 74%), ropinirole (1.35; I² = 73%), and rotigotine trials (1.34; I² = 0%; see comparison 1.16). Divergent confidence intervals indicate markedly lower effects in pramipexole, ropinirole, and rotigotine compared to pergolide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9a) Number of patients experiencing adverse events</HEADING>
<P>In 33 trials reporting on this safety parameter, significantly more patients experienced adverse events when treated with dopamine agonists compared to placebo-treated patients (OR 1.82, 95% CI 1.59 to 2.08, I² = 24%, see comparison 1.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9b) Medication subgroup analysis of number of patients experiencing adverse events</HEADING>
<P>Study data of patients with adverse events showed significantly higher odds ratios in rotigotine (OR 2.41, I² = 2%), ropinirole (OR 2.07, I² = 12%), and pramipexole trials (OR 1.48, I² = 0%) than in placebo trials. The effects of lisuride, pergolide, and cabergoline did not significantly differ from those of placebo treatment. Cabergoline trials showed considerable heterogeneity (I² = 79%). In the only sumanirole trial, the numbers of patients with adverse events did not differ between treatment and placebo (see comparison 1.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10a) Change in daytime tiredness</HEADING>
<P>In 21 trials assessing daytime tiredness, dopamine agonist treatment reduced daytime tiredness compared to placebo treatment (SMD &#8722;0.24, 95% CI &#8722;0.31 to &#8722;0.17, I² = 29%) representing a small effect (see comparison 1.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10b) Medication subgroup analysis of change in daytime tiredness</HEADING>
<P>Largest treatment differences in daytime tiredness were shown in lisuride trials (SMD &#8722;0.47; I² = 36%). Lower treatment differences were seen in one cabergoline trial (SMD &#8722;0.31), pramipexole (SMD &#8722;0.25; I² = 75%), rotigotine (SMD &#8722;0.24, I² = 0%), and ropinirole trials (SMD &#8722;0.19; I² = 10%, see comparison 1.20).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10a) Augmentation</HEADING>
<P>Augmentation was not reliably and comparably assessed in the included trials; therefore, we could not perform a meta-analysis on this outcome.</P>
<P>Visual inspection of funnel plots and asymmetry coefficients showed a possibility of publication bias or small study effects for the outcomes IRLS and PLMSI (IRLS coefficient = &#8722;3.31, P = 0.001 and PLMSI coefficient = &#8722;2.48, P = 0.009; see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK> for IRLS). When examining the two funnel plots of IRLS and PLMSI effects, medication subgroups differed in treatment effects and precision (presented as the inverse of the standard error) with, for example, cabergoline and lisuride showing larger effects with larger standard errors, whereas other medication subgroups showed treatment effects closer to the mean treatment effect and smaller standard errors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11) Additional subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis of effect of randomisation on IRLS treatment effect</HEADING>
<P>A descriptive subgroup analysis of 30 studies was performed to investigate study quality as a source of heterogeneity of IRLS treatment effects. To this aim, studies were divided into those with low and those with unclear risk of bias regarding randomisation. Noteworthy, studies with unclear risk of bias regarding randomisation were those studies which did not report adequately on the randomisation procedure. The IRLS treatment difference was &#8722;3.54 in studies with unclear risk of randomisation bias (95% CI &#8722;5.83 to &#8722;1.24, I² = 66%) and &#8722;6.07 in studies with low risk of bias (95% CI &#8722;7.14 to &#8722;5.00, I² = 74%, see comparison 1.21). In conclusion, study quality was no source of heterogeneity of the overall effect as both subgroups showed substantial heterogeneity and an overlap of the confidence intervals by inspection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Explorative analyses of possible predictors for treatment effects</HEADING>
<P>We performed explorative univariable and multiple meta-regressions with the three predictors: baseline severity of RLS, treatment duration, and number of investigating sites. Mean treatment difference of the IRLS was regressed on these predictors.</P>
<P>Results of the univariable meta-regression: The number of investigating sites within a trial was negatively associated with the size of treatment difference (P = 0.001). Studies with longer duration showed smaller treatment effects than studies with shorter duration (P = 0.027). Baseline scores of the IRLS had no effect on IRLS treatment effects (P = 0.12; see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
<P>Result of the multiple meta-regression: When analysing the association between each of the three factors and treatment effects on the IRLS, we found that the number of study sites within a trial was still associated with the magnitude of IRLS mean differences (P = 0.001). Treatment duration was no longer predictive (P = 0.43) whereas higher baseline IRLS scores tended to lead to larger treatment differences on the IRLS (P = 0.09, see <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
<P>A further explorative subgroup analysis investigating the effect of the location of study sites on IRLS treatment effect was performed. This was due to the fact that more than half of the studies were conducted predominantly in Europe (N = 18 European sites versus N = 12 other study sites assessing IRLS). Indirect comparisons of the two subgroups showed that IRLS treatment differences were larger in studies conducted in European countries (MD &#8722;6.88, 95% CI &#8722;8.31 to &#8722;5.45, I² = 77%) compared to studies conducted predominantly in other countries (MD &#8722;4.13, 95% CI &#8722;5.31 to &#8722;2.95, I² = 61%). Noteworthy, results of both subgroups showed substantial to considerable heterogeneity (see comparison 1.22).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison II: Dopamine agonists versus levodopa</HEADING>
<P>In three trials, the dopamine agonists cabergoline, pergolide, and pramipexole were compared to levodopa.</P>
<SUBSECTION>
<HEADING LEVEL="4">1) Change on the severity scale IRLS</HEADING>
<P>In two trials (cabergoline or pramipexole versus levodopa), the change from baseline on the IRLS was larger with dopamine agonists compared to levodopa (MD &#8722;5.25 points, 95% CI &#8722;8.40 to &#8722;2.10). Results showed a moderate heterogeneity (I² = 55%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2) Change in periodic limb movements index (PLMI)</HEADING>
<P>One trial investigated the index of periodic limb movements per time in bed (PLMI) when treated with pramipexole in comparison to levodopa. Pramipexole and levodopa effects were not different on the PLMI (MD &#8722;3.80/h, 95% CI &#8722;9.08 to 1.48; P = 0.16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3) Number of dropouts due to adverse events</HEADING>
<P>Numbers of patients dropping out of treatment due to adverse events were slightly, but not significantly, larger when treated with dopamine agonists compared to levodopa (OR 1.70, 95% CI 0.96 to 3.01; P = 0.07). The effect of one trial investigating pergolide was not estimable as no patients dropped out of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4) Responder rates on CGI-I</HEADING>
<P>On the CGI-I, patients were more likely to respond to treatment when treated with cabergoline compared to levodopa, whereas response to pramipexole treatment was similar to response to levodopa treatment (see comparison 2.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5) Change in self rated quality of sleep</HEADING>
<P>One trial investigated change in self rated quality of sleep during treatment with cabergoline versus treatment with levodopa. Quality of sleep showed a tendency to improve after treatment for six weeks with cabergoline, but this change was not statistically significant (P = 0.09; see comparison 2.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6) Change in disease-specific quality of life</HEADING>
<P>One trial investigating change in disease-specific quality of life in cabergoline versus levodopa found a larger improvement with cabergoline treatment (MD &#8722;5.54 points, 95% CI &#8722;8.43 to &#8722;2.65).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7) Number of patients experiencing adverse events</HEADING>
<P>The experience of adverse events was investigated in all of the three trials. The number of patients with adverse events was slightly lower in pramipexole treatment compared to levodopa treatment (OR 0.32), but higher in cabergoline (OR 2.06) and pergolide (OR 26.67) when comparing these to levodopa. The pooled effect of dopamine agonists was not different from levodopa and substantial heterogeneity was seen (I² = 63%, see comparison 2.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8) Change in daytime tiredness</HEADING>
<P>Treatment effects did not differ between cabergoline and levodopa in one trial investigating daytime tiredness (see comparison 2.8).</P>
<P>No active controlled trial investigated the endpoints sleep efficiency and Patient Global Impressions. Therefore, we cannot draw any conclusions regarding these endpoints in actively controlled trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison III: Lisuride versus ropinirole</HEADING>
<P>One trial compared treatment with lisuride to ropinirole directly and to placebo . Reductions on the IRLS after treatment were larger with lisuride compared to ropinirole with a mean difference of &#8722;3.00 points (95% CI &#8722;5.70 to &#8722;0.30). Quality of life was more improved with lisuride treatment than with ropinirole (MD &#8722;4.50, 95% CI &#8722;8.12 to &#8722;0.88) whereas response to both treatments and daytime tiredness did not differ between treatments (comparisons 3.3 and 3.7). Patients dropped out of treatments and experienced adverse events at a similar rate (comparisons 3.2 and 3.6).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-01-12 14:17:50 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-01-12 14:17:32 +0000" MODIFIED_BY="[Empty name]">
<P>Dopamine agonist treatment showed superiority over placebo treatment regarding all investigated efficacy endpoints. Marked effects were seen on the IRLS and PLMSI as well as on PGI and CGI-I. The mean treatment effect of the IRLS was close to six points which is regarded as a difference of clinical relevance (<LINK REF="REF-Trenkwalder-2007" TYPE="REFERENCE">Trenkwalder 2007</LINK>). Small to moderate effects were shown in outcomes such as sleep efficiency, self rated quality of sleep, quality of life, and daytime tiredness as well as the safety parameters number of dropouts due to adverse events and number of patients experiencing adverse events (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>All medication subgroups indicated efficacy on the IRLS above the non-inferiority margin of three points and four of seven medication subgroups (cabergoline, pergolide, lisuride, rotigotine) showed a treatment difference above six points which indicates a clinically relevant improvement (<LINK REF="REF-Trenkwalder-2007" TYPE="REFERENCE">Trenkwalder 2007</LINK>). Visual inspection of confidence intervals revealed that those of the subgroups cabergoline and pergolide showed highest effects, those of pramipexole and ropinirole showed lower effects. No significant effect was observed in sumanirole. The confidence interval of lisuride overlapped with those of cabergoline, pergolide, pramipexole, and rotigotine and was higher than that of ropinirole.</P>
<P>Sleep efficiency was overall slightly, but significantly, improved. When looking at improvement in each dopamine agonist, a favourable effect was only present with pergolide.</P>
<P>Patients rated their daytime tiredness as improved with dopamine agonist treatment. The only exception was patients treated with cabergoline in one trial, who rated their daytime tiredness as similarly improved as with placebo (comparison 1.21).</P>
<P>Dropouts due to adverse events occurred more often in patients receiving lisuride and ropinirole compared to placebo, whereas there were no differences in the treatments with cabergoline, pergolide, pramipexole, rotigotine, and sumanirole. Patients receiving pramipexole, ropinirole, or rotigotine experienced more adverse events compared to placebo, whereas treatments with cabergoline, lisuride, and pergolide showed a similar risk of adverse events compared with placebo.</P>
<P>When looking at symptom improvement on the outcomes IRLS, PLMSI, quality of life, and PGI, treatment effects were evident in all but the sumanirole medication subgroups. However, substantial heterogeneity remained in the pramipexole and ropinirole trials.</P>
<P>Sumanirole was the only dopamine agonist with low or no efficacy in RLS treatment. The dopamine agonist differed from placebo only when measuring PLMSI. Treatment effects on the IRLS were larger in treatment groups with higher doses.</P>
<P>Univariable meta-regression showed a negative effect of higher number of study sites and longer treatment duration on IRLS treatment effect. In a multiple meta-regression, effects of number of study sites remained significant, and a tendency towards higher treatment effects in the more severely affected patients was seen.</P>
<P>Three trials comparing a dopamine agonist (cabergoline, pergolide, pramipexole) to levodopa showed superiority of dopamine agonists on the IRLS (cabergoline, pramipexole) and with regard to quality of life (cabergoline). The number of patients experiencing adverse events was higher during treatment with cabergoline and pergolide compared to levodopa. No treatment difference between dopamine agonists and levodopa was seen on the following outcomes: PLMSI, dropout rates due to adverse events, CGI-I, self rated quality of sleep, and daytime tiredness (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Only one study compared two dopamine agonists (and placebo). In this study, lisuride was superior in reduction of IRLS score and improvement of quality of life compared to ropinirole. </P>
<P>In summary, dopamine agonist treatment shows a greater efficacy in RLS treatment than placebo. In some aspects, dopamine agonists are even more effective than levodopa. However, treatment effects have to be weighed against an increase in the dropout rate due to adverse events and in a higher number of patients experiencing adverse events.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-01-12 13:35:40 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were recruited from outpatient settings. They suffered from moderate to very severe RLS and represent the patient population requiring treatment.</P>
<P>Treatment durations varied from one week to 30 weeks with durations of 12 weeks in many studies. Efficacy of drug treatment can be investigated reliably in these time periods. However, there is a general lack of controlled evidence for long-term efficacy and safety of dopamine agonists in RLS, although RLS is a chronic disorder and treatment with dopaminergic agents is symptomatic, i.e. a long-term medication. An indication regarding long-term efficacy is provided by univariable meta-regression. The results of this analysis indicated a slight decrease of efficacy on the IRLS with increased treatment duration.</P>
<P>Earlier reviews including meta-analyses reported greater effects in pramipexole treatment compared to ropinirole treatment acknowledging that pramipexole studies were of shorter duration (<LINK REF="REF-Baker-2008" TYPE="REFERENCE">Baker 2008</LINK>; <LINK REF="REF-Quilici-2008" TYPE="REFERENCE">Quilici 2008</LINK>). The presented meta-analyses included a further number of studies with longer treatment durations. In these meta-analyses, we were not able to replicate findings indicating differences in treatment efficacy between pramipexole and ropinirole (<LINK REF="REF-Kohnen-2008" TYPE="REFERENCE">Kohnen 2008</LINK>).</P>
<P>In summary, dopamine agonist treatment showed superiority over placebo. All relevant aspects of symptom severity and wellbeing-related improvements were assessed. The only three active controlled studies showed greater effects with dopamine agonists compared to levodopa regarding symptom severity and quality of life improvement and overall similar numbers of patients experiencing adverse events.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-01-12 14:17:50 +0000" MODIFIED_BY="[Empty name]">
<P>We searched all relevant databases and public trial registers provided by the pharmaceutical companies and by government (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) and included unpublished trials, which were only presented in online trial registers. We furthermore contacted pharmaceutical companies. Therefore, we presume that there are not many additional, relevant RCTs, if any.</P>
<P>Due to only one obtained trial investigating a small number of exclusively uremic (secondary) RLS patients (N = 8), we cannot draw any conclusions regarding uremic RLS. Evidence for treatment of uremic or any other form of secondary RLS is clearly missing.</P>
<P>The majority of the included studies were adequately planned and performed according to requirements for RCTs. Most study publications adequately described the methods for randomisation, allocation concealment, and blinding during the study either in study reports or on request. The majority of studies were initiated by pharmaceutical companies. In those studies, standard study procedures were applied. In a few sponsored studies, we could not obtain satisfactory information on randomisation and blinding, which led to some restriction in the quality rating of methodological appropriateness. We did not obtain sufficient information regarding study procedures and performance of a few investigator-initiated trials. Therefore, we had to rate their likelihood for bias as &#8220;unclear&#8221;, even though we are aware that an insufficient study report does not necessarily represent inadequate performance of the study. In summary, methodological standards were adequately reported in the majority of studies.</P>
<P>When investigating parameters with marked heterogeneity (I² &gt; 50%) of overall treatment effects (IRLS, PLMSI, quality of life, PGI), medication subgroup analyses showed homogeneous effects, with the exception of pramipexole and ropinirole. Both pramipexole and ropinirole showed heterogeneous treatment results on the IRLS, PLMSI, and quality of life (I² = 52% to 85%). Additionally, treatment differences on the PGI were heterogeneous in pramipexole (I² = 74%). One pramipexole (<LINK REF="STD-BI-2008" TYPE="STUDY">BI 2008</LINK>) and one ropinirole trial (<LINK REF="STD-GSK-2005" TYPE="STUDY">GSK 2005</LINK>) contributed predominantly to the heterogeneous treatment effects on the IRLS. Both studies were unpublished and retrieved from online registers. In the pramipexole study, the medication dose was relatively low (0.25 mg) compared to the other included pramipexole studies (mean dose of 0.46 mg). The ropinirole study used an escalating dose regimen (<LINK REF="STD-GSK-2005" TYPE="STUDY">GSK 2005</LINK>). Heterogeneity of studies contributing to the treatment effect on PLMSI could not be traced back to methodological factors. The lower treatment effect of the only middle-term, 26-week pramipexole study (<LINK REF="STD-BI-2009" TYPE="STUDY">BI 2009</LINK>) contributed considerably to the heterogeneity in pramipexole studies on the disease-specific QoL (I² = 60%). Heterogeneity of PGI in the pramipexole subgroup was increased markedly by the lower treatment effect of the pramipexole study (<LINK REF="STD-BI-2008" TYPE="STUDY">BI 2008</LINK>). Furthermore, a general reason for heterogeneity might be the wide range of RLS severity at baseline due to inclusion of patients with an IRLS score of &#8805; 15 in most studies. Although baseline severity might not substantially have influenced treatment results, we found a non-significant tendency towards larger treatment effects in patients with more severe RLS symptoms. </P>
<P>In active controlled trials, heterogeneity of treatment effect was present on the IRLS, as well as in the number of patients with adverse events in the studies investigating cabergoline and pramipexole. These differences in treatment effects can be traced back to the different medications.</P>
<P>Only four studies investigated the effects of dopamine agonists against other dopaminergic agents. Therefore, a conclusive comparison of dopaminergic medications regarding their efficacy in RLS cannot be made. In the meta-analyses of dopamine agonists against placebo, treatment effects in medication subgroups did not differ markedly and confidence intervals of the medication subgroups overlapped in most endpoints. Marked treatment differences only resulted pertaining to the IRLS treatment effect when indirectly comparing medication subgroups of non-ergoline substances to subgroups of ergoline treatments by visually inspecting forest plots. IRLS treatment effects of the ergoline treatments with cabergoline and pergolide were higher compared with non-ergoline treatments such as pramipexole and ropinirole. Confidence intervals of the ergoline lisuride overlapped with those of cabergoline and pergolide and were superior to ropinirole. This finding was supported by a larger effect of pergolide on the PGI compared to pramipexole, ropinirole, and rotigotine. It has to be mentioned that the highest treatment differences were found in medication subgroups with few trials investigating a relatively low number of patients (cabergoline, pergolide), whereas studies with lower treatment effects such as in the medication subgroups ropinirole and pramipexole investigated a large number of patients and therefore are more likely to be representative. Notably, ergoline dopamine agonists, which were investigated in the earlier studies showing higher efficacy results, are considered today as third-line treatment because of the risk of cardiac valvular fibrosis. Only one study (<LINK REF="STD-Axxonis-2008" TYPE="STUDY">Axxonis 2008</LINK>) compared dopamine agonist substances directly. All other comparisons of medication subgroups are indirect and descriptive. The results show low to substantial heterogeneity both considering overall treatment effects and the medication subgroups. Thus, differences in treatment effects between medication subgroups observed by visual inspection of the forest plots should be considered as hypothesis generating and should be treated with caution. In future, direct head-to-head trials of dopamine agonists are needed.</P>
<P>Results on all endpoints showed small to moderate treatment effects which were precise in every endpoint.</P>
<P>Asymmetry in funnel plots of the IRLS (see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>) and PLMSI might be an indication of selective publication of studies with positive results. A closer inspection of the studies, however, shows that a number of small studies were conducted in &#8220;expert&#8221; study centres. These centres focus on clinical and experimental research on RLS and might, therefore, investigate a more severely affected patient population which shows the higher treatment effects. Varying effects between the medication subgroups, i.e. larger effects in cabergoline and lisuride with larger standard errors, also contribute to the skewed funnel plots. These factors put the seemingly skewed distribution of effects into perspective.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-11-30 14:00:52 +0000" MODIFIED_BY="[Empty name]">
<P>We made extensive efforts to prevent bias in the search for relevant trials and respective data as well as meta-analyses of included data; therefore, we assume that the potential biases in the review process are limited. We searched all relevant databases without language restrictions. The reviewers decided separately upon eligibility, collected data independently, and checked resulting data files as well as data directly contributing to meta-analyses, resolving disagreements and errors. When data had been insufficiently presented, we asked pharmaceutical companies and authors for more information in order to include all assessed questionnaires and instruments and information relevant to bias.</P>
<P>The presented work is independent from sponsoring of pharmaceutical companies, as it was supported by the German Ministry for Education and Research (Bundesministerium für Bildung und Forschung - BMBF, Project number DLR 01KG0723).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-30 14:03:57 +0000" MODIFIED_BY="[Empty name]">
<P>A recent meta-analysis included a considerable number of dopamine agonist studies and investigated effects on the IRLS and CGI-I (<LINK REF="REF-Zintzaras-2010" TYPE="REFERENCE">Zintzaras 2010</LINK>). Two other meta-analyses especially compared pramipexole to ropinirole on the IRLS and CGI-I (<LINK REF="REF-Baker-2008" TYPE="REFERENCE">Baker 2008</LINK>; <LINK REF="REF-Quilici-2008" TYPE="REFERENCE">Quilici 2008</LINK>). The meta-analysis results overlap with our results. Contrary to reported superiority of pramipexole over ropinirole, we could not find a marked difference between pramipexole and ropinirole. Confidence intervals overlapped to a great extent in our analysis (pramipexole: 95% CI &#8722;6.87 to &#8722;3.45 versus ropinirole: 95% CI &#8722;5.4 to &#8722;2.97). Possibly, the differences between effects become smaller due to the inclusion of a higher number of studies and of studies with longer duration.</P>
<P>One meta-analysis pooled results of individual patient data assessed in six ropinirole studies investigating sleep related data and found moderate changes regarding subjective sleep data, including daytime somnolence in favour of ropinirole compared to placebo (<LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>). These data are supported by our data, indicating modest changes in daytime somnolence represented by small effect sizes.</P>
<P>The presented results on quality of life instruments are similar to previous results of a meta-analysis evaluating pramipexole, ropinirole, and rotigotine (<LINK REF="REF-Talati-2009" TYPE="REFERENCE">Talati 2009</LINK>). Our findings, which include more detailed data provided by pharmaceutical companies and data on additional dopamine agonists, however, indicate slightly more pronounced effects compared to previous results (SMD of 0.34, 95% CI 0.23 to 0.44 versus SMD of 0.2, 95% CI 0.10 to 0.30; <LINK REF="REF-Talati-2009" TYPE="REFERENCE">Talati 2009</LINK>). </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-01-12 14:17:57 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-01-12 14:17:57 +0000" MODIFIED_BY="[Empty name]">
<P>This meta-analysis according to Cochrane criteria has been the first to comprehensively assess efficacy and safety of dopamine agonist treatment in an extended number of clinically relevant outcome parameters. Meta-analysis results show that all dopamine agonists except sumanirole are superior to placebo in the treatment of RLS. Therefore, the use of dopamine agonists can be recommended for the treatment of RLS. In the three studies with the active comparator levodopa, the dopamine agonists cabergoline, pergolide, and pramipexole showed superiority over levodopa in some, but not all outcomes.</P>
<P>The efficacy of three cabergoline and pergolide studies was the highest but has to be weighed against the known side effects such as fibrosis, especially cardiac valve fibrosis, which need to be monitored regularly. The non-ergoline dopamine agonists pramipexole, rotigotine, and ropinirole showed adequate efficacy. By inspecting the forest plots, the number of dropouts due to adverse events and the presence of adverse events were slightly higher in non-ergoline dopamine agonists.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-30 14:04:34 +0000" MODIFIED_BY="[Empty name]">
<P>Additional studies are needed in order to enhance the robustness of findings especially for those dopamine agonists (including cabergoline, pergolide, lisuride, and sumanirole) which have been investigated in only a few studies. Furthermore, there is a lack of large scale studies comparing efficacious dopamine agonist treatments directly against other dopamine agonists. Additionally, dopamine agonist treatments need to be compared to other treatment options like anticonvulsants and opioids. A major limitation of the majority of previous studies is the lack of identification of augmentation. Generally, long-term studies are needed in order to evaluate sustained efficacy as well as safety, especially regarding the development of augmentation over time.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-05-11 15:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>The presented work was supported by a grant from the German Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung - BMBF, grant number DLR 01KG0723) to MH. </P>
<P>We also thank Carolin Laux for supporting the project during data collection and data management.</P>
<P>We are grateful to Bruce Grant for language correction of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-11-30 14:05:56 +0000" MODIFIED_BY="[Empty name]">
<P>Hanna Scholz has no conflicts of interest to declare.</P>
<P>Claudia Trenkwalder has been an advisor for Boehringer Ingelheim, Cephalon, Mundipharm, Orion Pharma, Novartis, Solvay, Axxonis and UCB. She has received lecture honoraria from Boehringer Ingelheim, UCB, TEVA and AstraZeneca.</P>
<P>Ralf Kohnen received honoraria for advisory board membership from Pfizer, USA; Axxonis, Germany; Roche, Germany; UCB, Germany; Jazzpharma, USA.</P>
<P>Dieter Riemann received research support from DFG, BMBF, EU (public funding) and from Takeda, Sanofi-Aventis, Organon, Actelion and Omron. He was on the speakers bureau of Sanofi-Aventis, Takeda, Servier, Lundbeck, Boehringer Ingelheim, GSK, Cephalon and Merz Pharmaceuticals. He was also a member of advisory boards for Sanofi-Aventis, Lundbeck, GSK, Takeda and Actelion. Dr. Riemann declares that the above mentioned activities have no influence on the content of this article.</P>
<P>Levente Kriston has no conflicts of interest to declare.</P>
<P>Magdolna Hornyak received honoraria and/or lecture fees from Boehringer Ingelheim, Germany; GlaxoSmithKline, Germany; Roche, Germany; Pfizer Inc., Germany.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-11 15:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>MH: Performing previous work that was the foundation of the current review, conceiving the review, designing the review, coordinating the review, providing general advice on the review, securing funding for the review, screening of obtained publications regarding eligibility, appraising quality of papers, data collection for the review, writing to study authors for additional information, interpretation of data, writing the review, providing a clinical perspective, providing a policy perspective, providing a consumer perspective.</P>
<P>HS: Undertaking searches, screening search results, organizing retrieval of papers, screening retrieved publications regarding eligibility, appraising quality of papers, extracting data from papers, writing to study authors for additional information, obtaining and screening data on unpublished studies, data management for the review, entering data into RevMan, analysis of data, interpretation of data, writing the review, providing a methodological perspective.</P>
<P>CT: Performing previous work that was the foundation of the current review, coordinating the review, securing funding for the review, providing general advice on the review, interpretation of data, writing the review, providing a clinical perspective, providing a policy perspective, providing a consumer perspective.</P>
<P>RK: Performing previous work that was the foundation of the current review, conceiving the review, designing the review, coordinating the review, securing funding for the review, providing general advice on the review, providing additional data of included trials, interpretation of data, providing a methodological perspective.</P>
<P>LK: Conceiving the review, designing the review, providing general advice on the review, writing the protocol, designing search strategies, analysis of data, interpretation of data.</P>
<P>DR: Coordinating the review, securing funding for the review, providing general advice on the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-01-12 13:13:31 +0000" MODIFIED_BY="[Empty name]">
<P>Two outcomes defined in the protocol were specified in detail, three outcomes were added and one outcome parameter was dropped after discussion in the light of actual research before search for publications.</P>
<P>PLMS-Index and number of patients dropping out due to adverse events were defined as primary and not as secondary outcome parameters. Sleep efficiency assessed in polysomnography was appended as primary outcome.</P>
<P>We added questionnaires assessing self and clinician rated general improvement (PGI and CGI-I) in the secondary outcome section. We excluded the planned outcome patient satisfaction with treatment as the number of RLS trials investigating this parameter was very low.</P>
<P>We investigated not only the first phase of cross-over trials, but included both phases of cross-over trials and partly corrected statistically for the different design (see <LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 16.4).</P>
<P>We included search dates from 1985 (instead of 1995) to 2009 in order to obtain all possibly relevant trials. The only relevant study published before 1995 (<LINK REF="REF-Walters-1988" TYPE="REFERENCE">Walters 1988</LINK>), however, could not be included in the meta-analysis due to the predefined exclusion criteria.</P>
<P>We conducted additional searches in online trial registers provided by pharmaceutical companies, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the U.S. National Institutes for Health.</P>
<P>Instead of implementing fixed-effect models where data were homogeneous, we performed all meta-analyses using random-effects models as recommended by the Reviewer's Handbook.</P>
<P>We did not conduct subgroup analyses but separate meta-analyses on efficacy of dopamine agonist treatment compared to other active treatments. The influence of treatment duration was assessed in additional meta-regressions instead of subgroup analysis. Furthermore, meta-regressions of the influence of number of investigating sites and baseline IRLS score on IRLS treatment effect were performed.</P>
<P>Due to the study designs of the included trials (flexible dosing regimen, mostly similar dosing), it was not possible to investigate influence of different dosages on treatment effect.</P>
<P>As we performed subgroup analyses by comparing studies at low risk of bias and studies at moderate risk of bias, sensitivity analyses were considered as redundant and were not performed as described in the protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-12-06 14:09:45 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-12-06 14:09:45 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-12-06 14:09:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-2004" MODIFIED="2009-02-18 14:00:28 +0000" MODIFIED_BY="[Empty name]" NAME="Adler 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 14:00:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, et al</AU>
<TI>Ropinirole for restless legs syndrome: a placebo-controlled crossover trial</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>8</NO>
<PG>1405-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Allen-2004" MODIFIED="2010-11-30 14:32:35 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-30 14:32:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, et al</AU>
<TI>Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome</TI>
<SO>Sleep: Journal of Sleep and Sleep Disorders Research</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>5</NO>
<PG>907-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:04:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SKF-101468/191</AU>
<TI>A 12 week, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of ropinirole in subjects with restless legs syndrome (RLS) suffering from periodic leg movements of sleep (PLMS)</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f191&amp;studyId=2514&amp;compound=Ropinirole</SO>
<YR>(accessed 15 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Axxonis-2005" MODIFIED="2010-04-13 10:33:08 +0100" MODIFIED_BY="[Empty name]" NAME="Axxonis 2005" YEAR="2005a">
<REFERENCE MODIFIED="2010-01-27 16:32:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benes H on behalf of the TULIR study group</AU>
<TI>Transdermal lisuride in patients with idiopathic restless legs syndrome: results from a placebo-controlled, double-blind, randomized, multicenter, 12-week dose-finding study</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>S2</NO>
<PG>S156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Axxonis-2008" MODIFIED="2010-05-05 14:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Axxonis 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-05 14:06:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benes H, Kohnen R</AU>
<TI>Transdermal lisuride in patients with severe restless legs syndrome: results from a placebo- and ropinirole-controlled, double-blind, randomized, multicenter, 12-week efficacy and tolerability study</TI>
<SO>Sleep</SO>
<YR>2008</YR>
<VL>31 Abstract Suppl</VL>
<PG>A266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Benes-2010" MODIFIED="2010-12-06 14:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="Benes 2010" YEAR="2009">
<REFERENCE MODIFIED="2010-12-06 14:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Benes H, Mattern W, Peglau I, Dreykluft T, Bergmann L, Hansen C, et al. on behalf of the ROAD-RLS study group</AU>
<TI>Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomised, placebo-controlled study</TI>
<SO>Journal of Neurology</SO>
<YR>revision submitted</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:08:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>RRL 106721</AU>
<TI>A multi-center, randomized, placebo-controlled, double-blind phase IIIb study of the effects of ropinirole on mood and (sub-clinical) depression in the therapy of patients with moderate and severe idiopathic restless legs syndrome</TI>
<SO>http://www.gsk-clinicalstudyregister.com/files/pdf/21025.pdf</SO>
<YR>(accessed 12 June 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-BI-2006" MODIFIED="2010-11-30 14:34:12 +0000" MODIFIED_BY="[Empty name]" NAME="BI 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-30 14:34:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.518</AU>
<TI>A double-blind, randomised, crossover trial investigating the efficacy and safety of the dopamine agonist pramipexole (Sifrol®, 0.25-0.75 mg per day) versus levodopa / benserazide (Madopar® DR, 125-375 mg per day) in patients with restless legs syndrome</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.518_U08-2249_upload.pdf</SO>
<YR>(accessed 16 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 13:51:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathis J, Bassetti C</AU>
<TI>Comparison of pramipexole (PPX) versus levodopa/benserazide (L/B) in the treatment of restless legs syndrome (RLS): A double blind, randomized, Swiss multi-centre crossover trial</TI>
<SO>Movement Disorders</SO>
<YR>2006</YR>
<VL>21 Suppl 15</VL>
<PG>S442</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-BI-2008" MODIFIED="2010-05-05 14:08:05 +0100" MODIFIED_BY="[Empty name]" NAME="BI 2008" YEAR="">
<REFERENCE MODIFIED="2010-05-05 14:08:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.616</AU>
<TI>A Phase IV randomised, double-blind, active and placebo-controlled, 6-week trial to investigate the efficacy and safety of a starting (and fixed) dose 0.25 mg pramipexole (Mirapex®) in patients with idiopathic Restless Legs Syndrome</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.616_U08-3876_upload19194.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-BI-2009" MODIFIED="2010-11-30 14:34:34 +0000" MODIFIED_BY="[Empty name]" NAME="BI 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-05 14:08:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.629</AU>
<TI>A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerability in patients with idiopathic moderate to severe Restless Legs Syndrome for 26 weeks</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.629_U09-1047.pdf</SO>
<YR>(accessed 4 December 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:34:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Högl B, Poewe W, Garcia-Borreguero D, Ferini-Strambi L, Trenkwalder C</AU>
<TI>26-week effects of pramipexole on quality of life in restless legs syndrome</TI>
<SO>Presented at The Movement Disorder Society&#8217;s13th Annual International Congress of Parkinson&#8217;s Disease and Movement Disorders; 2009 June 7&#8211;11; Paris</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:21:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Högl B</AU>
<TI>Efficacy and safety of pramipexole for restless legs syndrome: a 26-week, randomized, placebo-controlled, clinical trial in the European Union</TI>
<SO>AAN Congress; 2009 May 25-June 2, Seattle</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bogan-2006" MODIFIED="2010-11-30 14:35:21 +0000" MODIFIED_BY="[Empty name]" NAME="Bogan 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-08 09:50:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY, Group TRUS</AU>
<TI>Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>1</NO>
<PG>17-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:35:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SKF-101468/249</AU>
<TI>A 12 week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of ropinirole in patients suffering from restless legs syndrome (RLS)</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f249&amp;studyId=19934&amp;compound=Ropinirole</SO>
<YR>(accessed 4 February 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Earley-1998" MODIFIED="2010-03-24 09:34:51 +0000" MODIFIED_BY="[Empty name]" NAME="Earley 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-18 14:00:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Earley CJ, Yaffee JB, Allen RP</AU>
<TI>Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>6</NO>
<PG>1599-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Ferini_x002d_Strambi-2008" MODIFIED="2010-03-24 09:35:13 +0000" MODIFIED_BY="[Empty name]" NAME="Ferini-Strambi 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-04-08 08:25:02 +0100" MODIFIED_BY="[Empty name]" NOTES="English" NOTES_MODIFIED="2009-04-08 08:25:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D, et al</AU>
<TI>Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Sleep Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>8</NO>
<PG>874-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Borreguero-2007" MODIFIED="2009-02-18 14:30:11 +0000" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-18 14:30:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, et al</AU>
<TI>Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study</TI>
<SO>Sleep Medicine</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>2</NO>
<PG>119-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GSK-2005" MODIFIED="2010-11-30 14:35:51 +0000" MODIFIED_BY="[Empty name]" NAME="GSK 2005" YEAR="">
<REFERENCE MODIFIED="2009-04-17 13:53:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly M, Mistry P</AU>
<TI>Tolerability of a forced-dose escalating regimen of ropinirole in patients with RLS</TI>
<SO>Movement Disorders</SO>
<YR>2005</YR>
<VL>20 Suppl 10</VL>
<PG>S63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:35:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>SKF-101468/207</AU>
<TI>A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS)</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f207&amp;studyId=2523&amp;compound=Ropinirole</SO>
<YR>(accessed 12 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GSK-2006" MODIFIED="2010-05-05 14:22:27 +0100" MODIFIED_BY="[Empty name]" NAME="GSK 2006" YEAR="1892">
<REFERENCE MODIFIED="2010-05-05 14:22:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ROP 101892</AU>
<TI>A 12-week, double-blind, placebo-controlled, parallel-group study to assess the effectiveness of ropinirole in patients willing to take regular medication for their restless legs syndrome in a primary care setting</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101892&amp;studyId=23627&amp;compound=Ropinirole</SO>
<YR>(accessed 12 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GSK-2007" MODIFIED="2010-05-05 14:22:44 +0100" MODIFIED_BY="[Empty name]" NAME="GSK 2007" YEAR="">
<REFERENCE MODIFIED="2009-12-04 12:00:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becker P, Bogan R, Earl N</AU>
<TI>Ropinirole CR - a novel extended-release formulation - demonstrates onset of symptom improvement from the first night of treatment in patients with moderate-to-severe primary restless legs syndrome</TI>
<SO>Sleep</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>Abstract Suppl</NO>
<PG>A282</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:22:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>SKF-101468/205</AU>
<TI>A 12-week, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of ropinirole controlled release for RLS (CR-RLS) in patients with restless legs syndrome</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f205&amp;studyId=19930&amp;compound=Ropinirole</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GSK-2008" MODIFIED="2010-11-30 14:36:11 +0000" MODIFIED_BY="[Empty name]" NAME="GSK 2008" YEAR="3660">
<REFERENCE MODIFIED="2010-11-30 14:36:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>RRL 103660</AU>
<TI>A 12-week, multi-center, double-blind, placebo-controlled, parallel-group, flexible dose polysomnography study of ropinirole controlled release for restless legs syndrome (CR-RLS) in RLS patients with sleep disturbance and periodic limb movements (PLM) during sleep</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=RRL103660&amp;studyId=21024&amp;compound=Ropinirole</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GSK-2009" MODIFIED="2010-05-05 14:23:07 +0100" MODIFIED_BY="[Empty name]" NAME="GSK 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-05 14:23:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ROR 104836</AU>
<TI>A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe restless legs syndrome</TI>
<SO>http://www.gsk-clinicalstudyregister.com/files/pdf/21020.pdf</SO>
<YR>(accessed 4 November 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hening-2010" MODIFIED="2010-12-06 09:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Hening 2010" YEAR="">
<REFERENCE MODIFIED="2010-12-06 09:07:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, et al; the SP792 Study Group.</AU>
<TI>Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.</TI>
<SO>Movement Disorders</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1675-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:49:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SP792</AU>
<TI>A multicenter, randomized, double-blind, placebo-controlled, 5-arm parallel-group trial to investigate theefficacy and safety of 4 different transdermal doses of rotigotine in subjects with idiopathic restless legs syndrome</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00135993</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Inoue-2010" MODIFIED="2010-11-30 14:38:20 +0000" MODIFIED_BY="[Empty name]" NAME="Inoue 2010" YEAR="">
<REFERENCE MODIFIED="2010-05-05 14:23:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.557</AU>
<TI>A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of pramipexole with the dose range from 0.125 mg to 0.75 mg orally once daily for 6 weeks in patients with primary restless legs syndrome</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.557_U06-3385_new.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:38:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue Y, Fujita M, Shimizu T, Emura N, Kuroda K, Uchimura N</AU>
<TI>Efficacy and safety of pramipexole in Japanese patients with restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>2006</YR>
<VL>21 Suppl 15</VL>
<PG>S442</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-14 15:40:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue Y, Hirata K, Kuroda K, Fujita M, Shimizu T, Emura N, et al</AU>
<TI>Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study</TI>
<SO>Sleep Medicine</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>11-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kushida-2008" MODIFIED="2010-05-05 14:23:32 +0100" MODIFIED_BY="[Empty name]" NAME="Kushida 2008" YEAR="0013">
<REFERENCE MODIFIED="2010-04-29 11:54:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kushida CA, Geyer J, Tolson JM, Asgharian A</AU>
<TI>Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>5</NO>
<PG>281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:23:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>RRL 100013</AU>
<TI>A 12-week, double-blind, placebo-controlled, twice-daily dosing study to assess the efficacy and safety of ropinirole in patients suffering from restless legs syndrome (RLS) requiring extended treatment coverage</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=100013&amp;studyId=23628&amp;compound=Ropinirole</SO>
<YR>(accessed 12 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Montagna-2010" MODIFIED="2010-11-30 14:42:59 +0000" MODIFIED_BY="[Empty name]" NAME="Montagna 2010" YEAR="2008">
<REFERENCE MODIFIED="2010-05-05 14:23:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.604</AU>
<TI>A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole (Sifrol®, Mirapexin®) orally for 12 weeks to investigate the safety and efficacy in out-patients with idiopathic Restless Legs Syndrome associated with mood disturbances</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.604_U07-2329upload_new19148.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 08:44:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Montagna P, Ulfberg J, Hong S, Koester J, Crespi G</AU>
<TI>Treatment of daytime RLS symptoms with pramipexole in patients with mood disturbance</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>11 Suppl 1</NO>
<PG>A293 [P05.167]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:42:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Montagna P, Hornyak M, Ulfberg J, Bong Hong S, Koester J, Crespi G, et al</AU>
<TI>Randomized trial of pramipexole for patients with restless legs syndrome and mood disturbance</TI>
<SO>Sleep Medicine</SO>
<YR>in press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 08:47:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montagna P, Hornyak M, Ulfberg J, Hong S, Koester J, Crespi G</AU>
<TI>Pramipexole for the treatment of RLS and associated depressive symptoms</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>11 Suppl 1</NO>
<PG>A294 [P085.173]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:41:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montagna P, Hornyak M, Ulfberg J, Hong S, Koester J, Crespi G</AU>
<TI>Rapid onset of action and sustained efficacy of pramipexole in RLS patients with mood disturbance</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>11 Suppl 1</NO>
<PG>A292-3 [P05.166]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-11 11:36:03 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montplaisir-1999" MODIFIED="2009-04-07 16:16:46 +0100" MODIFIED_BY="[Empty name]" NAME="Montplaisir 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-07 16:16:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B</AU>
<TI>Restless legs syndrome improved by pramipexole: a double-blind randomized trial</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>5</NO>
<PG>938-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Oertel-2006" MODIFIED="2010-11-30 14:44:07 +0000" MODIFIED_BY="[Empty name]" NAME="Oertel 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-30 14:43:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>CABAS-0067-033</AU>
<TI>A double-blind, randomized, placebo-controlled multi-center efficacy study for the treatment of patients with Restless Legs Syndrome (RLS)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00627003</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:44:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oertel WH, Benes H, Bodenschatz R, Peglau I, Warmuth R, Happe S, et al</AU>
<TI>Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR)</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>6</NO>
<PG>1040-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Oertel-2007" MODIFIED="2010-05-05 14:24:18 +0100" MODIFIED_BY="[Empty name]" NAME="Oertel 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-05 14:24:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.520</AU>
<TI>A randomised, double-blind, placebo-controlled dose titration trial with 0.125-0.75 mg pramipexole (Sifrol®) orally to investigate the safety and efficacy in out-patients with idiopathic Restless Legs Syndrome for 6 weeks followed by 46 weeks open-label or double-blind treatment period</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.520__U05-1394-01_new.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-29 11:55:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oertel WH, Stiasny-Kolster K, Bertholdt B, Hallström Y, Albo J, Leissner L, et al. for The Pramipexole RLS Study Group</AU>
<TI>Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)</TI>
<SO>Movement Disorders: Official Journal of the Movement Disorder Society</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>2</NO>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Oertel-2008" MODIFIED="2010-11-30 14:44:53 +0000" MODIFIED_BY="[Empty name]" NAME="Oertel 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-04-08 10:50:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, et al</AU>
<TI>Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe</TI>
<SO>Sleep Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>3</NO>
<PG>228-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:44:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SP709</AU>
<TI>Multi-center, double-blind, randomized, placebo-controlled, six-arm, parallel-group, dose-finding trial to determine efficacy, safety and tolerability of five different transdermal doses of rotigotine in subjects with idiopathic restless legs syndrome</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00243217</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Oertel-2010" MODIFIED="2010-12-06 09:14:34 +0000" MODIFIED_BY="[Empty name]" NAME="Oertel 2010" YEAR="">
<REFERENCE MODIFIED="2010-12-06 09:14:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oertel W, Benes H, Garcia-Borreguero D, Hoegl B, Poewe W, Montagna P, et al</AU>
<TI>Rotigotine transdermal patch in idiopathic restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>9</NO>
<PG>848-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-30 14:45:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SP794</AU>
<TI>A multicenter, double-blind, randomized, placebo-controlled, two-arm, parallel-group, sleep lab trial to investigate the efficacy and safety of transdermal rotigotine in subjects with idiopathic restless legs syndrome</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00275236</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Partinen-2006" MODIFIED="2010-05-05 14:25:01 +0100" MODIFIED_BY="[Empty name]" NAME="Partinen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-05 14:25:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.515</AU>
<TI>A double-blind, placebo-controlled dose-finding study to investigate efficacy and safety of different doses (0.125, 0.25, 0.5, 0.75 mg) of pramipexole administered once daily orally over three weeks in patients with idiopathic restless legs syndrome (RLS), followed by a 26-week open-label dose-finding study (0.125 mg &#8211; 0.75 mg) to investigate long-term efficacy of pramipexole in patients with RLS</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.515_U04-2112_new.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-24 09:41:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, et al</AU>
<TI>Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>5</NO>
<PG>407-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pieta-1998" MODIFIED="2010-11-30 14:45:31 +0000" MODIFIED_BY="[Empty name]" NAME="Pieta 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-30 14:45:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pieta J, Millar T, Zacharias J, Fine A, Kryger M</AU>
<TI>Effect of pergolide on restless legs and leg movements in sleep in uremic patients</TI>
<SO>Sleep</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>617-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staedt-1997" MODIFIED="2009-09-24 08:42:46 +0100" MODIFIED_BY="[Empty name]" NAME="Staedt 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-09-24 08:42:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staedt J, Wassmuth F, Ziemann U, Hajak G, Ruther E, Stoppe G</AU>
<TI>Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>4-5</NO>
<PG>461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stiasny_x002d_Kolster-2004a" MODIFIED="2010-03-24 09:36:53 +0000" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 14:00:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster K, Benes H, Peglau I, Hornyak M, Holinka B, Wessel K, et al</AU>
<TI>Effective cabergoline treatment in idiopathic restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>12</NO>
<PG>2272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stiasny_x002d_Kolster-2004b" MODIFIED="2010-03-24 09:36:59 +0000" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 14:32:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH, Rotigotine Sp 666 Study G</AU>
<TI>Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study</TI>
<SO>Movement Disorders</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1432-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2004a" MODIFIED="2009-04-08 09:10:06 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 14:32:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Hundemer HP, Lledo A, Swieca J, Polo O, Wetter TC, et al</AU>
<TI>Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>8</NO>
<PG>1391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Trenkwalder-2004b" MODIFIED="2010-11-30 14:45:48 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-11-30 14:45:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SKF-101468/190</AU>
<TI>A 12 week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of ropinirole in patients suffering from restless legs syndrome (RLS)</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f190&amp;studyId=2480&amp;compound=Ropinirole</SO>
<YR>(accessed 15 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 09:36:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P, et al</AU>
<TI>Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Trenkwalder-2007" MODIFIED="2010-11-30 14:46:15 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-30 14:46:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>CABAS-0067-031</AU>
<TI>A double-blind, randomized, active-controlled multicenter efficacy trial for the treatment of patients with Restless Legs Syndrome (RLS)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00625547</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 10:46:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Benes H, Grote L, Happe S, Hogl B, Mathis J, et al</AU>
<TI>Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>85</NO>
<PG>696-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Trenkwalder-2008" MODIFIED="2010-11-30 14:48:20 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-30 14:48:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SP790</AU>
<TI>A multi-center, randomized, double-blind, placebo-controlled, four-arm parallel-group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with idiopathic restless legs syndrome</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00136045</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 10:52:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW, et al</AU>
<TI>Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.[see comment]</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>7</NO>
<PG>595-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Walters-2004" MODIFIED="2010-05-05 14:26:30 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-05-05 14:26:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SKF-101468/194</AU>
<TI>A 12 week, double.blind, placebo-controlled, parallel group study to assess the efficacy and safety of ropinirole in patients suffering from restless legs syndrome (RLS).</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f194&amp;studyId=2363&amp;compound=Ropinirole</SO>
<YR>(accessed 15 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 09:42:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K, et al</AU>
<TI>Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study</TI>
<SO>Movement Disorders</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1414-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetter-1999" MODIFIED="2009-02-18 14:34:33 +0000" MODIFIED_BY="[Empty name]" NAME="Wetter 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-18 14:34:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T, et al</AU>
<TI>A randomized controlled study of pergolide in patients with restless legs syndrome.[see comment]</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>5</NO>
<PG>944-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Winkelman-2006" MODIFIED="2010-05-05 14:26:51 +0100" MODIFIED_BY="[Empty name]" NAME="Winkelman 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-05 14:26:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>248.543</AU>
<TI>A randomized, double-blind, placebo-controlled, parallel group clinical trial comparing fixed doses of 0.25 mg, 0.50 mg and 0.75 mg pramipexole (Mirapex®) administered orally to investigate the safety and efficacy in patients with idiopathic restless legs syndrome for 12 weeks</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.543_U05-3094_new.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-24 09:41:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, et al</AU>
<TI>Efficacy and safety of pramipexole in restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>6</NO>
<PG>1034-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-30 14:54:37 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abetz-2005" MODIFIED="2009-02-18 14:35:01 +0000" MODIFIED_BY="[Empty name]" NAME="Abetz 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-18 14:35:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abetz L, Arbuckle R, Allen RP, Mavraki E, Kirsch J</AU>
<TI>The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population</TI>
<SO>Health &amp; Quality of Life Outcomes</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abetz-2006" MODIFIED="2009-02-18 14:35:31 +0000" MODIFIED_BY="[Empty name]" NAME="Abetz 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-18 14:35:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abetz L, Arbuckle R, Allen RP, Garcia-Borreguero D, Hening W, Walters AS, et al</AU>
<TI>The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>4</NO>
<PG>340-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1998" MODIFIED="2010-04-13 10:53:07 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-13 10:53:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ, Hening WA, Walters AS, Yaffee J, Wagner ML</AU>
<TI>Pergolide treatment of the restless legs syndrome: a double-blind placebo-controlled study with objective assessment of leg movements</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>4 Suppl 4</NO>
<PG>A68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2006" MODIFIED="2009-02-18 14:35:54 +0000" MODIFIED_BY="[Empty name]" NAME="Anonymous 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-18 14:35:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Ropinirole: new indication. Restless legs: disproportionate adverse effects</TI>
<SO>Prescrire International</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>85</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benes-2005" MODIFIED="2010-05-05 14:27:19 +0100" MODIFIED_BY="[Empty name]" NAME="Benes 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-05 14:27:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benes H</AU>
<TI>Transdermal lisuride in patients with idiopathic restless legs syndrome: results from a placebo controlled double blind randomized multicenter 12 week dose-finding study</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6 Suppl 2</VL>
<PG>S136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benes-2006" MODIFIED="2009-04-17 12:47:09 +0100" MODIFIED_BY="[Empty name]" NAME="Benes 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-17 12:47:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benes H</AU>
<TI>Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benes-2006a" MODIFIED="2009-02-18 14:36:17 +0000" MODIFIED_BY="[Empty name]" NAME="Benes 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-02-18 14:36:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benes H, Deissler A, Rodenbeck A, Engfer A, Kohnen R</AU>
<TI>Lisuride treatment of restless legs syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>1</NO>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bingham-2002" MODIFIED="2010-11-30 14:49:33 +0000" MODIFIED_BY="[Empty name]" NAME="Bingham 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-30 14:49:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pergolide for restless legs in Uraemia1.2 excluded 1 excluded. not publishedper&lt;/p&gt;" NOTES_MODIFIED="2010-11-30 14:49:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bingham C</AU>
<TI>Pergolide for restless legs in uraemia</TI>
<SO>National Research Register, UK [http://www.nrr.nhs.uk/]</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bliwise-2005" MODIFIED="2009-04-17 12:47:13 +0100" MODIFIED_BY="[Empty name]" NAME="Bliwise 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-17 12:47:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL</AU>
<TI>Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebell-1999" MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="Ebell 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebell M</AU>
<TI>Is pergolide effective in the short-term treatment of restless leg syndrome (RLS)?</TI>
<SO>Evidence-Based Practice</SO>
<YR>1999</YR>
<VL>2</VL>
<NO>4</NO>
<PG>5, insert 2p</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-2001" MODIFIED="2010-11-30 14:50:10 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-30 14:50:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ropinirole for Restless Legs Syndrome (RLS): An Open Label and Double Blind Placebo-Controlled Study1.2 excluded 1 excluded. openlabelrop&lt;/p&gt;" NOTES_MODIFIED="2010-11-30 14:50:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman A, Rye DB, Bliwise D, Chakravorty S, Krulewicz S, Watts RL</AU>
<TI>Ropinirole for Restless Legs Syndrome (RLS): An open label and double blind placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>8 Suppl 3</NO>
<PG>A5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunning-1999" MODIFIED="2010-04-13 10:37:09 +0100" MODIFIED_BY="[Empty name]" NAME="Gunning 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-13 10:37:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Treatment of restless leg syndrome with pergolidemed&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:37:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunning K, Gay C</AU>
<TI>Treatment of restless leg syndrome with pergolide</TI>
<SO>Journal of Family Practice</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>4</NO>
<PG>250</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinge-2005" MODIFIED="2010-04-13 10:54:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kinge 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-13 10:54:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[Ropinirole treatment of restless legs].[see comment]. [Danish]rop&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:54:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinge E, Lossius M I, Mowincel P</AU>
<TI>[Ropinirole treatment of restless legs] [Danish]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2005</YR>
<VL>167</VL>
<NO>11</NO>
<PG>1284-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manconi-2003" MODIFIED="2010-04-13 10:39:49 +0100" MODIFIED_BY="[Empty name]" NAME="Manconi 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-04-13 10:39:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pramipexole in Restless Legs syndrome. Evaluation by suggested immobilization test1.2 excluded 1 excluded. open designResearch Support, Non-U.S&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:39:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manconi M, Casetta I, Govoni V, Cesnik E, Ferini-Strambi L, Granieri E</AU>
<TI>Pramipexole in Restless Legs syndrome. Evaluation by suggested immobilization test</TI>
<SO>Journal of Neurology</SO>
<YR>2003</YR>
<VL>250</VL>
<NO>12</NO>
<PG>1494-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miranda-2003" MODIFIED="2010-05-05 14:30:16 +0100" MODIFIED_BY="[Empty name]" NAME="Miranda 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-05 14:30:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[Treatment of restless legs syndrome in uremic patients undergoing dialysis with pramipexole: preliminary results]. [Spanish]1.2 excluded 1 excluded. open design no controlResearch Support, Non-U.S&lt;/p&gt;" NOTES_MODIFIED="2010-05-05 14:30:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miranda M, Fabres L, Kagi M, Aguilera L, Alvo M, Elgueta L, et al</AU>
<TI>[Treatment of restless legs syndrome in uremic patients undergoing dialysis with pramipexole: preliminary results]. [Spanish]</TI>
<SO>Revista Medica de Chile</SO>
<YR>2003</YR>
<VL>131</VL>
<NO>6</NO>
<PG>700-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miranda-2004" MODIFIED="2009-02-18 14:36:36 +0000" MODIFIED_BY="[Empty name]" NAME="Miranda 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 14:36:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miranda M, Kagi M, Fabres L, Aguilera L, Alvo M, Elgueta L, et al</AU>
<TI>Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>5</NO>
<PG>831-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montplaisir-1998" MODIFIED="2010-04-13 10:42:24 +0100" MODIFIED_BY="[Empty name]" NAME="Montplaisir 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-13 10:42:24 +0100" MODIFIED_BY="[Empty name]" NOTES="central" NOTES_MODIFIED="2010-04-13 10:42:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B</AU>
<TI>Pramipexole alleviates sensory and motor symptoms of restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>1</NO>
<PG>311-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montplaisir-2006" MODIFIED="2010-05-05 14:32:13 +0100" MODIFIED_BY="[Empty name]" NAME="Montplaisir 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-05 14:30:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>101468/188</AU>
<TI>A study of the maintained efficacy and safety of ropinirole versus placebo in the long term treatment of restless legs syndrome (RLS)</TI>
<SO>http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101468%2f188&amp;studyId=2482&amp;compound=Ropinirole</SO>
<YR>(accessed 15 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:32:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montplaisir J, Karrasch J, Haan J, Volc D</AU>
<TI>Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial</TI>
<SO>Movement Disorders</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1627-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-2008" MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="Morgan 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan JC, Ames M, Sethi KD</AU>
<TI>Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2008</YR>
<VL>79</VL>
<NO>8</NO>
<PG>964-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-1998" MODIFIED="2010-04-29 11:57:32 +0100" MODIFIED_BY="[Empty name]" NAME="Noel 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-29 11:57:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel S, Korri H, Vanderheyden JE</AU>
<TI>Low dosage of pergolide in the treatment of restless legs syndrome</TI>
<SO>Acta Neurologica Belgica</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>1</NO>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oertel-2005" MODIFIED="2010-05-05 14:30:53 +0100" MODIFIED_BY="[Empty name]" NAME="Oertel 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-05 14:30:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oertel WH, Benes H, Geisler P, Eisensehr I, Garcia-Borreguero D, Clarencach P, et al</AU>
<TI>Rotigotine patch efficacy and safety in the treatment of severe idiopathic restless legs syndrome results from a multinational double blind placebo controlled multi center dose finding study</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6 Suppl 2</VL>
<PG>S159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Partinen-2006a" MODIFIED="2010-11-30 14:51:19 +0000" MODIFIED_BY="[Empty name]" NAME="Partinen 2006a" YEAR="2006">
<REFERENCE MODIFIED="2010-11-30 14:51:19 +0000" MODIFIED_BY="[Empty name]" NOTES="central" NOTES_MODIFIED="2010-11-30 14:51:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Partinen M, Hirvonen K, Jama L, Alakuijala A, Hubin C, Tamminen I, et al</AU>
<TI>Effects of pramipexole on periodic limb movements (PLMs) in restless legs syndrome (RLS) a polysomnographic study</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>S126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Partinen-2006b" MODIFIED="2010-11-30 14:51:34 +0000" MODIFIED_BY="[Empty name]" NAME="Partinen 2006b" YEAR="2006">
<REFERENCE MODIFIED="2010-11-30 14:51:34 +0000" MODIFIED_BY="[Empty name]" NOTES="central" NOTES_MODIFIED="2010-11-30 14:51:34 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, et al</AU>
<TI>Clinician ratings and patient self-ratings of improvement after 3 weeks of double-blind placebo-controlled pramipexole for restless legs syndrome (RLS)</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>S126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penzel-2002" MODIFIED="2010-11-30 14:52:01 +0000" MODIFIED_BY="[Empty name]" NAME="Penzel 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-30 14:52:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AprA new design of a polysomnography-based multi-center treatment study for the restless legs syndrome1.2 excluded 1 excluded. open no controlper&lt;/p&gt;" NOTES_MODIFIED="2010-11-30 14:52:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penzel T, Brandenburg U, Peter JH, Otto R, Hundemer HP, Lledo A, et al for the PEARLS Study Group</AU>
<TI>A new design of a polysomnography-based multi-center treatment study for the restless legs syndrome</TI>
<SO>Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology</SO>
<YR>2002</YR>
<VL>113</VL>
<NO>4</NO>
<PG>571-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plowman-2005" MODIFIED="2010-04-13 10:59:29 +0100" MODIFIED_BY="[Empty name]" NAME="Plowman 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-13 10:59:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical consultation. Sleep attacks in patients receiving dopamine-receptor agonistsAccession Number: 2009080170. Language: English. Entry Date: 20060120. Publication Type: journal article; review. Journal Subset: Biomedical; Blind Peer Reviewed; Online/Print; Peer Reviewed; USA. No. of Refs: 17 ref. NLM UID: 9503023. Email: brian.plowman@med.va.gov.&lt;br&gt;PMID: 15745920&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:59:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plowman BK, Boggie DT, Morreale AP, Schaefer MG, DeLattre ML, Chan H</AU>
<TI>Clinical consultation. Sleep attacks in patients receiving dopamine-receptor agonists</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>5</NO>
<PG>537-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powell-2007" MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="Powell 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-18 14:05:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell D</AU>
<TI>Advance reports. Patch for Parkinson's disease improves restless legs syndrome</TI>
<SO>Geriatric Medicine</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>2</NO>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reading-2007" MODIFIED="2010-04-13 08:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Reading 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-13 08:59:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Parasomnias: the spectrum of things that go bump in the nightAccession Number: 2009525024. Language: English. Entry Date: 20070406. Publication Type: journal article; pictorial; review; tables/charts; tracings. Journal Subset: Biomedical; Online/Print; UK &amp;amp; Ireland. Special Interest: Perioperative Care; Psychiatry/Psychology. No. of Refs: 26 ref. NLM UID: 101130961. Email: paul.reading@stees.nhs.uk.&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 08:59:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reading P</AU>
<TI>Parasomnias: the spectrum of things that go bump in the night</TI>
<SO>Practical Neurology</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>1</NO>
<PG>6-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuter-1999" MODIFIED="2010-04-13 10:47:55 +0100" MODIFIED_BY="[Empty name]" NAME="Reuter 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-13 10:47:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndromeAccession Number: 1999-03958-003. First Author &amp;amp; Affiliation: Reuter, I.; King's College Hosp, Regional Neuroscience Ctr, Autonomic &amp;amp; Movement Disorder Unit, London, England. Other Journal Title: Acta Neurologica Scandinavica. Other Publishers: Wiley-Blackwell Publishing Ltd.. Release Date: 19991101. Publication Type: Journal, (0100) Peer Reviewed Journal, (0110). Media Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Apomorphine; Drug Therapy; Parkinsons Disease; Sleep Disorders; Syndromes. Minor Descriptor: Restless Leg Syndrome. Classification: Clinical Psychopharmacology (3340) . Population: Human (10) . Age Group: Adulthood (18 yrs &amp;amp; older) (300) Middle Age (40-64 yrs) (360) Aged (65 yrs &amp;amp; older) (380) . Methodology: Empirical Studypsyc&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:47:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuter I, Ellis CM, Chaudhuri KR</AU>
<TI>Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>3</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staedt-1998" MODIFIED="2009-02-18 14:37:24 +0000" MODIFIED_BY="[Empty name]" NAME="Staedt 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-18 14:37:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staedt J, Hunerjager H, Ruther E, Stoppe G</AU>
<TI>Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>2-3</NO>
<PG>265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiasny-2000" MODIFIED="2010-04-13 10:48:36 +0100" MODIFIED_BY="[Empty name]" NAME="Stiasny 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-04-13 10:48:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Safety of pramipexole in patients with restless legs syndromemed&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 10:48:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny K, Moller JC, Oertel WH</AU>
<TI>Safety of pramipexole in patients with restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>10</NO>
<PG>1589-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiasny-2001" MODIFIED="2009-02-18 14:37:00 +0000" MODIFIED_BY="[Empty name]" NAME="Stiasny 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-18 14:37:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny K, Wetter TC, Winkelmann J, Brandenburg U, Penzel T, Rubin M, et al</AU>
<TI>Long-term effects of pergolide in the treatment of restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>10</NO>
<PG>1399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiasny-2002" MODIFIED="2010-04-29 11:59:05 +0100" MODIFIED_BY="[Empty name]" NAME="Stiasny 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-04-29 11:59:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cabergoline in restless legs syndrome (RLS) - a double-blind placebo-controlled multicenter dose-finding trial1.2 excluded 1 excluded. published in ...cab&lt;/p&gt;" NOTES_MODIFIED="2010-04-29 11:59:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny K, Uberall M, Oertel WH</AU>
<TI>Cabergoline in restless legs syndrome (RLS) - a double-blind placebo-controlled multicenter dose-finding trial</TI>
<SO>European Journal of Neurology</SO>
<YR>2002</YR>
<VL>9 Suppl 2</VL>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tagaya-2002" MODIFIED="2010-11-30 14:53:44 +0000" MODIFIED_BY="[Empty name]" NAME="Tagaya 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-30 14:53:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pergolide restores sleep maintenance but impairs sleep EEG&lt;br&gt;synchronization in patients with restless legs syndromeper&lt;/p&gt;" NOTES_MODIFIED="2010-11-30 14:53:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tagaya H, Wetter T, Winkelmann J, Rubin M, Hundemer H, Trenkwalder C, et al</AU>
<TI>Pergolide restores sleep maintenance but impairs sleep EEG</TI>
<SO>Sleep Medicine</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorpy-2005" MODIFIED="2010-04-29 11:59:42 +0100" MODIFIED_BY="[Empty name]" NAME="Thorpy 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-29 11:59:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorpy M</AU>
<TI>Ropinirole in the treatment of restless legs syndrome</TI>
<SO>Current Neurology and Neuroscience Reports</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2001a" MODIFIED="2010-11-30 14:54:37 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2001a" YEAR="2001">
<REFERENCE MODIFIED="2010-11-30 14:54:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Brandenburg U, Hundemer P, Lledo A, Quail D, Swieca J</AU>
<TI>A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of Restless Legs Syndrome with central evaluation of polysomnographic data</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>8 Suppl 3</NO>
<PG>A5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2001b" MODIFIED="2010-11-19 22:28:24 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2001b" YEAR="2001">
<REFERENCE MODIFIED="2010-04-29 12:00:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A long-term controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data1.2 excluded 1 excluded. published in Trenkwalder 04per&lt;/p&gt;" NOTES_MODIFIED="2010-04-29 12:00:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Brandenburg U, Hundemer HP, Lledo A, Quail D, Swieca J</AU>
<TI>A long-term controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>187 Suppl 1</VL>
<PG>S432</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2005" MODIFIED="2010-04-29 12:00:50 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-29 12:00:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Augmentation and lack of efficacy with dopaminergic treatment in [patients with RLS double blind comparison between cabergoline and l-dopa in the treatment of patients with severe restless legs syndrome [Abstract]1.2 excluded 1 excluded. published in Trenkwalder 07cab lev&lt;/p&gt;" NOTES_MODIFIED="2010-04-29 12:00:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Kohen R</AU>
<TI>Augmentation and lack of efficacy with dopaminergic treatment in [patients with RLS double blind comparison between cabergoline and l-dopa in the treatment of patients with severe restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6 Suppl 2</VL>
<PG>S162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2006" MODIFIED="2010-05-05 14:31:47 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-05 14:31:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>245.546</AU>
<TI>A double-blind, placebo-controlled, randomised withdrawal study of 3 months&#8217; duration in patients suffering from idiopathic Restless Legs Syndrome who responded to a preceding, 6-month treatment with open-label pramipexole including titration (0.125, 0.25, 0.5, 0.75 mg orally q.n.)</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.546_U05-1532_new_upload.pdf</SO>
<YR>(accessed 4 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-05 14:31:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J</AU>
<TI>Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1404-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetter-1998" MODIFIED="2010-05-05 14:31:57 +0100" MODIFIED_BY="[Empty name]" NAME="Wetter 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-05 14:31:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Peter JH, et al</AU>
<TI>A polysomnographic, controlled study of pergolide in the treatment of restless legs syndrome</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>4 Suppl 4</NO>
<PG>A69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winkelman-2005" MODIFIED="2010-05-05 14:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Winkelman 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-05 14:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winkelman J, Sethi K, Kushida C, Becker P, Mahowald M</AU>
<TI>Pramipexole is efficacious and safe in treating RLS patients results of a 12 weeks placebo controlled fixed dose study</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6 Suppl 2</VL>
<PG>S74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yee-2004" MODIFIED="2010-04-14 15:38:24 +0100" MODIFIED_BY="[Empty name]" NAME="Yee 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-14 15:38:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yee B, Dreykluft T, Walters A, Ondo W, Sethi K, Hyman N, et al</AU>
<TI>Ropinirole versus placebo in restless legs syndrome: efficacy, safety and quality of life results from a 12-week double-blind international study</TI>
<SO>Internal Medicine Journal</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>3</NO>
<PG>A26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-26 10:23:42 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-12-01 13:32:58 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-12-01 13:32:58 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abetz-2005" MODIFIED="2009-04-20 16:10:59 +0100" MODIFIED_BY="[Empty name]" NAME="Abetz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ</AU>
<TI>Validation of the Restless Legs Syndrome Quality of Life questionnaire</TI>
<SO>Health and quality of life outcomes</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>2</NO>
<PG>157-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2003" MODIFIED="2010-05-10 15:20:31 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J</AU>
<TI>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>101-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2007" MODIFIED="2010-05-04 15:37:32 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ</AU>
<TI>The role of iron in restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22 Suppl 18</VL>
<PG>S440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-American-Academy-of-Sleep-Medicine-2005" MODIFIED="2010-05-11 14:38:51 +0100" MODIFIED_BY="[Empty name]" NAME="American Academy of Sleep Medicine 2005" TYPE="BOOK_SECTION">
<AU>American Academy of Sleep Medicine</AU>
<TI>Periodic limb movement disorder</TI>
<SO>The International classification of sleep disorders, 2nd edition: Diagnostic and coding manual</SO>
<YR>2005</YR>
<PG>182-6</PG>
<ED>American Academy of Sleep Medicine</ED>
<PB>American Academy of Sleep Medicine</PB>
<CY>Westchester, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baker-2008" MODIFIED="2009-11-05 16:01:12 +0000" MODIFIED_BY="[Empty name]" NAME="Baker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Baker WL, White CM, Coleman CI</AU>
<TI>Effect of nonergot dopamine agonists on symptoms of restless legs syndrome</TI>
<SO>Annals of Family Medicine</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>3</NO>
<PG>253-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2004" NAME="Berger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Berger K, Luedemann J, Trenkwalder C, John U, Kessler C</AU>
<TI>Parity and the risk of restless legs syndrome in the general population</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>2</NO>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2007" MODIFIED="2010-05-18 14:04:52 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Berger K, Kurth T</AU>
<TI>RLS epidemiology - Frequencies, risk factors and methods in population studies</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>S420-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonnet-1993" MODIFIED="2010-11-30 15:06:22 +0000" MODIFIED_BY="[Empty name]" NAME="Bonnet 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet M, Carley D, Carskadon M, Easton P, Guilleminault C, Harper R, et al</AU>
<TI>Recording and scoring leg movements</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>748-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buysse-1989" MODIFIED="2010-11-30 15:06:35 +0000" MODIFIED_BY="[Empty name]" NAME="Buysse 1989" TYPE="JOURNAL_ARTICLE">
<AU>Buysse D, Reynolds C, Monk T, Berman S, Kupfer D</AU>
<TI>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>2</NO>
<PG>193-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2010-11-30 14:55:28 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical power analysis in the behavioral sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum Associates, Inc</PB>
<CY>Hillsdale (NJ)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-2008" MODIFIED="2010-05-04 15:39:12 +0100" MODIFIED_BY="[Empty name]" NAME="Connor 2008" TYPE="JOURNAL_ARTICLE">
<AU>Connor JR</AU>
<TI>Pathophysiology of restless legs syndrome: evidence for iron involvement</TI>
<SO>Current Neurology and Neuroscience Reports</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conti-2007" MODIFIED="2010-11-30 15:06:49 +0000" MODIFIED_BY="[Empty name]" NAME="Conti 2007" TYPE="JOURNAL_ARTICLE">
<AU>Conti CF, de Oliveira MM, Andriolo RB, Saconato H, Atallah AN, Valbuza JS, et al</AU>
<TI>Levodopa for idiopathic restless legs syndrome: evidence-based review</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>13</NO>
<PG>1943-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conti-2008" MODIFIED="2010-04-26 09:17:42 +0100" MODIFIED_BY="[Empty name]" NAME="Conti 2008" TYPE="JOURNAL_ARTICLE">
<AU>Conti CF, Oliveira MM, Valbuza JS, Prado LB, Carvalho LB, Prado GF</AU>
<TI>Anticonvulsants to treat idiopathic restless legs syndrome: systematic review</TI>
<SO>Arquivos de neuro-psiquiatria</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>2B</NO>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-11-30 14:55:53 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eisensehr-2004" NAME="Eisensehr 2004" TYPE="JOURNAL_ARTICLE">
<AU>Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S</AU>
<TI>Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<PG>579-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekbom-1945" NAME="Ekbom 1945" TYPE="JOURNAL_ARTICLE">
<AU>Ekbom K</AU>
<TI>Restless legs: a clinical study</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1945</YR>
<VL>158</VL>
<PG>1-123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2002" MODIFIED="2010-05-10 11:55:35 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2002" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G</AU>
<TI>Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1573-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goertelmeyer-1985" MODIFIED="2009-04-17 14:10:01 +0100" MODIFIED_BY="[Empty name]" NAME="Goertelmeyer 1985" TYPE="BOOK_SECTION">
<AU>Goertelmeyer R</AU>
<TI>On the development of a standardized sleep inventory for the assessment of sleep</TI>
<SO>Methods of sleep research</SO>
<YR>1985</YR>
<ED>Kubicki S, Herrmann W</ED>
<PB>Fischer</PB>
<CY>Stuttgart/New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2009" MODIFIED="2009-11-05 16:03:28 +0000" MODIFIED_BY="[Empty name]" NAME="Hansen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD</AU>
<TI>Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hays-2005" MODIFIED="2009-04-17 13:40:33 +0100" MODIFIED_BY="[Empty name]" NAME="Hays 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hays RD, Martin SA, Sesti AM, Spritzer KL</AU>
<TI>Psychometric properties of the Medical Outcomes Study Sleep measure</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heckman-2009" MODIFIED="2010-04-26 08:50:53 +0100" MODIFIED_BY="[Empty name]" NAME="Heckman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Heckman CJ, Mottram C, Quinlan K, Theiss R, Schuster J</AU>
<TI>Motoneuron excitability: the importance of neuromodulatory inputs</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2009</YR>
<VL>120</VL>
<NO>12</NO>
<PG>2040-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hening-2004a" MODIFIED="2010-04-26 10:57:39 +0100" MODIFIED_BY="[Empty name]" NAME="Hening 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L</AU>
<TI>Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>3</NO>
<PG>237-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hening-2004b" MODIFIED="2010-04-26 10:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hening 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Hening W</AU>
<TI>The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2004</YR>
<VL>115</VL>
<NO>9</NO>
<PG>1965-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hornyak-2004" MODIFIED="2010-11-30 14:56:18 +0000" MODIFIED_BY="[Empty name]" NAME="Hornyak 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Trenkwalder C</AU>
<TI>Restless legs syndrome and periodic limb movement disorder in the elderly</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>5</NO>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00f6_gl-2003" MODIFIED="2010-04-14 15:22:59 +0100" MODIFIED_BY="[Empty name]" NAME="Högl 2003" TYPE="JOURNAL_ARTICLE">
<AU>Högl B, Saletu M, Brandauer E, Frauscher B, Müller J, Seppi K, et al</AU>
<TI>Prevalence of Restless Legs Syndrome in the central European alpine region of South Tyrol</TI>
<SO>Sleep</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>A344</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iber-2007" MODIFIED="2010-11-30 14:56:23 +0000" MODIFIED_BY="[Empty name]" NAME="Iber 2007" TYPE="BOOK">
<AU>Iber C, Ancoli-Israel S, Chesson A, Quan SF for the American Academy of Sleep Medicine</AU>
<SO>The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications</SO>
<YR>2007</YR>
<EN>1st</EN>
<PB>American Academy of Sleep Medicine</PB>
<CY>Westchester, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohnen-2002" MODIFIED="2009-04-17 14:00:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kohnen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kohnen R, Benes H, Heinrich CR, Kurella B</AU>
<TI>Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire</TI>
<SO>Movement Disorders</SO>
<YR>2002</YR>
<VL>17 Suppl 5</VL>
<PG>P743</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohnen-2004" MODIFIED="2009-04-17 13:50:40 +0100" MODIFIED_BY="[Empty name]" NAME="Kohnen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C</AU>
<TI>Severity rating of restless legs syndrome: validation of the RLS-6 scales</TI>
<SO>Sleep</SO>
<YR>2004</YR>
<VL>27 Suppl 1</VL>
<PG>A304. Abstract 680</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohnen-2008" MODIFIED="2010-05-18 14:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="Kohnen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kohnen R</AU>
<TI>The promises of meta-analyses in current RLS research: is 1+1 more than 2?</TI>
<SO>Sleep Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>7</NO>
<PG>709-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushida-2007" MODIFIED="2010-11-30 14:56:30 +0000" MODIFIED_BY="[Empty name]" NAME="Kushida 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, et al</AU>
<TI>Burden of restless legs syndrome on health-related quality of life</TI>
<SO>Quality of Life Research</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>4</NO>
<PG>617-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushida-2009" MODIFIED="2010-04-26 10:56:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kushida 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group</AU>
<TI>Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>5</NO>
<PG>439-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manconi-2004" MODIFIED="2010-11-30 14:56:35 +0000" MODIFIED_BY="[Empty name]" NAME="Manconi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Manconi M, Govoni V, De Vito A, Economou NT, Cesnik E, Mollica G, et al</AU>
<TI>Pregnancy as a risk factor for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>3</NO>
<PG>305-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montplaisir-1997" MODIFIED="2010-04-30 10:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Montplaisir 1997" TYPE="JOURNAL_ARTICLE">
<AU>Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P</AU>
<TI>Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria</TI>
<SO>Movement Disorders</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-National-Institute-of-Mental-Health-1976" MODIFIED="2009-04-17 13:32:51 +0100" MODIFIED_BY="[Empty name]" NAME="National Institute of Mental Health 1976" TYPE="BOOK_SECTION">
<AU>National Institute of Mental Health (NIMH)</AU>
<TI>Early clinical drug evaluation unit (ECDEU). Clinical Global Impressions</TI>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>revised</EN>
<ED>Guy W</ED>
<PB>NIMH, Psychopharmacology Research Branch</PB>
<CY>Rockville MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paulus-2006" MODIFIED="2010-05-04 15:36:25 +0100" MODIFIED_BY="[Empty name]" NAME="Paulus 2006" TYPE="JOURNAL_ARTICLE">
<AU>Paulus W, Schomburg ED</AU>
<TI>Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis of augmentation?</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>185-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-2000" NAME="Phillips 2000" TYPE="JOURNAL_ARTICLE">
<AU>Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C</AU>
<TI>Epidemiology of restless legs symptoms in adults</TI>
<SO>Archives of Internal medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>2137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quilici-2008" MODIFIED="2010-11-30 14:56:42 +0000" MODIFIED_BY="[Empty name]" NAME="Quilici 2008" TYPE="JOURNAL_ARTICLE">
<AU>Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, et al</AU>
<TI>Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>7</NO>
<PG>715-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reviewer_x0027_s-Handbook" MODIFIED="2010-11-30 14:57:11 +0000" MODIFIED_BY="[Empty name]" NAME="Reviewer's Handbook" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothdach-2000" NAME="Rothdach 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K</AU>
<TI>Prevalence and risk factors of RLS in an elderly population</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<PG>1064-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00f6_ls-1998" MODIFIED="2010-05-04 15:33:31 +0100" MODIFIED_BY="[Empty name]" NAME="Schöls 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schöls L, Haan J, Riess O, Amoridis G, Przuntek H</AU>
<TI>Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>1603-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silber-2004" MODIFIED="2010-04-14 15:25:21 +0100" MODIFIED_BY="[Empty name]" NAME="Silber 2004" TYPE="JOURNAL_ARTICLE">
<AU>Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, et al</AU>
<TI>An algorithm for the management of restless legs syndrome</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>7</NO>
<PG>916-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stefansson-2007" MODIFIED="2010-11-30 14:58:33 +0000" MODIFIED_BY="[Empty name]" NAME="Stefansson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE</AU>
<TI>A genetic risk factor for periodic limb movements in sleep</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>7</NO>
<PG>639-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stiasny_x002d_Kolster-2006" MODIFIED="2009-06-25 08:40:13 +0100" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2006" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster K, Kohnen R, Möller JC, Trenkwalder C, Oertel WH</AU>
<TI>Validation of the "L-DOPA test" for diagnosis of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stiasny_x002d_Kolster-2009" MODIFIED="2010-11-30 14:58:38 +0000" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2009" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster</AU>
<TI>Restless legs syndrome</TI>
<TO>Restless-Legs-Syndrom</TO>
<SO>Somnology</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>1</NO>
<PG>115-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talati-2009" MODIFIED="2010-04-29 11:45:10 +0100" MODIFIED_BY="[Empty name]" NAME="Talati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Talati R, Phung OJ, Mather J, Coleman CI</AU>
<TI>Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2009</YR>
<VL>43</VL>
<PG>813-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tison-2005" MODIFIED="2010-04-14 14:02:38 +0100" MODIFIED_BY="[Empty name]" NAME="Tison 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tison F, Crochard A, Léger D, Bouée S, Lainey E, El Hasnaoui A</AU>
<TI>Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>2</NO>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2004" NAME="Trenkwalder 2004" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Paulus W</AU>
<TI>Why do restless legs occur at rest?-pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2)</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2004</YR>
<VL>115</VL>
<NO>9</NO>
<PG>1975-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2007" MODIFIED="2010-12-01 13:32:55 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2007" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Kohnen R, Allen RP, Benes H, Ferini-Strambi L, Garcia-Borreguero D, et al</AU>
<TI>Clinical trials in restless legs syndrome - recommendations of the european RLS Study Group (EURLSSG)</TI>
<SO>Sleep Medicine</SO>
<YR>2007</YR>
<VL>22 Suppl 18</VL>
<PG>S495-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2008" MODIFIED="2010-04-14 15:25:11 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2008" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et al</AU>
<TI>Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice</TI>
<SO>Movement Disorders</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>16</NO>
<PG>2267-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2010" MODIFIED="2010-11-30 15:07:10 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2010" TYPE="OTHER">
<AU>Trenkwalder C, Paulus W</AU>
<TI>Restless legs syndrome: pathophysiology, clinical presentation and management</TI>
<SO>Nature Reviews Neurology</SO>
<YR>in press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulfberg-2001" NAME="Ulfberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ulfberg J, Nyström B, Carter N, Edling C</AU>
<TI>Prevalence of restless legs syndrome among men aged 18 to 64 years: An association with somatic disease and neuropsychiatric symptoms</TI>
<SO>Movement Disorders</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1988" MODIFIED="2010-05-18 15:49:12 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 1988" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S</AU>
<TI>A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1988</YR>
<VL>24</VL>
<NO>3</NO>
<PG>455-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1993" MODIFIED="2010-04-14 15:26:11 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 1993" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al</AU>
<TI>Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>327-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1995" NAME="Walters 1995" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, The International Restless Legs Syndrome Study Group</AU>
<TI>Toward a better definition of restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>634-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2003" MODIFIED="2010-11-30 15:08:58 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 2003" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al; International Restless Legs Syndrome Study Group</AU>
<TI>Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>121-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2007" MODIFIED="2010-11-30 15:09:08 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 2007" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS</AU>
<TI>Restless legs syndrome and periodic limb movements in sleep</TI>
<SO>Continuum: Lifelong Learning in Neurology</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>115-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winkelmann-2007" MODIFIED="2010-11-30 15:09:32 +0000" MODIFIED_BY="[Empty name]" NAME="Winkelmann 2007" TYPE="JOURNAL_ARTICLE">
<AU>Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al</AU>
<TI>Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions</TI>
<SO>Nature Genetics</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1000-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zintzaras-2010" MODIFIED="2010-11-30 15:09:41 +0000" MODIFIED_BY="[Empty name]" NAME="Zintzaras 2010" TYPE="JOURNAL_ARTICLE">
<AU>Zintzaras E, Kitsios GD, Papathanasiou AA, Konitsiotis S, Miligkos M, Rodopoulou P, et al</AU>
<TI>Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>2</NO>
<PG>221-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zucconi-2006" MODIFIED="2010-11-30 14:58:57 +0000" MODIFIED_BY="[Empty name]" NAME="Zucconi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al; International Restless Legs Syndrome Study Group (IRLSSG)</AU>
<TI>The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG)</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>2</NO>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-01-12 14:00:27 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-01-12 14:00:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="funding source" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-30 14:10:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-2004">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled cross-over trial of ropinirole versus placebo</P>
<P>Drop outs/withdrawals: ITT analysis of 22 patients (6 men), premature discontinuations in ropinirole (one in each period) and placebo (one in period 1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:25:58 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 22/22</P>
<P>Demographics: 6 male, age 60 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and IRLS &gt; 10</P>
<P>Setting: 1 site in the USA</P>
<P>Baseline: IRLS score of 25.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:06:47 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: forced up-titration of ropinirole (twice daily) from 0.5 mg to 6 mg per day in 3 weeks (lower doses if up-titration not tolerated), maintenance for 1 week</P>
<P>Control: placebo for 4 weeks</P>
<P>Washout between phases of 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-01 14:24:00 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout and 4 weeks each treatment period</P>
<P>Change of symptoms: IRLS</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:10:23 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (CH Adler and MD Sethi) received compensation in excess of $10,000.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:06:51 +0000" MODIFIED_BY="[Empty name]">
<P>ITT: intention-to-treat; IRLS: International Restless Legs Study Group Rating Scale; AE: adverse event</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:07:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-2004">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (29/30), premature discontinuations of 4 in ropinirole group, 6 in placebo group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:20:07 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 32 (ropinirole) and 33 (placebo)/ 29 (ropinirole) and 30 (placebo)</P>
<P>Demographics: 26 male, age 55.4 (ropinirole) and 53.3 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and IRLS &#8805; 15, symptoms &#8805; 15 nights/last month and PLMS &#8805; 5/H</P>
<P>Setting: 15 sites in USA</P>
<P>Baseline: PLMS-Index of 48.5 (ropinirole) and 35.7 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:07:17 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 to 4 mg in 8 weeks, maintenance for 4 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 15:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8805; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective quality of sleep: SE, PLM-Index (TIB, using PSG)</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 12:17:34 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-10 09:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>CGI: Clinical Global Impressions; SE: sleep efficiency; PLMS-I: Periodic Limb Movements in Sleep Index per hour of time in bed (TIB); MOS: Medical Outcomes Study Sleep Scale with scales sleep problems index II and somnolence; RLS-QoL: RLS Quality of Life Questionnaire</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-18 15:20:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Axxonis-2005">
<CHAR_METHODS MODIFIED="2010-02-19 11:16:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of lisuride patches versus placebo</P>
<P>Dropouts/withdrawals: ITT (210)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-19 11:15:54 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 157 (lisuride) and 53 (placebo)/ 154 (lisuride) and 51 (placebo)</P>
<P>Demographics: 31.9% male, age 60.5 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and RLS Diagnostic Clinical Interview &#8805; 10, IRLS total score &#8805; 15, RLS severity during rest &#8805; 3</P>
<P>Setting: 25 sites in Germany and Austria</P>
<P>Baseline: IRLS score of 28.8 (lisuride) and 29 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-28 15:04:16 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed doses of lisuride patches (every 48 hours) in 3 arms: 2.5 mg, 5.0 mg, 10.0 mg, maintenance for 12 weeks</P>
<P>Control: fixed dose of placebo patches for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 15:20:16 +0100" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8805; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-28 15:06:20 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Axxonis Pharma AG.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-18 15:20:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Axxonis-2008">
<CHAR_METHODS MODIFIED="2010-02-19 11:12:45 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of lisuride patches versus ropinirole and placebo</P>
<P>Dropouts/withdrawals: ITT (309)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-19 11:17:29 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: both 152 (lisuride), 78 (ropinirole) and 79 (placebo)</P>
<P>Demographics: 26.2% male, age 58.6 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and RLS Diagnostic Clinical Interview &gt; 10, IRLS total score &#8805; 15, RLS severity during rest &#8805; 3</P>
<P>Setting: 37 sites in Germany and Austria</P>
<P>Baseline: IRLS score of 28.8 (lisuride) and 29 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-28 15:06:41 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed doses of lisuride patches (every 48 hours) in 3 arms: 2.5 mg, 5.0 mg, 10.0 mg, maintenance for 12 weeks</P>
<P>Control: fixed dose of placebo patches for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 15:20:22 +0100" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8805; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: RLS-6</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-28 15:06:54 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Axxonis Pharma AG.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:48:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benes-2010">
<CHAR_METHODS MODIFIED="2009-06-12 09:01:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (171/60) with premature discontinuations of 54 (ropinirole) and 29 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-12 09:04:02 +0100" MODIFIED_BY="[Empty name]">
<P>Included/ analysed: 199 (ropinirole) and 67 (placebo)/ 171 (ropinirole) and 60 (placebo)</P>
<P>Demographics: 27.3% (ropinirole) and 32.8% male, age 58.2 (ropinirole) and 59.5 (placebo) years</P>
<P>Setting: 62 centres in Germany</P>
<P>Baseline: IRLS of 28.5 (ropinirole) and 29.0 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 09:48:37 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 mg to 0.5 (1 week) to 4 mg in 12 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:04:40 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-12-01 09:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:08:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BI-2006">
<CHAR_METHODS MODIFIED="2010-02-19 11:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled cross-over trial of pramipexole versus levodopa</P>
<P>Dropouts/withdrawals: PP (39), with 6 (levodopa) and 3 (ppx) premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 67/ 39</P>
<P>Demographics: 16 male, age: 56.9 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, symptom presence almost every day, PLMI &gt; 5</P>
<P>Setting: 6 Swiss centres including Basel, Bern, Lugano, Luzern, Zürich, Zurzach</P>
<P>Baseline: IRLS score of 21.1 (levodopa) and 20.8 (ppx), PLMI (actigraphy) of 21.1 (levodopa) and 21.5 (ppx)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:08:49 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention 1: flexible up-titration of pramipexole (once daily) from 0.25 to 0.75 mg in 2 weeks, maintenance for 2 weeks</P>
<P>Intervention 2: flexible up-titration of levodopa-dual-release (once daily) from 100/25 mg to 300/75 mg for 2 weeks, maintenance for 2 weeks</P>
<P>Washout between phases of 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 10:42:45 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks run-in, 4 weeks each treatment period</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective quality of sleep: PLM-Index (using actigraphy)</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 11:39:36 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-11 14:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:08:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BI-2008">
<CHAR_METHODS MODIFIED="2010-01-12 14:32:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: ITT (123/126/127) with premature exclusions of (18/15/11)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:08:54 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 132 (intervention A), 137 (intervention B), 132 (placebo) / 123 (intervention A), 126 (intervention B), 127 (placebo)</P>
<P>Demographics: 35 (A), 45 (B) and 52 (C) male, age 49.8 (A), 47.6 (B) and 49.6 (C) years</P>
<P>Diagnosis: Idiopathic RLS according to IRLSSG criteria, IRLS &gt; 15</P>
<P>Setting: 50 sites in the USA</P>
<P>Baseline: IRLS of 25 (both treatment groups) and 24.9 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:08:55 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention A: fixed dose of pramipexole 0.25 mg (once daily) for 6 weeks</P>
<P>Intervention B: fixed up-titration of pramipexole (once daily) from 0.125 mg (1 week) to 0.25 mg (once daily) for 5 weeks</P>
<P>Control C: placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 14:27:55 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 6 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:19:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BI-2009">
<CHAR_METHODS MODIFIED="2009-12-04 13:30:33 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole verus placebo</P>
<P>Dropouts/withdrawals: Analysis with LOCF (166/163) with premature discontinuations of 35 (pramipexole) and 60 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-04 13:37:59 +0000" MODIFIED_BY="[Empty name]">
<P>Included/ analysed for primary endpoint: 166 (pramipexole) and 163 (placebo)/ 162 (pramipexole) and 159 (placebo)</P>
<P>Demographics: 38.2% (pramipexole) and 52.3% male, age 57.9 (ropinirole) and 55.8 (placebo) years</P>
<P>Setting: 42 centres in 9 European countries</P>
<P>Baseline: IRLS of 23.9 (pramipexole) and 23.5 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:09:04 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pramipexole (once daily) from 0.125 mg to 0.75 mg in 4 weeks and further 26 weeks</P>
<P>Control: placebo for 12 weeks and further 26 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:09:04 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 26 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:19:00 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-12-04 13:30:58 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:19:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogan-2006">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (187/193) with premature discontinuations of 23 in ropinirole and 26 in placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:19:22 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 187 (ropinirole) and 194 (placebo)/187 (ropinirole) and 193 (placebo)</P>
<P>Demographics: 78 (ropinirole) and 70 (placebo) male, age 52.2 (ropinirole) and 52.4 (placebo)</P>
<P>Diagnosis: RLS according to IRLSSG criteria and IRLS &#8805; 15, symptoms &#8805; 15 nights/previous month</P>
<P>Setting: 47 sites in USA</P>
<P>Baseline: IRLS score of 22.0 (ropinirole) and 21.6 (placebo), PLM-I (actigraphy) of 39.8 (ropinirole) and 32.8 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:19:29 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 to 4 mg in 10 weeks, maintenance for 2 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 15:20:40 +0100" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8805; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective sleep quality: PLM-Index (using actigraphy)</P>
<P>Subjective sleep quality: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:19:33 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-11-05 11:12:51 +0000" MODIFIED_BY="[Empty name]">
<P>PLM-Index per time in bed (TIB)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:19:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Earley-1998">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pergolide versus placebo</P>
<P>Dropouts/withdrawals: ITT (15) with missing post data of 1 patient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:19:46 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 16/15</P>
<P>Demographics: 3 (pergolide) and 5 (placebo) male, age 62.5 (pergolide) and 56.5 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and PLMS &gt; 15/h</P>
<P>Setting: 1 centre in the USA</P>
<P>Baseline: PLMS-I (TST) 48.9 (pergolide) and 48.7 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:19:47 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pergolide (twice daily) from 0.1 mg to 0.65 mg per day in 2 weeks, maintenance for 5 days</P>
<P>Control: placebo for 18 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 10:40:18 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 4 days washout, 18 days treatment</P>
<P>Quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 13:40:09 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported in part by a gift from Athena Neurosciences, Inc. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:19:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole (ppx) versus placebo</P>
<P>Dropouts/withdrawals: ITT (178/179) with dropouts of 27 (ppx) and 52 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed:182 (ppx) and 187 (placebo)/ 178 (ppx) and 179 (placebo)</P>
<P>Demographics: 50 (ppx) and 68 (placebo) male, age 56.3 (ppx) and 56.9 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline; IRLS total score &gt; 15 at baseline</P>
<P>Setting: 49 sites in Europe</P>
<P>Baseline: IRLS score of 24.2 (ppx) and 24.6 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:19:54 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pramipexole (once daily) from 0.125 mg to 0.75 mg in 4 weeks, maintenance for 8 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-19 11:19:20 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-05-11 14:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:19:57 +0000" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole; PGI: Patient Global Impressions</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:20:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<CHAR_METHODS MODIFIED="2009-11-05 10:56:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of sumanirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (56/49/59/54 for sumanirole doses of 0.5, 1.0, 2.0, 4.0 mg and 52 for placebo) with premature discontinuations of 8/9/10/7 (in sumanirole doses) and 10 (placebo) and PP analysis for IRLS (40/39/44/35 for sumanirole doses and 38 for placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:21:08 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: both as ITT: 56/49/59/54 (sumanirole) and 52 (placebo); PP: 40/39/44/35 (sumanirole) and 38 (placebo)</P>
<P>Demographics: 25/30/18/13 (sumanirole) and 22 (placebo) male, age 52.9 (placebo) to 55.4 years (4 mg sumanirole)</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 20 and RLS-6 scale &#8805;4 in &#8805;12 weeks and PLMS &#8805;11/h</P>
<P>Setting: 48 sites in the USA, Canada, Spain, Germany, Italy, UK</P>
<P>Baseline: IRLS score of 25.4, 24.7, 26.1 and 26.5 (ascending sumanirole groups) and 25.2 (placebo), PLMS-I of 39.9, 53.8, 39.2, 33.8 (ascending sumanirole groups) and 33.4 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:19:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of sumanirole (once daily) to arms of 0.5 mg, 1 mg, 2 mg and 4 mg in 5 weeks, maintenance for 3 weeks</P>
<P>Control: placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:20:01 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 8 weeks treatment</P>
<P>Change of symptoms: IRLS (PP population), CGI responders</P>
<P>Objective quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 13:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>The study was funded by Pfizer Inc. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:20:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-2005">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (37/17) with premature discontinuations of 8 (ropinirole) and 4 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:21:17 +0100" MODIFIED_BY="[Empty name]">
<P>Included/ analysed: both 37 (ropinirole) and 17 (placebo)</P>
<P>Demographics: 10 (ropinirole) and 4 (placebo) male, age 50.9 (ropinirole) and 56.2 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS total score &#8805; 15, RLS symptoms &#8805; 15 nights/ per month</P>
<P>Setting: 11 centres in the USA</P>
<P>Baseline: IRLS score of 26.0 (ropinirole) and 27.4 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:20:02 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: forced up-titration of ropinirole (once daily) from 0.25 mg to 4 mg in 7 weeks</P>
<P>Control: placebo for 7 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:20:04 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8804; 7 days washout, 7 weeks treatment</P>
<P>Change of symptoms: IRLS</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-06-04 14:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:04:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-2006">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (154/149) with premature discontinuations of 48 in ropinirole and 37 in placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 158 (ropinirole) and 151 (placebo)/ 154 (ropinirole) and 149 (placebo)</P>
<P>Demographics: 45 (ropinirole) and 37 (placebo) male, age 56.2 (ropinirole) and 56.8 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, RLS symptoms &#8805; 15 nights/ previous four weeks, which were considered to be moderate/severe</P>
<P>Setting: 60 centres in the UK</P>
<P>Baseline: IRLS score of 23.5 in both groups, PLMI (actigraphy) of 19.93 (ropinirole) and 22.67 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 15:04:51 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 (2 days) to 0.5 mg (5 days) and finally to 4 mg in 11 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-19 11:20:06 +0000" MODIFIED_BY="[Empty name]">
<P>Obsevation period: 12 weeks treatment</P>
<P>Change of symptoms: CGI responders, PGI responders</P>
<P>Objective sleep quality: PLM-Index ("time down during night", using actigraphy)</P>
<P>Subjective sleep quality: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:20:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-2007">
<CHAR_METHODS MODIFIED="2010-11-30 14:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (187/195) with premature discontinuations of 34 (ropinirole) and 35 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:20:47 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 189 (ropinirole) and 195 (placebo)/187 (ropinirole) and 195 (placebo)</P>
<P>Demographics: 66 (ropinirole) and 63 (placebo) male, age 52.1 (ropinirole) years and 52.3 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria and the RLS Diagnostic Clinical Interview, IRLS total score &#8805; 15</P>
<P>Setting: 57 centres in the USA and 8 centres in Canada</P>
<P>Baseline: IRLS score of 25.2 (ropinirole) and 25.3 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:20:48 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.5 mg to 6 mg in 12 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 15:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8805; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:20:50 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-09-03 14:59:15 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:52:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-2008">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of ropinirole-CR versus placebo</P>
<P>Dropouts/withdrawals: ITT (19/18) with premature discontinuations of 3 in ropinirole-CR and 5 in placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 15:04:54 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 20 (ropinirole) and 19 (placebo)/19 (ropinirole) and 18 (placebo)</P>
<P>Demographics: 4 (ropinirole) and 2 (placebo) male, age 50.9 (ropinirole) and 49.8 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, PLMAI &#8805; 5, sleep efficiency &lt; 85% or latency &gt; 20 minutes, RLS symptoms present &#8805; 20 evenings or nights/ previous month, IRLS score &#8805; 20</P>
<P>Setting: 18 study sites in the United States</P>
<P>Baseline: IRLS score of 27.3 (ropinirole) and 26.5 (placebo), PLMI (TIB) of 50.2 (ropinirole) and 41.2 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.5 mg to 6 mg in 12 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:21:00 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective quality of sleep: SE, PLM-Index (TIB, using PSG)</P>
<P>Subjective sleep quality: VAS (0-10 = excellent)</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-12-01 09:52:38 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-10 09:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>PLMAI: Periodic Limb Movement Arousal Index per TIB</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:52:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-2009">
<CHAR_METHODS MODIFIED="2010-05-11 14:55:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (196/205) with premature discontinuations of 76 (ropinirole) and 59 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 15:04:55 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 197 (ropinirole) and 207 (placebo)/196 (ropinirole) and 205 (placebo)</P>
<P>Demographics: 37.2% (ropinirole) and 36.6% male, age 56.5 (ropinirole) and 56.1 (placebo) years</P>
<P>Setting: 35 centres in 9 European countries and Australia</P>
<P>Baseline: IRLS of 27.7 (ropinirole) and 27.5 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:22:05 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 mg to 2.0 mg in 12 weeks and further 26 weeks</P>
<P>Control: placebo for 12 weeks and further 26 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:08:37 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-12-01 09:52:53 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-12-04 13:30:52 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:27:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hening-2010">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of rotigotine versus placebo</P>
<P>Dropouts/withdrawals: ITT (99/101/99/106 (rotigotine groups in ascending order) and 100 (placebo)) with dropouts of 23/47/36/46 (rotigotine) and 33 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:27:53 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 99/101/99/106 (rotigotine) and 100 (placebo)/99/101/99/106 (rotigotine) and 100 (placebo)</P>
<P>Demographics: 35.5% (2 mg rotigotine) to 43% (placebo) male, age ranging from 51.3 (3 mg rotigotine) to 52.9 (0.5 mg rotigotine) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS total score &#8805; 15, CGI-S &#8805; 4</P>
<P>Setting: 63 sites in the USA</P>
<P>Baseline: IRLS score of 23.5, 23.1, 23.2, 23.6 (ascending rotigotine groups) and 23.5 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:27:54 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed doses of rotigotine (once daily, up-titrated in 4 weeks) in 4 arms of 1.125 mg, 2.25 mg, 4.5 mg and 6.75 mg, maintenance for 6 months</P>
<P>Control: placebo patches for 7 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-01 14:54:08 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 1 week washout, 7 months treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: MOS sleep problems index II, additionally RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: MOS somnolence, additionally RLS-6 daytime tiredness</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:27:55 +0000" MODIFIED_BY="[Empty name]">
<P>The study was sponsored by Schwarz Biosciences GmbH, UCB Group.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-19 12:05:26 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:13:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inoue-2010">
<CHAR_METHODS MODIFIED="2010-02-19 11:22:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole verus placebo</P>
<P>Dropouts/withdrawals: ITT analysis (20/21), with premature discontinuations of 4 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 15:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 20 (ppx) and 21 (placebo)</P>
<P>Demographics: 45% (ppx) and 52% (placebo) male, 48.7 (ppx) and 62.3 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, PLMI &#8805; 5/hour, RLSRS &gt; 15, symptoms &#8805; once a week/ previous month</P>
<P>Setting: Yoyogi Somnological Clinic and other 7 hospitals in Japan</P>
<P>Baseline: IRLS of 23.4 (ppx) and 25.1 (placebo) and PLMS-I of 25.8 (ppx) and 46.1 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 15:13:10 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: forced up-titration of pramipexole (once daily) from 0.125 mg to 0.75 mg as tolerated in 3 weeks, maintenance for 3 weeks</P>
<P>Control: placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-25 08:50:43 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 14 days washout, 6 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Objective sleep quality: SE, PLMS-Index (using PSG)</P>
<P>Subjective quality of sleep: PSQI</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 13:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>This study was supported by Boehringer Ingelheim GmbH. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:22:28 +0000" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole; PSQI: Pittsburgh Sleep Quality Index</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-12 14:00:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kushida-2008">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/ withdrawals: ITT (175/184) with premature discontinuations of 24 (ropinirole) and 25 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-12 14:00:27 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 176 (ropinirole) and 187 (placebo)/175 (ropinirole) and 184 (placebo)</P>
<P>Demographics: 67 (ropinirole) and 78 (placebo) male, age 51.4 (ropinirole) and 50.4 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 20, Insomnia Severity Index &#8805; 15, symptom onset after 5 pm, RLS symptoms &#8805; 15 nights/ previous month</P>
<P>Setting: 47 centres in the USA</P>
<P>Baseline: IRLS score of 26.0 (both groups) PLMI (of "time down during night", actigraphy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 15:05:02 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (twice daily) from 0.5 to 6.0 mg in 12 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-19 11:27:12 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 10 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Objective quality of sleep: PLM-Index (using actigraphy)</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-12-01 09:53:27 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:23:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montagna-2010">
<CHAR_METHODS MODIFIED="2010-11-30 14:22:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: ITT (404) and exclusion of 1 patient not having received at least 1 dose of drug</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:23:00 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 203 (ppx) and 200 (placebo)</P>
<P>Demographics: 33% and 27% male, age 55.0 (ppx) and 56.1 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &gt; 15, rating of item 10 &gt; 2, BDI total &#8804; 28 </P>
<P>Setting: 52 sites in 8 European countries and Korea</P>
<P>Baseline: IRLS score of 25.9 (ppx) and 25.8 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pramipexole (once daily) from 0.125 mg to 0.75 mg in 4 weeks, maintenance for 8 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:37:42 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 13:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:23:04 +0000" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:23:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montplaisir-1999">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled cross-over trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: PP (10) and exclusion of 1 patient due to scheduling problems</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 11/10</P>
<P>Demographics: 5 male, age 49.3 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, disturbed sleep onset, symptoms for 3 nights/week &#8805; 1 year and PLMS &#8805; 10/H</P>
<P>Setting: 1 site in Canada</P>
<P>Baseline: PLMS-I (TST) of 77.1 in all 10 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:23:04 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pramipexole (once daily) from 0.375 mg, 0.75 mg to 1.5 mg in 2 weeks, maintenance for 2 weeks</P>
<P>Control: placebo for 4 weeks</P>
<P>Washout in between phases of 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:52:30 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout, 4 weeks each treatment period</P>
<P>Objective quality of sleep: PLMS-Index (using PSG)</P>
<P>Safety: number of withdrawals due to AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 13:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by a grant from Pharmacia and Upjohn Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:23:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oertel-2006">
<CHAR_METHODS MODIFIED="2010-05-11 14:57:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of cabergoline versus placebo</P>
<P>Dropouts/ withdrawals: PP (20/20) with premature discontinuations of 3 patients in the cabergoline group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:23:28 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 43/ 40</P>
<P>Demographics: 6 (cabergoline) and 5 (placebo) male, age 57.3 (cabergoline) and 55.5 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 10, RLS-6 "severity at night" &#8805; 4 and PLMS-AI &gt; 5</P>
<P>Setting: 7 German centres</P>
<P>Baseline: IRLS score of 31.2 (cabergoline) and 31.8 (placebo), PLMS-I (TST) 52.3 (cabergoline) and 61.7 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of cabergoline (once daily) from 0.5 mg to 2.0 mg in 2 weeks, maintenance for 3 weeks</P>
<P>Control: placebo for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:55:13 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 5 half lives washout, 5 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: QoL-RLS</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:03:28 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Pfizer GmbH and by the Bundesministerium für Bildung und Forschung (BMBF, Germany).</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-11-05 11:38:16 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:24:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oertel-2007">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: ITT (224/114) with premature discontinuations of 12 (ppx) and 8 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:23:58 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 230 (ppx) and 115 (placebo)/224 (ppx) and 114 (placebo)</P>
<P>Demographics: 80 (ppx) and 36 (placebo) male, age 55.4 (ppx) and 55.8 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &gt; 15, symptoms for 2 to 3 days per week/ past 3 months</P>
<P>Setting: 37 sites in 5 European countries</P>
<P>Baseline: IRLS score of 24.7 (ppx) and 24.9 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:23:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pramipexole (once daily) from 0.125 mg, 0.25 mg, 0.5 mg to 0.75 mg in 4 weeks, maintenance for 2 weeks</P>
<P>Control: placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:24:00 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout, 6 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: VAS (0-10 = very dissatisfied with sleep)</P>
<P>Daytime tiredness: IRLS item 5</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:00:00 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim International. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:05:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oertel-2008">
<CHAR_METHODS MODIFIED="2010-11-30 15:05:07 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of rotigotine versus placebo</P>
<P>Dropouts/withdrawals: ITT (50/64/49/64/53 (rotigotine doses) and 53 (placebo)) with premature discontinuations of 5/5/1/7/5 (rotigotine doses) and 8 (placebo) patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 52/64/49/65/56 (rotigotine doses) and 55 (placebo)/ 50/64/49/64/53 (rotigotine doses) and 53 (placebo)</P>
<P>Demographics: 26% (1.125 mg cabergoline) to 42.9% (2.25 mg rotigotine) male, age 57.3 (1 mg rotigotine) to 59.9 years (4 mg rotigotine)</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 15</P>
<P>Setting: 34 hospital outpatient units, sleep centres or private practices of neurologists in Austria, Germany, Spain</P>
<P>Baseline: IRLS score of 27.4 (3 mg rotigotine) to 28.2 (4 mg rotigotine)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:24:20 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed doses of rotigotine patches (once daily, partly up-titrated in up to 2 weeks) in 6 arms: 1.125 mg, 2.25 mg, 4.5 mg, 6.75 mg and 9 mg, maintenance for 4 weeks</P>
<P>Control: fixed dose of placebo patches for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:57:09 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 4 weeks washout for DAs, otherwise 1 week washout, 6 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:24:21 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Schwarz Pharma.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-04-07 13:56:38 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:24:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oertel-2010">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel-group trial of rotigotine versus placebo</P>
<P>Dropouts/withdrawals: ITT (46/21) with dropouts of 5 (rotigotine) and 1 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: both 46 (rotigotine) and 21 (placebo)</P>
<P>Demographics: 11 (rotigotine) and 7 (placebo) male, age 60.8 (rotigotine) and 55.2 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS total score &#8805; 15, CGI Item-S &#8805; 4, PLMI (time in bed) &#8805; 15</P>
<P>Setting: 11 sites in 5 European countries</P>
<P>Baseline: IRLS score of 26.3 (rotigotine) and 25.4 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of rotigotine (once daily) from 2.25 mg, 4.5 mg to 6.75 mg in 3 weeks (± 3 days), maintenance for 4 weeks</P>
<P>Control: placebo patches for 7 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-01 14:57:12 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 7 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Objective quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>The study was sponsored by Schwarz Biosciences GmbH, UCB Group.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:56:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Partinen-2006">
<CHAR_METHODS MODIFIED="2010-11-30 15:05:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: ITT (21/22/22/21 (ppx) and 21 (placebo)) with premature discontinuations of 1 patient in the pramipexole group and 1 patient in the placebo group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 15:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 109/107</P>
<P>Demographics: 28 male, age 56.2 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 15, weekly symptoms = 3 months and PLMS &#8805; 5/h</P>
<P>Setting: 1 research centre in Finland</P>
<P>Baseline: IRLS score of 22.4, 23.0, 23.6 and 21.7 (ascending ppx groups) and 22.9 (placebo); PLMS-I (TST) 22.3, 29.4, 24.75, 29.68 (ppx groups) and 42.85 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 09:56:04 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed doses of pramipexole (once daily, partly up-titrated) in 4 arms of 0.125 mg, 0.25 mg, 0.5 mg and 0.75 mg for 3 weeks</P>
<P>Control: placebo for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 1 week washout of RLS medication, 3 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Objective quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Subjective quality of sleep: SSQ (1-10 = excellent sleep quality)</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole; SSQ: subjective sleep quality scale - VAS</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:25:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pieta-1998">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled cross-over trial of pergolide versus placebo</P>
<P>Dropouts/withdrawals: PP (8) with dropouts of 6</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:25:53 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 14/8</P>
<P>Demographics: 3 male, age 42.5 years</P>
<P>Diagnosis: Patients on chronic haemodialysis, continuous peritoneal dialysis and symptoms of restless legs</P>
<P>Setting: 2 university hospitals in Canada</P>
<P>Baseline: none; severe secondary RLS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:25:21 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of pergolide (once daily) from 0.05 mg to 0.25 mg in 8 nights, maintenance 2 nights</P>
<P>Control: placebo for 10 nights</P>
<P>Washout between phases of 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 10:40:28 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 3 days washout before trial, 10 days each treatment period</P>
<P>Objective quality of sleep: SE, PLMS-Index (using PSG)</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:25:56 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by the Kidney Foundation of Canada.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-08-12 14:19:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:26:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staedt-1997">
<CHAR_METHODS MODIFIED="2010-11-30 14:26:03 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised active controlled cross-over trial of levodopa versus pergolide</P>
<P>Dropouts/ withdrawals: ITT (11), no premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:26:07 +0000" MODIFIED_BY="[Empty name]">
<P>Included/ analysed: 11</P>
<P>Demographics: 6 male, age 57.6 years</P>
<P>Diagnosis: patients with a history of restlessness and paraesthesias at night and/or day</P>
<P>Setting: 1 centre in Germany</P>
<P>Baseline: PLMS-disturbed time of sleep 164 ± 80.4 min</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention 1: flexible up-titration of single dose levodopa/benserazide from 250 mg to 500 mg in 16 days</P>
<P>Intervention 2: flexible up-titration of single dose pergolide from 0.125 mg to 0.25 mg in 16 days</P>
<P>Washout of 24 hours between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:58:26 +0000" MODIFIED_BY="[Empty name]">
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-24 13:45:59 +0100" MODIFIED_BY="[Empty name]">
<P>No funding stated</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-09-24 13:45:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:26:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of cabergoline versus placebo</P>
<P>Dropouts/withdrawals: ITT (84) with 6 premature discontinuations in the cabergoline group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 85/ 84</P>
<P>Demographics: 29.4% male, age 56.1 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, RLS-6 "severity at night" &#8805; 4</P>
<P>Setting: 10 German centres</P>
<P>Baseline: IRLS score of 27.2, 25.2 and 27.7 (ascending cabergoline groups) and 26.0 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of cabergoline (once daily) from 0.5 to 1.0 mg (3 days), to 1.5 mg and to 2.0 mg (4 and 7 days) in 2 weeks, 3 weeks maintenance</P>
<P>Control: placebo for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:01:26 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 1 to 2 (for levodopa) weeks washout, 5 weeks treatment</P>
<P>Change of symptoms: IRLS</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:26:11 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Pfizer GmbH and the Bundersministerium für Bildung und Forschung (BMBF, Germany).</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:26:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<CHAR_METHODS MODIFIED="2009-06-09 14:49:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of rotigotine versus placebo</P>
<P>Dropouts/withdrawals: ITT (63) with one premature discontinuation in the placebo group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:24:38 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: both 17/13/19 (rotigotine) and 14 (placebo)</P>
<P>Demographics: 36.5% male, age 58.3 years (ranging from 54.6 to 60.1 years in groups)</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 10 and RLS-6 "severity during the day when at rest" &#8805; 3</P>
<P>Setting: 9 sites in Germany</P>
<P>Baseline: IRLS score of 26.1, 26.6 and 25.9 (ascending rotigotine groups) and 25.0 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-05 10:02:46 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed dose of rotigotine patch (once daily) in 3 arms of 1.125 mg, 2.25 mg and 4.5 mg for 1 week</P>
<P>Control: placebo patches for 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-19 12:02:49 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 1 to 4 (for DAs) weeks washout, 1 week treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:26:22 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Schwarz Pharma AG.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-06-10 15:07:08 +0100" MODIFIED_BY="[Empty name]">
<P>DA: dopamine agonist</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:05:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2004a">
<CHAR_METHODS MODIFIED="2010-11-30 15:05:11 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pergolide versus placebo</P>
<P>Dropouts/withdrawals: ITT (100) with premature discontinuations of 8 (pergolide) and 9 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:26:39 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: both 100</P>
<P>Demographics: 40 male, age 56.2 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, sleep disturbances requiring treatment for the past 3 months, PLMS-AI &gt; 5 and SOL &gt; 25 or sleep efficiency &#8804; 85%</P>
<P>Setting: 17 centres in 6 European countries (Belgium, Finland, Germany, Italy, The Netherlands, Spain) and Australia</P>
<P>Baseline: IRLS score of 23.7 (pergolide) and 25.0 (placebo), PLM-I (TIB) of 39.6 (pergolide) and 44.2 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of pergolide (once daily) from 0.05 mg to 0.25 mg in 8 days, flexible adjustment to 0.75 mg in 6 weeks total including a minimum of 10 days maintenance</P>
<P>Control: placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-19 21:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: single-blind washout period of 10 to 14 days, 6 weeks treatment</P>
<P>Change of symptoms: IRLS, PGI responders</P>
<P>Objective quality of sleep: SE, PLM-Index (TIB, using PSG)</P>
<P>Safety: number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:26:42 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Eli Lilly and Company.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2004b">
<CHAR_METHODS MODIFIED="2009-06-09 14:51:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT (146/138) with premature discontinuations of 34 (ropinirole) and 29 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:26:50 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 147 (ropinirole) and 139 (placebo)/146 (ropinirole) and 138 (placebo)</P>
<P>Demographics: 58 (ropinirole) and 47 (placebo) male, age 54.0 (ropinirole) and 56.2 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 15 and symptoms &#8805; 15 nights in the previous month (or same frequency before treatment)</P>
<P>Setting: 43 hospitals, sleep centres, and neurology clinics in 10 European countries (Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom)</P>
<P>Baseline: IRLS score of 24.4 (ropinirole) and 25.2 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:27:01 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of ropinirole (once daily) from 0.25 mg to 4.0 mg (2 reductions due to AEs possible) in 7 weeks, maintenance for 5 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:27:02 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: &#8804; 7 days washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithkline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:57:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2007">
<CHAR_METHODS MODIFIED="2010-05-11 14:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised active controlled parallel-group trial with cabergoline and levodopa</P>
<P>Dropouts/withdrawals: ITT (178 (cabergoline/183 (levodopa)) with premature discontinuations of 39 (cabergoline) and 38 (levodopa) in 6 weeks and PP (104 (cabergoline) and 100 (levodopa))</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 15:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 178 (cabergoline) and 183 (levodopa)/ ITT: 178 (cabergoline), 183 (levodopa), PP: 104 (cabergoline), 100 (levodopa)</P>
<P>Demographics of ITT: 58 (cabergoline) and 46 (levodopa), age 56.9 (cabergoline) and 58.7 (levodopa) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 10 and RLS-6 "severity at night" &#8805; 4</P>
<P>Setting: 51 centres in four European countries</P>
<P>Baseline: IRLS score of 25.6 (cabergoline) and 25.8 (levodopa)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 09:57:57 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention 1: forced up-titration to single dose levodopa/benserazide 250 mg (in 8 days), severe cases 375 mg (81 patients)</P>
<P>Intervention 2: forced up-titration to single dose cabergoline 2 mg (in 14 days), severe cases 3 mg (30 patients)</P>
<P>for 42 (short term) and 210 days (long term)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:04:52 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period:1 week single-blind placebo run-in, 6 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI</P>
<P>Subjective quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:27:10 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Pfizer GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:05:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2008">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of rotigotine versus placebo</P>
<P>Dropouts/withdrawals: ITT (112/109/112 (rotigotine groups in ascending order) and 114 (placebo)) with dropouts of 31/25/40 (rotigotine) and 49 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:27:15 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 115/112/114 (rotigotine) and 117 (placebo)/112/109/112 (rotigotine) and 114 (placebo)</P>
<P>Demographics: 27% to 34% male, age ranging from 56.5 (3 mg rotigotine) to 59.7 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 15 and CGI "severity of symptoms" &#8805; 4</P>
<P>Setting: 49 centres in eight European countries (Austria, Finland, Germany, Italy, Netherlands, Spain, Sweden, UK)</P>
<P>Baseline: IRLS score of 28.1, 28.2 and 28.0 (ascending rotigotine groups) and 28.1 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 15:05:32 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of rotigotine (once daily) to 3 arms: 2.25 mg, 4.5 mg and 6.75 mg in 3 weeks, maintenance until month 6</P>
<P>Control: placebo patches for 6 months and 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-24 12:09:30 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: up to 4 weeks washout, 6 months and 3 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of Life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:27:20 +0000" MODIFIED_BY="[Empty name]">
<P>The study was sponsored by Schwarz Biosciences GmbH, UCB Group.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 09:58:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walters-2004">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of ropinirole versus placebo</P>
<P>Dropouts/withdrawals: ITT(131/135) with premature discontinuations of 29 (ropinirole) and 29 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:28:00 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 131 (ropinirole) and 136 (placebo)/131 (ropinirole) and 135 (placebo)</P>
<P>Demographics: 42% (ropinirole) and 38.5 % (placebo) male, age 54.9 (ropinirole) and 56.0 (placebo) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &#8805; 15 and symptoms &#8805; 15 nights/ previous month</P>
<P>Setting: 46 centres in Australia, Europe and North America</P>
<P>Baseline: IRLS score of 23.6 (ropinirole) and 24.8 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 09:58:37 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: Flexible up-titration of ropinirole (once daily) from 0.25 mg to 4.0 mg in 7 weeks, maintenance for 5 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:10:43 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 1 week washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Subjective quality of sleep: MOS sleep problems index II</P>
<P>Daytime tiredness: MOS somnolence</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 14:28:02 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by GlaxoSmithKline Research and Development.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 14:28:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wetter-1999">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled cross-over trial of pergolide versus placebo</P>
<P>Dropouts/withdrawals: PP (28) with premature discontinuations of 1 (pergolide) and 1 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 14:28:21 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 30/28</P>
<P>Demographics: 12 male, age 57.2 years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, PLMS-I &gt; 5, SOL &gt; 25 and/or sleep efficiency &lt; 85%</P>
<P>Setting: Max Planck Institute of Psychiatry in Munich and Department of Neurology at University of Marburg, Germany</P>
<P>Baseline: CGI-Severity of condition rating of 5.1 (rating 1-7 = extremely ill)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:28:25 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible up-titration of pergolide (once daily) from 0.05 mg to 0.75 mg in 2 weeks, maintenance for 2 weeks</P>
<P>Control: placebo for 4 weeks</P>
<P>Washout between phases of 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-19 12:12:47 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout before trial, 4 weeks each treatment period</P>
<P>Objective quality of sleep: SE, PLM-Index (using PSG)</P>
<P>Safety: number of withdrawals due to AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-06-04 15:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company provided the drugs for this study. Lilly Deutschland GmbH provided a $25,000 grant for a part-time research nurse. No pertinent financial support to the authors or their immediate families was given.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:05:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkelman-2006">
<CHAR_METHODS MODIFIED="2009-06-09 14:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled parallel group trial of pramipexole versus placebo</P>
<P>Dropouts/withdrawals: ITT (88/79/87 (ppx) and 85 (placebo)) with dropouts of 10/19/23 (ppx) and 11 (placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 15:05:34 +0000" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 88/80/90 (ppx) and 86 (placebo)/88/79/87 (ppx) and 85 (placebo)</P>
<P>Demographics: 33.3% (0.75 mg ppx) to 45.6% (0.5 mg ppx) male, age ranging from 49.6 (0.5 mg ppx) to 53.4 (0.25 mg ppx) years</P>
<P>Diagnosis: RLS according to IRLSSG criteria, IRLS &gt; 15, symptoms for 2-3 days &#8805; previous 3 months</P>
<P>Setting: 43 sites in the United States</P>
<P>Baseline: IRLS score of 23.4, 22.9 and 24.1 (ascending ppx groups) and 23.5 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 14:28:36 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed up-titration of pramipexole (once daily) from 0.125 mg in 1 week to 3 arms in 3 weeks: 0.25 mg, 0.5 mg, 0.75 mg, maintenance for 9 weeks</P>
<P>Control: placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:12:23 +0000" MODIFIED_BY="[Empty name]">
<P>Observation period: 2 weeks washout, 12 weeks treatment</P>
<P>Change of symptoms: IRLS, CGI responders, PGI responders</P>
<P>Subjective quality of sleep: VAS (0-50)</P>
<P>Quality of life: RLS-QOL</P>
<P>Safety: number of withdrawals due to AEs, number of patients with AEs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-05-11 15:00:26 +0100" MODIFIED_BY="[Empty name]">
<P>JW Winkelman has received honoraria during the course of this study from Boehringer Ingelheim, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-11-30 14:28:39 +0000" MODIFIED_BY="[Empty name]">
<P>ppx: pramipexole</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-30 14:29:17 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abetz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>Validation study of the RLS-QoL using pooled data from TREAT RLS 1 (<LINK REF="STD-Trenkwalder-2004b" TYPE="STUDY">Trenkwalder 2004b</LINK>) and TREAT RLS 2 (<LINK REF="STD-Walters-2004" TYPE="STUDY">Walters 2004</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abetz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:50 +0000" MODIFIED_BY="[Empty name]">
<P>Validation study of the IRLS using pooled data from TREAT RLS 1 and TREAT RLS (see above).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>Overview on RLS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benes-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:52 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Benes-2006" TYPE="STUDY">Benes 2006</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benes-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>Study included a first open label phase and a second withdrawal phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benes-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>Publication presenting two open label studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bingham-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>Planned study, data were not analysed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bliwise-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>Study included a first open label phase and a second withdrawal phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ebell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:55 +0000" MODIFIED_BY="[Empty name]">
<P>The reference which had been cited in CINAHL was not detectable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:56 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunning-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:56 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Earley-1998" TYPE="STUDY">Earley 1998</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinge-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:57 +0000" MODIFIED_BY="[Empty name]">
<P>No control group was implemented in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manconi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:58 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miranda-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:58 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:28:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miranda-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:28:59 +0000" MODIFIED_BY="[Empty name]">
<P>No control group was implemented in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montplaisir-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:01 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Montplaisir-1999" TYPE="STUDY">Montplaisir 1999</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montplaisir-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:01 +0000" MODIFIED_BY="[Empty name]">
<P>Study included a first open label phase and a second withdrawal phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morgan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis using pooled data from TREAT RLS 1 and 2 (<LINK REF="STD-Trenkwalder-2004b" TYPE="STUDY">Trenkwalder 2004b</LINK>; <LINK REF="STD-Walters-2004" TYPE="STUDY">Walters 2004</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:05 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oertel-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:05 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Oertel-2008" TYPE="STUDY">Oertel 2008</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Partinen-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Partinen-2006" TYPE="STUDY">Partinen 2006</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Partinen-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Partinen-2006" TYPE="STUDY">Partinen 2006</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Penzel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plowman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>Overview on RLS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Powell-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>Overview on RLS treatment results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reading-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:09 +0000" MODIFIED_BY="[Empty name]">
<P>Overview on sleep problems.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:09 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staedt-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>No control group was implemented in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>Survey study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:11 +0000" MODIFIED_BY="[Empty name]">
<P>Open label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:11 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Stiasny_x002d_Kolster-2004a" TYPE="STUDY">Stiasny-Kolster 2004a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tagaya-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were fully published in <LINK REF="STD-Wetter-1999" TYPE="STUDY">Wetter 1999</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thorpy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Discussion of TREAT RLS 2 (<LINK REF="STD-Walters-2004" TYPE="STUDY">Walters 2004</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:13 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Trenkwalder-2004b" TYPE="STUDY">Trenkwalder 2004b</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:13 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Trenkwalder-2001b" TYPE="STUDY">Trenkwalder 2001b</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:14 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:15 +0000" MODIFIED_BY="[Empty name]">
<P>Study included a first open label phase and a second withdrawal phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wetter-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:16 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Wetter-1999" TYPE="STUDY">Wetter 1999</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkelman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:16 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Winkelman-2006" TYPE="STUDY">Winkelman 2006</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-30 14:29:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yee-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-30 14:29:17 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the study were published in <LINK REF="STD-Walters-2004" TYPE="STUDY">Walters 2004</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-06-26 10:23:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-12-01 09:59:21 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-12-01 09:57:22 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:52:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>The project statistician created the randomised treatment allocation schedule by using a computer random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:53:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>The allocation schedule was generated in blocks using the Sponsor's Coding Memo System.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:53:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>The computer-based randomised treatment period was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:53:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>The computer-based randomised treatment period was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Randomization schedule was provided by BI Pharma GmbH &amp; Co KG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:08:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Randomisation code provided by BI Pharma GmbH &amp; Co. KG, the commercial program PMX CTM Release 3.3.0, Propack Data GmbH, was used to generate the code listing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-18 21:00:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>The allocation schedule was generated by the sponsor´s (GlaxoSmithKline</P>
<P>Germany) coding system. Investigators were not aware of the block size used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>Randomised using sponsor&#8217;s coding memo system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Randomly generated schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 12:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>Clin-Pro/LBL Version 5.2 release 1 software (Clinical Systems, Inc.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:45:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>A randomisation schedule was prepared prior to the start of the study by Clinical Pharmacology Statistics and Data Sciences (CPSDS), GlaxoSmithKline, Harlow, UK. Patients were assigned to study treatment in accordance with the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>The randomisation was produced using GSK internal software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>The randomisation was created in the GSK RANDALL system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:21:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>The randomization schedule was generated in GSK RANDALL system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>The randomisation schedule was generated in GSK RANDALL system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 12:51:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>Randomization was performed in blocks by the sponsor based on a computer-generated randomisation list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>Randomisation code present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 13:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>Randomisation code was provided by BI Pharmaceuticals, Inc., USA, using ClinPro/LBL Version 5.2 release 1 software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Allocation generated electronically by the department responsible for packaging new investigational drugs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>Randomisation performed at sponsor&#8217;s statistical department before patient enrolment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:55:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Randomisation code provided by BI Pharma GmbH &amp; Co KG, Medical Data Services, using the commercial programme ClinPro/LBL version 5.2 release 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:24:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>Randomization by the sponsor&#8217;s biometrical department using the procedure &#8220;PLAN&#8221; from the SAS statistical package, Version 8.2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:58:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>Randomization and patch supply were performed by the study sponsor and managed by an interactive voice response telephone system based on a computer-generated randomisation list stratified by site in blocks of 6.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Randomisation code provided by BI Pharma GmbH &amp; Co KG, Medical Data Services, using the commercial programme ClinPro/LBL version 5.2 release 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 14:14:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-24 13:47:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:26:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>Randomization was performed [...] centrally with a computer program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-23 11:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Randomization was done by the Sponsor by use of a SAS procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>Computer-generated random number sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:05:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>Sponsor&#8217;s coding memo system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:27:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Sequentially assigned to one of the two treatments by the investigators using medication numbers in ascending order for each block of 4 which was allocated to the study site after central randomisation using the program SAS Proc. Plan Version v 8.2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:07:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>Centralized allocation system, the Registration and Medication Order System (RAMOS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 15:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>Standard randomisation program ClinPro/LBL, Version 5.2, release 1 (Clinical Systems Inc.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-12-01 09:58:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-23 11:27:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>Study drug was packaged for each patient by the Mayo Clinic Pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:07:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>RAMOS assigned a randomisation number and one container number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>Each patient was provided with the respective patient kit according to his/her randomisation number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:53:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>A patient received the lowest available randomisation number and was treated with the corresponding batch of study medication throughout the double-blind treatment period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Medication package with the lowest available number was allocated to the patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-12 08:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Assigning the next available medication kit by lowest kit number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Patients were assigned the lowest available medication number available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-23 11:40:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>Numbered boxes were distributed in ascending order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:50:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>Two bottles of study medication were distributed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Two separate packets containing the maximum number of capsules.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>Patients were assigned to the lowest medication number available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:45:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>RAMOS assigned a randomisation number and two container numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>Bottles were uniquely numbered according to the randomisation schedule. Patients were not aware which treatment these numbers applied to and neither were the physicians.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:55:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>Investigators... obtain a randomisation number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:21:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>RAMOS (Registration and Medication Ordering System) was used to manage the randomisation of the patients and the ordering, dispensing and tracking of study medication. The study coordinator obtained a bottle number from RAMOS and ensured that the bottle dispensed to the subject was the correct bottle. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:56:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>RAMOS was used to mange the randomisation of the patients and the ordering, dispensing and tracking of study medication. Investigators phoned into RAMOS at screening to register the subject and again at baseline to obtain a randomisation number.  Each patient was assigned to a subject number and randomisation number. The study coordinator obtained a bottle number from RAMOS and ensured that the bottle dispensed to the subject was the correct bottle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 12:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 14:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>To enrol a subject, the investigator must call the Interactive Voice Response System (IVRS). To randomise a subject, the investigator had to call the IVRS and provide brief details of the subject to be randomised. The IVRS automatically informed the investigator of the subjects randomisation number. The IVRS allocated kit numbers to the subject based on the randomisation number during the course of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>A randomised treatment number was allocated in ascending numerical order. Corresponding coded medication packages were provided by Nippon BI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>Subjects will be assigned to one of the two treatment arms in accordance with the randomisation schedule and randomisation number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>Coded medication packages provided by BI and assigned lowest available treatment number at the site to each patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Allocation concealed by coded packaging and papers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>Numbered boxes, patients assigned by the investigators to one of the two treatments after the medication numbers in ascending order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:24:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Coded medication packages were provided by BI GmbH &amp; Co KG, a randomised treatment number was allocated in ascending numerical order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:24:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>Medication numbers in ascending order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 16:29:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-12 13:09:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Coded medication packages were provided by BI GmbH &amp; Co KG, a randomised treatment number was allocated in ascending numerical order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 14:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Medication concealed in capsules for double-blind administration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>Patients assigned to one of the available medication numbers in ascending order, numbered containers dispensed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:26:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Subject numbers were attributed to subjects in a consecutive, ascending order. If at the baseline visit the subject fulfilled all inclusion and exclusion criteria, the subject was allocated to the next free consecutive randomisation number, starting from 80001.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>Kit numbers were assigned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>Randomisation and medication ordering system (RAMOS) to register and randomise patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:58:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Medication numbers in ascending order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>Interactive voice response system to allocate patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:09:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>Allocation of container number for the medication via RAMOS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:10:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>Study numbers in consecutive order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-13 09:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>Medication numbers in ascending numerical order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-12-01 09:59:16 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-11 14:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>Placebo tablets of the same size, shape, colour, and taste as the ropinirole tablets were provided by GlaxoSmithKline. The investigators, clinical staff, and patients did not know the treatment assignments until after the data were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-12 08:38:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>Tablets were identical in appearance and packaged to be indistinguishable irrespective of treatment. Blinded status of study team, site monitors, investigators and patients was maintained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:47:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>The placebo and lisuride patches were identical in composition, size and colour with the exception that placebo patches did not contain lisuride. Every patient received an identical number of active patches or matched placebo patches of identical size. [...] statistical Analysis Plan which was to be finalized prior to unblinding of the randomisation code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:08:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>Active drug and placebo, i.e. lisuride patches and placebo patches as well as ropinirole capsules and placebo capsules, were identical in shape, size, and colour with the exception that placebo patches did not contain lisuride and placebo capsules did not contain ropinirole. (2) Active drug and placebo and their accompanying packaging and labelling were identical in appearance. A detailed description of the planned analysis was fixed in a Statistical Analysis Plan which was to be finalized prior to unblinding of the randomisation code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-11 14:54:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Tablets were packaged in identical hard gelatine capsules, the code was restricted to authorised personnel, such as staff involved in packaging of study medication. Blinding of data analysts not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-12 09:43:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Each placebo tablet matched the corresponding pramipexole tablet by size and shape; both patient and investigator were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:19:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Both patients and investigators were blinded as to the treatment allocation, persons involved had no access to the treatment allocation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:08:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>Identical tablets for active and placebo treatment; neither investigator nor patient knew if treatment was active or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:51:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>Study tablets and their packaging were identical in appearance, a blinded central reader was used for PSG. Patients, investigators and site monitors were kept blind during whole study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:19:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Implementation of identical capsules, the investigator (R.P.A.) was blinded to any dose adjustments or reports of adverse reactions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:51:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>Patients, investigators, and study site personnel were blinded to treatment identity without access to randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-24 14:45:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>Active ropinirole and placebo tablets were identical in appearance and packaging to maintain the double-blind nature of the study. The blinded status of the site monitors, investigators, and patient was thus maintained at all times.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:52:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-12 08:42:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>The blinded status of the study team, site monitors, investigators, and patient maintained at all times.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:21:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>The blinded status of study was maintained at all times for the study team (including statistician), site monitors, subjects, investigators and polysomnography technologists. </P>
<P>Once all subjects had completed the study, all data were in-house and all queries resolved; the protocol violators were determined and the database frozen, the study was then unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:22:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>The blinded status of the study was maintained at all times for the study team (including statistician), site monitors, subjects, and investigators. Once all subjects had completed the study, all data were in-house and all queries resolved; the protocol violators were determined and the database frozen, the study was then unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-12 12:52:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:27:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>Subjects and investigators were blinded as to trial medication and dose. Subjects were randomised to receive placebo or rotigotine. Rotigotine and placebo-matched patches and their accompanying packaging were identical in appearance. A detailed description was described in a Statistical Analysis Plan which was finalized prior to unblinding of the randomisation code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 15:05:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>No persons who were directly involved in the planning or analysis of the trial were granted access to the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:22:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>The blinded status of the study team, site monitors, investigators and subjects will be maintained at all times.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:54:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>Patients, investigators, and study site personnel were blinded to treatment identity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:54:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Pramipexole tablets and identical looking placebo tablets, patients, investigators, sleep specialist and sponsor were all blinded to treatment sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:54:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>Visually identical placebo tablets, blinding was not broken before the total trial database had been locked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:24:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Tablets were identical in size, colour, shape and appearance. No person directly involved in the planning or analysis, neither patient nor investigator was granted access to the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:24:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>Placebo and rotigotine patches were identical in composition, size and colour. All placebo and active rotigotine patches and their accompanying packaging were identical in appearance. Each subject received an identical number of active patches or matched placebo patches of identical size.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-11 14:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>Rotigotine and placebo patches were identical in size and appearance. Participants, investigators and polysomnography raters were blinded to the treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-12 13:10:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Tablets were identical in size, colour, shape and appearance. No person directly involved in the planning or analysis, neither patient nor investigator was granted access to the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 14:26:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>Leg movements were counted separately by blinded scorers and scored for association with arousals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:56:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Insufficient information, not mentioned if research staff was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:56:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>Visually identical placebo tablets, study blind was not broken before the total database of the trial had been frozen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-11 14:59:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Placebo and rotigotine patches were identical in composition with the exception that the placebo patches did not contain rotigotine. All placebo and active rotigotine patches and their accompanying packaging were identical in appearance. Each subject received an identical number of active patches or matched placebo of identical size. By these measures, the subjects and all other persons involved in the trial, remained blind until the randomisation code list was opened.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:57:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>Identical capsules, PSG recordings were read at an independent centre by a blinded rater.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:57:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>Identical looking tablets; investigators, patients and study monitors were blinded to the treatment status of the patients at all times.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:58:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Identical looking tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-12 15:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>Identical looking tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-12 15:15:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>Identical looking tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-24 15:06:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>No information about blinding of PSG raters or other investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:59:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>Sub-investigators who performed solely the CGI-I assessment were unaware of the patients&#8217; IRLS self-ratings and of reported adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-12-01 09:59:18 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-23 11:27:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>Subjects who discontinued study drug prematurely had outcomes measured at the time of discontinuation and were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 15:04:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>Dropouts and LOCF method reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-10 15:47:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>LOCF method used for incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-10 15:47:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>LOCF method used for incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:49:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Dropouts and reasons reported by BI on request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:08:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:49:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:08:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:51:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>All drop outs and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:51:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Description of invalid data of 1 patient (placebo) present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:51:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:20:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:21:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 15:04:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-24 14:39:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-10 16:26:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>Numbers of patients in groups and dropouts were given by monitoring company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:22:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:53:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:54:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:54:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Dropout of one patient before treatment start reported and explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:55:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>3 patients dropped out due to intolerable AEs in cabergoline group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:55:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Drop outs and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 15:05:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:56:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:56:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:56:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>Dropouts before and during trial and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:26:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:57:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:57:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:58:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Dropouts and reasons described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:58:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>Dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:28:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>Dropouts and reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-30 14:28:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>Dropouts and reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-01 09:59:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>All dropouts and reasons reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-12-01 09:59:20 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-23 11:27:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:07:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 15:47:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>All review specific outcomes reported after request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 15:47:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>All review specific outcomes reported after request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:13:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Outcomes reported by pharmaceutical company after request as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:50:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Outcomes reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:18:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>Outcomes changed in planning phase of study, investigated and reported as in lastly updated protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Results reported as prespecified, results of placebo-group only in graph.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>All results reported as prespecified with additional report of RLS-6 scales 4-6 on request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:47:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>All endpoints were investigated as presented in protocol. However, primary endpoints were changed from PLMAI and sleep latency and several secondary outcomes in the study protocol to the primary endpoint PLMI and several secondary outcomes in the online publication of the pharmaceutical company. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:42:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Results reported as prespecified in methods section without report of CGI-S and ESS. Additionally, sleep efficiency and sleep latency were described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 16:26:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>All relevant results reported by monitoring company after request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-25 08:58:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>Results reported as prespecified in the study protocol. Additionally, data were reported in the online publication of the pharmaceutical company for parameters not prespecified in the study protocol such as polysomnography data, SIT, PSQI, ESS, CGI and PGI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:53:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>Results reported as prespecified with additional information for PGI, CGI and IRLS data by pharmaceutical publication and requested information of GSK.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>All results reported as prespecified with additional PGI and IRLS data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Results reported as prespecified without data report for non significant sleep data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>All results reported as prespecified with no report of CGI-therapeutic effect and side effects in results section as prespecified in methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:24:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Results reported as prespecified. Additionally, SF-36 and ESS were reported in online publication of the pharmaceutical company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:54:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>All results were reported as prespecified. CGI therapeutic effect was not reported as described in methods section of the online publication of the pharmaceutical company and in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 15:01:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>Results reported as prespecified in the study protocol and methods section. Additionally, polysomnography data, the RLS-6 scales, the MOS, ESS, ASRS, CGI 2 and 3, RLS-QoL and ratings of depression and tolerability were implemented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 16:19:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>Results described as prespecified and data partly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>All results reported as prespecified, additional sleep data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 15:04:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Results were reported as prespecified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 09:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>All results reported as prespecified with further report of short term data for secondary outcomes following request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:27:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>All results reported as prespecified with additional results for MOS, CGI-I responders and RLS-QoL.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:28:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>All results reported as prespecified without data report of MOS, SF-36 and WPAI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:28:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>All results reported as prespecified without report of SOL and PLMS total data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:59:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>All results reported as prespecified, with IRLS and quality of sleep described in figures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-12-01 09:59:21 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-23 11:27:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adler-2004">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:07:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-2004">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:04:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2005">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:08:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Axxonis-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:18:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:49:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2009">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:18:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-2010">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogan-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Earley-1998">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:51:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferini_x002d_Strambi-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:45:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-2005">
<DESCRIPTION>
<P>Population size was based on feasibility.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:20:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2007">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:21:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2008">
<DESCRIPTION>
<P>The study was abandoned prematurely after 39 subjects were randomised for administrative reasons unrelated to safety or efficacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GSK-2009">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:39:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Borreguero-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:05:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hening-2010">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:22:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2010">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:53:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kushida-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montagna-2010">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:54:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montplaisir-1999">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:55:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:55:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2007">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:13:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oertel-2010">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:25:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Partinen-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pieta-1998">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:56:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:26:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004a">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:57:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2004b">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:58:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:58:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2008">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:58:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walters-2004">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetter-1999">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 09:59:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkelman-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-11-30 14:31:41 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-11-30 14:30:40 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-30 14:30:09 +0000" MODIFIED_BY="[Empty name]">Summary of findings: dopamine agonists versus placebo</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Dopamine agonists compared with placebo for restless legs syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients with restless legs syndrome according to IRLSSG, 18 years or older</P>
<P>
<B>Settings: </B>outpatient settings in Europe, North America and Japan.</P>
<P>
<B>Intervention: </B>treatment with dopamine agonists for at least seven days</P>
<P>
<B>Comparison: </B>placebo treatment for at least seven days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Dopamine agonists</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>1</B>
</P>
<P>
<B>IRLS</B>
</P>
<P>range: 0 to 40</P>
<P>(= severe)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS change from baseline ranged across control groups from<BR/>-1.8 to -13.4.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS change from baseline in the intervention groups was<BR/>-5.74 larger<BR/>(95% CI -6.74 to -4.74).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6380</P>
<P>(30 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (I² = 75%) which can be explained partly by medication subgroups and possibility of publication bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>2</B>
</P>
<P>
<B>Periodic limb movements in sleep (PLMS Index)</B>
</P>
<P>PLMS per hour of sleep (8 trials) or time in bed (7 trials)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean PLMS Index change ranged across control groups from<BR/>21 to -16.6.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean PLMS Index change in the intervention groups was<BR/>-22.86 larger (95%CI -28.3 to -17.41).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1141</P>
<P>(15 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (I² = 73%) which can be explained partly by medication subgroups and possibility of publication bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>3</B>
</P>
<P>
<B>Sleep efficiency</B>
</P>
<P>Percentage of total sleep time per time in bed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean sleep efficiency change ranged across control groups from<BR/>0.6 to 6.1 percent.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean sleep efficiency change in the intervention groups was<BR/>4.61 percent larger (95% CI 2.14 to 7.04).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>677</P>
<P>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>4</B>
</P>
<P>
<B>Number of dropouts due to adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
<P>66 per 1000 (50 to 86)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OR 1.82 (1.35 to 2.45)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7054</P>
<P>(34 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>5</B>
</P>
<P>
<B>Clinical Global Impressions - Improvement of condition (CGI-I)</B>
</P>
<P>Rating of 1 = very much improved to 7 = very much worse</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50 per 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 per 100</P>
<P>(67 to 77)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.44 (1.34 to 1.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6338</P>
<P>(27 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>6</B>
</P>
<P>
<B>Subjective quality of sleep</B>
</P>
<P>SMD on questionnaires MOS, RLS-6, PSQI, VAS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No comparable data can be given for placebo group as SMDs of different questionnaires were calculated.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean subjective quality of sleep in the intervention groups had a<BR/>SMD of 0.40 (95% CI 0.33 to 0.47).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<BR/>4592</P>
<P>(22 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>7</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>SMD on 2 RLS-QoL questionnaires</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean subjective quality of life in the intervention groups had a SMD of<BR/>0.34 (95% CI 0.23 to 0.44).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4312</P>
<P>(17 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (I² = 61%) which can be explained partly by medication subgroups.</P>
<P>No comparable data can be given for placebo group as SMDs of different questionnaires were calculated.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; OR: Odds Ratio; RR: Risk Ratio; SMD: standardised mean difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-11-30 14:31:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-30 14:31:04 +0000" MODIFIED_BY="[Empty name]">Summary of findings: dopamine agonists versus levodopa</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Dopamine agonists compared with levodopa for restless legs syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients with restless legs syndrome</P>
<P>
<B>Settings: </B>outpatient settings in Europe</P>
<P>
<B>Intervention: </B>treatment with dopamine agonists cabergoline, pergolide, pramipexole for at least seven days</P>
<P>
<B>Comparison: </B>treatment with levodopa for at least seven days<B> </B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Levodopa</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Other dopamine agonists</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>1</B>
</P>
<P>
<B>IRLS</B>
</P>
<P>range: 0 to 40</P>
<P>(= severe)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS change ranged across levodopa groups from<BR/>-4.4 to -9.55.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS change in the intervention groups was<BR/>-5.25 larger (95% CI -8.40 to -2.10).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>383<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Estimated effect based on only two studies.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>2</B>
</P>
<P>
<B>Periodic limb movements per hour of time in bed</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean PLMI was -7.7 in the levodopa group.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean PLMI in the pramipexole was<BR/>-3.80 larger (95% CI -9.08 to 1.48, P = 0.16).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++OO</P>
<P>low</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methods of the study were not sufficiently reported. Estimated effect based on only one study.</P>
<P>Treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
<P>
<B>3</B>
</P>
<P>
<B>Number of drop outs due to adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 per 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 per 100 (2 to 5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OR 1.70 (95% CI 0.96 to 3.01, P = 0.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>504</P>
<P>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment difference was not significant and the result shows no to a significant effect.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>4</B>
</P>
<P>
<B>Clinical Global Impressions - Improvement of condition (CGI-I)</B>
</P>
<P>Rating of 1 = very much improved to 7 = very much worse</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58 per 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 per 100 (58 to 72)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.19 (95% CI 0.91 to 1.56)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>422<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment difference was not significant and the result shows no to a significant effect.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>5</B>
</P>
<P>
<B>Subjective quality of sleep</B>
</P>
<P>RLS-6; scale satisfaction with sleep: 0 to 10 (= low satisfaction)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in satisfaction with sleep was -2.8 in levodopa.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in satisfaction with sleep in cabergoline was<BR/>-0.63 larger (95% CI -1.35 to 0.09, P = 0.09).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>344<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++OO</P>
<P>low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Estimated effect based on only one study.</P>
<P>Treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>6</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>RLS-QoL: 0 to 60 (= severe impairment)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in quality of life was -10.38 in levodopa.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean difference in RLS-QoL in the intervention group was<BR/>-5.54 larger (95% CI -8.43 to -2.65).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>314<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Estimated effect based on only one study.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>7</B>
</P>
<P>
<B>Number of patients experiencing adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54 per 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 per 100 (63 to 80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OR 2.87 (95% CI 0.43 to 19.00)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>461<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment difference was not significant and the result shows no to a significant effect.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; OR: Odds Ratio; RR: Risk Ratio</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2010-11-30 14:31:41 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-01-08 13:22:44 +0000" MODIFIED_BY="[Empty name]">Summary of findings: subgroups of dopamine agonists on IRLS</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Subgroups of dopamine agonists compared with placebo for restless legs syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients with restless legs syndrome</P>
<P>
<B>Settings: </B>outpatient settings in Europe, North America, Australia and Japan</P>
<P>
<B>Intervention: </B>treatment with dopamine agonists for at least seven days</P>
<P>
<B>Comparison: </B>treatment with placebo for at least seven days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Dopamine agonists</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>IRLS all dopamine agonists</B>
</P>
<P>range: 0 to 40</P>
<P>(= severe)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-1.8 to -13.4.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-5.74 larger<BR/>(95% CI -6.74 to -4.74).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6380<BR/>(30 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (I² = 75%) which can be explained partly by medication subgroups and possibility of publication bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>1</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>cabergoline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-3.3 to -7.9.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-11.49 larger (95% CI -15.14 to -7.84).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>127<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>3</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>lisuride</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-6.9 to -8.2.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-8.00 larger (95% CI -10.28 to -5.72).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<BR/>378<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>2</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>pergolide</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The post mean IRLS was 23.2 in the control group.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention group was<BR/>-11.70 larger (95% CI -14.8 to -8.6).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>4</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>pramipexole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-5.7 to -12.2.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-5.16 larger (95% CI -6.87 to -3.45).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2256<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (76%) in pramipexole trials.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>5</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>ropinirole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-0.3 to -13.4.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-4.19 larger (95% CI -5.4 to -2.97).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2301<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>+++O</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inconsistent results (58%) in ropinirole trials.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>6</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>rotigotine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS ranged across control groups from<BR/>-8.0 to -9.9.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention groups was<BR/>-6.98 larger (95% CI -8.99 to -4.96).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>958<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>7</B>
</P>
<P>
<B>IRLS </B>
</P>
<P>sumanirole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS was -10.1 in the control group.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IRLS in the intervention group was<BR/>-1.83 larger (95% CI -4.71 to 1.05).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>263<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>++++</P>
<P>high</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; I²: Inconsistency</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-01-12 15:21:58 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-12 15:21:58 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-05-10 13:27:25 +0100" MODIFIED_BY="[Empty name]">Diagnosis criteria of restless legs syndrome</TITLE>
<TABLE COLS="1" ROWS="4">
<TR>
<TH>
<P>
<B>Essential criteria</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).</P>
<P>2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.</P>
<P>3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</P>
<P>4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been present previously).</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Supportive criteria and associated features of RLS</B>
</P>
</TH>
</TR>
<TR>
<TD>
<UL>
<LI>Positive family history</LI>
<LI>Response to dopaminergic therapy</LI>
<LI>Periodic limb movements (during wakefulness or sleep)</LI>
<LI>Natural clinical course</LI>
<LI>Sleep disturbance</LI>
</UL>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-11-30 14:31:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-06-17 14:19:22 +0100" MODIFIED_BY="[Empty name]">Number of retrieved trials/ additional information for published trials in online searches</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Online resource</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Retrieved additional trials</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Additional information for published trials</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>clinical trials</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>GlaxoSmithKline</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Boehringer Ingelheim</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Lilly</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>clinical study results</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<U>Internet sites: </U>
</P>
<P>www.clinicaltrials.gov</P>
<P>www.gsk-clinicalstudyregister.com</P>
<P>http://trials.boehringer-ingelheim.com</P>
<P>www.lillytrials.com</P>
<P>www.clinicalstudyresults.org</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-11-30 14:31:47 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-04-01 14:17:39 +0100" MODIFIED_BY="[Empty name]">Summary of questionnaires in trials and their scoring</TITLE>
<TABLE COLS="3" ROWS="11">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Questionnaire</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Description</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Measurement</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>IRLS</P>
</TD>
<TD>
<P>Symptom severity scale with a total score of 0 to 40 for 10 questions (rating 0 to 4; <LINK REF="REF-Walters-2003" TYPE="REFERENCE">Walters 2003</LINK>).</P>
</TD>
<TD>
<P>Mild RLS: 0 to 10</P>
<P>Moderate RLS: 11 to 20</P>
<P>Severe RLS: 21 to 30</P>
<P>Very severe RLS: 31 to 40</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Impressions - Improvement Scale</P>
</TD>
<TD>
<P>Evaluation by clinician regarding improvement of condition (<LINK REF="REF-National-Institute-of-Mental-Health-1976" TYPE="REFERENCE">National Institute of Mental Health 1976</LINK>).</P>
</TD>
<TD>
<P>Rating 1 (very much better) to 7 (very much worse)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>SF-A</P>
</TD>
<TD>
<P>Subscore of questions regarding subjective quality of sleep (<LINK REF="REF-Goertelmeyer-1985" TYPE="REFERENCE">Goertelmeyer 1985</LINK>).</P>
</TD>
<TD>
<P>Rating 1 to 5</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>PSQI</P>
</TD>
<TD>
<P>Index score of 18 questions regarding sleep of the past 4 weeks with a cut-off score of &#8805; 5 for "bad" sleepers (<LINK REF="REF-Buysse-1989" TYPE="REFERENCE">Buysse 1989</LINK>).</P>
</TD>
<TD>
<P>0 to 21 points</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>MOS Sleep Problems Index II</P>
</TD>
<TD>
<P>Index score of 6 questions regarding severity of sleep problems (<LINK REF="REF-Hays-2005" TYPE="REFERENCE">Hays 2005</LINK>).</P>
</TD>
<TD>
<P>Rating 0 (lowest) to 100 (highest)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>MOS somnolence</P>
</TD>
<TD>
<P>Score of 3 questions regarding severity of sleep problems (<LINK REF="REF-Hays-2005" TYPE="REFERENCE">Hays 2005</LINK>).</P>
</TD>
<TD>
<P>Rating 0 (lowest) to 100 (highest)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>RLS-6 satisfaction with sleep</P>
</TD>
<TD>
<P>Question regarding satisfaction with sleep in the past 7 days (<LINK REF="REF-Kohnen-2004" TYPE="REFERENCE">Kohnen 2004</LINK>).</P>
</TD>
<TD>
<P>Rating 0 (totally satisfied) to 10 (totally unsatisfied)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>RLS-6 daytime tiredness</P>
</TD>
<TD>
<P>Question regarding daytime somnolence in the past 7 days (<LINK REF="REF-Kohnen-2004" TYPE="REFERENCE">Kohnen 2004</LINK>).</P>
</TD>
<TD>
<P>Rating 0 (not at all) to 10 (very tired)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>John Hopkins RLS QoL</P>
</TD>
<TD>
<P>Total score of 10 questions investigating health related quality of life in RLS patients (<LINK REF="REF-Abetz-2005" TYPE="REFERENCE">Abetz 2005</LINK>).</P>
</TD>
<TD>
<P>0 (lowest) to 100 (highest)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>QoL-RLS</P>
</TD>
<TD>
<P>Total score of 12 questions investigating health related quality of life in RLS patients (6-point Likert scale; <LINK REF="REF-Kohnen-2002" TYPE="REFERENCE">Kohnen 2002</LINK>).</P>
</TD>
<TD>
<P>0 to 60 (high impairment)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IRLS: International RLS Severity Rating Scale; SF-A: Schlaffragebogen-A; PSQI: Pittsburgh Sleep Quality Inventory; MOS: Medical Outcomes Study 12-item Sleep Scale; John Hopkins RLS QoL: Restless Legs Syndrome Quality of Life questionnaire; QoL-RLS: Restless Legs Syndrome Quality of Life questionnaire.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-01-11 16:00:44 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Dopamine agonists versus placebo</NAME>
<IV_OUTCOME CHI2="115.19823454566136" CI_END="-4.739084163740584" CI_START="-6.740265777158733" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_SIZE="-5.739674970449658" ESTIMABLE="YES" I2="74.82600309425297" I2_Q="81.69287679994024" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-11-30 15:10:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.1644686870890837E-12" P_Q="0.019430532795616906" P_Z="2.5095965862810475E-29" Q="5.462354675128509" RANDOM="YES" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.2316721950380645" TOTALS="YES" TOTAL_1="1600" TOTAL_2="1780" WEIGHT="100.0" Z="11.242913836123405">
<NAME>Change on IRLS</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-5.996504804988441" CI_START="-17.40349519501156" DF="0" EFFECT_SIZE="-11.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-11-30 15:10:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.804552775633436E-5" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.9024072353402006" Z="4.020618556701031">
<NAME>Cross-over trial</NAME>
<IV_DATA CI_END="-5.996504804988441" CI_START="-17.40349519501156" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:37:21 +0000" MODIFIED_BY="[Empty name]" ORDER="458" SE="2.91" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.9024072353402006"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="109.73587987053286" CI_END="-4.617206662440428" CI_START="-6.604779233644213" DF="28" EFFECT_SIZE="-5.610992948042321" ESTIMABLE="YES" I2="74.48418873295171" ID="CMP-001.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-04-14 11:31:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.266031723901051E-11" P_Z="1.831894786823076E-28" STUDIES="29" TAU2="4.998146765667989" TOTAL_1="1578" TOTAL_2="1758" WEIGHT="98.0975927646598" Z="11.06610571609022">
<NAME>Parallel group trials</NAME>
<IV_DATA CI_END="2.75912724877091" CI_START="-5.1591272487709094" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:28:21 +0000" MODIFIED_BY="[Empty name]" ORDER="400" SE="2.02" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.7987912035562115"/>
<IV_DATA CI_END="-4.785668069219298" CI_START="-12.194331930780702" EFFECT_SIZE="-8.49" ESTIMABLE="YES" ESTIMATE="-8.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:46:25 +0000" MODIFIED_BY="[Empty name]" ORDER="503" SE="1.89" STUDY_ID="STD-Axxonis-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.960383931906161"/>
<IV_DATA CI_END="-4.79925330288072" CI_START="-10.60074669711928" EFFECT_SIZE="-7.7" ESTIMABLE="YES" ESTIMATE="-7.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:46:00 +0000" MODIFIED_BY="[Empty name]" ORDER="499" SE="1.48" STUDY_ID="STD-Axxonis-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.511491812728084"/>
<IV_DATA CI_END="-1.3816554638083165" CI_START="-7.418344536191684" EFFECT_SIZE="-4.4" ESTIMABLE="YES" ESTIMATE="-4.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:11:08 +0000" MODIFIED_BY="[Empty name]" ORDER="407" SE="1.54" STUDY_ID="STD-Benes-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.427806486181235"/>
<IV_DATA CI_END="0.050364344694653784" CI_START="-3.8303643446946536" EFFECT_SIZE="-1.89" ESTIMABLE="YES" ESTIMATE="-1.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:53 +0000" MODIFIED_BY="[Empty name]" ORDER="427" SE="0.99" STUDY_ID="STD-BI-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-0.7224381763875423" CI_START="-4.877561823612457" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:55 +0000" MODIFIED_BY="[Empty name]" ORDER="434" SE="1.06" STUDY_ID="STD-BI-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.100933043702121"/>
<IV_DATA CI_END="-2.034030613140954" CI_START="-5.365969386859046" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:28:35 +0000" MODIFIED_BY="[Empty name]" ORDER="403" SE="0.85" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="192" WEIGHT="4.3771904628610265"/>
<IV_DATA CI_END="-1.8596356553053461" CI_START="-5.740364344694654" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="405" SE="0.99" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="1.0511470572738797" CI_START="-4.71114705727388" EFFECT_SIZE="-1.83" ESTIMABLE="YES" ESTIMATE="-1.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:38:59 +0000" MODIFIED_BY="[Empty name]" ORDER="406" SE="1.47" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.525504392618072"/>
<IV_DATA CI_END="-5.010090038649865" CI_START="-14.809909961350137" EFFECT_SIZE="-9.91" ESTIMABLE="YES" ESTIMATE="-9.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:01:00 +0000" MODIFIED_BY="[Empty name]" ORDER="413" SE="2.5" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" WEIGHT="2.2699259570932657"/>
<IV_DATA CI_END="-4.086432774068551" CI_START="-7.653567225931449" EFFECT_SIZE="-5.87" ESTIMABLE="YES" ESTIMATE="-5.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:58 +0000" MODIFIED_BY="[Empty name]" ORDER="402" SE="0.91" STUDY_ID="STD-GSK-2007" TOTAL_1="181" TOTAL_2="193" WEIGHT="4.300911801221465"/>
<IV_DATA CI_END="0.8074987965575522" CI_START="-10.207498796557552" EFFECT_SIZE="-4.7" ESTIMABLE="YES" ESTIMATE="-4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:57 +0000" MODIFIED_BY="[Empty name]" ORDER="410" SE="2.81" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.9852984466171526"/>
<IV_DATA CI_END="-0.38323889669674127" CI_START="-4.616761103303259" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:55 +0000" MODIFIED_BY="[Empty name]" ORDER="432" SE="1.08" STUDY_ID="STD-GSK-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.073499790540869"/>
<IV_DATA CI_END="-2.941237095923744" CI_START="-6.978762904076255" EFFECT_SIZE="-4.96" ESTIMABLE="YES" ESTIMATE="-4.96" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:59:32 +0000" MODIFIED_BY="[Empty name]" ORDER="513" SE="1.03" STUDY_ID="STD-Hening-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-4.251300122978649" CI_START="-15.14869987702135" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:01:00 +0000" MODIFIED_BY="[Empty name]" ORDER="412" SE="2.78" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.010987697763853"/>
<IV_DATA CI_END="-2.1500360154599463" CI_START="-6.069963984540054" EFFECT_SIZE="-4.11" ESTIMABLE="YES" ESTIMATE="-4.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:22:00 +0000" MODIFIED_BY="[Empty name]" ORDER="414" SE="1.0" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="4.182271616774881"/>
<IV_DATA CI_END="-4.159635655305346" CI_START="-8.040364344694654" EFFECT_SIZE="-6.1" ESTIMABLE="YES" ESTIMATE="-6.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:22:07 +0000" MODIFIED_BY="[Empty name]" ORDER="415" SE="0.99" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="196" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-6.213328935346606" CI_START="-20.246671064653395" EFFECT_SIZE="-13.23" ESTIMABLE="YES" ESTIMATE="-13.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:26:54 +0000" MODIFIED_BY="[Empty name]" ORDER="416" SE="3.58" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.44406258267951"/>
<IV_DATA CI_END="-4.483238896696741" CI_START="-8.71676110330326" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:29:18 +0000" MODIFIED_BY="[Empty name]" ORDER="417" SE="1.08" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" WEIGHT="4.073499790540869"/>
<IV_DATA CI_END="-3.7612551036537165" CI_START="-9.758744896346283" EFFECT_SIZE="-6.76" ESTIMABLE="YES" ESTIMATE="-6.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:49:27 +0000" MODIFIED_BY="[Empty name]" ORDER="418" SE="1.53" STUDY_ID="STD-Oertel-2008" TOTAL_1="0" TOTAL_2="53" WEIGHT="3.4417031723290035"/>
<IV_DATA CI_END="-1.5824921995774606" CI_START="-11.617507800422539" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-23 15:00:04 +0000" MODIFIED_BY="[Empty name]" ORDER="467" SE="2.56" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.2114504709807203"/>
<IV_DATA CI_END="-6.488861946591106" CI_START="-13.231138053408893" EFFECT_SIZE="-9.86" ESTIMABLE="YES" ESTIMATE="-9.86" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:47:53 +0000" MODIFIED_BY="[Empty name]" ORDER="419" SE="1.72" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.1822119665981514"/>
<IV_DATA CI_END="-6.577278513702681" CI_START="-15.12272148629732" EFFECT_SIZE="-10.85" ESTIMABLE="YES" ESTIMATE="-10.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 09:23:38 +0000" MODIFIED_BY="[Empty name]" ORDER="420" SE="2.18" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.6104123885748356"/>
<IV_DATA CI_END="-6.696504804988442" CI_START="-18.103495195011558" EFFECT_SIZE="-12.4" ESTIMABLE="YES" ESTIMATE="-12.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:52:34 +0000" MODIFIED_BY="[Empty name]" ORDER="421" SE="2.91" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.9024072353402006"/>
<IV_DATA CI_END="-8.603256904426713" CI_START="-14.796743095573285" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:29:38 +0000" MODIFIED_BY="[Empty name]" ORDER="422" SE="1.58" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="51" WEIGHT="3.372451122168191"/>
<IV_DATA CI_END="-0.991237095923744" CI_START="-5.028762904076256" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:29:41 +0000" MODIFIED_BY="[Empty name]" ORDER="423" SE="1.03" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-4.842456184117516" CI_START="-10.957543815882484" EFFECT_SIZE="-7.9" ESTIMABLE="YES" ESTIMATE="-7.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:53:56 +0000" MODIFIED_BY="[Empty name]" ORDER="425" SE="1.56" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="0" TOTAL_2="114" WEIGHT="3.4000809212259804"/>
<IV_DATA CI_END="-0.40283853654214186" CI_START="-4.597161463457859" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:29:55 +0000" MODIFIED_BY="[Empty name]" ORDER="426" SE="1.07" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.087234481032539"/>
<IV_DATA CI_END="-1.9860414177789378" CI_START="-6.493958582221063" EFFECT_SIZE="-4.24" ESTIMABLE="YES" ESTIMATE="-4.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:30:32 +0000" MODIFIED_BY="[Empty name]" ORDER="428" SE="1.15" STUDY_ID="STD-Winkelman-2006" TOTAL_1="0" TOTAL_2="85" WEIGHT="3.976481693002201"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="115.19823454566136" CI_END="-4.73908416374058" CI_START="-6.7402657771587275" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_SIZE="-5.739674970449654" ESTIMABLE="YES" I2="74.82600309425297" I2_Q="88.93183113094847" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-12-01 11:23:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.1644686870890837E-12" P_Q="6.693229304133297E-10" P_Z="2.5095965862812454E-29" Q="54.20950900719462" RANDOM="YES" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.2316721950380645" TOTALS="YES" TOTAL_1="1600" TOTAL_2="1780" WEIGHT="100.0" Z="11.242913836123398">
<NAME>Medication subgroups: change on IRLS</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.322412458449069" CI_END="-7.844436588932994" CI_START="-15.14315414008663" DF="1" EFFECT_SIZE="-11.493795364509811" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-03-22 13:29:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5701615725304006" P_Z="6.701396870435915E-10" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="42" WEIGHT="4.054474971254345" Z="6.172981705957911">
<NAME>Cabergoline</NAME>
<IV_DATA CI_END="-6.213328935346606" CI_START="-20.246671064653395" EFFECT_SIZE="-13.23" ESTIMABLE="YES" ESTIMATE="-13.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:29:55 +0000" MODIFIED_BY="[Empty name]" ORDER="441" SE="3.58" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.4440625826795097"/>
<IV_DATA CI_END="-6.577278513702681" CI_START="-15.12272148629732" EFFECT_SIZE="-10.85" ESTIMABLE="YES" ESTIMATE="-10.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 08:59:00 +0000" MODIFIED_BY="[Empty name]" ORDER="442" SE="2.18" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.610412388574835"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.10830368763557485" CI_END="-5.7164466584126545" CI_START="-10.28413156284548" DF="1" EFFECT_SIZE="-8.000289110629067" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-03-11 14:48:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.742083726323187" P_Z="6.614541561737556E-12" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.471875744634244" Z="6.865744398228359">
<NAME>Lisuride</NAME>
<IV_DATA CI_END="-4.785668069219298" CI_START="-12.194331930780702" EFFECT_SIZE="-8.49" ESTIMABLE="YES" ESTIMATE="-8.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:48:18 +0000" MODIFIED_BY="[Empty name]" ORDER="504" SE="1.89" STUDY_ID="STD-Axxonis-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.9603839319061604"/>
<IV_DATA CI_END="-4.79925330288072" CI_START="-10.60074669711928" EFFECT_SIZE="-7.7" ESTIMABLE="YES" ESTIMATE="-7.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-28 08:45:19 +0000" MODIFIED_BY="[Empty name]" ORDER="500" SE="1.48" STUDY_ID="STD-Axxonis-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5114918127280834"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-8.603256904426713" CI_START="-14.796743095573285" DF="0" EFFECT_SIZE="-11.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-01-28 08:44:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.3108793404707733E-13" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="51" WEIGHT="3.3724511221681905" Z="7.40506329113924">
<NAME>Pergolide</NAME>
<IV_DATA CI_END="-8.603256904426713" CI_START="-14.796743095573285" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:06:21 +0000" MODIFIED_BY="[Empty name]" ORDER="443" SE="1.58" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="51" WEIGHT="3.3724511221681905"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="29.561975538701862" CI_END="-3.448197041977865" CI_START="-6.867054823906901" DF="7" EFFECT_SIZE="-5.157625932942383" ESTIMABLE="YES" I2="76.32093298082951" ID="CMP-001.02.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-12-01 11:23:25 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.142307419251809E-4" P_Z="3.348500712103132E-9" STUDIES="8" TAU2="4.385775734951668" TOTAL_1="604" TOTAL_2="574" WEIGHT="29.931123950515392" Z="5.913531196137185">
<NAME>Pramipexole</NAME>
<IV_DATA CI_END="0.050364344694653784" CI_START="-3.8303643446946536" EFFECT_SIZE="-1.89" ESTIMABLE="YES" ESTIMATE="-1.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-01 11:23:25 +0000" MODIFIED_BY="[Empty name]" ORDER="499" SE="0.99" STUDY_ID="STD-BI-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-0.7224381763875423" CI_START="-4.877561823612457" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-01 11:23:25 +0000" MODIFIED_BY="[Empty name]" ORDER="501" SE="1.06" STUDY_ID="STD-BI-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.1009330437021205"/>
<IV_DATA CI_END="-1.8596356553053461" CI_START="-5.740364344694654" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-17 12:16:21 +0000" MODIFIED_BY="[Empty name]" ORDER="500" SE="0.99" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-4.251300122978649" CI_START="-15.14869987702135" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-18 13:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="502" SE="2.78" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.0109876977638526"/>
<IV_DATA CI_END="-4.159635655305346" CI_START="-8.040364344694654" EFFECT_SIZE="-6.1" ESTIMABLE="YES" ESTIMATE="-6.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:21:13 +0000" MODIFIED_BY="[Empty name]" ORDER="504" SE="0.99" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="196" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-4.483238896696741" CI_START="-8.71676110330326" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-18 13:57:30 +0000" MODIFIED_BY="[Empty name]" ORDER="506" SE="1.08" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" WEIGHT="4.073499790540868"/>
<IV_DATA CI_END="-6.488861946591106" CI_START="-13.231138053408893" EFFECT_SIZE="-9.86" ESTIMABLE="YES" ESTIMATE="-9.86" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-18 13:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="505" SE="1.72" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.182211966598151"/>
<IV_DATA CI_END="-1.9860414177789378" CI_START="-6.493958582221063" EFFECT_SIZE="-4.24" ESTIMABLE="YES" ESTIMATE="-4.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 09:16:23 +0000" MODIFIED_BY="[Empty name]" ORDER="507" SE="1.15" STUDY_ID="STD-Winkelman-2006" TOTAL_1="0" TOTAL_2="85" WEIGHT="3.9764816930022007"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="23.815439855370677" CI_END="-2.969609625514334" CI_START="-5.400657176469133" DF="10" EFFECT_SIZE="-4.185133400991734" ESTIMABLE="YES" I2="58.010433312467775" ID="CMP-001.02.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-12-01 11:23:39 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.008105645055893618" P_Z="1.4959449800379845E-11" STUDIES="11" TAU2="2.1671141846814135" TOTAL_1="930" TOTAL_2="932" WEIGHT="37.547132750076344" Z="6.748293124268829">
<NAME>Ropinirole</NAME>
<IV_DATA CI_END="-5.996504804988441" CI_START="-17.40349519501156" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-01 10:19:53 +0000" MODIFIED_BY="[Empty name]" ORDER="546" SE="2.91" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.9024072353402004"/>
<IV_DATA CI_END="2.75912724877091" CI_START="-5.1591272487709094" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 12:06:39 +0000" MODIFIED_BY="[Empty name]" ORDER="508" SE="2.02" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.7987912035562115"/>
<IV_DATA CI_END="-1.3816554638083165" CI_START="-7.418344536191684" EFFECT_SIZE="-4.4" ESTIMABLE="YES" ESTIMATE="-4.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 13:11:18 +0000" MODIFIED_BY="[Empty name]" ORDER="512" SE="1.54" STUDY_ID="STD-Benes-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.4278064861812347"/>
<IV_DATA CI_END="-2.034030613140954" CI_START="-5.365969386859046" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="510" SE="0.85" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="192" WEIGHT="4.377190462861026"/>
<IV_DATA CI_END="-5.010090038649865" CI_START="-14.809909961350137" EFFECT_SIZE="-9.91" ESTIMABLE="YES" ESTIMATE="-9.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-01 11:23:30 +0000" MODIFIED_BY="[Empty name]" ORDER="515" SE="2.5" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" WEIGHT="2.2699259570932653"/>
<IV_DATA CI_END="-4.086432774068551" CI_START="-7.653567225931449" EFFECT_SIZE="-5.87" ESTIMABLE="YES" ESTIMATE="-5.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-16 13:18:52 +0000" MODIFIED_BY="[Empty name]" ORDER="509" SE="0.91" STUDY_ID="STD-GSK-2007" TOTAL_1="181" TOTAL_2="193" WEIGHT="4.300911801221465"/>
<IV_DATA CI_END="0.8074987965575522" CI_START="-10.207498796557552" EFFECT_SIZE="-4.7" ESTIMABLE="YES" ESTIMATE="-4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-16 13:18:51 +0000" MODIFIED_BY="[Empty name]" ORDER="511" SE="2.81" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.9852984466171524"/>
<IV_DATA CI_END="-0.38323889669674127" CI_START="-4.616761103303259" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-01 11:23:39 +0000" MODIFIED_BY="[Empty name]" ORDER="513" SE="1.08" STUDY_ID="STD-GSK-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.073499790540868"/>
<IV_DATA CI_END="-2.1500360154599463" CI_START="-6.069963984540054" EFFECT_SIZE="-4.11" ESTIMABLE="YES" ESTIMATE="-4.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-16 13:18:48 +0000" MODIFIED_BY="[Empty name]" ORDER="516" SE="1.0" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="4.182271616774881"/>
<IV_DATA CI_END="-0.991237095923744" CI_START="-5.028762904076256" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:12:07 +0000" MODIFIED_BY="[Empty name]" ORDER="517" SE="1.03" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-0.40283853654214186" CI_START="-4.597161463457859" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 12:06:38 +0000" MODIFIED_BY="[Empty name]" ORDER="518" SE="1.07" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.087234481032538"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="7.1805939983095595" CI_END="-4.962193296295183" CI_START="-8.994098896280043" DF="4" EFFECT_SIZE="-6.978146096287613" ESTIMABLE="YES" I2="44.294302101724845" ID="CMP-001.02.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-03-11 14:59:50 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1266469657819267" P_Z="1.1661606892808434E-11" STUDIES="5" TAU2="2.2259999243447335" TOTAL_1="0" TOTAL_2="181" WEIGHT="15.097437068733406" Z="6.784342881258856">
<NAME>Rotigotine</NAME>
<IV_DATA CI_END="-2.941237095923744" CI_START="-6.978762904076255" EFFECT_SIZE="-4.96" ESTIMABLE="YES" ESTIMATE="-4.96" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:59:50 +0000" MODIFIED_BY="[Empty name]" ORDER="514" SE="1.03" STUDY_ID="STD-Hening-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-3.7612551036537165" CI_START="-9.758744896346283" EFFECT_SIZE="-6.76" ESTIMABLE="YES" ESTIMATE="-6.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:49:46 +0000" MODIFIED_BY="[Empty name]" ORDER="519" SE="1.53" STUDY_ID="STD-Oertel-2008" TOTAL_1="0" TOTAL_2="53" WEIGHT="3.441703172329003"/>
<IV_DATA CI_END="-1.5824921995774606" CI_START="-11.617507800422539" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:12:32 +0000" MODIFIED_BY="[Empty name]" ORDER="522" SE="2.56" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.2114504709807203"/>
<IV_DATA CI_END="-6.696504804988442" CI_START="-18.103495195011558" EFFECT_SIZE="-12.4" ESTIMABLE="YES" ESTIMATE="-12.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:53:12 +0000" MODIFIED_BY="[Empty name]" ORDER="520" SE="2.91" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.9024072353402004"/>
<IV_DATA CI_END="-4.842456184117516" CI_START="-10.957543815882484" EFFECT_SIZE="-7.9" ESTIMABLE="YES" ESTIMATE="-7.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 14:57:16 +0000" MODIFIED_BY="[Empty name]" ORDER="519" SE="1.56" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="0" TOTAL_2="114" WEIGHT="3.40008092122598"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.2816329573933658E-32" CI_END="1.05114705727388" CI_START="-4.711147057273879" DF="0" EFFECT_SIZE="-1.8299999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.07" LOG_CI_END="0.021663478820695747" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-02-15 10:51:50 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.21316928518882894" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5255043926180716" Z="1.2448979591836733">
<NAME>Sumanirole</NAME>
<IV_DATA CI_END="1.0511470572738797" CI_START="-4.71114705727388" EFFECT_SIZE="-1.83" ESTIMABLE="YES" ESTIMATE="-1.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 10:51:50 +0000" MODIFIED_BY="[Empty name]" ORDER="523" SE="1.47" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5255043926180716"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="52.751620505793596" CI_END="-16.93984827661038" CI_START="-27.819622232915417" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="-22.3797352547629" ESTIMABLE="YES" I2="73.46053094527701" I2_Q="95.00314038848437" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-11-30 15:11:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.0967513805203453E-6" P_Q="7.693566315802869E-6" P_Z="7.425813592384955E-16" Q="20.012569448527735" RANDOM="YES" SCALE="65.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="69.43405577791175" TOTALS="YES" TOTAL_1="447" TOTAL_2="460" WEIGHT="100.00000000000001" Z="8.063306325855583">
<NAME>Change in periodic limb movements in sleep index</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.7824955772927242" CI_END="-27.575597497583022" CI_START="-71.7070020979491" DF="2" EFFECT_SIZE="-49.64129979776606" ESTIMABLE="YES" I2="47.124855558153065" ID="CMP-001.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-11-30 15:11:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15088353148218192" P_Z="1.036866518050247E-5" STUDIES="3" TAU2="177.76572599617657" TOTAL_1="46" TOTAL_2="46" WEIGHT="8.916351473379041" Z="4.409338910938261">
<NAME>Cross-over trials</NAME>
<IV_DATA CI_END="-41.624053434640714" CI_START="-90.97594656535928" EFFECT_SIZE="-66.3" ESTIMABLE="YES" ESTIMATE="-66.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:29:54 +0100" MODIFIED_BY="[Empty name]" ORDER="432" SE="12.59" STUDY_ID="STD-Montplaisir-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.379550340961497"/>
<IV_DATA CI_END="24.96441234189099" CI_START="-60.76441234189099" EFFECT_SIZE="-17.9" ESTIMABLE="YES" ESTIMATE="-17.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="433" SE="21.87" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" WEIGHT="1.4064240520871534"/>
<IV_DATA CI_END="-28.09318968727661" CI_START="-70.50681031272339" EFFECT_SIZE="-49.3" ESTIMABLE="YES" ESTIMATE="-49.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:21 +0100" MODIFIED_BY="[Empty name]" ORDER="435" SE="10.82" STUDY_ID="STD-Wetter-1999" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.1303770803303905"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="28.956555479973137" CI_END="-14.543588949788298" CI_START="-23.457126043892227" DF="11" EFFECT_SIZE="-19.000357496840262" ESTIMABLE="YES" I2="62.01205627648705" ID="CMP-001.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-04-14 11:32:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.002305462763456556" P_Z="6.497224166831604E-17" STUDIES="12" TAU2="33.32811068233187" TOTAL_1="401" TOTAL_2="414" WEIGHT="91.08364852662098" Z="8.355833603211417">
<NAME>Parallel group trials</NAME>
<IV_DATA CI_END="-15.773409970131484" CI_START="-38.62659002986852" EFFECT_SIZE="-27.2" ESTIMABLE="YES" ESTIMATE="-27.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:20 +0100" MODIFIED_BY="[Empty name]" ORDER="526" SE="5.83" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="7.448462331060777"/>
<IV_DATA CI_END="-8.620108046379837" CI_START="-20.379891953620163" EFFECT_SIZE="-14.5" ESTIMABLE="YES" ESTIMATE="-14.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:19 +0100" MODIFIED_BY="[Empty name]" ORDER="523" SE="3.0" STUDY_ID="STD-Bogan-2006" TOTAL_1="110" TOTAL_2="113" WEIGHT="9.82152437023001"/>
<IV_DATA CI_END="-6.919541426560286" CI_START="-44.080458573439714" EFFECT_SIZE="-25.5" ESTIMABLE="YES" ESTIMATE="-25.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:02 +0100" MODIFIED_BY="[Empty name]" ORDER="520" SE="9.48" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="7" WEIGHT="4.835658780019833"/>
<IV_DATA CI_END="-10.393756307096163" CI_START="-27.406243692903836" EFFECT_SIZE="-18.9" ESTIMABLE="YES" ESTIMATE="-18.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:02 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SE="4.34" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.72714392607281"/>
<IV_DATA CI_END="-2.6841296556558047" CI_START="-16.795870344344195" EFFECT_SIZE="-9.74" ESTIMABLE="YES" ESTIMATE="-9.74" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="529" SE="3.6" STUDY_ID="STD-GSK-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.349485020559626"/>
<IV_DATA CI_END="4.5109939915691095" CI_START="-17.91099399156911" EFFECT_SIZE="-6.7" ESTIMABLE="YES" ESTIMATE="-6.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="524" SE="5.72" STUDY_ID="STD-GSK-2008" TOTAL_1="17" TOTAL_2="15" WEIGHT="7.5411010377815115"/>
<IV_DATA CI_END="-2.5466488668282246" CI_START="-29.633351133171775" EFFECT_SIZE="-16.09" ESTIMABLE="YES" ESTIMATE="-16.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:04 +0100" MODIFIED_BY="[Empty name]" ORDER="528" SE="6.91" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.57388477934066"/>
<IV_DATA CI_END="-10.152883555867074" CI_START="-19.247116444132924" EFFECT_SIZE="-14.7" ESTIMABLE="YES" ESTIMATE="-14.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:17 +0100" MODIFIED_BY="[Empty name]" ORDER="516" SE="2.32" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="10.296424526783987"/>
<IV_DATA CI_END="-8.730841549538933" CI_START="-56.78915845046106" EFFECT_SIZE="-32.76" ESTIMABLE="YES" ESTIMATE="-32.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:06 +0100" MODIFIED_BY="[Empty name]" ORDER="522" SE="12.26" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.505671182605944"/>
<IV_DATA CI_END="-16.96344598559143" CI_START="-43.73655401440857" EFFECT_SIZE="-30.35" ESTIMABLE="YES" ESTIMATE="-30.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:06 +0100" MODIFIED_BY="[Empty name]" ORDER="470" SE="6.83" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.636133488473083"/>
<IV_DATA CI_END="-11.340144061839784" CI_START="-27.019855938160216" EFFECT_SIZE="-19.18" ESTIMABLE="YES" ESTIMATE="-19.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:07 +0100" MODIFIED_BY="[Empty name]" ORDER="525" SE="4.0" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.01680229581124"/>
<IV_DATA CI_END="-24.299015012295875" CI_START="-47.700984987704125" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-12 15:30:16 +0100" MODIFIED_BY="[Empty name]" ORDER="518" SE="5.97" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="39" TOTAL_2="42" WEIGHT="7.331356787881485"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="52.75162050579359" CI_END="-16.93984827661038" CI_START="-27.819622232915417" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="-22.3797352547629" ESTIMABLE="YES" I2="73.460530945277" I2_Q="81.80818837659646" ID="CMP-001.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.0967513805203453E-6" P_Q="4.588640579550329E-5" P_Z="7.425813592384955E-16" Q="27.48489322288037" RANDOM="YES" SCALE="65.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="69.43405577791175" TOTALS="YES" TOTAL_1="447" TOTAL_2="460" WEIGHT="100.0" Z="8.063306325855583">
<NAME>Medication subgroups: change in periodic limb movements in sleep index</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-8.730841549538933" CI_START="-56.78915845046106" DF="0" EFFECT_SIZE="-32.76" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.007537719222086798" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.5056711826059432" Z="2.6721044045677">
<NAME>Cabergoline</NAME>
<IV_DATA CI_END="-8.730841549538933" CI_START="-56.78915845046106" EFFECT_SIZE="-32.76" ESTIMABLE="YES" ESTIMATE="-32.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:17 +0000" MODIFIED_BY="[Empty name]" ORDER="482" SE="12.26" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.5056711826059432"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.388800105787318" CI_END="-25.2864680793947" CI_START="-44.88102421945985" DF="3" EFFECT_SIZE="-35.08374614942728" ESTIMABLE="YES" I2="11.473090582219164" ID="CMP-001.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.33547340702114903" P_Z="2.241509501414148E-12" STUDIES="4" TAU2="12.96985834213783" TOTAL_1="83" TOTAL_2="85" WEIGHT="17.70381670031886" Z="7.018569688855901">
<NAME>Pergolide</NAME>
<IV_DATA CI_END="-6.919541426560286" CI_START="-44.080458573439714" EFFECT_SIZE="-25.5" ESTIMABLE="YES" ESTIMATE="-25.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:35 +0000" MODIFIED_BY="[Empty name]" ORDER="496" SE="9.48" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="7" WEIGHT="4.835658780019832"/>
<IV_DATA CI_END="24.96441234189099" CI_START="-60.76441234189099" EFFECT_SIZE="-17.9" ESTIMABLE="YES" ESTIMATE="-17.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:39 +0000" MODIFIED_BY="[Empty name]" ORDER="497" SE="21.87" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" WEIGHT="1.406424052087153"/>
<IV_DATA CI_END="-24.299015012295875" CI_START="-47.700984987704125" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:42 +0000" MODIFIED_BY="[Empty name]" ORDER="498" SE="5.97" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="39" TOTAL_2="42" WEIGHT="7.331356787881483"/>
<IV_DATA CI_END="-28.09318968727661" CI_START="-70.50681031272339" EFFECT_SIZE="-49.3" ESTIMABLE="YES" ESTIMATE="-49.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:45 +0000" MODIFIED_BY="[Empty name]" ORDER="499" SE="10.82" STUDY_ID="STD-Wetter-1999" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.130377080330389"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="13.604838030104736" CI_END="-9.349090613433564" CI_START="-51.584425399648055" DF="2" EFFECT_SIZE="-30.466758006540807" ESTIMABLE="YES" I2="85.29934722064013" ID="CMP-001.04.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0011110882396075938" P_Z="0.004688843276352349" STUDIES="3" TAU2="283.74433696569554" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.97023741611339" Z="2.827667815149307">
<NAME>Pramipexole</NAME>
<IV_DATA CI_END="-2.5466488668282246" CI_START="-29.633351133171775" EFFECT_SIZE="-16.09" ESTIMABLE="YES" ESTIMATE="-16.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:14:50 +0000" MODIFIED_BY="[Empty name]" ORDER="502" SE="6.91" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.573884779340658"/>
<IV_DATA CI_END="-41.624053434640714" CI_START="-90.97594656535928" EFFECT_SIZE="-66.3" ESTIMABLE="YES" ESTIMATE="-66.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="501" SE="12.59" STUDY_ID="STD-Montplaisir-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.3795503409614955"/>
<IV_DATA CI_END="-11.340144061839784" CI_START="-27.019855938160216" EFFECT_SIZE="-19.18" ESTIMABLE="YES" ESTIMATE="-19.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 15:04:55 +0000" MODIFIED_BY="[Empty name]" ORDER="500" SE="4.0" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.016802295811239"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="8.273089147021166" CI_END="-9.425177085642245" CI_START="-18.78652286769571" DF="4" EFFECT_SIZE="-14.105849976668976" ESTIMABLE="YES" I2="51.65046660423994" ID="CMP-001.04.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.08207162512882404" P_Z="3.491971395284838E-9" STUDIES="5" TAU2="13.863995982347191" TOTAL_1="334" TOTAL_2="345" WEIGHT="44.456997286415906" Z="5.906620387551126">
<NAME>Ropinirole</NAME>
<IV_DATA CI_END="-15.773409970131484" CI_START="-38.62659002986852" EFFECT_SIZE="-27.2" ESTIMABLE="YES" ESTIMATE="-27.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 14:17:22 +0000" MODIFIED_BY="[Empty name]" ORDER="503" SE="5.83" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="7.448462331060775"/>
<IV_DATA CI_END="-8.620108046379837" CI_START="-20.379891953620163" EFFECT_SIZE="-14.5" ESTIMABLE="YES" ESTIMATE="-14.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:16:17 +0000" MODIFIED_BY="[Empty name]" ORDER="504" SE="3.0" STUDY_ID="STD-Bogan-2006" TOTAL_1="110" TOTAL_2="113" WEIGHT="9.821524370230009"/>
<IV_DATA CI_END="-2.6841296556558047" CI_START="-16.795870344344195" EFFECT_SIZE="-9.74" ESTIMABLE="YES" ESTIMATE="-9.74" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-17 12:22:21 +0000" MODIFIED_BY="[Empty name]" ORDER="505" SE="3.6" STUDY_ID="STD-GSK-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.349485020559623"/>
<IV_DATA CI_END="4.5109939915691095" CI_START="-17.91099399156911" EFFECT_SIZE="-6.7" ESTIMABLE="YES" ESTIMATE="-6.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-17 12:22:22 +0000" MODIFIED_BY="[Empty name]" ORDER="506" SE="5.72" STUDY_ID="STD-GSK-2008" TOTAL_1="17" TOTAL_2="15" WEIGHT="7.54110103778151"/>
<IV_DATA CI_END="-10.152883555867074" CI_START="-19.247116444132924" EFFECT_SIZE="-14.7" ESTIMABLE="YES" ESTIMATE="-14.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:16:33 +0000" MODIFIED_BY="[Empty name]" ORDER="507" SE="2.32" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="10.296424526783985"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-16.96344598559143" CI_START="-43.73655401440857" DF="0" EFFECT_SIZE="-30.35" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="8.845324126960986E-6" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.636133488473082" Z="4.443631039531479">
<NAME>Rotigotine</NAME>
<IV_DATA CI_END="-16.96344598559143" CI_START="-43.73655401440857" EFFECT_SIZE="-30.35" ESTIMABLE="YES" ESTIMATE="-30.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:17:29 +0000" MODIFIED_BY="[Empty name]" ORDER="472" SE="6.83" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.636133488473082"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-10.393756307096163" CI_START="-27.406243692903836" DF="0" EFFECT_SIZE="-18.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="1.3316493049032968E-5" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.727143926072808" Z="4.354838709677419">
<NAME>Sumanirole</NAME>
<IV_DATA CI_END="-10.393756307096163" CI_START="-27.406243692903836" EFFECT_SIZE="-18.9" ESTIMABLE="YES" ESTIMATE="-18.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:17:38 +0000" MODIFIED_BY="[Empty name]" ORDER="509" SE="4.34" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.727143926072808"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="19.324991045096144" CI_END="7.064028334039249" CI_START="1.99510098742486" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="4.5295646607320545" ESTIMABLE="YES" I2="48.25353358941104" I2_Q="82.48276180867997" ID="CMP-001.05" LOG_CI_END="0.8490524325417966" LOG_CI_START="0.29996488356729684" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6560564637066217" MODIFIED="2010-11-30 15:11:21 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.03632380454699846" P_Q="0.016881423302222087" P_Z="4.60351200234552E-4" Q="5.708662456251297" RANDOM="YES" SCALE="30.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8.33788742595827" TOTALS="YES" TOTAL_1="141" TOTAL_2="143" WEIGHT="99.99999999999997" Z="3.5028253488816796">
<NAME>Change in sleep efficiency</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.71853624556648" CI_END="32.919636509333934" CI_START="-8.043583877754989" DF="1" EFFECT_SIZE="12.438026315789473" ESTIMABLE="YES" I2="88.53018474851766" ID="CMP-001.05.01" LOG_CI_END="1.5174550311920538" LOG_CI_START="NaN" LOG_EFFECT_SIZE="1.0947514713382591" MODIFIED="2010-11-30 15:11:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0031499269008340436" P_Z="0.2339511013497233" STUDIES="2" TAU2="193.35435" TOTAL_1="36" TOTAL_2="36" WEIGHT="10.016891223980856" Z="1.1902425340265699">
<NAME>Cross-over trials</NAME>
<IV_DATA CI_END="11.76062064300947" CI_START="-7.760620643009471" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:58:53 +0000" MODIFIED_BY="[Empty name]" ORDER="433" SE="4.98" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.045984348665553"/>
<IV_DATA CI_END="32.75861884223647" CI_START="13.041381157763524" EFFECT_SIZE="22.9" ESTIMABLE="YES" ESTIMATE="22.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:58:51 +0000" MODIFIED_BY="[Empty name]" ORDER="434" SE="5.03" STUDY_ID="STD-Wetter-1999" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.970906875315304"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.897792343278367" CI_END="5.41005121762157" CI_START="1.8099461331875777" DF="8" EFFECT_SIZE="3.6099986754045736" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.733201376645411" LOG_CI_START="0.2576656497821618" LOG_EFFECT_SIZE="0.5575070425525859" MODIFIED="2010-03-22 14:21:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.768442370285626" P_Z="8.469873501494754E-5" STUDIES="9" TAU2="0.0" TOTAL_1="105" TOTAL_2="107" WEIGHT="89.98310877601912" Z="3.9307004779515595">
<NAME>Parallel group trials</NAME>
<IV_DATA CI_END="9.178308520731738" CI_START="-0.7783085207317377" EFFECT_SIZE="4.2" ESTIMABLE="YES" ESTIMATE="4.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 14:21:23 +0000" MODIFIED_BY="[Empty name]" ORDER="563" SE="2.54" STUDY_ID="STD-Allen-2004" TOTAL_1="29" TOTAL_2="30" WEIGHT="11.30636071940346"/>
<IV_DATA CI_END="11.272303118412747" CI_START="0.7276968815872538" EFFECT_SIZE="6.0" ESTIMABLE="YES" ESTIMATE="6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="564" SE="2.69" STUDY_ID="STD-Earley-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.736831558901635"/>
<IV_DATA CI_END="8.196324727688712" CI_START="0.003675272311286726" EFFECT_SIZE="4.1" ESTIMABLE="YES" ESTIMATE="4.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="565" SE="2.09" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.160352996363429"/>
<IV_DATA CI_END="5.3858973559391545" CI_START="-5.785897355939155" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="566" SE="2.85" STUDY_ID="STD-GSK-2008" TOTAL_1="17" TOTAL_2="15" WEIGHT="10.158647871754527"/>
<IV_DATA CI_END="16.125825325019264" CI_START="-2.8858253250192627" EFFECT_SIZE="6.62" ESTIMABLE="YES" ESTIMATE="6.62" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="567" SE="4.85" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.2483755912122785"/>
<IV_DATA CI_END="10.85745377723262" CI_START="-5.05745377723262" EFFECT_SIZE="2.9" ESTIMABLE="YES" ESTIMATE="2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="568" SE="4.06" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.736714719122453"/>
<IV_DATA CI_END="8.49189375439316" CI_START="-3.0718937543931606" EFFECT_SIZE="2.71" ESTIMABLE="YES" ESTIMATE="2.71" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="571" SE="2.95" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.812880160121274"/>
<IV_DATA CI_END="6.047917164442125" CI_START="-2.9679171644421247" EFFECT_SIZE="1.54" ESTIMABLE="YES" ESTIMATE="1.54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 15:07:33 +0000" MODIFIED_BY="[Empty name]" ORDER="569" SE="2.3" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.270080788490803"/>
<IV_DATA CI_END="11.57030131763975" CI_START="0.8296986823602515" EFFECT_SIZE="6.2" ESTIMABLE="YES" ESTIMATE="6.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-03 11:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="570" SE="2.74" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="39" TOTAL_2="42" WEIGHT="10.552864370649264"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="19.324991045096144" CI_END="7.064028334039249" CI_START="1.99510098742486" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="4.5295646607320545" ESTIMABLE="YES" I2="48.25353358941104" I2_Q="16.271673123202543" ID="CMP-001.06" LOG_CI_END="0.8490524325417966" LOG_CI_START="0.29996488356729684" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6560564637066217" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03632380454699846" P_Q="0.30898318012225046" P_Z="4.60351200234552E-4" Q="5.971694630130708" RANDOM="YES" SCALE="30.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8.33788742595827" TOTALS="YES" TOTAL_1="141" TOTAL_2="143" WEIGHT="99.99999999999999" Z="3.5028253488816796">
<NAME>Medication subgroups: change in sleep efficiency</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="10.85745377723262" CI_START="-5.05745377723262" DF="0" EFFECT_SIZE="2.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="1.0357279891431277" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.4623979978989561" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4750505292803512" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.736714719122454" Z="0.7142857142857143">
<NAME>Cabergoline</NAME>
<IV_DATA CI_END="10.85745377723262" CI_START="-5.05745377723262" EFFECT_SIZE="2.9" ESTIMABLE="YES" ESTIMATE="2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-08 10:44:59 +0000" MODIFIED_BY="[Empty name]" ORDER="532" SE="4.06" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.736714719122454"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="11.129245689756104" CI_END="15.555043641248643" CI_START="1.846110090347592" DF="3" EFFECT_SIZE="8.700576865798118" ESTIMABLE="YES" I2="73.0439952209758" ID="CMP-001.06.02" LOG_CI_END="1.1918712339035382" LOG_CI_START="0.26625759604246624" LOG_EFFECT_SIZE="0.9395480481734952" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011047148551214803" P_Z="0.012852150334909879" STUDIES="4" TAU2="34.26029834327059" TOTAL_1="75" TOTAL_2="78" WEIGHT="31.30658715353176" Z="2.4878400990667666">
<NAME>Pergolide</NAME>
<IV_DATA CI_END="11.272303118412747" CI_START="0.7276968815872538" EFFECT_SIZE="6.0" ESTIMABLE="YES" ESTIMATE="6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="522" SE="2.69" STUDY_ID="STD-Earley-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.736831558901637"/>
<IV_DATA CI_END="11.76062064300947" CI_START="-7.760620643009471" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:20:32 +0000" MODIFIED_BY="[Empty name]" ORDER="523" SE="4.98" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.045984348665554"/>
<IV_DATA CI_END="11.57030131763975" CI_START="0.8296986823602515" EFFECT_SIZE="6.2" ESTIMABLE="YES" ESTIMATE="6.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:20:39 +0000" MODIFIED_BY="[Empty name]" ORDER="524" SE="2.74" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="39" TOTAL_2="42" WEIGHT="10.552864370649266"/>
<IV_DATA CI_END="32.75861884223647" CI_START="13.041381157763524" EFFECT_SIZE="22.9" ESTIMABLE="YES" ESTIMATE="22.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:20:59 +0000" MODIFIED_BY="[Empty name]" ORDER="525" SE="5.03" STUDY_ID="STD-Wetter-1999" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.970906875315305"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.8956668112798268" CI_END="6.545812305166217" CI_START="-1.6004274895479953" DF="1" EFFECT_SIZE="2.472692407809111" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.815963548176498" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.3931700953748158" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3439463778262869" P_Z="0.23410669180164256" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.518456379703085" Z="1.1898466498116405">
<NAME>Pramipexole</NAME>
<IV_DATA CI_END="16.125825325019264" CI_START="-2.8858253250192627" EFFECT_SIZE="6.62" ESTIMABLE="YES" ESTIMATE="6.62" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="527" SE="4.85" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.248375591212279"/>
<IV_DATA CI_END="6.047917164442125" CI_START="-2.9679171644421247" EFFECT_SIZE="1.54" ESTIMABLE="YES" ESTIMATE="1.54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 15:07:46 +0000" MODIFIED_BY="[Empty name]" ORDER="529" SE="2.3" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.270080788490807"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.3283839139295053" CI_END="6.485706286026455" CI_START="-2.105956286026454" DF="1" EFFECT_SIZE="2.1898750000000007" ESTIMABLE="YES" I2="24.72055785123968" ID="CMP-001.06.04" LOG_CI_END="0.811957277169786" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.34041932563483174" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.24909306786697205" P_Z="0.3177337384117649" STUDIES="2" TAU2="2.3929500000000004" TOTAL_1="46" TOTAL_2="45" WEIGHT="21.46500859115799" Z="0.9991258606002482">
<NAME>Ropinirole</NAME>
<IV_DATA CI_END="9.178308520731738" CI_START="-0.7783085207317377" EFFECT_SIZE="4.2" ESTIMABLE="YES" ESTIMATE="4.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-22 14:21:31 +0000" MODIFIED_BY="[Empty name]" ORDER="531" SE="2.54" STUDY_ID="STD-Allen-2004" TOTAL_1="29" TOTAL_2="30" WEIGHT="11.306360719403461"/>
<IV_DATA CI_END="5.3858973559391545" CI_START="-5.785897355939155" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:21:38 +0000" MODIFIED_BY="[Empty name]" ORDER="530" SE="2.85" STUDY_ID="STD-GSK-2008" TOTAL_1="17" TOTAL_2="15" WEIGHT="10.158647871754528"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.49189375439316" CI_START="-3.0718937543931606" DF="0" EFFECT_SIZE="2.71" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="0.9290045518894599" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.4329692908744057" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.35828178478968664" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.812880160121276" Z="0.9186440677966101">
<NAME>Rotigotine</NAME>
<IV_DATA CI_END="8.49189375439316" CI_START="-3.0718937543931606" EFFECT_SIZE="2.71" ESTIMABLE="YES" ESTIMATE="2.71" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:21:54 +0000" MODIFIED_BY="[Empty name]" ORDER="471" SE="2.95" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.812880160121276"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.196324727688712" CI_START="0.003675272311286726" DF="0" EFFECT_SIZE="4.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="0.9136191562505862" LOG_CI_START="-2.434710477285134" LOG_EFFECT_SIZE="0.6127838567197355" MODIFIED="2010-05-11 14:49:26 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.049794802209185744" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.16035299636343" Z="1.9617224880382775">
<NAME>Sumanirole</NAME>
<IV_DATA CI_END="8.196324727688712" CI_START="0.003675272311286726" EFFECT_SIZE="4.1" ESTIMABLE="YES" ESTIMATE="4.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-26 09:22:04 +0000" MODIFIED_BY="[Empty name]" ORDER="526" SE="2.09" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.16035299636343"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="48.944095760604405" CI_END="2.4524024841779988" CI_START="1.3503471540350074" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8197787544254227" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="160" I2="40.74872658421367" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.38959174737700814" LOG_CI_START="0.13044543345806794" LOG_EFFECT_SIZE="0.26001859041753805" METHOD="MH" MODIFIED="2010-11-30 15:11:38 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.011706467365234619" P_Q="0.0" P_Z="8.384954968567644E-5" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="34" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2348721206708686" TOTALS="YES" TOTAL_1="4171" TOTAL_2="2883" WEIGHT="99.99999999999999" Z="3.933122295450865">
<NAME>Number of dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.065102290569126" CI_START="0.0585991213514519" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2321088958432882" LOG_CI_START="-1.2321088958432882" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="1.4474937289114918" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" VAR="2.095238095238095" WEIGHT="0.9944634175767205"/>
<DICH_DATA CI_END="81.25009743259366" CI_START="0.12528155219063267" EFFECT_SIZE="3.1904761904761907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9098238904436802" LOG_CI_START="-0.9021128745098655" LOG_EFFECT_SIZE="0.5038555079669071" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="1.651745575045187" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="2.7282634446813554" WEIGHT="0.7820126070971088"/>
<DICH_DATA CI_END="6.992926753919564" CI_START="1.268157663105567" EFFECT_SIZE="2.9779411764705883" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="8" LOG_CI_END="0.8446589793291638" LOG_CI_START="0.10317325035973836" LOG_EFFECT_SIZE="0.47391611484445106" MODIFIED="2010-03-12 09:43:04 +0000" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.4355523876101946" STUDY_ID="STD-Axxonis-2005" TOTAL_1="104" TOTAL_2="53" VAR="0.1897058823529412" WEIGHT="5.4576764508294895"/>
<DICH_DATA CI_END="18.21102043910693" CI_START="1.5680430516226669" EFFECT_SIZE="5.34375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.2603342818002286" LOG_CI_START="0.19535798234426702" LOG_EFFECT_SIZE="0.7278461320722479" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.6255723500181354" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="79" VAR="0.39134076510721244" WEIGHT="3.7003540190075817"/>
<DICH_DATA CI_END="4.716622639086027" CI_START="0.7461581075239843" EFFECT_SIZE="1.8759920634920635" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.6736311312131769" LOG_CI_START="-0.1271691377421104" LOG_EFFECT_SIZE="0.27323099673553325" MODIFIED="2010-03-22 14:37:19 +0000" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.470394042009598" STUDY_ID="STD-Benes-2010" TOTAL_1="199" TOTAL_2="67" VAR="0.22127055475812746" WEIGHT="5.080010035158306"/>
<DICH_DATA CI_END="71.15345065235105" CI_START="1.2403498318592396" EFFECT_SIZE="9.394422310756973" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.8521959664433034" LOG_CI_START="0.09354419211276088" LOG_EFFECT_SIZE="0.9728700792780323" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="1.0330407577084435" STUDY_ID="STD-BI-2008" TOTAL_1="269" TOTAL_2="132" VAR="1.067173207086835" WEIGHT="1.7796687405912384"/>
<DICH_DATA CI_END="1.5073676316672073" CI_START="0.4106329040478758" EFFECT_SIZE="0.7867494824016563" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.17821918524965627" LOG_CI_START="-0.38654625351906025" LOG_EFFECT_SIZE="-0.10416353413470199" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.33174601436675344" STUDY_ID="STD-BI-2009" TOTAL_1="166" TOTAL_2="163" VAR="0.11005541804822616" WEIGHT="6.7179598858598775"/>
<DICH_DATA CI_END="1.9783820079067822" CI_START="0.20400958000994926" EFFECT_SIZE="0.6353021978021978" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.29631015374631947" LOG_CI_START="-0.6903494382222911" LOG_EFFECT_SIZE="-0.1970196422379858" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.579568728366111" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="193" VAR="0.33589991089991095" WEIGHT="4.059780859034451"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.0" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2518420965100625" CI_START="0.5384486297691414" EFFECT_SIZE="1.1011363636363636" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.35253793368434466" LOG_CI_START="-0.2688557238831513" LOG_EFFECT_SIZE="0.04184110490059668" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.3650097104033604" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="182" TOTAL_2="187" VAR="0.13323208868874503" WEIGHT="6.294981990764189"/>
<DICH_DATA CI_END="49.690667651537005" CI_START="0.14714887352020775" EFFECT_SIZE="2.704057279236277" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6962748320329224" LOG_CI_START="-0.8322430582387185" LOG_EFFECT_SIZE="0.43201588689710196" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="1.48526392511098" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="214" TOTAL_2="51" VAR="2.206008927236075" WEIGHT="0.9493331805866846"/>
<DICH_DATA CI_END="27.984718554170236" CI_START="0.34268739874098797" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4469209435105541" LOG_CI_START="-0.4651018650999629" LOG_EFFECT_SIZE="0.49090953920529573" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="1.1231316624433645" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" VAR="1.2614247311827957" WEIGHT="1.54862944861016"/>
<DICH_DATA CI_END="3.7718116064731833" CI_START="1.0882351334757117" EFFECT_SIZE="2.0259856630824373" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.5765499925720754" LOG_CI_START="0.036722742915524124" LOG_EFFECT_SIZE="0.30663636774379976" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.31709719863624053" STUDY_ID="STD-GSK-2006" TOTAL_1="158" TOTAL_2="151" VAR="0.10055063338295137" WEIGHT="6.908324914270582"/>
<DICH_DATA CI_END="4.687935979205195" CI_START="0.4556578170076402" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6709816721082079" LOG_CI_START="-0.34136117481622347" LOG_EFFECT_SIZE="0.16481024864599214" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.5946551994613225" STUDY_ID="STD-GSK-2007" TOTAL_1="189" TOTAL_2="195" VAR="0.3536148062463852" WEIGHT="3.937571529042781"/>
<DICH_DATA CI_END="78.27196626944439" CI_START="0.11498369632134046" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8936062438651577" LOG_CI_START="-0.9393637344258329" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="1.6641005886756874" STUDY_ID="STD-GSK-2008" TOTAL_1="20" TOTAL_2="19" VAR="2.769230769230769" WEIGHT="0.7713482039621918"/>
<DICH_DATA CI_END="5.180764230497673" CI_START="1.3797385106015911" EFFECT_SIZE="2.6735930735930737" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.7143938285882758" LOG_CI_START="0.13979678628279502" LOG_EFFECT_SIZE="0.4270953074355355" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.3375211469514711" STUDY_ID="STD-GSK-2009" TOTAL_1="197" TOTAL_2="207" VAR="0.11392052463943655" WEIGHT="6.643515566624809"/>
<DICH_DATA CI_END="32.60985779035677" CI_START="2.9966444977199087" EFFECT_SIZE="9.885350318471337" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="3" LOG_CI_END="1.5133489048777755" LOG_CI_START="0.47663522414809595" LOG_EFFECT_SIZE="0.9949920645129359" MODIFIED="2010-03-11 16:04:05 +0000" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="0.6089707478760983" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" VAR="0.37084537176877447" WEIGHT="3.8255612518473816"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="0.0" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.20324339492458" CI_START="0.48553370213937647" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6235845391874751" LOG_CI_START="-0.31378061921598877" LOG_EFFECT_SIZE="0.15490195998574316" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.5506129340785623" STUDY_ID="STD-Kushida-2008" TOTAL_1="176" TOTAL_2="186" VAR="0.30317460317460315" WEIGHT="4.306706585037707"/>
<DICH_DATA CI_END="1.9672651035017807" CI_START="0.32296607739988326" EFFECT_SIZE="0.7970946579194002" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2938628882518725" LOG_CI_START="-0.4908430912036368" LOG_EFFECT_SIZE="-0.0984901014758821" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.46094017668941056" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="200" VAR="0.21246584648646505" WEIGHT="5.179997091166354"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.0" STUDY_ID="STD-Montplaisir-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="144.26835462520611" CI_START="0.3396448245860763" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.15917107871058" LOG_CI_START="-0.4689749986820665" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="1.5437860153933387" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="2.3832752613240418" WEIGHT="0.8850568858647099"/>
<DICH_DATA CI_END="1.9733082808689335" CI_START="0.17597739614628882" EFFECT_SIZE="0.5892857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.29519493838022764" LOG_CI_START="-0.7545431126368535" LOG_EFFECT_SIZE="-0.22967408712831291" MODIFIED="2010-03-22 10:37:51 +0000" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="0.6166213274545906" STUDY_ID="STD-Oertel-2007" TOTAL_1="230" TOTAL_2="115" VAR="0.3802218614718615" WEIGHT="3.7672444145381982"/>
<DICH_DATA CI_END="7.07284120567657" CI_START="0.3102637997792985" EFFECT_SIZE="1.4813664596273293" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8495939077257983" LOG_CI_START="-0.5082688930372323" LOG_EFFECT_SIZE="0.17066250734428304" MODIFIED="2010-03-11 15:48:42 +0000" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.7976153306974714" STUDY_ID="STD-Oertel-2008" TOTAL_1="170" TOTAL_2="55" VAR="0.6361902157636365" WEIGHT="2.6602107239858697"/>
<DICH_DATA CI_END="10.619052121109458" CI_START="0.07782674682882998" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0260857524381166" LOG_CI_START="-1.1088711227545667" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="1.2540842366951563" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" VAR="1.5727272727272728" WEIGHT="1.2819263920459119"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 15:46:28 +0000" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.0" STUDY_ID="STD-Partinen-2006" TOTAL_1="66" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="188.72667149344264" CI_START="0.41276524588518376" EFFECT_SIZE="8.826086956521738" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.275833280471732" LOG_CI_START="-0.3842968766804922" LOG_EFFECT_SIZE="0.9457682018956199" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="1.562573622167863" STUDY_ID="STD-Pieta-1998" TOTAL_1="14" TOTAL_2="14" VAR="2.4416363246947954" WEIGHT="0.8657582876883774"/>
<DICH_DATA CI_END="65.79196334672261" CI_START="0.17605293796223573" EFFECT_SIZE="3.403361344537815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8181728466939626" LOG_CI_START="-0.7543567230496872" LOG_EFFECT_SIZE="0.5319080618221378" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="1.5111166034941652" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="63" TOTAL_2="22" VAR="2.283473389355742" WEIGHT="0.9201316338117452"/>
<DICH_DATA CI_END="6.102110992547956" CI_START="0.008727215538173277" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7854801028496061" LOG_CI_START="-2.059124298023955" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2010-03-11 15:50:23 +0000" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.67093470609201" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="2.7920227920227916" WEIGHT="0.7655400783574456"/>
<DICH_DATA CI_END="7.135694639444499" CI_START="1.0274539485768757" EFFECT_SIZE="2.707692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.8534362568330671" LOG_CI_START="0.011762365509521509" LOG_EFFECT_SIZE="0.43259931117129424" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.49440341011640676" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.24443473193473192" WEIGHT="4.83450081309391"/>
<DICH_DATA CI_END="16.42150687069345" CI_START="1.9855251507474774" EFFECT_SIZE="5.710106382978723" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" LOG_CI_END="1.2154130063522697" LOG_CI_START="0.2978753926649055" LOG_EFFECT_SIZE="0.7566441995085876" MODIFIED="2010-03-11 15:57:26 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.538966136164396" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="226" TOTAL_2="117" VAR="0.29048449593197834" WEIGHT="4.410736051307783"/>
<DICH_DATA CI_END="2.0942459932802526" CI_START="0.3355616490694411" EFFECT_SIZE="0.8383010432190761" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.321027693221305" LOG_CI_START="-0.47422767999248894" LOG_EFFECT_SIZE="-0.07659999338559195" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.4671369428033683" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="136" VAR="0.21821692333167741" WEIGHT="5.1142471867632215"/>
<DICH_DATA CI_END="8.235307327498598" CI_START="0.012621821467408088" EFFECT_SIZE="0.3224043715846995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9156798109309462" LOG_CI_START="-1.8988779671075169" LOG_EFFECT_SIZE="-0.49159907808828524" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Wetter-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="0.7806720065861212"/>
<DICH_DATA CI_END="5.712776704242825" CI_START="0.8037836891617983" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="0.7568472490893595" LOG_CI_START="-0.09486081100651074" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2010-02-08 13:57:54 +0000" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.5002975305232068" STUDY_ID="STD-Winkelman-2006" TOTAL_1="254" TOTAL_2="85" VAR="0.25029761904761905" WEIGHT="4.776079748889087"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.94409576060441" CI_END="2.452402484177999" CI_START="1.3503471540350072" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8197787544254227" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="160" I2="40.748726584213685" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.3895917473770082" LOG_CI_START="0.1304454334580679" LOG_EFFECT_SIZE="0.26001859041753805" METHOD="MH" MODIFIED="2010-11-30 15:11:56 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.011706467365235063" P_Q="0.0" P_Z="8.384954968567675E-5" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="34" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23487212067086874" TOTALS="YES" TOTAL_1="4171" TOTAL_2="2883" WEIGHT="100.00000000000001" Z="3.9331222954508642">
<NAME>Medication subgroups: number of dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11143800781470187" CI_END="40.211910221671786" CI_START="0.5833827699621221" DF="1" EFFECT_SIZE="4.843442533011728" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="1.6043547042649697" LOG_CI_START="-0.23404640178417815" LOG_EFFECT_SIZE="0.6851541512403958" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7385129279223572" P_Z="0.14403769933358337" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="42" WEIGHT="1.8051885196764559" Z="1.4609188994399838">
<NAME>Cabergoline</NAME>
<DICH_DATA CI_END="144.26835462520611" CI_START="0.3396448245860763" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.15917107871058" LOG_CI_START="-0.4689749986820665" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-12-08 10:48:05 +0000" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="1.5437860153933387" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="2.3832752613240418" WEIGHT="0.8850568858647102"/>
<DICH_DATA CI_END="65.79196334672261" CI_START="0.17605293796223573" EFFECT_SIZE="3.403361344537815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8181728466939626" LOG_CI_START="-0.7543567230496872" LOG_EFFECT_SIZE="0.5319080618221378" MODIFIED="2009-12-08 10:48:05 +0000" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="1.5111166034941652" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="63" TOTAL_2="22" VAR="2.283473389355742" WEIGHT="0.9201316338117456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.598794124576643" CI_END="7.262425651740715" CI_START="1.7887997277761174" DF="1" EFFECT_SIZE="3.6043064560089895" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="11" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.8610816993806214" LOG_CI_START="0.2525617201143463" LOG_EFFECT_SIZE="0.5568217097474839" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4390386549765052" P_Z="3.3463114588508017E-4" STUDIES="2" TAU2="0.0" TOTAL_1="259" TOTAL_2="132" WEIGHT="9.158030469837072" Z="3.5869011177939747">
<NAME>Lisuride</NAME>
<DICH_DATA CI_END="6.992926753919564" CI_START="1.268157663105567" EFFECT_SIZE="2.9779411764705883" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="8" LOG_CI_END="0.8446589793291638" LOG_CI_START="0.10317325035973836" LOG_EFFECT_SIZE="0.47391611484445106" MODIFIED="2010-03-12 09:42:52 +0000" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.4355523876101946" STUDY_ID="STD-Axxonis-2005" TOTAL_1="104" TOTAL_2="53" VAR="0.1897058823529412" WEIGHT="5.4576764508294895"/>
<DICH_DATA CI_END="18.21102043910693" CI_START="1.5680430516226669" EFFECT_SIZE="5.34375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.2603342818002286" LOG_CI_START="0.19535798234426702" LOG_EFFECT_SIZE="0.7278461320722479" MODIFIED="2010-02-08 12:10:04 +0000" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.6255723500181354" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="79" VAR="0.39134076510721244" WEIGHT="3.7003540190075825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1267978622797177" CI_END="45.455864266819034" CI_START="0.06834020666839498" DF="1" EFFECT_SIZE="1.7625161441203665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="52.98095706528035" ID="CMP-001.08.03" LOG_CI_END="1.6575899195586494" LOG_CI_START="-1.165323712180396" LOG_EFFECT_SIZE="0.2461331036891268" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14474291476628698" P_Z="0.7325141653251499" STUDIES="3" TAU2="2.915582810226736" TOTAL_1="52" TOTAL_2="52" WEIGHT="1.646430294274499" Z="0.34178305224064764">
<NAME>Pergolide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-08 10:47:57 +0000" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.0" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="188.72667149344264" CI_START="0.41276524588518376" EFFECT_SIZE="8.826086956521738" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.275833280471732" LOG_CI_START="-0.3842968766804922" LOG_EFFECT_SIZE="0.9457682018956199" MODIFIED="2009-12-08 10:47:57 +0000" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="1.562573622167863" STUDY_ID="STD-Pieta-1998" TOTAL_1="14" TOTAL_2="14" VAR="2.4416363246947954" WEIGHT="0.8657582876883777"/>
<DICH_DATA CI_END="8.235307327498598" CI_START="0.012621821467408088" EFFECT_SIZE="0.3224043715846995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9156798109309462" LOG_CI_START="-1.8988779671075169" LOG_EFFECT_SIZE="-0.49159907808828524" MODIFIED="2009-12-08 10:47:57 +0000" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Wetter-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="0.7806720065861215"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.931757603313256" CI_END="1.8692103896004695" CI_START="0.6626400037889318" DF="5" EFFECT_SIZE="1.1129301773458953" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="61" I2="44.019976559314166" ID="CMP-001.08.04" LOG_CI_END="0.2716581862906521" LOG_CI_START="-0.17872234916586358" LOG_EFFECT_SIZE="0.04646791856239427" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.11181740019090691" P_Z="0.6858908409008622" STUDIES="9" TAU2="0.17507405859331285" TOTAL_1="1400" TOTAL_2="935" WEIGHT="28.515931871808945" Z="0.4044377571802339">
<NAME>Pramipexole</NAME>
<DICH_DATA CI_END="71.15345065235105" CI_START="1.2403498318592396" EFFECT_SIZE="9.394422310756973" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.8521959664433034" LOG_CI_START="0.09354419211276088" LOG_EFFECT_SIZE="0.9728700792780323" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="1.0330407577084435" STUDY_ID="STD-BI-2008" TOTAL_1="269" TOTAL_2="132" VAR="1.067173207086835" WEIGHT="1.7796687405912386"/>
<DICH_DATA CI_END="1.5073676316672073" CI_START="0.4106329040478758" EFFECT_SIZE="0.7867494824016563" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.17821918524965627" LOG_CI_START="-0.38654625351906025" LOG_EFFECT_SIZE="-0.10416353413470199" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.33174601436675344" STUDY_ID="STD-BI-2009" TOTAL_1="166" TOTAL_2="163" VAR="0.11005541804822616" WEIGHT="6.7179598858598775"/>
<DICH_DATA CI_END="2.2518420965100625" CI_START="0.5384486297691414" EFFECT_SIZE="1.1011363636363636" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.35253793368434466" LOG_CI_START="-0.2688557238831513" LOG_EFFECT_SIZE="0.04184110490059668" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.3650097104033604" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="182" TOTAL_2="187" VAR="0.13323208868874503" WEIGHT="6.294981990764189"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="0.0" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9672651035017807" CI_START="0.32296607739988326" EFFECT_SIZE="0.7970946579194002" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2938628882518725" LOG_CI_START="-0.4908430912036368" LOG_EFFECT_SIZE="-0.0984901014758821" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="0.46094017668941056" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="200" VAR="0.21246584648646505" WEIGHT="5.179997091166355"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.0" STUDY_ID="STD-Montplaisir-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9733082808689335" CI_START="0.17597739614628882" EFFECT_SIZE="0.5892857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.29519493838022764" LOG_CI_START="-0.7545431126368535" LOG_EFFECT_SIZE="-0.22967408712831291" MODIFIED="2010-03-22 10:38:05 +0000" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.6166213274545906" STUDY_ID="STD-Oertel-2007" TOTAL_1="230" TOTAL_2="115" VAR="0.3802218614718615" WEIGHT="3.767244414538199"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-11 15:46:33 +0000" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="0.0" STUDY_ID="STD-Partinen-2006" TOTAL_1="66" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.712776704242825" CI_START="0.8037836891617983" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="0.7568472490893595" LOG_CI_START="-0.09486081100651074" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2009-12-08 10:47:49 +0000" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="0.5002975305232068" STUDY_ID="STD-Winkelman-2006" TOTAL_1="254" TOTAL_2="85" VAR="0.25029761904761905" WEIGHT="4.776079748889088"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.00383976940124" CI_END="2.3764739020879206" CI_START="1.3072889632447455" DF="11" EFFECT_SIZE="1.7625941403620724" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="76" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.37593304933078164" LOG_CI_START="0.11637159467458884" LOG_EFFECT_SIZE="0.24615232200268525" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6215380301682922" P_Z="2.012663741534668E-4" STUDIES="12" TAU2="0.0" TOTAL_1="1494" TOTAL_2="1364" WEIGHT="44.98111116627196" Z="3.7174216524191355">
<NAME>Ropinirole</NAME>
<DICH_DATA CI_END="17.065102290569126" CI_START="0.0585991213514519" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2321088958432882" LOG_CI_START="-1.2321088958432882" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="1.4474937289114918" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" VAR="2.095238095238095" WEIGHT="0.994463417576721"/>
<DICH_DATA CI_END="81.25009743259366" CI_START="0.12528155219063267" EFFECT_SIZE="3.1904761904761907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9098238904436802" LOG_CI_START="-0.9021128745098655" LOG_EFFECT_SIZE="0.5038555079669071" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="1.651745575045187" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="2.7282634446813554" WEIGHT="0.7820126070971092"/>
<DICH_DATA CI_END="4.716622639086027" CI_START="0.7461581075239843" EFFECT_SIZE="1.8759920634920635" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.6736311312131769" LOG_CI_START="-0.1271691377421104" LOG_EFFECT_SIZE="0.27323099673553325" MODIFIED="2010-03-22 14:37:32 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.470394042009598" STUDY_ID="STD-Benes-2010" TOTAL_1="199" TOTAL_2="67" VAR="0.22127055475812746" WEIGHT="5.080010035158306"/>
<DICH_DATA CI_END="1.9783820079067822" CI_START="0.20400958000994926" EFFECT_SIZE="0.6353021978021978" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.29631015374631947" LOG_CI_START="-0.6903494382222911" LOG_EFFECT_SIZE="-0.1970196422379858" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.579568728366111" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="193" VAR="0.33589991089991095" WEIGHT="4.0597808590344515"/>
<DICH_DATA CI_END="27.984718554170236" CI_START="0.34268739874098797" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4469209435105541" LOG_CI_START="-0.4651018650999629" LOG_EFFECT_SIZE="0.49090953920529573" MODIFIED="2010-02-02 14:11:55 +0000" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="1.1231316624433645" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" VAR="1.2614247311827957" WEIGHT="1.5486294486101602"/>
<DICH_DATA CI_END="3.7718116064731833" CI_START="1.0882351334757117" EFFECT_SIZE="2.0259856630824373" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.5765499925720754" LOG_CI_START="0.036722742915524124" LOG_EFFECT_SIZE="0.30663636774379976" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.31709719863624053" STUDY_ID="STD-GSK-2006" TOTAL_1="158" TOTAL_2="151" VAR="0.10055063338295137" WEIGHT="6.908324914270581"/>
<DICH_DATA CI_END="4.687935979205195" CI_START="0.4556578170076402" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6709816721082079" LOG_CI_START="-0.34136117481622347" LOG_EFFECT_SIZE="0.16481024864599214" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.5946551994613225" STUDY_ID="STD-GSK-2007" TOTAL_1="189" TOTAL_2="195" VAR="0.3536148062463852" WEIGHT="3.9375715290427813"/>
<DICH_DATA CI_END="78.27196626944439" CI_START="0.11498369632134046" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8936062438651577" LOG_CI_START="-0.9393637344258329" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="1.6641005886756874" STUDY_ID="STD-GSK-2008" TOTAL_1="20" TOTAL_2="19" VAR="2.769230769230769" WEIGHT="0.7713482039621922"/>
<DICH_DATA CI_END="5.180764230497673" CI_START="1.3797385106015911" EFFECT_SIZE="2.6735930735930737" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.7143938285882758" LOG_CI_START="0.13979678628279502" LOG_EFFECT_SIZE="0.4270953074355355" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.3375211469514711" STUDY_ID="STD-GSK-2009" TOTAL_1="197" TOTAL_2="207" VAR="0.11392052463943655" WEIGHT="6.64351556662481"/>
<DICH_DATA CI_END="4.20324339492458" CI_START="0.48553370213937647" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6235845391874751" LOG_CI_START="-0.31378061921598877" LOG_EFFECT_SIZE="0.15490195998574316" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.5506129340785623" STUDY_ID="STD-Kushida-2008" TOTAL_1="176" TOTAL_2="186" VAR="0.30317460317460315" WEIGHT="4.306706585037708"/>
<DICH_DATA CI_END="7.135694639444499" CI_START="1.0274539485768757" EFFECT_SIZE="2.707692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.8534362568330671" LOG_CI_START="0.011762365509521509" LOG_EFFECT_SIZE="0.43259931117129424" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.49440341011640676" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.24443473193473192" WEIGHT="4.834500813093909"/>
<DICH_DATA CI_END="2.0942459932802526" CI_START="0.3355616490694411" EFFECT_SIZE="0.8383010432190761" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.321027693221305" LOG_CI_START="-0.47422767999248894" LOG_EFFECT_SIZE="-0.07659999338559195" MODIFIED="2009-12-08 10:47:31 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.4671369428033683" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="136" VAR="0.21821692333167741" WEIGHT="5.1142471867632215"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.639771124302573" CI_END="8.674239122522978" CI_START="0.9961058502006985" DF="4" EFFECT_SIZE="2.939465995038029" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="11" I2="53.70247727108753" ID="CMP-001.08.06" LOG_CI_END="0.9382313901623863" LOG_CI_START="-0.0016945092515035136" LOG_EFFECT_SIZE="0.46826844045544136" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.07076199097265101" P_Z="0.05083179022304824" STUDIES="5" TAU2="0.7528198849911574" TOTAL_1="666" TOTAL_2="307" WEIGHT="12.943974497544396" Z="1.9528970931893896">
<NAME>Rotigotine</NAME>
<DICH_DATA CI_END="32.60985779035677" CI_START="2.9966444977199087" EFFECT_SIZE="9.885350318471337" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="3" LOG_CI_END="1.5133489048777755" LOG_CI_START="0.47663522414809595" LOG_EFFECT_SIZE="0.9949920645129359" MODIFIED="2010-03-11 16:03:36 +0000" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.6089707478760983" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" VAR="0.37084537176877447" WEIGHT="3.8255612518473825"/>
<DICH_DATA CI_END="7.07284120567657" CI_START="0.3102637997792985" EFFECT_SIZE="1.4813664596273293" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8495939077257983" LOG_CI_START="-0.5082688930372323" LOG_EFFECT_SIZE="0.17066250734428304" MODIFIED="2010-03-11 15:48:58 +0000" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.7976153306974714" STUDY_ID="STD-Oertel-2008" TOTAL_1="170" TOTAL_2="55" VAR="0.6361902157636365" WEIGHT="2.66021072398587"/>
<DICH_DATA CI_END="10.619052121109458" CI_START="0.07782674682882998" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0260857524381166" LOG_CI_START="-1.1088711227545667" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2009-12-08 10:48:13 +0000" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="1.2540842366951563" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" VAR="1.5727272727272728" WEIGHT="1.2819263920459123"/>
<DICH_DATA CI_END="6.102110992547956" CI_START="0.008727215538173277" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7854801028496061" LOG_CI_START="-2.059124298023955" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2010-03-11 15:50:28 +0000" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.67093470609201" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="2.7920227920227916" WEIGHT="0.765540078357446"/>
<DICH_DATA CI_END="16.42150687069345" CI_START="1.9855251507474774" EFFECT_SIZE="5.710106382978723" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" LOG_CI_END="1.2154130063522697" LOG_CI_START="0.2978753926649055" LOG_EFFECT_SIZE="0.7566441995085876" MODIFIED="2010-03-11 15:57:34 +0000" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.538966136164396" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="226" TOTAL_2="117" VAR="0.29048449593197834" WEIGHT="4.410736051307785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="49.690667651537005" CI_START="0.14714887352020775" DF="0" EFFECT_SIZE="2.7040572792362774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.08.07" LOG_CI_END="1.6962748320329224" LOG_CI_START="-0.8322430582387185" LOG_EFFECT_SIZE="0.432015886897102" MODIFIED="2010-05-11 14:49:28 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5030181091449877" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="51" WEIGHT="0.949333180586685" Z="0.6697485371372902">
<NAME>Sumanirole</NAME>
<DICH_DATA CI_END="49.690667651537005" CI_START="0.14714887352020775" EFFECT_SIZE="2.704057279236277" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6962748320329224" LOG_CI_START="-0.8322430582387185" LOG_EFFECT_SIZE="0.43201588689710196" MODIFIED="2009-12-08 10:48:07 +0000" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.48526392511098" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="214" TOTAL_2="51" VAR="2.206008927236075" WEIGHT="0.949333180586685"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="50.961739414384446" CI_END="1.5389920916708024" CI_START="1.3424263465186712" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4373529597641503" ESTIMABLE="YES" EVENTS_1="2562" EVENTS_2="1232" I2="48.9813332535874" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.18723638815340463" LOG_CI_START="0.1278904670509194" LOG_EFFECT_SIZE="0.157563427602162" METHOD="MH" MODIFIED="2010-05-11 13:22:28 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.00240937054172774" P_Q="0.0" P_Z="2.293791625071083E-25" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01428997736775227" TOTALS="YES" TOTAL_1="3750" TOTAL_2="2588" WEIGHT="100.0" Z="10.407409225231133">
<NAME>Responder rates on CGI-I</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6404539733303065" CI_START="0.6482818657453844" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.21496404977291325" LOG_CI_START="-0.18823612665695016" LOG_EFFECT_SIZE="0.013363961557981502" ORDER="443" O_E="0.0" SE="0.23684177950796415" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="0.056094028520499106" WEIGHT="1.7265651587550739"/>
<DICH_DATA CI_END="2.2809974677089757" CI_START="1.1758290307287984" EFFECT_SIZE="1.6377005347593583" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="22" LOG_CI_END="0.3581248031369603" LOG_CI_START="0.07034417853521957" LOG_EFFECT_SIZE="0.21423449083608992" MODIFIED="2010-03-11 16:06:15 +0000" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.16904376342812893" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="49" VAR="0.02857579395394522" WEIGHT="2.8349559229500056"/>
<DICH_DATA CI_END="2.4749745092429936" CI_START="1.3653893477438253" EFFECT_SIZE="1.8382882882882883" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="30" LOG_CI_END="0.3935707303192372" LOG_CI_START="0.13525651032602737" LOG_EFFECT_SIZE="0.26441362032263227" MODIFIED="2010-01-28 08:46:48 +0000" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.15173505150002267" STUDY_ID="STD-Axxonis-2008" TOTAL_1="148" TOTAL_2="77" VAR="0.02302352585371453" WEIGHT="3.2567987942325862"/>
<DICH_DATA CI_END="1.717856627626839" CI_START="0.9578268427054646" EFFECT_SIZE="1.2827350427350428" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="30" LOG_CI_END="0.23498691477531483" LOG_CI_START="-0.01871299619765957" LOG_EFFECT_SIZE="0.10813695928882762" MODIFIED="2009-11-04 11:16:58 +0000" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.14902458354033832" STUDY_ID="STD-Benes-2010" TOTAL_1="195" TOTAL_2="67" VAR="0.022208326499371274" WEIGHT="3.329540264191024"/>
<DICH_DATA CI_END="1.289353804346063" CI_START="0.908181199174079" EFFECT_SIZE="1.0821122327146424" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="74" LOG_CI_END="0.11037210602012051" LOG_CI_START="-0.04182749294316434" LOG_EFFECT_SIZE="0.03427230653847809" MODIFIED="2010-01-21 11:44:57 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.0894027978311991" STUDY_ID="STD-BI-2008" TOTAL_1="249" TOTAL_2="127" VAR="0.00799286026004626" WEIGHT="5.453639896772557"/>
<DICH_DATA CI_END="1.6408811570936106" CI_START="1.1301942027457732" EFFECT_SIZE="1.3618055555555555" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="80" LOG_CI_END="0.21507712786145688" LOG_CI_START="0.053153075283611816" LOG_EFFECT_SIZE="0.13411510157253437" MODIFIED="2009-12-04 11:18:41 +0000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.0951149900212135" STUDY_ID="STD-BI-2009" TOTAL_1="162" TOTAL_2="159" VAR="0.009046861326735543" WEIGHT="5.207327945792871"/>
<DICH_DATA CI_END="1.5088243604534695" CI_START="1.1152721467696771" EFFECT_SIZE="1.2972084580287495" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="109" LOG_CI_END="0.17863868727362986" LOG_CI_START="0.04738085610048603" LOG_EFFECT_SIZE="0.11300977168705793" ORDER="431" O_E="0.0" SE="0.0771014997678478" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="193" VAR="0.005944641266451435" WEIGHT="6.005676434882266"/>
<DICH_DATA CI_END="2.0272148906000664" CI_START="1.339878108522574" EFFECT_SIZE="1.6480961298377028" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="72" LOG_CI_END="0.3068997875954485" LOG_CI_START="0.12706529149626364" LOG_EFFECT_SIZE="0.21698253954585608" ORDER="436" O_E="0.0" SE="0.10563567320377378" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" VAR="0.011158895453214489" WEIGHT="4.775165216753611"/>
<DICH_DATA CI_END="1.331193073999192" CI_START="0.7294565474965581" EFFECT_SIZE="0.98541742617572" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="26" LOG_CI_END="0.12424104938252802" LOG_CI_START="-0.13700057319413603" LOG_EFFECT_SIZE="-0.006379761905804014" MODIFIED="2009-10-26 16:10:14 +0000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.15345462226842013" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="211" TOTAL_2="51" VAR="0.023548321095543508" WEIGHT="3.2116288849020824"/>
<DICH_DATA CI_END="1.4227111926775382" CI_START="0.9502770867964607" EFFECT_SIZE="1.1627423822714682" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="76" LOG_CI_END="0.15311674818241053" LOG_CI_START="-0.022149742373553542" LOG_EFFECT_SIZE="0.06548350290442849" MODIFIED="2010-02-04 09:47:14 +0000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.10295240413569372" STUDY_ID="STD-GSK-2006" TOTAL_1="152" TOTAL_2="146" VAR="0.010599197517319206" WEIGHT="4.88254724639972"/>
<DICH_DATA CI_END="1.8744839870028396" CI_START="1.3608726372238045" EFFECT_SIZE="1.597164351851852" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="96" LOG_CI_END="0.27288173476236566" LOG_CI_START="0.13381748189755652" LOG_EFFECT_SIZE="0.2033496083299611" MODIFIED="2010-02-04 11:39:24 +0000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.08168703051194257" STUDY_ID="STD-GSK-2007" TOTAL_1="180" TOTAL_2="193" VAR="0.006672770953859036" WEIGHT="5.7970725229279445"/>
<DICH_DATA CI_END="2.647981513532279" CI_START="0.941500074491882" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4229149488194198" LOG_CI_START="-0.0261796412857529" LOG_EFFECT_SIZE="0.19836765376683346" ORDER="435" O_E="0.0" SE="0.26380038528185246" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" VAR="0.06959064327485379" WEIGHT="1.4487562367718223"/>
<DICH_DATA CI_END="1.5385986866365524" CI_START="1.1165571803458503" EFFECT_SIZE="1.3106995884773662" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="72" LOG_CI_END="0.18712535738371125" LOG_CI_START="0.04788096876240288" LOG_EFFECT_SIZE="0.11750316307305704" MODIFIED="2010-02-01 09:22:01 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.08179284314699663" STUDY_ID="STD-GSK-2009" TOTAL_1="108" TOTAL_2="112" VAR="0.006690069190069193" WEIGHT="5.7922927847346735"/>
<DICH_DATA CI_END="1.6274121915934892" CI_START="1.0805539158061965" EFFECT_SIZE="1.326086956521739" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="48" LOG_CI_END="0.21149756514487525" LOG_CI_START="0.03364644151351065" LOG_EFFECT_SIZE="0.12257200332919292" MODIFIED="2010-03-11 16:18:36 +0000" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.10447063039832409" STUDY_ID="STD-Hening-2010" TOTAL_1="161" TOTAL_2="84" VAR="0.010914112615823236" WEIGHT="4.821541756891765"/>
<DICH_DATA CI_END="2.4264407236666403" CI_START="0.9613101036098242" EFFECT_SIZE="1.5272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.3849696862554956" LOG_CI_START="-0.017136493120219927" LOG_EFFECT_SIZE="0.18391659656763784" ORDER="432" O_E="0.0" SE="0.2361991602229849" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.05579004329004329" WEIGHT="1.734054458883052"/>
<DICH_DATA CI_END="1.6846801558640756" CI_START="1.1920920838062359" EFFECT_SIZE="1.417142857142857" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="92" LOG_CI_END="0.22651746026463698" LOG_CI_START="0.07630980401520661" LOG_EFFECT_SIZE="0.1514136321399218" ORDER="450" O_E="0.0" SE="0.08823272082080545" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" VAR="0.0077850130234421965" WEIGHT="5.504988683879163"/>
<DICH_DATA CI_END="2.3044262363234562" CI_START="1.5289551679871867" EFFECT_SIZE="1.877062706270627" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="72" LOG_CI_END="0.3625628111064936" LOG_CI_START="0.18439475121923404" LOG_EFFECT_SIZE="0.27347878116286384" ORDER="446" O_E="0.0" SE="0.10465680032389654" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" VAR="0.010953045854035951" WEIGHT="4.814105316647493"/>
<DICH_DATA CI_END="4.773299690670669" CI_START="1.1264789522056988" EFFECT_SIZE="2.318840579710145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6788187023148333" LOG_CI_START="0.05172308152250559" LOG_EFFECT_SIZE="0.36527089191866946" MODIFIED="2010-01-27 13:50:46 +0000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.3683590718267998" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="0.13568840579710145" WEIGHT="0.8102672514257685"/>
<DICH_DATA CI_END="2.5744293242126943" CI_START="1.4610580435991183" EFFECT_SIZE="1.939430501930502" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="37" LOG_CI_END="0.4106809736440266" LOG_CI_START="0.16466746953736286" LOG_EFFECT_SIZE="0.2876742215906947" ORDER="437" O_E="0.0" SE="0.1445095500987398" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" VAR="0.020883010069740193" WEIGHT="3.4549971769168075"/>
<DICH_DATA CI_END="1.8518949362647097" CI_START="1.1061395677487678" EFFECT_SIZE="1.4312422102201912" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="29" LOG_CI_END="0.26761634417378477" LOG_CI_START="0.0438099277634445" LOG_EFFECT_SIZE="0.15571313596861464" MODIFIED="2010-03-11 16:09:03 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.13146499685906243" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" VAR="0.017283045399153294" WEIGHT="3.848936897725396"/>
<DICH_DATA CI_END="2.319380462246032" CI_START="1.0078611892432974" EFFECT_SIZE="1.5289256198347108" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="11" LOG_CI_END="0.36537199447723645" LOG_CI_START="0.003400721695890976" LOG_EFFECT_SIZE="0.18438635808656373" MODIFIED="2010-01-28 14:17:17 +0000" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.21262371741846017" STUDY_ID="STD-Oertel-2010" TOTAL_1="44" TOTAL_2="20" VAR="0.0452088452088452" WEIGHT="2.042436590132877"/>
<DICH_DATA CI_END="3.104203891352448" CI_START="1.1224921320894072" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="9" LOG_CI_END="0.49195023899760815" LOG_CI_START="0.05018330557546776" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2010-03-11 16:07:30 +0000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.25949608347375364" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" VAR="0.06733821733821732" WEIGHT="1.4887328176005792"/>
<DICH_DATA CI_END="3.8972968686813494" CI_START="1.1183576758785332" EFFECT_SIZE="2.087719298245614" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.5907634885536871" LOG_CI_START="0.04858072288639159" LOG_EFFECT_SIZE="0.31967210572003935" MODIFIED="2010-03-11 16:15:48 +0000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.31848084040094393" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="0.1014300457024915" WEIGHT="1.0501430009783248"/>
<DICH_DATA CI_END="1.6945050140892433" CI_START="1.022875447858761" EFFECT_SIZE="1.316536203522505" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="56" LOG_CI_END="0.22904285826520487" LOG_CI_START="0.009822754336954011" LOG_EFFECT_SIZE="0.11943280630107943" ORDER="433" O_E="0.0" SE="0.12877097420447017" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.016581963797568322" WEIGHT="3.9363437384616704"/>
<DICH_DATA CI_END="2.071057256480157" CI_START="1.3137016893036928" EFFECT_SIZE="1.6494700410988536" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="46" LOG_CI_END="0.31619210557122024" LOG_CI_START="0.11849675837627782" LOG_EFFECT_SIZE="0.21734443197374906" MODIFIED="2010-03-11 16:16:51 +0000" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.1161272255500606" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="201" TOTAL_2="101" VAR="0.013485532513954646" WEIGHT="4.375169810304802"/>
<DICH_DATA CI_END="1.9530234464028056" CI_START="1.1777549948511994" EFFECT_SIZE="1.5166354601757166" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="53" LOG_CI_END="0.29070745710364365" LOG_CI_START="0.07105495475422285" LOG_EFFECT_SIZE="0.18088120592893323" ORDER="441" O_E="0.0" SE="0.1290249671774721" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" VAR="0.016647442155147758" WEIGHT="3.928012554838815"/>
<DICH_DATA CI_END="1.7573003468482473" CI_START="1.1257466391477182" EFFECT_SIZE="1.4065116279069767" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="43" LOG_CI_END="0.2448459947515876" LOG_CI_START="0.051440659075539616" LOG_EFFECT_SIZE="0.14814332691356358" ORDER="434" O_E="0.0" SE="0.11360725154796249" STUDY_ID="STD-Winkelman-2006" TOTAL_1="250" TOTAL_2="84" VAR="0.012906607604282024" WEIGHT="4.468302635247257"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="50.961739414384446" CI_END="1.5389920916708026" CI_START="1.3424263465186717" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4373529597641506" ESTIMABLE="YES" EVENTS_1="2562" EVENTS_2="1232" I2="48.9813332535874" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.18723638815340468" LOG_CI_START="0.12789046705091953" LOG_EFFECT_SIZE="0.15756342760216205" METHOD="MH" MODIFIED="2010-05-11 13:22:37 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.00240937054172774" P_Q="0.0" P_Z="2.2937916250709845E-25" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.014289977367752268" TOTALS="YES" TOTAL_1="3750" TOTAL_2="2588" WEIGHT="100.00000000000003" Z="10.407409225231136">
<NAME>Medication subgroups: responder rates on CGI-I</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.773299690670669" CI_START="1.1264789522056988" DF="0" EFFECT_SIZE="2.318840579710145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.6788187023148333" LOG_CI_START="0.05172308152250559" LOG_EFFECT_SIZE="0.36527089191866946" MODIFIED="2010-01-27 13:51:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02241381495891919" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="0.8102672514257685" Z="2.2832811106442152">
<NAME>Cabergoline</NAME>
<DICH_DATA CI_END="4.773299690670669" CI_START="1.1264789522056988" EFFECT_SIZE="2.318840579710145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6788187023148333" LOG_CI_START="0.05172308152250559" LOG_EFFECT_SIZE="0.36527089191866946" MODIFIED="2010-01-27 13:51:07 +0000" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.3683590718267998" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="0.13568840579710145" WEIGHT="0.8102672514257685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.25970848917355616" CI_END="2.1784105690561693" CI_START="1.3992903090168523" DF="1" EFFECT_SIZE="1.7459177524557634" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="52" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.3381397354158405" LOG_CI_START="0.1459078263748669" LOG_EFFECT_SIZE="0.24202378089535376" MODIFIED="2010-03-11 16:06:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6103205387777475" P_Z="8.004120402694923E-7" STUDIES="2" TAU2="0.0" TOTAL_1="250" TOTAL_2="126" WEIGHT="6.091754717182592" Z="4.9352669525432304">
<NAME>Lisuride</NAME>
<DICH_DATA CI_END="2.2809974677089757" CI_START="1.1758290307287984" EFFECT_SIZE="1.6377005347593583" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="22" LOG_CI_END="0.3581248031369603" LOG_CI_START="0.07034417853521957" LOG_EFFECT_SIZE="0.21423449083608992" MODIFIED="2010-03-11 16:06:28 +0000" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.16904376342812893" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="49" VAR="0.02857579395394522" WEIGHT="2.834955922950006"/>
<DICH_DATA CI_END="2.4749745092429936" CI_START="1.3653893477438253" EFFECT_SIZE="1.8382882882882883" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="30" LOG_CI_END="0.3935707303192372" LOG_CI_START="0.13525651032602737" LOG_EFFECT_SIZE="0.26441362032263227" MODIFIED="2010-01-28 08:47:13 +0000" MODIFIED_BY="[Empty name]" ORDER="502" O_E="0.0" SE="0.15173505150002267" STUDY_ID="STD-Axxonis-2008" TOTAL_1="148" TOTAL_2="77" VAR="0.02302352585371453" WEIGHT="3.2567987942325862"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="24.249510797782417" CI_END="1.796435303854918" CI_START="1.2997604444253827" DF="7" EFFECT_SIZE="1.52804958981046" ESTIMABLE="YES" EVENTS_1="915" EVENTS_2="398" I2="71.1334382851132" ID="CMP-001.10.03" LOG_CI_END="0.2544115813042396" LOG_CI_START="0.11386331595988568" LOG_EFFECT_SIZE="0.18413744863206258" MODIFIED="2010-03-11 16:07:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0010298049383566932" P_Z="2.8118289364455395E-7" STUDIES="8" TAU2="0.03576154243067037" TOTAL_1="1350" TOTAL_2="900" WEIGHT="31.396325464614225" Z="5.135641719087713">
<NAME>Pramipexole</NAME>
<DICH_DATA CI_END="1.289353804346063" CI_START="0.908181199174079" EFFECT_SIZE="1.0821122327146424" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="74" LOG_CI_END="0.11037210602012051" LOG_CI_START="-0.04182749294316434" LOG_EFFECT_SIZE="0.03427230653847809" MODIFIED="2010-02-16 14:20:13 +0000" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.0894027978311991" STUDY_ID="STD-BI-2008" TOTAL_1="249" TOTAL_2="127" VAR="0.00799286026004626" WEIGHT="5.453639896772557"/>
<DICH_DATA CI_END="1.6408811570936106" CI_START="1.1301942027457732" EFFECT_SIZE="1.3618055555555555" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="80" LOG_CI_END="0.21507712786145688" LOG_CI_START="0.053153075283611816" LOG_EFFECT_SIZE="0.13411510157253437" MODIFIED="2010-02-16 14:20:15 +0000" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="0.0951149900212135" STUDY_ID="STD-BI-2009" TOTAL_1="162" TOTAL_2="159" VAR="0.009046861326735543" WEIGHT="5.207327945792871"/>
<DICH_DATA CI_END="2.0272148906000664" CI_START="1.339878108522574" EFFECT_SIZE="1.6480961298377028" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="72" LOG_CI_END="0.3068997875954485" LOG_CI_START="0.12706529149626364" LOG_EFFECT_SIZE="0.21698253954585608" MODIFIED="2010-02-16 14:20:14 +0000" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.10563567320377378" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" VAR="0.011158895453214489" WEIGHT="4.775165216753611"/>
<DICH_DATA CI_END="2.4264407236666403" CI_START="0.9613101036098242" EFFECT_SIZE="1.5272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.3849696862554956" LOG_CI_START="-0.017136493120219927" LOG_EFFECT_SIZE="0.18391659656763784" MODIFIED="2010-02-16 14:20:15 +0000" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.2361991602229849" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.05579004329004329" WEIGHT="1.734054458883052"/>
<DICH_DATA CI_END="2.3044262363234562" CI_START="1.5289551679871867" EFFECT_SIZE="1.877062706270627" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="72" LOG_CI_END="0.3625628111064936" LOG_CI_START="0.18439475121923404" LOG_EFFECT_SIZE="0.27347878116286384" MODIFIED="2010-02-16 14:20:16 +0000" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.10465680032389654" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" VAR="0.010953045854035951" WEIGHT="4.814105316647493"/>
<DICH_DATA CI_END="2.5744293242126943" CI_START="1.4610580435991183" EFFECT_SIZE="1.939430501930502" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="37" LOG_CI_END="0.4106809736440266" LOG_CI_START="0.16466746953736286" LOG_EFFECT_SIZE="0.2876742215906947" MODIFIED="2010-02-16 13:20:47 +0000" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="0.1445095500987398" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" VAR="0.020883010069740193" WEIGHT="3.4549971769168075"/>
<DICH_DATA CI_END="3.104203891352448" CI_START="1.1224921320894072" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="9" LOG_CI_END="0.49195023899760815" LOG_CI_START="0.05018330557546776" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2010-03-11 16:07:06 +0000" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.25949608347375364" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" VAR="0.06733821733821732" WEIGHT="1.4887328176005792"/>
<DICH_DATA CI_END="1.7573003468482473" CI_START="1.1257466391477182" EFFECT_SIZE="1.4065116279069767" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="43" LOG_CI_END="0.2448459947515876" LOG_CI_START="0.051440659075539616" LOG_EFFECT_SIZE="0.14814332691356358" MODIFIED="2009-12-08 10:50:35 +0000" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="0.11360725154796249" STUDY_ID="STD-Winkelman-2006" TOTAL_1="250" TOTAL_2="84" VAR="0.012906607604282024" WEIGHT="4.468302635247258"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.602952577220568" CI_END="1.4563952436662446" CI_START="1.2691143684043347" DF="9" EFFECT_SIZE="1.3595337913463437" ESTIMABLE="YES" EVENTS_1="887" EVENTS_2="610" I2="6.278824896530772" ID="CMP-001.10.04" LOG_CI_END="0.16327925193392137" LOG_CI_START="0.10350076104569812" LOG_EFFECT_SIZE="0.13339000648980978" MODIFIED="2010-02-16 15:16:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.38357357638342116" P_Z="2.1920500512160153E-18" STUDIES="10" TAU2="7.871507691041789E-4" TOTAL_1="1325" TOTAL_2="1219" WEIGHT="42.351795625842186" Z="8.746945757009621">
<NAME>Ropinirole</NAME>
<DICH_DATA CI_END="1.6404539733303065" CI_START="0.6482818657453844" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.21496404977291325" LOG_CI_START="-0.18823612665695016" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="0.23684177950796415" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="0.056094028520499106" WEIGHT="1.7265651587550739"/>
<DICH_DATA CI_END="1.717856627626839" CI_START="0.9578268427054646" EFFECT_SIZE="1.2827350427350428" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="30" LOG_CI_END="0.23498691477531483" LOG_CI_START="-0.01871299619765957" LOG_EFFECT_SIZE="0.10813695928882762" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="0.14902458354033832" STUDY_ID="STD-Benes-2010" TOTAL_1="195" TOTAL_2="67" VAR="0.022208326499371274" WEIGHT="3.329540264191024"/>
<DICH_DATA CI_END="1.5088243604534695" CI_START="1.1152721467696771" EFFECT_SIZE="1.2972084580287495" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="109" LOG_CI_END="0.17863868727362986" LOG_CI_START="0.04738085610048603" LOG_EFFECT_SIZE="0.11300977168705793" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="0.0771014997678478" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="193" VAR="0.005944641266451435" WEIGHT="6.005676434882267"/>
<DICH_DATA CI_END="1.4227111926775382" CI_START="0.9502770867964607" EFFECT_SIZE="1.1627423822714682" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="76" LOG_CI_END="0.15311674818241053" LOG_CI_START="-0.022149742373553542" LOG_EFFECT_SIZE="0.06548350290442849" MODIFIED="2010-02-04 09:47:39 +0000" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="0.10295240413569372" STUDY_ID="STD-GSK-2006" TOTAL_1="152" TOTAL_2="146" VAR="0.010599197517319206" WEIGHT="4.88254724639972"/>
<DICH_DATA CI_END="1.8744839870028396" CI_START="1.3608726372238045" EFFECT_SIZE="1.597164351851852" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="96" LOG_CI_END="0.27288173476236566" LOG_CI_START="0.13381748189755652" LOG_EFFECT_SIZE="0.2033496083299611" MODIFIED="2010-02-04 11:39:35 +0000" MODIFIED_BY="[Empty name]" ORDER="624" O_E="0.0" SE="0.08168703051194257" STUDY_ID="STD-GSK-2007" TOTAL_1="180" TOTAL_2="193" VAR="0.006672770953859036" WEIGHT="5.797072522927945"/>
<DICH_DATA CI_END="2.647981513532279" CI_START="0.941500074491882" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4229149488194198" LOG_CI_START="-0.0261796412857529" LOG_EFFECT_SIZE="0.19836765376683346" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="0.26380038528185246" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" VAR="0.06959064327485379" WEIGHT="1.4487562367718223"/>
<DICH_DATA CI_END="1.5385986866365524" CI_START="1.1165571803458503" EFFECT_SIZE="1.3106995884773662" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="72" LOG_CI_END="0.18712535738371125" LOG_CI_START="0.04788096876240288" LOG_EFFECT_SIZE="0.11750316307305704" MODIFIED="2010-02-16 15:16:04 +0000" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="0.08179284314699663" STUDY_ID="STD-GSK-2009" TOTAL_1="108" TOTAL_2="112" VAR="0.006690069190069193" WEIGHT="5.792292784734674"/>
<DICH_DATA CI_END="1.6846801558640756" CI_START="1.1920920838062359" EFFECT_SIZE="1.417142857142857" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="92" LOG_CI_END="0.22651746026463698" LOG_CI_START="0.07630980401520661" LOG_EFFECT_SIZE="0.1514136321399218" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.08823272082080545" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" VAR="0.0077850130234421965" WEIGHT="5.504988683879164"/>
<DICH_DATA CI_END="1.6945050140892433" CI_START="1.022875447858761" EFFECT_SIZE="1.316536203522505" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="56" LOG_CI_END="0.22904285826520487" LOG_CI_START="0.009822754336954011" LOG_EFFECT_SIZE="0.11943280630107943" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.12877097420447017" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.016581963797568322" WEIGHT="3.9363437384616704"/>
<DICH_DATA CI_END="1.9530234464028056" CI_START="1.1777549948511994" EFFECT_SIZE="1.5166354601757166" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="53" LOG_CI_END="0.29070745710364365" LOG_CI_START="0.07105495475422285" LOG_EFFECT_SIZE="0.18088120592893323" MODIFIED="2009-12-08 10:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.1290249671774721" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" VAR="0.016647442155147758" WEIGHT="3.928012554838816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.266041188840126" CI_END="1.6740093657484172" CI_START="1.3100201124522926" DF="4" EFFECT_SIZE="1.4808733698611547" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="140" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.2237578834550178" LOG_CI_START="0.11727796333515103" LOG_EFFECT_SIZE="0.1705179233950844" MODIFIED="2010-03-11 16:18:09 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5143308381474121" P_Z="3.442622881638445E-10" STUDIES="5" TAU2="0.0" TOTAL_1="591" TOTAL_2="272" WEIGHT="16.138228056033167" Z="6.2774087019730835">
<NAME>Rotigotine</NAME>
<DICH_DATA CI_END="1.6274121915934892" CI_START="1.0805539158061965" EFFECT_SIZE="1.326086956521739" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="48" LOG_CI_END="0.21149756514487525" LOG_CI_START="0.03364644151351065" LOG_EFFECT_SIZE="0.12257200332919292" MODIFIED="2010-03-11 16:18:09 +0000" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="0.10447063039832409" STUDY_ID="STD-Hening-2010" TOTAL_1="161" TOTAL_2="84" VAR="0.010914112615823236" WEIGHT="4.821541756891765"/>
<DICH_DATA CI_END="1.8518949362647097" CI_START="1.1061395677487678" EFFECT_SIZE="1.4312422102201912" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="29" LOG_CI_END="0.26761634417378477" LOG_CI_START="0.0438099277634445" LOG_EFFECT_SIZE="0.15571313596861464" MODIFIED="2010-03-11 16:14:57 +0000" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.13146499685906243" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" VAR="0.017283045399153294" WEIGHT="3.8489368977253964"/>
<DICH_DATA CI_END="2.319380462246032" CI_START="1.0078611892432974" EFFECT_SIZE="1.5289256198347108" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="11" LOG_CI_END="0.36537199447723645" LOG_CI_START="0.003400721695890976" LOG_EFFECT_SIZE="0.18438635808656373" MODIFIED="2010-01-28 14:17:45 +0000" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.21262371741846017" STUDY_ID="STD-Oertel-2010" TOTAL_1="44" TOTAL_2="20" VAR="0.0452088452088452" WEIGHT="2.042436590132877"/>
<DICH_DATA CI_END="3.8972968686813494" CI_START="1.1183576758785332" EFFECT_SIZE="2.087719298245614" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.5907634885536871" LOG_CI_START="0.04858072288639159" LOG_EFFECT_SIZE="0.31967210572003935" MODIFIED="2010-03-11 16:15:33 +0000" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.31848084040094393" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="0.1014300457024915" WEIGHT="1.0501430009783248"/>
<DICH_DATA CI_END="2.071057256480157" CI_START="1.3137016893036928" EFFECT_SIZE="1.6494700410988536" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="46" LOG_CI_END="0.31619210557122024" LOG_CI_START="0.11849675837627782" LOG_EFFECT_SIZE="0.21734443197374906" MODIFIED="2010-03-11 16:17:16 +0000" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.1161272255500606" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="201" TOTAL_2="101" VAR="0.013485532513954646" WEIGHT="4.3751698103048025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.331193073999192" CI_START="0.7294565474965581" DF="0" EFFECT_SIZE="0.98541742617572" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="26" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="0.12424104938252802" LOG_CI_START="-0.13700057319413603" LOG_EFFECT_SIZE="-0.006379761905804014" MODIFIED="2009-12-08 10:50:37 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9237363922062697" STUDIES="1" TAU2="0.0" TOTAL_1="211" TOTAL_2="51" WEIGHT="3.2116288849020824" Z="0.09572826444719412">
<NAME>Sumanirole</NAME>
<DICH_DATA CI_END="1.331193073999192" CI_START="0.7294565474965581" EFFECT_SIZE="0.98541742617572" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="26" LOG_CI_END="0.12424104938252802" LOG_CI_START="-0.13700057319413603" LOG_EFFECT_SIZE="-0.006379761905804014" MODIFIED="2009-12-08 10:50:37 +0000" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.15345462226842013" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="211" TOTAL_2="51" VAR="0.023548321095543508" WEIGHT="3.2116288849020824"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="24.96217968510859" CI_END="0.4670718838116283" CI_START="0.330420314883543" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.39874609934758565" ESTIMABLE="YES" I2="15.872731208133496" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2010-05-11 13:22:50 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.24880590524786017" P_Q="1.0" P_Z="2.6923515419088958E-30" Q="0.0" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0040690626320261545" TOTALS="YES" TOTAL_1="2714" TOTAL_2="1878" UNITS="" WEIGHT="100.0" Z="11.438258628532656">
<NAME>Change in self rated quality of sleep</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8302452481960363" CI_START="-0.2636328287813356" EFFECT_SIZE="0.2833062097073504" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="9.9" MODIFIED="2010-03-22 11:05:57 +0000" MODIFIED_BY="[Empty name]" ORDER="714" SD_1="19.12" SD_2="16.09" SE="0.2790556575543588" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="1.4831024811368034"/>
<CONT_DATA CI_END="0.9051032081374946" CI_START="0.2207999989386798" EFFECT_SIZE="0.5629516035380872" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="2.1" MODIFIED="2010-03-11 16:21:07 +0000" MODIFIED_BY="[Empty name]" ORDER="728" SD_1="3.6" SD_2="3.4" SE="0.17457035297498094" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="3.5180505135583995"/>
<CONT_DATA CI_END="0.7831125441817788" CI_START="0.2314758848896889" EFFECT_SIZE="0.5072942145357339" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="1.3" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="711" SD_1="3.8" SD_2="3.6" SE="0.14072622345189234" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="5.090580380012046"/>
<CONT_DATA CI_END="0.6676902118174233" CI_START="0.25003510113967964" EFFECT_SIZE="0.45886265647855146" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="14.3" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="718" SD_1="20.43" SD_2="19.6" SE="0.10654662891057026" STUDY_ID="STD-Bogan-2006" TOTAL_1="176" TOTAL_2="186" WEIGHT="7.880496574633474"/>
<CONT_DATA CI_END="0.5651566610749353" CI_START="0.14633496312809877" EFFECT_SIZE="0.35574581210151707" ESTIMABLE="YES" MEAN_1="19.5" MEAN_2="12.9" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="721" SD_1="19.2" SD_2="17.8" SE="0.10684423317225436" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="178" WEIGHT="7.848177101521942"/>
<CONT_DATA CI_END="0.26423927732188" CI_START="-0.20629354222797108" EFFECT_SIZE="0.028972867546954474" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="14.45" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="716" SD_1="19.36" SD_2="18.46" SE="0.12003608822951695" STUDY_ID="STD-GSK-2006" TOTAL_1="144" TOTAL_2="134" WEIGHT="6.576950440713499"/>
<CONT_DATA CI_END="0.883672399578402" CI_START="-0.41069339361818125" EFFECT_SIZE="0.23648950298011043" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.6" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="723" SD_1="2.04" SD_2="1.11" SE="0.3302014229359252" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.0744906085407606"/>
<CONT_DATA CI_END="0.5917191947787006" CI_START="0.11030677864013821" EFFECT_SIZE="0.35101298670941944" ESTIMABLE="YES" MEAN_1="21.76" MEAN_2="14.7" MODIFIED="2010-03-11 16:32:50 +0000" MODIFIED_BY="[Empty name]" ORDER="712" SD_1="20.95" SD_2="18.1" SE="0.122811546522253" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" WEIGHT="6.345485644727244"/>
<CONT_DATA CI_END="1.6193221932572863" CI_START="0.3176152206512788" EFFECT_SIZE="0.9684687069542826" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.4" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="731" SD_1="4.0" SD_2="3.9" SE="0.3320742071981184" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" WEIGHT="1.0628353458208135"/>
<CONT_DATA CI_END="0.4521985607322886" CI_START="0.03558110918547555" EFFECT_SIZE="0.24388983495888206" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="16.8" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="713" SD_1="23.48" SD_2="22.36" SE="0.10628191508441948" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" WEIGHT="7.90939206817377"/>
<CONT_DATA CI_END="0.736524446887253" CI_START="0.33591508324429376" EFFECT_SIZE="0.5362197650657734" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="1.3" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="719" SD_1="3.4" SD_2="2.9" SE="0.10219814415033003" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" WEIGHT="8.3733687397469"/>
<CONT_DATA CI_END="1.413576538774599" CI_START="0.12418176588506946" EFFECT_SIZE="0.7688791523298343" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.2" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="722" SD_1="0.9" SD_2="0.6" SE="0.32893328220827295" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.0824907075007917"/>
<CONT_DATA CI_END="0.6899845350006982" CI_START="0.23254131152936985" EFFECT_SIZE="0.46126292326503404" ESTIMABLE="YES" MEAN_1="29.9" MEAN_2="12.3" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="715" SD_1="40.0" SD_2="34.0" SE="0.11669684419703172" STUDY_ID="STD-Oertel-2007" TOTAL_1="221" TOTAL_2="114" WEIGHT="6.870899398137197"/>
<CONT_DATA CI_END="0.8089948548095369" CI_START="0.1834681128948804" EFFECT_SIZE="0.49623148385220867" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="2.5" MODIFIED="2010-03-11 16:24:30 +0000" MODIFIED_BY="[Empty name]" ORDER="732" SD_1="3.28" SD_2="2.9" SE="0.15957608069554635" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="4.114876988016963"/>
<CONT_DATA CI_END="0.8160762722858723" CI_START="-0.2214761424057219" EFFECT_SIZE="0.2973000649400752" ESTIMABLE="YES" MEAN_1="20.5" MEAN_2="14.1" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="717" SD_1="21.4" SD_2="21.0" SE="0.26468660212016015" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="1.6394207853926697"/>
<CONT_DATA CI_END="0.8035226952127883" CI_START="-0.1849408677313113" EFFECT_SIZE="0.30929091374073847" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="0.7" MODIFIED="2010-03-11 16:22:11 +0000" MODIFIED_BY="[Empty name]" ORDER="725" SD_1="1.75" SD_2="1.19" SE="0.2521637057468846" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" WEIGHT="1.7962605824340627"/>
<CONT_DATA CI_END="1.1407240834160732" CI_START="0.1476939323212581" EFFECT_SIZE="0.6442090078686656" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="1.1" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="720" SD_1="1.82" SD_2="1.8" SE="0.2533286731102485" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="62" TOTAL_2="22" WEIGHT="1.780760636383121"/>
<CONT_DATA CI_END="0.8439997622815636" CI_START="-0.5389101995822476" EFFECT_SIZE="0.152544781349658" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.6" MODIFIED="2010-03-11 16:26:48 +0000" MODIFIED_BY="[Empty name]" ORDER="710" SD_1="2.0" SD_2="1.8" SE="0.3527896361290382" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.9455183223536197"/>
<CONT_DATA CI_END="0.5253528589296322" CI_START="0.04544993593857194" EFFECT_SIZE="0.2854013974341021" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="9.0" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="730" SD_1="22.04" SD_2="18.16" SE="0.12242646466375742" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="130" WEIGHT="6.376930116026059"/>
<CONT_DATA CI_END="0.7526311462370999" CI_START="0.2639927456982064" EFFECT_SIZE="0.5083119459676532" ESTIMABLE="YES" MEAN_1="19.85" MEAN_2="10.0" MODIFIED="2010-03-11 16:32:10 +0000" MODIFIED_BY="[Empty name]" ORDER="724" SD_1="20.5" SD_2="16.7" SE="0.12465494376254126" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="200" TOTAL_2="99" WEIGHT="6.197857648896315"/>
<CONT_DATA CI_END="0.7481282729794515" CI_START="0.2464316713831145" EFFECT_SIZE="0.497279972181283" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="7.0" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="727" SD_1="20.02" SD_2="18.07" SE="0.12798617871390897" STUDY_ID="STD-Walters-2004" TOTAL_1="123" TOTAL_2="129" WEIGHT="5.942782770496683"/>
<CONT_DATA CI_END="0.5852901097032976" CI_START="0.09118465002536894" EFFECT_SIZE="0.3382373798643333" ESTIMABLE="YES" MEAN_1="39.32" MEAN_2="25.9" MODIFIED="2010-02-15 13:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="729" SD_1="39.65" SD_2="39.4" SE="0.1260496273338106" STUDY_ID="STD-Winkelman-2006" TOTAL_1="253" TOTAL_2="85" WEIGHT="6.089272145776883"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="24.96217968510859" CI_END="0.46707188381162823" CI_START="0.33042031488354295" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3987460993475856" ESTIMABLE="YES" I2="15.872731208133496" I2_Q="49.691817212319734" ID="CMP-001.12" MODIFIED="2010-05-11 14:49:31 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.24880590524786017" P_Q="0.0933900230124789" P_Z="2.692351541908819E-30" Q="7.950992817374317" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.004069062632026154" TOTALS="YES" TOTAL_1="2714" TOTAL_2="1878" UNITS="" WEIGHT="100.0" Z="11.438258628532658">
<NAME>Medication subgroups: change in self rated quality of sleep</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.09016892513418032" CI_END="1.083999052010799" CI_START="0.2972499837218267" DF="1" EFFECT_SIZE="0.6906245178663128" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2010-02-15 13:27:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7639625282211415" P_Z="5.795826366180804E-4" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="42" WEIGHT="2.8632513438839116" Z="3.4409934156061475">
<NAME>Cabergoline</NAME>
<CONT_DATA CI_END="1.413576538774599" CI_START="0.12418176588506946" EFFECT_SIZE="0.7688791523298343" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.2" MODIFIED="2010-02-15 13:27:41 +0000" MODIFIED_BY="[Empty name]" ORDER="779" SD_1="0.9" SD_2="0.6" SE="0.32893328220827295" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.0824907075007912"/>
<CONT_DATA CI_END="1.1407240834160732" CI_START="0.1476939323212581" EFFECT_SIZE="0.6442090078686656" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="1.1" MODIFIED="2010-02-15 13:27:41 +0000" MODIFIED_BY="[Empty name]" ORDER="780" SD_1="1.82" SD_2="1.8" SE="0.2533286731102485" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="62" TOTAL_2="22" WEIGHT="1.7807606363831205"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.061611503470712606" CI_END="0.743951094708444" CI_START="0.3144822298954298" DF="1" EFFECT_SIZE="0.5292166623019369" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2010-03-11 16:20:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8039667904081762" P_Z="1.3628327268491999E-6" STUDIES="2" TAU2="0.0" TOTAL_1="254" TOTAL_2="130" WEIGHT="8.608630893570444" Z="4.830364588044804">
<NAME>Lisuride</NAME>
<CONT_DATA CI_END="0.9051032081374946" CI_START="0.2207999989386798" EFFECT_SIZE="0.5629516035380872" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="2.1" MODIFIED="2010-03-11 16:20:10 +0000" MODIFIED_BY="[Empty name]" ORDER="781" SD_1="3.6" SD_2="3.4" SE="0.17457035297498094" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="3.5180505135583986"/>
<CONT_DATA CI_END="0.7831125441817788" CI_START="0.2314758848896889" EFFECT_SIZE="0.5072942145357339" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="1.3" MODIFIED="2010-02-15 13:27:51 +0000" MODIFIED_BY="[Empty name]" ORDER="782" SD_1="3.8" SD_2="3.6" SE="0.14072622345189234" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="5.090580380012045"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.994314511073482" CI_END="0.5447987596065103" CI_START="0.33360635320812526" DF="5" EFFECT_SIZE="0.43920255640731776" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.03" MODIFIED="2010-05-11 14:49:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4165746165671478" P_Z="3.5792783143072796E-16" STUDIES="6" TAU2="0.0" TOTAL_1="939" TOTAL_2="614" WEIGHT="32.04081331343779" Z="8.152008939681716">
<NAME>Pramipexole</NAME>
<CONT_DATA CI_END="0.5651566610749353" CI_START="0.14633496312809877" EFFECT_SIZE="0.35574581210151707" ESTIMABLE="YES" MEAN_1="19.5" MEAN_2="12.9" MODIFIED="2010-02-15 13:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="784" SD_1="19.2" SD_2="17.8" SE="0.10684423317225436" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="178" WEIGHT="7.848177101521941"/>
<CONT_DATA CI_END="1.6193221932572863" CI_START="0.3176152206512788" EFFECT_SIZE="0.9684687069542826" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.4" MODIFIED="2010-02-15 13:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="785" SD_1="4.0" SD_2="3.9" SE="0.3320742071981184" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" WEIGHT="1.062835345820813"/>
<CONT_DATA CI_END="0.736524446887253" CI_START="0.33591508324429376" EFFECT_SIZE="0.5362197650657734" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="1.3" MODIFIED="2010-02-15 13:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="786" SD_1="3.4" SD_2="2.9" SE="0.10219814415033003" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" WEIGHT="8.373368739746896"/>
<CONT_DATA CI_END="0.6899845350006982" CI_START="0.23254131152936985" EFFECT_SIZE="0.46126292326503404" ESTIMABLE="YES" MEAN_1="29.9" MEAN_2="12.3" MODIFIED="2010-02-15 13:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="787" SD_1="40.0" SD_2="34.0" SE="0.11669684419703172" STUDY_ID="STD-Oertel-2007" TOTAL_1="221" TOTAL_2="114" WEIGHT="6.870899398137196"/>
<CONT_DATA CI_END="0.8035226952127883" CI_START="-0.1849408677313113" EFFECT_SIZE="0.30929091374073847" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="0.7" MODIFIED="2010-03-11 16:23:06 +0000" MODIFIED_BY="[Empty name]" ORDER="788" SD_1="1.75" SD_2="1.19" SE="0.2521637057468846" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" WEIGHT="1.796260582434062"/>
<CONT_DATA CI_END="0.5852901097032976" CI_START="0.09118465002536894" EFFECT_SIZE="0.3382373798643333" ESTIMABLE="YES" MEAN_1="39.32" MEAN_2="25.9" MODIFIED="2010-02-15 13:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="789" SD_1="39.65" SD_2="39.4" SE="0.1260496273338106" STUDY_ID="STD-Winkelman-2006" TOTAL_1="253" TOTAL_2="85" WEIGHT="6.089272145776883"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.030018984938376" CI_END="0.43391237134114924" CI_START="0.1644150933824494" DF="6" EFFECT_SIZE="0.29916373236179933" ESTIMABLE="YES" I2="40.179574844175995" ID="CMP-001.12.04" MODIFIED="2010-05-11 14:49:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12339361912832236" P_Z="1.3524851647564843E-5" STUDIES="7" TAU2="0.012479444195615676" TOTAL_1="803" TOTAL_2="805" WEIGHT="37.24414505972104" Z="4.35143646237172">
<NAME>Ropinirole</NAME>
<CONT_DATA CI_END="0.8302452481960363" CI_START="-0.2636328287813356" EFFECT_SIZE="0.2833062097073504" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="9.9" MODIFIED="2010-03-22 11:06:05 +0000" MODIFIED_BY="[Empty name]" ORDER="790" SD_1="19.12" SD_2="16.09" SE="0.2790556575543588" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="1.4831024811368028"/>
<CONT_DATA CI_END="0.6676902118174233" CI_START="0.25003510113967964" EFFECT_SIZE="0.45886265647855146" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="14.3" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="791" SD_1="20.43" SD_2="19.6" SE="0.10654662891057026" STUDY_ID="STD-Bogan-2006" TOTAL_1="176" TOTAL_2="186" WEIGHT="7.880496574633473"/>
<CONT_DATA CI_END="0.26423927732188" CI_START="-0.20629354222797108" EFFECT_SIZE="0.028972867546954474" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="14.45" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="792" SD_1="19.36" SD_2="18.46" SE="0.12003608822951695" STUDY_ID="STD-GSK-2006" TOTAL_1="144" TOTAL_2="134" WEIGHT="6.576950440713498"/>
<CONT_DATA CI_END="0.883672399578402" CI_START="-0.41069339361818125" EFFECT_SIZE="0.23648950298011043" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.6" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="793" SD_1="2.04" SD_2="1.11" SE="0.3302014229359252" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.0744906085407604"/>
<CONT_DATA CI_END="0.4521985607322886" CI_START="0.03558110918547555" EFFECT_SIZE="0.24388983495888206" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="16.8" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="794" SD_1="23.48" SD_2="22.36" SE="0.10628191508441948" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" WEIGHT="7.909392068173769"/>
<CONT_DATA CI_END="0.5253528589296322" CI_START="0.04544993593857194" EFFECT_SIZE="0.2854013974341021" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="9.0" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="795" SD_1="22.04" SD_2="18.16" SE="0.12242646466375742" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="130" WEIGHT="6.376930116026057"/>
<CONT_DATA CI_END="0.7481282729794515" CI_START="0.2464316713831145" EFFECT_SIZE="0.497279972181283" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="7.0" MODIFIED="2010-02-15 13:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="796" SD_1="20.02" SD_2="18.07" SE="0.12798617871390897" STUDY_ID="STD-Walters-2004" TOTAL_1="123" TOTAL_2="129" WEIGHT="5.942782770496681"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8350729431175257" CI_END="0.5624163431197897" CI_START="0.27969266845147234" DF="4" EFFECT_SIZE="0.42105450578563103" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.05" MODIFIED="2010-05-11 14:49:31 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7660597337774671" P_Z="5.287319801353133E-9" STUDIES="5" TAU2="0.0" TOTAL_1="636" TOTAL_2="287" WEIGHT="19.243159389386808" Z="5.837867436013687">
<NAME>Rotigotine</NAME>
<CONT_DATA CI_END="0.5917191947787006" CI_START="0.11030677864013821" EFFECT_SIZE="0.35101298670941944" ESTIMABLE="YES" MEAN_1="21.76" MEAN_2="14.7" MODIFIED="2010-03-11 16:33:02 +0000" MODIFIED_BY="[Empty name]" ORDER="800" SD_1="20.95" SD_2="18.1" SE="0.122811546522253" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" WEIGHT="6.345485644727244"/>
<CONT_DATA CI_END="0.8089948548095369" CI_START="0.1834681128948804" EFFECT_SIZE="0.49623148385220867" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="2.5" MODIFIED="2010-03-11 16:24:19 +0000" MODIFIED_BY="[Empty name]" ORDER="797" SD_1="3.28" SD_2="2.9" SE="0.15957608069554635" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="4.114876988016961"/>
<CONT_DATA CI_END="0.8160762722858723" CI_START="-0.2214761424057219" EFFECT_SIZE="0.2973000649400752" ESTIMABLE="YES" MEAN_1="20.5" MEAN_2="14.1" MODIFIED="2010-02-15 13:29:04 +0000" MODIFIED_BY="[Empty name]" ORDER="801" SD_1="21.4" SD_2="21.0" SE="0.26468660212016015" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="1.639420785392669"/>
<CONT_DATA CI_END="0.8439997622815636" CI_START="-0.5389101995822476" EFFECT_SIZE="0.152544781349658" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.6" MODIFIED="2010-03-11 16:26:30 +0000" MODIFIED_BY="[Empty name]" ORDER="798" SD_1="2.0" SD_2="1.8" SE="0.3527896361290382" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.9455183223536193"/>
<CONT_DATA CI_END="0.7526311462370999" CI_START="0.2639927456982064" EFFECT_SIZE="0.5083119459676532" ESTIMABLE="YES" MEAN_1="19.85" MEAN_2="10.0" MODIFIED="2010-03-11 16:31:12 +0000" MODIFIED_BY="[Empty name]" ORDER="799" SD_1="20.5" SD_2="16.7" SE="0.12465494376254126" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="200" TOTAL_2="99" WEIGHT="6.197857648896313"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.20435634743054" CI_END="0.442071087891219" CI_START="0.2348810944424629" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.33847609116684096" ESTIMABLE="YES" I2="61.169154384818476" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2011-01-11 16:00:44 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="5.179874919538641E-4" P_Q="1.0" P_Z="1.5156324941727446E-10" Q="0.0" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.027071683381173224" TOTALS="YES" TOTAL_1="2420" TOTAL_2="1892" UNITS="" WEIGHT="100.0" Z="6.403793322952945">
<NAME>Change in disease specific quality of life</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7120580210234071" CI_START="-0.3779872412633348" EFFECT_SIZE="0.16703538988003613" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="9.1" MODIFIED="2010-02-15 13:36:14 +0000" MODIFIED_BY="[Empty name]" ORDER="876" SD_1="16.55" SD_2="13.89" SE="0.2780778807378298" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="2.6759936474153183"/>
<CONT_DATA CI_END="0.9141548405663682" CI_START="0.22947299729866222" EFFECT_SIZE="0.5718139189325152" ESTIMABLE="YES" MEAN_1="19.52" MEAN_2="10.9" MODIFIED="2010-03-11 16:34:08 +0000" MODIFIED_BY="[Empty name]" ORDER="886" SD_1="14.95" SD_2="15.1" SE="0.17466694507358016" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="4.851857329115322"/>
<CONT_DATA CI_END="0.8974532060589533" CI_START="0.34194497275967256" EFFECT_SIZE="0.619699089409313" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="6.2" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="878" SD_1="13.9" SD_2="13.7" SE="0.1417138880308666" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="5.924587921380544"/>
<CONT_DATA CI_END="0.2965611091914764" CI_START="-0.14890346311315328" EFFECT_SIZE="0.07382882303916155" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="14.4" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="873" SD_1="16.7" SD_2="15.7" SE="0.11364100968650377" STUDY_ID="STD-BI-2009" TOTAL_1="157" TOTAL_2="153" WEIGHT="6.9867278381011175"/>
<CONT_DATA CI_END="0.5121783328952447" CI_START="0.09695222248869426" EFFECT_SIZE="0.3045652776919695" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="12.0" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="871" SD_1="17.25" SD_2="18.1" SE="0.10592697459795207" STUDY_ID="STD-Bogan-2006" TOTAL_1="175" TOTAL_2="186" WEIGHT="7.295767378488922"/>
<CONT_DATA CI_END="0.47937445645921284" CI_START="0.06194363698917815" EFFECT_SIZE="0.2706590467241955" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="13.4" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="875" SD_1="18.8" SD_2="17.3" SE="0.10648941071434877" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="178" WEIGHT="7.273075580222002"/>
<CONT_DATA CI_END="0.15861227912395426" CI_START="-0.3179756737806745" EFFECT_SIZE="-0.0796816973283601" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="15.0" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="870" SD_1="19.3" SD_2="18.2" SE="0.12158079349005739" STUDY_ID="STD-GSK-2006" TOTAL_1="139" TOTAL_2="132" WEIGHT="6.674962706337773"/>
<CONT_DATA CI_END="0.6981847989152301" CI_START="0.2489523866423772" EFFECT_SIZE="0.47356859277880364" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="15.5" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="884" SD_1="18.09" SD_2="18.14" SE="0.11460221101416679" STUDY_ID="STD-GSK-2007" TOTAL_1="149" TOTAL_2="165" WEIGHT="6.948603507564572"/>
<CONT_DATA CI_END="0.5229596918926587" CI_START="0.1047649832992848" EFFECT_SIZE="0.31386233759597176" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="18.3" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="880" SD_1="21.72" SD_2="23.36" SE="0.1066842839695118" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="182" WEIGHT="7.265218318093427"/>
<CONT_DATA CI_END="0.6866974154673994" CI_START="0.28478835276374304" EFFECT_SIZE="0.4857428841155712" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="12.3" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="872" SD_1="19.1" SD_2="17.4" SE="0.10252970612569" STUDY_ID="STD-Montagna-2010" TOTAL_1="200" TOTAL_2="192" WEIGHT="7.433239105385054"/>
<CONT_DATA CI_END="1.3910173187698445" CI_START="0.1042850639625813" EFFECT_SIZE="0.7476511913662129" ESTIMABLE="YES" MEAN_1="23.7" MEAN_2="11.4" MODIFIED="2010-02-15 13:36:22 +0000" MODIFIED_BY="[Empty name]" ORDER="882" SD_1="14.5" SD_2="17.6" SE="0.3282540559308342" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.0721409737897587"/>
<CONT_DATA CI_END="0.6407120658622997" CI_START="0.01912125998085057" EFFECT_SIZE="0.3299166629215751" ESTIMABLE="YES" MEAN_1="16.94" MEAN_2="12.4" MODIFIED="2010-03-11 16:35:31 +0000" MODIFIED_BY="[Empty name]" ORDER="885" SD_1="13.1" SD_2="15.5" SE="0.1585719969306778" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="5.350217603743432"/>
<CONT_DATA CI_END="0.8743356381589179" CI_START="-0.16540207405294016" EFFECT_SIZE="0.35446678205298887" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="10.3" MODIFIED="2010-02-15 13:36:39 +0000" MODIFIED_BY="[Empty name]" ORDER="874" SD_1="14.5" SD_2="14.5" SE="0.26524408622127155" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="2.867517146390317"/>
<CONT_DATA CI_END="0.4041531869860333" CI_START="-0.07317301287037295" EFFECT_SIZE="0.1654900870578302" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="13.4" MODIFIED="2010-02-15 13:36:30 +0000" MODIFIED_BY="[Empty name]" ORDER="879" SD_1="18.51" SD_2="18.86" SE="0.12176912525472264" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="131" WEIGHT="6.66766148041024"/>
<CONT_DATA CI_END="0.9190531187467949" CI_START="0.45507919581535294" EFFECT_SIZE="0.6870661572810739" ESTIMABLE="YES" MEAN_1="16.61" MEAN_2="7.3" MODIFIED="2010-03-11 16:38:48 +0000" MODIFIED_BY="[Empty name]" ORDER="881" SD_1="13.53" SD_2="13.5" SE="0.11836286957087194" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="221" TOTAL_2="114" WEIGHT="6.8004177460389315"/>
<CONT_DATA CI_END="0.42677018665368904" CI_START="-0.07219936310557681" EFFECT_SIZE="0.1772854117740561" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="10.9" MODIFIED="2010-02-15 13:36:39 +0000" MODIFIED_BY="[Empty name]" ORDER="877" SD_1="13.72" SD_2="15.43" SE="0.12729048944140656" STUDY_ID="STD-Walters-2004" TOTAL_1="121" TOTAL_2="127" WEIGHT="6.455781137612615"/>
<CONT_DATA CI_END="0.6130856710601238" CI_START="0.11416250867764449" EFFECT_SIZE="0.36362408986888417" ESTIMABLE="YES" MEAN_1="19.76" MEAN_2="13.6" MODIFIED="2010-02-15 13:36:39 +0000" MODIFIED_BY="[Empty name]" ORDER="883" SD_1="16.6" SD_2="17.8" SE="0.1272786557094726" STUDY_ID="STD-Winkelman-2006" TOTAL_1="253" TOTAL_2="83" WEIGHT="6.456230579910655"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.204356347430554" CI_END="0.44207108789121907" CI_START="0.23488109444246294" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.338476091166841" ESTIMABLE="YES" I2="61.16915438481849" I2_Q="76.75923065807011" ID="CMP-001.14" MODIFIED="2010-05-11 14:49:33 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="5.17987491953753E-4" P_Q="0.0017586257094721613" P_Z="1.5156324941727555E-10" Q="17.211134197624812" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.02707168338117324" TOTALS="YES" TOTAL_1="2420" TOTAL_2="1892" UNITS="" WEIGHT="99.99999999999997" Z="6.403793322952944">
<NAME>Medication subgroups: change in disease specific quality of life</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3910173187698445" CI_START="0.1042850639625813" DF="0" EFFECT_SIZE="0.7476511913662129" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2010-04-14 11:40:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.022746832088545398" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.0721409737897587" Z="2.277660177712318">
<NAME>Cabergoline</NAME>
<CONT_DATA CI_END="1.3910173187698445" CI_START="0.1042850639625813" EFFECT_SIZE="0.7476511913662129" ESTIMABLE="YES" MEAN_1="23.7" MEAN_2="11.4" MODIFIED="2010-04-14 11:40:36 +0100" MODIFIED_BY="[Empty name]" ORDER="736" SD_1="14.5" SD_2="17.6" SE="0.3282540559308342" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.0721409737897587"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04532373116243239" CI_END="0.8163820134463922" CI_START="0.3849990256064366" DF="1" EFFECT_SIZE="0.6006905195264144" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" MODIFIED="2010-04-14 11:40:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8314100177018102" P_Z="4.804275997958002E-8" STUDIES="2" TAU2="0.0" TOTAL_1="254" TOTAL_2="130" WEIGHT="10.776445250495865" Z="5.458406183431695">
<NAME>Lisuride</NAME>
<CONT_DATA CI_END="0.9141548405663682" CI_START="0.22947299729866222" EFFECT_SIZE="0.5718139189325152" ESTIMABLE="YES" MEAN_1="19.52" MEAN_2="10.9" MODIFIED="2010-04-14 11:40:38 +0100" MODIFIED_BY="[Empty name]" ORDER="737" SD_1="14.95" SD_2="15.1" SE="0.17466694507358016" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="4.8518573291153215"/>
<CONT_DATA CI_END="0.8974532060589533" CI_START="0.34194497275967256" EFFECT_SIZE="0.619699089409313" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="6.2" MODIFIED="2010-04-14 11:40:39 +0100" MODIFIED_BY="[Empty name]" ORDER="738" SD_1="13.9" SD_2="13.7" SE="0.1417138880308666" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="5.924587921380542"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.561750573428681" CI_END="0.4746200689065744" CI_START="0.12612552695134197" DF="3" EFFECT_SIZE="0.30037279792895816" ESTIMABLE="YES" I2="60.32664697323219" ID="CMP-001.14.03" MODIFIED="2010-05-11 14:49:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05599291372891646" P_Z="7.284370984845238E-4" STUDIES="4" TAU2="0.019016314181881714" TOTAL_1="788" TOTAL_2="606" WEIGHT="28.14927310361882" Z="3.3786461192377146">
<NAME>Pramipexole</NAME>
<CONT_DATA CI_END="0.2965611091914764" CI_START="-0.14890346311315328" EFFECT_SIZE="0.07382882303916155" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="14.4" MODIFIED="2010-03-17 13:29:58 +0000" MODIFIED_BY="[Empty name]" ORDER="740" SD_1="16.7" SD_2="15.7" SE="0.11364100968650377" STUDY_ID="STD-BI-2009" TOTAL_1="157" TOTAL_2="153" WEIGHT="6.9867278381011175"/>
<CONT_DATA CI_END="0.47937445645921284" CI_START="0.06194363698917815" EFFECT_SIZE="0.2706590467241955" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="13.4" MODIFIED="2010-02-15 13:37:57 +0000" MODIFIED_BY="[Empty name]" ORDER="739" SD_1="18.8" SD_2="17.3" SE="0.10648941071434877" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="178" WEIGHT="7.273075580222"/>
<CONT_DATA CI_END="0.6866974154673994" CI_START="0.28478835276374304" EFFECT_SIZE="0.4857428841155712" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="12.3" MODIFIED="2010-02-15 13:37:57 +0000" MODIFIED_BY="[Empty name]" ORDER="741" SD_1="19.1" SD_2="17.4" SE="0.10252970612569" STUDY_ID="STD-Montagna-2010" TOTAL_1="200" TOTAL_2="192" WEIGHT="7.433239105385052"/>
<CONT_DATA CI_END="0.6130856710601238" CI_START="0.11416250867764449" EFFECT_SIZE="0.36362408986888417" ESTIMABLE="YES" MEAN_1="19.76" MEAN_2="13.6" MODIFIED="2010-02-15 13:37:57 +0000" MODIFIED_BY="[Empty name]" ORDER="742" SD_1="16.6" SD_2="17.8" SE="0.1272786557094726" STUDY_ID="STD-Winkelman-2006" TOTAL_1="253" TOTAL_2="83" WEIGHT="6.456230579910653"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.599798247870599" CI_END="0.36441096190638156" CI_START="0.09225302460428494" DF="6" EFFECT_SIZE="0.22833199325533327" ESTIMABLE="YES" I2="52.38018988904035" ID="CMP-001.14.04" MODIFIED="2010-05-11 14:49:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.049850229570532534" P_Z="0.0010065235091460249" STUDIES="7" TAU2="0.01700111930705861" TOTAL_1="925" TOTAL_2="948" WEIGHT="43.98398817592285" Z="3.288696906913603">
<NAME>Ropinirole</NAME>
<CONT_DATA CI_END="0.7120580210234071" CI_START="-0.3779872412633348" EFFECT_SIZE="0.16703538988003613" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="9.1" MODIFIED="2010-02-15 13:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="743" SD_1="16.55" SD_2="13.89" SE="0.2780778807378298" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="2.675993647415318"/>
<CONT_DATA CI_END="0.5121783328952447" CI_START="0.09695222248869426" EFFECT_SIZE="0.3045652776919695" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="12.0" MODIFIED="2010-02-15 13:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="745" SD_1="17.25" SD_2="18.1" SE="0.10592697459795207" STUDY_ID="STD-Bogan-2006" TOTAL_1="175" TOTAL_2="186" WEIGHT="7.295767378488921"/>
<CONT_DATA CI_END="0.15861227912395426" CI_START="-0.3179756737806745" EFFECT_SIZE="-0.0796816973283601" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="15.0" MODIFIED="2010-03-17 13:14:09 +0000" MODIFIED_BY="[Empty name]" ORDER="746" SD_1="19.3" SD_2="18.2" SE="0.12158079349005739" STUDY_ID="STD-GSK-2006" TOTAL_1="139" TOTAL_2="132" WEIGHT="6.674962706337772"/>
<CONT_DATA CI_END="0.6981847989152301" CI_START="0.2489523866423772" EFFECT_SIZE="0.47356859277880364" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="15.5" MODIFIED="2010-03-17 13:14:04 +0000" MODIFIED_BY="[Empty name]" ORDER="744" SD_1="18.09" SD_2="18.14" SE="0.11460221101416679" STUDY_ID="STD-GSK-2007" TOTAL_1="149" TOTAL_2="165" WEIGHT="6.94860350756457"/>
<CONT_DATA CI_END="0.5229596918926587" CI_START="0.1047649832992848" EFFECT_SIZE="0.31386233759597176" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="18.3" MODIFIED="2010-02-15 13:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="747" SD_1="21.72" SD_2="23.36" SE="0.1066842839695118" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="182" WEIGHT="7.265218318093425"/>
<CONT_DATA CI_END="0.4041531869860333" CI_START="-0.07317301287037295" EFFECT_SIZE="0.1654900870578302" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="13.4" MODIFIED="2010-02-15 13:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="748" SD_1="18.51" SD_2="18.86" SE="0.12176912525472264" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="131" WEIGHT="6.6676614804102385"/>
<CONT_DATA CI_END="0.42677018665368904" CI_START="-0.07219936310557681" EFFECT_SIZE="0.1772854117740561" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="10.9" MODIFIED="2010-02-15 13:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="749" SD_1="13.72" SD_2="15.43" SE="0.12729048944140656" STUDY_ID="STD-Walters-2004" TOTAL_1="121" TOTAL_2="127" WEIGHT="6.455781137612613"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.78634959734403" CI_END="0.7602460558892594" CI_START="0.2348714063921839" DF="2" EFFECT_SIZE="0.4975587311407217" ESTIMABLE="YES" I2="47.17867569854304" ID="CMP-001.14.05" MODIFIED="2010-05-11 14:49:33 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.15059305885835728" P_Z="2.0531316667094055E-4" STUDIES="3" TAU2="0.025341126215893284" TOTAL_1="433" TOTAL_2="188" WEIGHT="15.018152496172679" Z="3.7123876995693936">
<NAME>Rotigotine</NAME>
<CONT_DATA CI_END="0.6407120658622997" CI_START="0.01912125998085057" EFFECT_SIZE="0.3299166629215751" ESTIMABLE="YES" MEAN_1="16.94" MEAN_2="12.4" MODIFIED="2010-03-11 16:35:40 +0000" MODIFIED_BY="[Empty name]" ORDER="750" SD_1="13.1" SD_2="15.5" SE="0.1585719969306778" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="5.350217603743432"/>
<CONT_DATA CI_END="0.8743356381589179" CI_START="-0.16540207405294016" EFFECT_SIZE="0.35446678205298887" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="10.3" MODIFIED="2010-02-15 13:38:31 +0000" MODIFIED_BY="[Empty name]" ORDER="752" SD_1="14.5" SD_2="14.5" SE="0.26524408622127155" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="2.8675171463903166"/>
<CONT_DATA CI_END="0.9190531187467949" CI_START="0.45507919581535294" EFFECT_SIZE="0.6870661572810739" ESTIMABLE="YES" MEAN_1="16.61" MEAN_2="7.3" MODIFIED="2010-03-11 16:38:57 +0000" MODIFIED_BY="[Empty name]" ORDER="751" SD_1="13.53" SD_2="13.5" SE="0.11836286957087194" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="221" TOTAL_2="114" WEIGHT="6.80041774603893"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="43.17741945797498" CI_END="1.748043766545989" CI_START="1.3379854969541944" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.529332275105615" ESTIMABLE="YES" EVENTS_1="1281" EVENTS_2="615" I2="72.20769524755939" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.2425523020578021" LOG_CI_START="0.12645140593785759" LOG_EFFECT_SIZE="0.18450185399782984" METHOD="IV" MODIFIED="2010-05-11 13:23:28 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="2.106997450213033E-5" P_Q="1.0" P_Z="4.683521999296335E-10" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.038597361755139295" TOTALS="YES" TOTAL_1="1929" TOTAL_2="1392" WEIGHT="100.0" Z="6.229357412418681">
<NAME>Responder rates on PGI</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2621216461716651" CI_START="0.8917316935462567" EFFECT_SIZE="1.0608835341365461" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="75" LOG_CI_END="0.10110121522116329" LOG_CI_START="-0.04976579757519916" LOG_EFFECT_SIZE="0.025667708822982048" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="823" O_E="0.0" SE="0.08862003012034093" STUDY_ID="STD-BI-2008" TOTAL_1="249" TOTAL_2="127" VAR="0.007853509738530134" WEIGHT="10.01272944543918"/>
<DICH_DATA CI_END="1.7509491750882988" CI_START="1.1453476975566106" EFFECT_SIZE="1.4161375661375661" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="70" LOG_CI_END="0.2432735399731955" LOG_CI_START="0.058937347119217075" LOG_EFFECT_SIZE="0.15110544354620628" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="824" O_E="0.0" SE="0.10827999216129783" STUDY_ID="STD-BI-2009" TOTAL_1="162" TOTAL_2="159" VAR="0.011724556702450718" WEIGHT="9.242493589805193"/>
<DICH_DATA CI_END="2.0608295803759478" CI_START="1.331196594254462" EFFECT_SIZE="1.656311962987442" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="68" LOG_CI_END="0.3140420794247922" LOG_CI_START="0.12424219784509673" LOG_EFFECT_SIZE="0.21914213863494444" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.11148938996447942" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" VAR="0.012429884074651766" WEIGHT="9.114738630463917"/>
<DICH_DATA CI_END="1.4428579562312058" CI_START="0.9733313624223583" EFFECT_SIZE="1.1850649350649352" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="77" LOG_CI_END="0.159223578590799" LOG_CI_START="-0.011739282678738049" LOG_EFFECT_SIZE="0.07374214795603048" MODIFIED="2010-03-23 11:08:14 +0000" MODIFIED_BY="[Empty name]" ORDER="832" O_E="0.0" SE="0.10042443098953796" STUDY_ID="STD-GSK-2006" TOTAL_1="152" TOTAL_2="146" VAR="0.010085066339572471" WEIGHT="9.553755368695299"/>
<DICH_DATA CI_END="1.5763161917157964" CI_START="1.1111061534519076" EFFECT_SIZE="1.3234253361641897" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="54" LOG_CI_END="0.19764333659516034" LOG_CI_START="0.045755552780720306" LOG_EFFECT_SIZE="0.12169944468794035" MODIFIED="2010-03-11 16:52:51 +0000" MODIFIED_BY="[Empty name]" ORDER="825" O_E="0.0" SE="0.08921963606925774" STUDY_ID="STD-Hening-2010" TOTAL_1="157" TOTAL_2="85" VAR="0.007960143460330797" WEIGHT="9.989796631466247"/>
<DICH_DATA CI_END="4.341381206102098" CI_START="1.43244482971435" EFFECT_SIZE="2.49375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6376279218529535" LOG_CI_START="0.15607790420869333" LOG_EFFECT_SIZE="0.39685291303082343" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="822" O_E="0.0" SE="0.28286486407526973" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.08001253132832081" WEIGHT="3.921258140277614"/>
<DICH_DATA CI_END="1.7881319815110301" CI_START="1.294870156658433" EFFECT_SIZE="1.5216434336023477" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="94" LOG_CI_END="0.2523995707946628" LOG_CI_START="0.1122262216420343" LOG_EFFECT_SIZE="0.18231289621834856" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.08233851916152285" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" VAR="0.006779631737712464" WEIGHT="10.249687627370964"/>
<DICH_DATA CI_END="2.3204349481987445" CI_START="1.4879985764480614" EFFECT_SIZE="1.8581721932210866" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="67" LOG_CI_END="0.3655693977779632" LOG_CI_START="0.17260251572528507" LOG_EFFECT_SIZE="0.26908595675162417" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.11334970171921457" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="199" VAR="0.012848154879834914" WEIGHT="9.040632482535639"/>
<DICH_DATA CI_END="2.6054158419232873" CI_START="1.4607967291860362" EFFECT_SIZE="1.9508928571428572" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="36" LOG_CI_END="0.4158770494933336" LOG_CI_START="0.16458978777918448" LOG_EFFECT_SIZE="0.29023341863625907" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="820" O_E="0.0" SE="0.1476073814228979" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" VAR="0.02178793905052486" WEIGHT="7.702205711747466"/>
<DICH_DATA CI_END="2.0498614459441558" CI_START="0.9582329204800559" EFFECT_SIZE="1.4015151515151516" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" LOG_CI_END="0.31172450725308815" LOG_CI_START="-0.018528912858760172" LOG_EFFECT_SIZE="0.14659779719716395" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.19399249375449462" STUDY_ID="STD-Oertel-2010" TOTAL_1="44" TOTAL_2="20" VAR="0.037633087633087633" WEIGHT="6.101236612187749"/>
<DICH_DATA CI_END="2.879645597463327" CI_START="0.906176599620445" EFFECT_SIZE="1.6153846153846154" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.4593390417394578" LOG_CI_START="-0.04278715688529274" LOG_EFFECT_SIZE="0.2082759424270825" MODIFIED="2010-03-11 16:41:02 +0000" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.2949514146369483" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" VAR="0.08699633699633699" WEIGHT="3.7032113346013573"/>
<DICH_DATA CI_END="8.795865510278313" CI_START="2.313116069187023" EFFECT_SIZE="4.51063829787234" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="8" LOG_CI_END="0.9442785803305749" LOG_CI_START="0.36419742565549296" LOG_EFFECT_SIZE="0.6542380029930339" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="0.3407425417041689" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="47" TOTAL_2="53" VAR="0.11610547972701726" WEIGHT="3.0064089600100847"/>
<DICH_DATA CI_END="1.7741433615216755" CI_START="1.0638091247398844" EFFECT_SIZE="1.3738085370907585" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="38" LOG_CI_END="0.2489887105363928" LOG_CI_START="0.026863711127619483" LOG_EFFECT_SIZE="0.13792621083200612" MODIFIED="2010-03-11 16:39:53 +0000" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.1304773241891936" STUDY_ID="STD-Winkelman-2006" TOTAL_1="254" TOTAL_2="85" VAR="0.01702433212757193" WEIGHT="8.361845465399274"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="44.52111499319963" CI_END="1.753861547541766" CI_START="1.3370362495796535" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5313315989057399" ESTIMABLE="YES" EVENTS_1="1281" EVENTS_2="615" I2="73.04649714672928" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.24399530652608975" LOG_CI_START="0.12614318196580018" LOG_EFFECT_SIZE="0.18506924424594495" METHOD="MH" MODIFIED="2010-05-11 13:23:41 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.2444628350039011E-5" P_Q="0.0" P_Z="7.476347734419767E-10" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0402608446079052" TOTALS="YES" TOTAL_1="1929" TOTAL_2="1392" WEIGHT="100.0" Z="6.155664222795366">
<NAME>Medication subgroups: responder rates on PGI</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.795865510278313" CI_START="2.313116069187023" DF="0" EFFECT_SIZE="4.51063829787234" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="8" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.9442785803305749" LOG_CI_START="0.36419742565549296" LOG_EFFECT_SIZE="0.6542380029930339" MODIFIED="2009-12-08 10:58:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="9.822396265287365E-6" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="53" WEIGHT="3.0648329550311812" Z="4.4210466513155176">
<NAME>Pergolide</NAME>
<DICH_DATA CI_END="8.795865510278313" CI_START="2.313116069187023" EFFECT_SIZE="4.51063829787234" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="8" LOG_CI_END="0.9442785803305749" LOG_CI_START="0.36419742565549296" LOG_EFFECT_SIZE="0.6542380029930339" MODIFIED="2009-12-08 10:57:51 +0000" MODIFIED_BY="[Empty name]" ORDER="725" O_E="0.0" SE="0.3407425417041689" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="47" TOTAL_2="53" VAR="0.11610547972701726" WEIGHT="3.0648329550311812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.2020226406702" CI_END="1.887173918763766" CI_START="1.3020560621307085" DF="7" EFFECT_SIZE="1.567547843359598" ESTIMABLE="YES" EVENTS_1="849" EVENTS_2="370" I2="74.26661946257562" ID="CMP-001.16.02" LOG_CI_END="0.2758119258558943" LOG_CI_START="0.11462968388643041" LOG_EFFECT_SIZE="0.1952208048711624" MODIFIED="2010-03-17 13:29:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.064958444796151E-4" P_Z="2.057015000935261E-6" STUDIES="8" TAU2="0.04859400623076833" TOTAL_1="1355" TOTAL_2="905" WEIGHT="61.137768396946285" Z="4.74774071765162">
<NAME>Pramipexole</NAME>
<DICH_DATA CI_END="1.2621216461716651" CI_START="0.8917316935462567" EFFECT_SIZE="1.0608835341365461" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="75" LOG_CI_END="0.10110121522116329" LOG_CI_START="-0.04976579757519916" LOG_EFFECT_SIZE="0.025667708822982048" MODIFIED="2010-03-17 13:29:49 +0000" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="0.08862003012034093" STUDY_ID="STD-BI-2008" TOTAL_1="249" TOTAL_2="127" VAR="0.007853509738530134" WEIGHT="9.960367761108072"/>
<DICH_DATA CI_END="1.7509491750882988" CI_START="1.1453476975566106" EFFECT_SIZE="1.4161375661375661" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="70" LOG_CI_END="0.2432735399731955" LOG_CI_START="0.058937347119217075" LOG_EFFECT_SIZE="0.15110544354620628" MODIFIED="2009-12-08 10:58:11 +0000" MODIFIED_BY="[Empty name]" ORDER="733" O_E="0.0" SE="0.10827999216129783" STUDY_ID="STD-BI-2009" TOTAL_1="162" TOTAL_2="159" VAR="0.011724556702450718" WEIGHT="9.218677778742022"/>
<DICH_DATA CI_END="2.0608295803759478" CI_START="1.331196594254462" EFFECT_SIZE="1.656311962987442" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="68" LOG_CI_END="0.3140420794247922" LOG_CI_START="0.12424219784509673" LOG_EFFECT_SIZE="0.21914213863494444" MODIFIED="2009-12-08 10:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="727" O_E="0.0" SE="0.11148938996447942" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" VAR="0.012429884074651766" WEIGHT="9.095274934723264"/>
<DICH_DATA CI_END="4.341381206102098" CI_START="1.43244482971435" EFFECT_SIZE="2.49375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6376279218529535" LOG_CI_START="0.15607790420869333" LOG_EFFECT_SIZE="0.39685291303082343" MODIFIED="2009-12-08 10:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="728" O_E="0.0" SE="0.28286486407526973" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.08001253132832081" WEIGHT="3.9845615053898205"/>
<DICH_DATA CI_END="2.3204349481987445" CI_START="1.4879985764480614" EFFECT_SIZE="1.8581721932210866" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="67" LOG_CI_END="0.3655693977779632" LOG_CI_START="0.17260251572528507" LOG_EFFECT_SIZE="0.26908595675162417" MODIFIED="2009-12-08 10:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="729" O_E="0.0" SE="0.11334970171921457" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="199" VAR="0.012848154879834914" WEIGHT="9.023643233749741"/>
<DICH_DATA CI_END="2.6054158419232873" CI_START="1.4607967291860362" EFFECT_SIZE="1.9508928571428572" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="36" LOG_CI_END="0.4158770494933336" LOG_CI_START="0.16458978777918448" LOG_EFFECT_SIZE="0.29023341863625907" MODIFIED="2009-12-08 10:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="730" O_E="0.0" SE="0.1476073814228979" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" VAR="0.02178793905052486" WEIGHT="7.723546468161179"/>
<DICH_DATA CI_END="2.879645597463327" CI_START="0.906176599620445" EFFECT_SIZE="1.6153846153846154" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.4593390417394578" LOG_CI_START="-0.04278715688529274" LOG_EFFECT_SIZE="0.2082759424270825" MODIFIED="2010-03-11 16:40:47 +0000" MODIFIED_BY="[Empty name]" ORDER="731" O_E="0.0" SE="0.2949514146369483" STUDY_ID="STD-Partinen-2006" TOTAL_1="65" TOTAL_2="21" VAR="0.08699633699633699" WEIGHT="3.765890913482158"/>
<DICH_DATA CI_END="1.7741433615216755" CI_START="1.0638091247398844" EFFECT_SIZE="1.3738085370907585" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="38" LOG_CI_END="0.2489887105363928" LOG_CI_START="0.026863711127619483" LOG_EFFECT_SIZE="0.13792621083200612" MODIFIED="2009-12-08 10:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="732" O_E="0.0" SE="0.1304773241891936" STUDY_ID="STD-Winkelman-2006" TOTAL_1="254" TOTAL_2="85" VAR="0.01702433212757193" WEIGHT="8.365805801590026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7185395937134187" CI_END="1.7271147239249642" CI_START="1.057928747169294" DF="1" EFFECT_SIZE="1.3517264205820565" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="171" I2="73.10772213665265" ID="CMP-001.16.03" LOG_CI_END="0.2373211866194184" LOG_CI_START="0.024456418404975255" LOG_EFFECT_SIZE="0.13088880251219687" MODIFIED="2010-03-23 11:08:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.053811662662597626" P_Z="0.01593802709863156" STUDIES="2" TAU2="0.022923674729560837" TOTAL_1="326" TOTAL_2="329" WEIGHT="19.70663066838803" Z="2.410331602128182">
<NAME>Ropinirole</NAME>
<DICH_DATA CI_END="1.4428579562312058" CI_START="0.9733313624223583" EFFECT_SIZE="1.1850649350649352" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="77" LOG_CI_END="0.159223578590799" LOG_CI_START="-0.011739282678738049" LOG_EFFECT_SIZE="0.07374214795603048" MODIFIED="2010-03-23 11:08:35 +0000" MODIFIED_BY="[Empty name]" ORDER="734" O_E="0.0" SE="0.10042443098953796" STUDY_ID="STD-GSK-2006" TOTAL_1="152" TOTAL_2="146" VAR="0.010085066339572471" WEIGHT="9.518879584455592"/>
<DICH_DATA CI_END="1.7881319815110301" CI_START="1.294870156658433" EFFECT_SIZE="1.5216434336023477" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="94" LOG_CI_END="0.2523995707946628" LOG_CI_START="0.1122262216420343" LOG_EFFECT_SIZE="0.18231289621834856" MODIFIED="2009-12-08 10:58:17 +0000" MODIFIED_BY="[Empty name]" ORDER="735" O_E="0.0" SE="0.08233851916152285" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" VAR="0.006779631737712464" WEIGHT="10.187751083932438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07229955873980276" CI_END="1.5669063615460095" CI_START="1.1403807444099046" DF="1" EFFECT_SIZE="1.336738509582354" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="66" I2="0.0" ID="CMP-001.16.04" LOG_CI_END="0.19504304376982853" LOG_CI_START="0.05704987553752232" LOG_EFFECT_SIZE="0.12604645965367542" MODIFIED="2010-03-23 09:05:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7880175917096941" P_Z="3.4285646709956844E-4" STUDIES="2" TAU2="0.0" TOTAL_1="201" TOTAL_2="105" WEIGHT="16.090767979634514" Z="3.5805616243855134">
<NAME>Rotigotine</NAME>
<DICH_DATA CI_END="1.5763161917157964" CI_START="1.1111061534519076" EFFECT_SIZE="1.3234253361641897" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="54" LOG_CI_END="0.19764333659516034" LOG_CI_START="0.045755552780720306" LOG_EFFECT_SIZE="0.12169944468794035" MODIFIED="2010-03-11 16:53:17 +0000" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.08921963606925774" STUDY_ID="STD-Hening-2010" TOTAL_1="157" TOTAL_2="85" VAR="0.007960143460330797" WEIGHT="9.938341852319821"/>
<DICH_DATA CI_END="2.0498614459441558" CI_START="0.9582329204800559" EFFECT_SIZE="1.4015151515151516" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" LOG_CI_END="0.31172450725308815" LOG_CI_START="-0.018528912858760172" LOG_EFFECT_SIZE="0.14659779719716395" MODIFIED="2010-01-28 09:16:09 +0000" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.19399249375449462" STUDY_ID="STD-Oertel-2010" TOTAL_1="44" TOTAL_2="20" VAR="0.037633087633087633" WEIGHT="6.152426127314691"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="42.047933754681715" CI_END="2.0756584940095264" CI_START="1.5898271570310167" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="OR" EFFECT_SIZE="1.816573214186108" ESTIMABLE="YES" EVENTS_1="3088" EVENTS_2="1793" I2="23.896379340073885" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.3171559010225087" LOG_CI_START="0.20134991122110227" LOG_EFFECT_SIZE="0.2592529061218055" METHOD="MH" MODIFIED="2010-05-11 13:24:14 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.11013109291801904" P_Q="0.0" P_Z="1.7018204222934222E-18" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="33" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03298082164914565" TOTALS="YES" TOTAL_1="4160" TOTAL_2="2889" WEIGHT="100.0" Z="8.775476290258542">
<NAME>Number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.64205794884544" CI_START="1.555583403525429" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.6497442068799417" LOG_CI_START="0.19189330102480837" LOG_EFFECT_SIZE="0.9208187539523752" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.8563488385776753" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" VAR="0.7333333333333334" WEIGHT="0.6038518512305983"/>
<DICH_DATA CI_END="17.068654639484716" CI_START="1.0349003246465902" EFFECT_SIZE="4.202898550724638" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="1.2321992911396844" LOG_CI_START="0.014898523183717122" LOG_EFFECT_SIZE="0.6235489071617007" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.7150484968333184" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="0.5112943528235881" WEIGHT="0.8501953475255615"/>
<DICH_DATA CI_END="8.862050497656444" CI_START="0.951415837805517" EFFECT_SIZE="2.903703703703704" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="45" LOG_CI_END="0.9475342203955547" LOG_CI_START="-0.021629623344652543" LOG_EFFECT_SIZE="0.46295229852545117" MODIFIED="2010-03-12 09:45:42 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.5692916392513964" STUDY_ID="STD-Axxonis-2005" TOTAL_1="104" TOTAL_2="53" VAR="0.32409297052154196" WEIGHT="1.2959232272336119"/>
<DICH_DATA CI_END="2.50624243875998" CI_START="0.7786747058896659" EFFECT_SIZE="1.396978021978022" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="52" LOG_CI_END="0.39902307971597006" LOG_CI_START="-0.10864393249655528" LOG_EFFECT_SIZE="0.14518957360970736" MODIFIED="2010-02-08 12:10:14 +0000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.2982061159658768" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="79" VAR="0.08892688759945397" WEIGHT="3.795824103024863"/>
<DICH_DATA CI_END="5.240649551358231" CI_START="1.6747752349680898" EFFECT_SIZE="2.9625850340136055" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="28" LOG_CI_END="0.7193851188706859" LOG_CI_START="0.22395653032032597" LOG_EFFECT_SIZE="0.4716708245955059" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="0.2910172053255467" STUDY_ID="STD-Benes-2010" TOTAL_1="197" TOTAL_2="67" VAR="0.0846910137954914" WEIGHT="3.9324636975522855"/>
<DICH_DATA CI_END="2.0150723725936412" CI_START="0.8674572258597409" EFFECT_SIZE="1.3221153846153846" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="72" LOG_CI_END="0.3042906487171383" LOG_CI_START="-0.061751930982136126" LOG_EFFECT_SIZE="0.12126935886750109" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.2150152232553459" STUDY_ID="STD-BI-2008" TOTAL_1="269" TOTAL_2="132" VAR="0.04623154623154623" WEIGHT="5.841767308450515"/>
<DICH_DATA CI_END="2.2402867466255216" CI_START="0.878377494535948" EFFECT_SIZE="1.4027891714520098" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="106" LOG_CI_END="0.350303609631944" LOG_CI_START="-0.056318800084400274" LOG_EFFECT_SIZE="0.1469924047737719" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.238852016280771" STUDY_ID="STD-BI-2009" TOTAL_1="166" TOTAL_2="163" VAR="0.05705028568138969" WEIGHT="5.139781513643968"/>
<DICH_DATA CI_END="5.040739823514114" CI_START="1.8362418602384403" EFFECT_SIZE="3.0423703703703704" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="125" LOG_CI_END="0.7024942820189581" LOG_CI_START="0.26392988364576586" LOG_EFFECT_SIZE="0.48321208283236206" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="0.2576148985331974" STUDY_ID="STD-Bogan-2006" TOTAL_1="178" TOTAL_2="193" VAR="0.0663654359462696" WEIGHT="4.657852568487055"/>
<DICH_DATA CI_END="24.91862084290609" CI_START="0.3611756869185698" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3965240019963447" LOG_CI_START="-0.4422814925570199" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="8" VAR="1.1666666666666667" WEIGHT="0.38573016291646095"/>
<DICH_DATA CI_END="2.47234786146662" CI_START="1.0852275608174495" EFFECT_SIZE="1.6380048959608322" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="86" LOG_CI_END="0.39310957632243293" LOG_CI_START="0.03552081472367465" LOG_EFFECT_SIZE="0.21431519552305373" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.2100494086560282" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="182" TOTAL_2="187" VAR="0.044120754076747135" WEIGHT="6.001696032199001"/>
<DICH_DATA CI_END="1.9237080005965557" CI_START="0.49028929724339626" EFFECT_SIZE="0.9711711711711711" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="37" LOG_CI_END="0.2841391511978086" LOG_CI_START="-0.30954758706968366" LOG_EFFECT_SIZE="-0.012704217935937553" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.34873452885507567" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="214" TOTAL_2="51" VAR="0.12161577161577161" WEIGHT="2.9932109843936097"/>
<DICH_DATA CI_END="32.99560312383867" CI_START="0.8787256511546848" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="1.5184560712027966" LOG_CI_START="-0.05614669578795636" LOG_EFFECT_SIZE="0.7311546877074201" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.9249294597397715" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" VAR="0.8554945054945056" WEIGHT="0.5208250662379557"/>
<DICH_DATA CI_END="2.9563839362340354" CI_START="1.0438888125095598" EFFECT_SIZE="1.7567401960784315" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="102" LOG_CI_END="0.47076083383655243" LOG_CI_START="0.0186542432207319" LOG_EFFECT_SIZE="0.24470753852864216" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.26556964929144994" STUDY_ID="STD-GSK-2006" TOTAL_1="154" TOTAL_2="149" VAR="0.07052723862478372" WEIGHT="4.470571855812587"/>
<DICH_DATA CI_END="2.2694987251434813" CI_START="0.9253511424998007" EFFECT_SIZE="1.4491663942464859" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="133" LOG_CI_END="0.35592994312059223" LOG_CI_START="-0.03369343449128049" LOG_EFFECT_SIZE="0.16111825431465585" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="0.22886670067603831" STUDY_ID="STD-GSK-2007" TOTAL_1="189" TOTAL_2="195" VAR="0.05237996667833532" WEIGHT="5.420992825594693"/>
<DICH_DATA CI_END="5.930966006830866" CI_START="0.46835166051846033" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.7731254348935465" LOG_CI_START="-0.32942793566083367" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.6476453075908483" STUDY_ID="STD-GSK-2008" TOTAL_1="20" TOTAL_2="19" VAR="0.4194444444444444" WEIGHT="1.0227992461735276"/>
<DICH_DATA CI_END="2.8677330583451113" CI_START="1.2297995091130987" EFFECT_SIZE="1.8779607843137256" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="125" LOG_CI_END="0.4575387227686889" LOG_CI_START="0.08983431535563306" LOG_EFFECT_SIZE="0.273686519062161" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.215991389080601" STUDY_ID="STD-GSK-2009" TOTAL_1="197" TOTAL_2="207" VAR="0.04665228015696757" WEIGHT="5.810902886051567"/>
<DICH_DATA CI_END="3.1710552956385483" CI_START="0.7916521504975744" EFFECT_SIZE="1.5844155844155845" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="84" LOG_CI_END="0.5012038151527005" LOG_CI_START="-0.10146560414816772" LOG_EFFECT_SIZE="0.19986910550226636" MODIFIED="2010-03-11 17:02:23 +0000" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.35401100015906894" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" VAR="0.1253237882336243" WEIGHT="2.9231001008312814"/>
<DICH_DATA CI_END="8.295300427097489" CI_START="0.48220073946129427" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.9188321192896103" LOG_CI_START="-0.316772127961648" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.7258000511750562" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.5267857142857142" WEIGHT="0.8266664607550436"/>
<DICH_DATA CI_END="3.2632499179246803" CI_START="1.2811392194333378" EFFECT_SIZE="2.0446704997788587" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="119" LOG_CI_END="0.5136503357613008" LOG_CI_START="0.10759632642414321" LOG_EFFECT_SIZE="0.310623331092722" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.23851813508440942" STUDY_ID="STD-Kushida-2008" TOTAL_1="176" TOTAL_2="186" VAR="0.05689090076414458" WEIGHT="5.1488967684673135"/>
<DICH_DATA CI_END="2.195525680805058" CI_START="0.9952213530915833" EFFECT_SIZE="1.4781860636598254" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="103" LOG_CI_END="0.34153852136147217" LOG_CI_START="-0.002080314495739603" LOG_EFFECT_SIZE="0.16972910343286626" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.20184340512319607" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="200" VAR="0.040740760191726656" WEIGHT="6.276862345536809"/>
<DICH_DATA CI_END="36.50056632144239" CI_START="1.8189394010899955" EFFECT_SIZE="8.148148148148149" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="1.562299602767965" LOG_CI_START="0.25981823055847286" LOG_EFFECT_SIZE="0.9110589166632189" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.7650840054226302" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="0.5853535353535353" WEIGHT="0.748365695468504"/>
<DICH_DATA CI_END="3.225662645901987" CI_START="1.297061954955531" EFFECT_SIZE="2.0454545454545454" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="55" LOG_CI_END="0.5086189449858833" LOG_CI_START="0.1129607209203916" LOG_EFFECT_SIZE="0.31078983295313745" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.2324115993558659" STUDY_ID="STD-Oertel-2007" TOTAL_1="230" TOTAL_2="115" VAR="0.054015151515151516" WEIGHT="5.3190993132115265"/>
<DICH_DATA CI_END="4.4176406647561866" CI_START="1.2810889366507126" EFFECT_SIZE="2.3789473684210525" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="25" LOG_CI_END="0.6451903870310483" LOG_CI_START="0.10757928068605793" LOG_EFFECT_SIZE="0.37638483385855315" MODIFIED="2010-03-11 16:56:19 +0000" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.3157954250849433" STUDY_ID="STD-Oertel-2008" TOTAL_1="170" TOTAL_2="55" VAR="0.09972675050458002" WEIGHT="3.4869164856271575"/>
<DICH_DATA CI_END="6.29701440416825" CI_START="0.7171057123532899" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.7991346867344327" LOG_CI_START="-0.14441681796177194" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.5542468245138262" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" VAR="0.3071895424836601" WEIGHT="1.3603190339347824"/>
<DICH_DATA CI_END="2.4395768244756324" CI_START="0.25215357590738374" EFFECT_SIZE="0.7843137254901961" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="17" LOG_CI_END="0.387314498988764" LOG_CI_START="-0.598334868528712" LOG_EFFECT_SIZE="-0.10551018476997398" MODIFIED="2010-03-11 16:54:40 +0000" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.5789753175228229" STUDY_ID="STD-Partinen-2006" TOTAL_1="66" TOTAL_2="22" VAR="0.3352124183006536" WEIGHT="1.2567863037720983"/>
<DICH_DATA CI_END="160.96788152667514" CI_START="0.26559012198254073" EFFECT_SIZE="6.538461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.2067392284090355" LOG_CI_START="-0.5757880815941236" LOG_EFFECT_SIZE="0.8154755734074559" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.6344703156281801" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" VAR="2.671493212669683" WEIGHT="0.17110174297788408"/>
<DICH_DATA CI_END="3.3053026719097045" CI_START="0.26986191498360385" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="18" LOG_CI_END="0.5192112346905066" LOG_CI_START="-0.5688584021405709" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2010-03-29 09:09:28 +0100" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="0.639137490706142" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="63" TOTAL_2="22" VAR="0.4084967320261438" WEIGHT="1.0481625107733812"/>
<DICH_DATA CI_END="5.250812445324192" CI_START="0.2388963637650082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.7202265059245593" LOG_CI_START="-0.621790460584196" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-12 09:46:56 +0000" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="0.7883074092183654" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="0.6214285714285714" WEIGHT="0.7071112150974687"/>
<DICH_DATA CI_END="3.883669539612203" CI_START="0.7532256283429795" EFFECT_SIZE="1.710344827586207" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.5892422688084051" LOG_CI_START="-0.12307491162592246" LOG_EFFECT_SIZE="0.23308367859124138" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.41841863781403427" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="53" VAR="0.175074156470152" WEIGHT="2.224124725557149"/>
<DICH_DATA CI_END="2.7778832995383698" CI_START="0.8854487692463741" EFFECT_SIZE="1.568334578043316" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="103" LOG_CI_END="0.4437139968259653" LOG_CI_START="-0.05283656138214464" LOG_EFFECT_SIZE="0.1954387177219103" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.29167625585634843" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.08507503823037803" WEIGHT="3.919671768793257"/>
<DICH_DATA CI_END="5.431493587552723" CI_START="2.0427002510752796" EFFECT_SIZE="3.3309027777777778" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="64" LOG_CI_END="0.7349192711428555" LOG_CI_START="0.31020464227863004" LOG_EFFECT_SIZE="0.5225619567107427" MODIFIED="2010-03-11 16:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.24947947536616544" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="226" TOTAL_2="117" VAR="0.06224000862897715" WEIGHT="4.859653289714038"/>
<DICH_DATA CI_END="3.6606557166450386" CI_START="1.0546963630852002" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="102" LOG_CI_END="0.5635588855621596" LOG_CI_START="0.023127448433220652" LOG_EFFECT_SIZE="0.2933431669976902" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.3174521013482973" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="136" VAR="0.10077583665044965" WEIGHT="3.459567747826888"/>
<DICH_DATA CI_END="1.944059520868371" CI_START="0.5680551688765235" EFFECT_SIZE="1.0508725229222124" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="69" LOG_CI_END="0.2887095574981631" LOG_CI_START="-0.24560948405104513" LOG_EFFECT_SIZE="0.02155003672355899" MODIFIED="2010-02-04 09:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.3138616499279174" STUDY_ID="STD-Winkelman-2006" TOTAL_1="258" TOTAL_2="86" VAR="0.09850913529547455" WEIGHT="3.5192058151275725"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="42.04793375468172" CI_END="2.075658494009527" CI_START="1.5898271570310167" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="OR" EFFECT_SIZE="1.816573214186108" ESTIMABLE="YES" EVENTS_1="3088" EVENTS_2="1793" I2="23.896379340073896" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.3171559010225088" LOG_CI_START="0.20134991122110227" LOG_EFFECT_SIZE="0.2592529061218055" METHOD="MH" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.11013109291801892" P_Q="0.0" P_Z="1.7018204222934469E-18" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="33" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03298082164914566" TOTALS="YES" TOTAL_1="4160" TOTAL_2="2889" WEIGHT="100.00000000000003" Z="8.77547629025854">
<NAME>Medication subgroups: number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.677646730440238" CI_END="21.993814342814336" CI_START="0.32235255153288694" DF="1" EFFECT_SIZE="2.6626607315515822" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="27" I2="78.62172888148214" ID="CMP-001.18.01" LOG_CI_END="1.3423005547078644" LOG_CI_START="-0.4916688878469576" LOG_EFFECT_SIZE="0.4253158334304534" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.030557657413861072" P_Z="0.36331294850093876" STUDIES="2" TAU2="1.827515093188017" TOTAL_1="86" TOTAL_2="42" WEIGHT="1.7965282062418857" Z="0.9090704525775183">
<NAME>Cabergoline</NAME>
<DICH_DATA CI_END="36.50056632144239" CI_START="1.8189394010899955" EFFECT_SIZE="8.148148148148149" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="1.562299602767965" LOG_CI_START="0.25981823055847286" LOG_EFFECT_SIZE="0.9110589166632189" MODIFIED="2010-03-29 09:17:08 +0100" MODIFIED_BY="[Empty name]" ORDER="799" O_E="0.0" SE="0.7650840054226302" STUDY_ID="STD-Oertel-2006" TOTAL_1="23" TOTAL_2="20" VAR="0.5853535353535353" WEIGHT="0.7483656954685042"/>
<DICH_DATA CI_END="3.3053026719097045" CI_START="0.26986191498360385" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="18" LOG_CI_END="0.5192112346905066" LOG_CI_START="-0.5688584021405709" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2010-03-29 09:10:48 +0100" MODIFIED_BY="[Empty name]" ORDER="800" O_E="0.0" SE="0.639137490706142" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="63" TOTAL_2="22" VAR="0.4084967320261438" WEIGHT="1.0481625107733814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2962658699328649" CI_END="3.2662113612568806" CI_START="0.9005772803004662" DF="1" EFFECT_SIZE="1.7150731018260432" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="97" I2="22.855332135544757" ID="CMP-001.18.02" LOG_CI_END="0.51404428513349" LOG_CI_START="-0.04547901358516621" LOG_EFFECT_SIZE="0.2342826357741619" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25489655149992874" P_Z="0.10072571313654129" STUDIES="2" TAU2="0.061181843782882654" TOTAL_1="259" TOTAL_2="132" WEIGHT="5.091747330258476" Z="1.64134551455511">
<NAME>Lisuride</NAME>
<DICH_DATA CI_END="8.862050497656444" CI_START="0.951415837805517" EFFECT_SIZE="2.903703703703704" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="45" LOG_CI_END="0.9475342203955547" LOG_CI_START="-0.021629623344652543" LOG_EFFECT_SIZE="0.46295229852545117" MODIFIED="2010-03-12 09:46:04 +0000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.5692916392513964" STUDY_ID="STD-Axxonis-2005" TOTAL_1="104" TOTAL_2="53" VAR="0.32409297052154196" WEIGHT="1.295923227233612"/>
<DICH_DATA CI_END="2.50624243875998" CI_START="0.7786747058896659" EFFECT_SIZE="1.396978021978022" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="52" LOG_CI_END="0.39902307971597006" LOG_CI_START="-0.10864393249655528" LOG_EFFECT_SIZE="0.14518957360970736" MODIFIED="2010-02-08 12:10:21 +0000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.2982061159658768" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="79" VAR="0.08892688759945397" WEIGHT="3.795824103024864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8070545956517864" CI_END="4.146114390961061" CI_START="0.936640468661216" DF="2" EFFECT_SIZE="1.9706391161937236" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.6176412800728052" LOG_CI_START="-0.028427081940902925" LOG_EFFECT_SIZE="0.2946070990659511" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6679600357943882" P_Z="0.0738588590563563" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="69" WEIGHT="2.7809566314514944" Z="1.787486704841419">
<NAME>Pergolide</NAME>
<DICH_DATA CI_END="24.91862084290609" CI_START="0.3611756869185698" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3965240019963447" LOG_CI_START="-0.4422814925570199" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-12-08 11:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Earley-1998" TOTAL_1="8" TOTAL_2="8" VAR="1.1666666666666667" WEIGHT="0.38573016291646106"/>
<DICH_DATA CI_END="160.96788152667514" CI_START="0.26559012198254073" EFFECT_SIZE="6.538461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.2067392284090355" LOG_CI_START="-0.5757880815941236" LOG_EFFECT_SIZE="0.8154755734074559" MODIFIED="2009-12-08 11:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="789" O_E="0.0" SE="1.6344703156281801" STUDY_ID="STD-Pieta-1998" TOTAL_1="8" TOTAL_2="8" VAR="2.671493212669683" WEIGHT="0.1711017429778841"/>
<DICH_DATA CI_END="3.883669539612203" CI_START="0.7532256283429795" EFFECT_SIZE="1.710344827586207" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.5892422688084051" LOG_CI_START="-0.12307491162592246" LOG_EFFECT_SIZE="0.23308367859124138" MODIFIED="2009-12-08 11:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="790" O_E="0.0" SE="0.41841863781403427" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="53" VAR="0.175074156470152" WEIGHT="2.2241247255571492"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.06251563064968" CI_END="1.7712831559337927" CI_START="1.2382995058570812" DF="7" EFFECT_SIZE="1.4810060961136475" ESTIMABLE="YES" EVENTS_1="938" EVENTS_2="522" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.24828799271455365" LOG_CI_START="0.09282569961897652" LOG_EFFECT_SIZE="0.17055684616676509" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6523344207220704" P_Z="1.70388635991427E-5" STUDIES="8" TAU2="0.0" TOTAL_1="1394" TOTAL_2="926" WEIGHT="34.18186509269654" Z="4.300531905805374">
<NAME>Pramipexole</NAME>
<DICH_DATA CI_END="2.0150723725936412" CI_START="0.8674572258597409" EFFECT_SIZE="1.3221153846153846" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="72" LOG_CI_END="0.3042906487171383" LOG_CI_START="-0.061751930982136126" LOG_EFFECT_SIZE="0.12126935886750109" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="782" O_E="0.0" SE="0.2150152232553459" STUDY_ID="STD-BI-2008" TOTAL_1="269" TOTAL_2="132" VAR="0.04623154623154623" WEIGHT="5.841767308450517"/>
<DICH_DATA CI_END="2.2402867466255216" CI_START="0.878377494535948" EFFECT_SIZE="1.4027891714520098" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="106" LOG_CI_END="0.350303609631944" LOG_CI_START="-0.056318800084400274" LOG_EFFECT_SIZE="0.1469924047737719" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="779" O_E="0.0" SE="0.238852016280771" STUDY_ID="STD-BI-2009" TOTAL_1="166" TOTAL_2="163" VAR="0.05705028568138969" WEIGHT="5.139781513643969"/>
<DICH_DATA CI_END="2.47234786146662" CI_START="1.0852275608174495" EFFECT_SIZE="1.6380048959608322" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="86" LOG_CI_END="0.39310957632243293" LOG_CI_START="0.03552081472367465" LOG_EFFECT_SIZE="0.21431519552305373" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="780" O_E="0.0" SE="0.2100494086560282" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="182" TOTAL_2="187" VAR="0.044120754076747135" WEIGHT="6.001696032199002"/>
<DICH_DATA CI_END="8.295300427097489" CI_START="0.48220073946129427" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.9188321192896103" LOG_CI_START="-0.316772127961648" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="781" O_E="0.0" SE="0.7258000511750562" STUDY_ID="STD-Inoue-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.5267857142857142" WEIGHT="0.8266664607550438"/>
<DICH_DATA CI_END="2.195525680805058" CI_START="0.9952213530915833" EFFECT_SIZE="1.4781860636598254" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="103" LOG_CI_END="0.34153852136147217" LOG_CI_START="-0.002080314495739603" LOG_EFFECT_SIZE="0.16972910343286626" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.20184340512319607" STUDY_ID="STD-Montagna-2010" TOTAL_1="203" TOTAL_2="200" VAR="0.040740760191726656" WEIGHT="6.276862345536808"/>
<DICH_DATA CI_END="3.225662645901987" CI_START="1.297061954955531" EFFECT_SIZE="2.0454545454545454" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="55" LOG_CI_END="0.5086189449858833" LOG_CI_START="0.1129607209203916" LOG_EFFECT_SIZE="0.31078983295313745" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="0.2324115993558659" STUDY_ID="STD-Oertel-2007" TOTAL_1="230" TOTAL_2="115" VAR="0.054015151515151516" WEIGHT="5.319099313211527"/>
<DICH_DATA CI_END="2.4395768244756324" CI_START="0.25215357590738374" EFFECT_SIZE="0.7843137254901961" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="17" LOG_CI_END="0.387314498988764" LOG_CI_START="-0.598334868528712" LOG_EFFECT_SIZE="-0.10551018476997398" MODIFIED="2010-03-11 16:54:39 +0000" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.5789753175228229" STUDY_ID="STD-Partinen-2006" TOTAL_1="66" TOTAL_2="22" VAR="0.3352124183006536" WEIGHT="1.2567863037720985"/>
<DICH_DATA CI_END="1.944059520868371" CI_START="0.5680551688765235" EFFECT_SIZE="1.0508725229222124" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="69" LOG_CI_END="0.2887095574981631" LOG_CI_START="-0.24560948405104513" LOG_EFFECT_SIZE="0.02155003672355899" MODIFIED="2009-12-08 11:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.3138616499279174" STUDY_ID="STD-Winkelman-2006" TOTAL_1="258" TOTAL_2="86" VAR="0.09850913529547455" WEIGHT="3.519205815127573"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.497143691956577" CI_END="2.499397317218462" CI_START="1.7093832518432832" DF="11" EFFECT_SIZE="2.0669852234003203" ESTIMABLE="YES" EVENTS_1="1152" EVENTS_2="884" I2="11.97988699545937" ID="CMP-001.18.05" LOG_CI_END="0.3978352993276826" LOG_CI_START="0.2328394445232745" LOG_EFFECT_SIZE="0.31533737192547856" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3274569055001174" P_Z="6.798612030250208E-14" STUDIES="12" TAU2="0.0133149369878585" TOTAL_1="1479" TOTAL_2="1362" WEIGHT="39.81859162975329" Z="7.491702051377087">
<NAME>Ropinirole</NAME>
<DICH_DATA CI_END="44.64205794884544" CI_START="1.555583403525429" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.6497442068799417" LOG_CI_START="0.19189330102480837" LOG_EFFECT_SIZE="0.9208187539523752" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="769" O_E="0.0" SE="0.8563488385776753" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" VAR="0.7333333333333334" WEIGHT="0.6038518512305984"/>
<DICH_DATA CI_END="17.068654639484716" CI_START="1.0349003246465902" EFFECT_SIZE="4.202898550724638" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="1.2321992911396844" LOG_CI_START="0.014898523183717122" LOG_EFFECT_SIZE="0.6235489071617007" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="770" O_E="0.0" SE="0.7150484968333184" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" VAR="0.5112943528235881" WEIGHT="0.8501953475255616"/>
<DICH_DATA CI_END="5.240649551358231" CI_START="1.6747752349680898" EFFECT_SIZE="2.9625850340136055" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="28" LOG_CI_END="0.7193851188706859" LOG_CI_START="0.22395653032032597" LOG_EFFECT_SIZE="0.4716708245955059" MODIFIED="2010-01-12 15:07:03 +0000" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.2910172053255467" STUDY_ID="STD-Benes-2010" TOTAL_1="197" TOTAL_2="67" VAR="0.0846910137954914" WEIGHT="3.9324636975522855"/>
<DICH_DATA CI_END="5.040739823514114" CI_START="1.8362418602384403" EFFECT_SIZE="3.0423703703703704" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="125" LOG_CI_END="0.7024942820189581" LOG_CI_START="0.26392988364576586" LOG_EFFECT_SIZE="0.48321208283236206" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="772" O_E="0.0" SE="0.2576148985331974" STUDY_ID="STD-Bogan-2006" TOTAL_1="178" TOTAL_2="193" VAR="0.0663654359462696" WEIGHT="4.657852568487055"/>
<DICH_DATA CI_END="32.99560312383867" CI_START="0.8787256511546848" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="1.5184560712027966" LOG_CI_START="-0.05614669578795636" LOG_EFFECT_SIZE="0.7311546877074201" MODIFIED="2009-12-08 11:00:39 +0000" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="0.9249294597397715" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" VAR="0.8554945054945056" WEIGHT="0.5208250662379558"/>
<DICH_DATA CI_END="2.9563839362340354" CI_START="1.0438888125095598" EFFECT_SIZE="1.7567401960784315" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="102" LOG_CI_END="0.47076083383655243" LOG_CI_START="0.0186542432207319" LOG_EFFECT_SIZE="0.24470753852864216" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="773" O_E="0.0" SE="0.26556964929144994" STUDY_ID="STD-GSK-2006" TOTAL_1="154" TOTAL_2="149" VAR="0.07052723862478372" WEIGHT="4.4705718558125875"/>
<DICH_DATA CI_END="2.2694987251434813" CI_START="0.9253511424998007" EFFECT_SIZE="1.4491663942464859" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="133" LOG_CI_END="0.35592994312059223" LOG_CI_START="-0.03369343449128049" LOG_EFFECT_SIZE="0.16111825431465585" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="771" O_E="0.0" SE="0.22886670067603831" STUDY_ID="STD-GSK-2007" TOTAL_1="189" TOTAL_2="195" VAR="0.05237996667833532" WEIGHT="5.420992825594693"/>
<DICH_DATA CI_END="5.930966006830866" CI_START="0.46835166051846033" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.7731254348935465" LOG_CI_START="-0.32942793566083367" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="774" O_E="0.0" SE="0.6476453075908483" STUDY_ID="STD-GSK-2008" TOTAL_1="20" TOTAL_2="19" VAR="0.4194444444444444" WEIGHT="1.0227992461735276"/>
<DICH_DATA CI_END="2.8677330583451113" CI_START="1.2297995091130987" EFFECT_SIZE="1.8779607843137256" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="125" LOG_CI_END="0.4575387227686889" LOG_CI_START="0.08983431535563306" LOG_EFFECT_SIZE="0.273686519062161" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="775" O_E="0.0" SE="0.215991389080601" STUDY_ID="STD-GSK-2009" TOTAL_1="197" TOTAL_2="207" VAR="0.04665228015696757" WEIGHT="5.810902886051567"/>
<DICH_DATA CI_END="3.2632499179246803" CI_START="1.2811392194333378" EFFECT_SIZE="2.0446704997788587" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="119" LOG_CI_END="0.5136503357613008" LOG_CI_START="0.10759632642414321" LOG_EFFECT_SIZE="0.310623331092722" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="776" O_E="0.0" SE="0.23851813508440942" STUDY_ID="STD-Kushida-2008" TOTAL_1="176" TOTAL_2="186" VAR="0.05689090076414458" WEIGHT="5.1488967684673135"/>
<DICH_DATA CI_END="2.7778832995383698" CI_START="0.8854487692463741" EFFECT_SIZE="1.568334578043316" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="103" LOG_CI_END="0.4437139968259653" LOG_CI_START="-0.05283656138214464" LOG_EFFECT_SIZE="0.1954387177219103" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="777" O_E="0.0" SE="0.29167625585634843" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" VAR="0.08507503823037803" WEIGHT="3.919671768793258"/>
<DICH_DATA CI_END="3.6606557166450386" CI_START="1.0546963630852002" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="102" LOG_CI_END="0.5635588855621596" LOG_CI_START="0.023127448433220652" LOG_EFFECT_SIZE="0.2933431669976902" MODIFIED="2009-12-08 10:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="778" O_E="0.0" SE="0.3174521013482973" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="136" VAR="0.10077583665044965" WEIGHT="3.459567747826888"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.084545809858254" CI_END="3.3106968957551395" CI_START="1.7478997302774535" DF="4" EFFECT_SIZE="2.40556983085522" ESTIMABLE="YES" EVENTS_1="525" EVENTS_2="195" I2="2.069895008992142" ID="CMP-001.18.06" LOG_CI_END="0.5199194216078041" LOG_CI_START="0.24251651534859983" LOG_EFFECT_SIZE="0.381217968478202" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3946849846254943" P_Z="7.167572948697893E-8" STUDIES="5" TAU2="0.0030464304887442653" TOTAL_1="666" TOTAL_2="307" WEIGHT="13.33710012520473" Z="5.386918966008564">
<NAME>Rotigotine</NAME>
<DICH_DATA CI_END="3.1710552956385483" CI_START="0.7916521504975744" EFFECT_SIZE="1.5844155844155845" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="84" LOG_CI_END="0.5012038151527005" LOG_CI_START="-0.10146560414816772" LOG_EFFECT_SIZE="0.19986910550226636" MODIFIED="2010-03-11 17:02:17 +0000" MODIFIED_BY="[Empty name]" ORDER="797" O_E="0.0" SE="0.35401100015906894" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" VAR="0.1253237882336243" WEIGHT="2.9231001008312822"/>
<DICH_DATA CI_END="4.4176406647561866" CI_START="1.2810889366507126" EFFECT_SIZE="2.3789473684210525" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="25" LOG_CI_END="0.6451903870310483" LOG_CI_START="0.10757928068605793" LOG_EFFECT_SIZE="0.37638483385855315" MODIFIED="2010-03-11 16:56:27 +0000" MODIFIED_BY="[Empty name]" ORDER="794" O_E="0.0" SE="0.3157954250849433" STUDY_ID="STD-Oertel-2008" TOTAL_1="170" TOTAL_2="55" VAR="0.09972675050458002" WEIGHT="3.4869164856271575"/>
<DICH_DATA CI_END="6.29701440416825" CI_START="0.7171057123532899" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.7991346867344327" LOG_CI_START="-0.14441681796177194" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2009-12-08 11:00:50 +0000" MODIFIED_BY="[Empty name]" ORDER="798" O_E="0.0" SE="0.5542468245138262" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" VAR="0.3071895424836601" WEIGHT="1.3603190339347828"/>
<DICH_DATA CI_END="5.250812445324192" CI_START="0.2388963637650082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.7202265059245593" LOG_CI_START="-0.621790460584196" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-12 09:47:09 +0000" MODIFIED_BY="[Empty name]" ORDER="795" O_E="0.0" SE="0.7883074092183654" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" VAR="0.6214285714285714" WEIGHT="0.7071112150974688"/>
<DICH_DATA CI_END="5.431493587552723" CI_START="2.0427002510752796" EFFECT_SIZE="3.3309027777777778" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="64" LOG_CI_END="0.7349192711428555" LOG_CI_START="0.31020464227863004" LOG_EFFECT_SIZE="0.5225619567107427" MODIFIED="2010-03-11 17:00:16 +0000" MODIFIED_BY="[Empty name]" ORDER="796" O_E="0.0" SE="0.24947947536616544" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="226" TOTAL_2="117" VAR="0.06224000862897715" WEIGHT="4.859653289714038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9237080005965557" CI_START="0.49028929724339626" DF="0" EFFECT_SIZE="0.9711711711711711" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="37" I2="0.0" ID="CMP-001.18.07" LOG_CI_END="0.2841391511978086" LOG_CI_START="-0.30954758706968366" LOG_EFFECT_SIZE="-0.012704217935937553" MODIFIED="2010-05-11 14:49:36 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.933150266797069" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="51" WEIGHT="2.9932109843936106" Z="0.0838819801798116">
<NAME>Sumanirole</NAME>
<DICH_DATA CI_END="1.9237080005965557" CI_START="0.49028929724339626" EFFECT_SIZE="0.9711711711711711" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="37" LOG_CI_END="0.2841391511978086" LOG_CI_START="-0.30954758706968366" LOG_EFFECT_SIZE="-0.012704217935937553" MODIFIED="2009-12-08 11:00:36 +0000" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.34873452885507567" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="214" TOTAL_2="51" VAR="0.12161577161577161" WEIGHT="2.9932109843936106"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="28.303958172661744" CI_END="-0.1698625827260136" CI_START="-0.3120508401203481" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.24095671142318087" ESTIMABLE="YES" I2="29.338504961056575" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2010-12-06 12:40:20 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.10239709000484554" P_Q="1.0" P_Z="3.0770889749978357E-11" Q="0.0" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0076481540812571676" TOTALS="YES" TOTAL_1="2846" TOTAL_2="2119" UNITS="" WEIGHT="100.00000000000001" Z="6.642833731521107">
<NAME>Change in daytime tiredness</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.28392265590120086" CI_START="-0.8091292700756145" EFFECT_SIZE="-0.26260330708720686" ESTIMABLE="YES" MEAN_1="-12.4" MEAN_2="-7.8" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="771" SD_1="17.86" SD_2="16.57" SE="0.27884490087539093" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="1.5406359600805521"/>
<CONT_DATA CI_END="-0.28206369049232705" CI_START="-0.9691661121764319" EFFECT_SIZE="-0.6256149013343795" ESTIMABLE="YES" MEAN_1="-2.45" MEAN_2="-0.4" MODIFIED="2010-03-11 17:03:45 +0000" MODIFIED_BY="[Empty name]" ORDER="760" SD_1="3.29" SD_2="3.2" SE="0.1752844509143742" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="3.4288452199860697"/>
<CONT_DATA CI_END="-0.07222879033855395" CI_START="-0.6196265836512516" EFFECT_SIZE="-0.34592768699490273" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.9" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="764" SD_1="3.3" SD_2="2.9" SE="0.13964486021949932" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="4.8464082460039295"/>
<CONT_DATA CI_END="0.16867445895417904" CI_START="-0.38880091677821754" EFFECT_SIZE="-0.11006322891201926" ESTIMABLE="YES" MEAN_1="-11.1" MEAN_2="-9.0" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="767" SD_1="18.9" SD_2="19.4" SE="0.14221571930139817" STUDY_ID="STD-Benes-2010" TOTAL_1="198" TOTAL_2="66" WEIGHT="4.720416629202707"/>
<CONT_DATA CI_END="0.25743137650381215" CI_START="-0.18087908144564485" EFFECT_SIZE="0.038276147529083634" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.8" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="761" SD_1="2.4" SD_2="2.8" SE="0.11181594697831031" STUDY_ID="STD-BI-2009" TOTAL_1="161" TOTAL_2="159" WEIGHT="6.5294341656514385"/>
<CONT_DATA CI_END="-0.007463264589638141" CI_START="-0.4214124010610011" EFFECT_SIZE="-0.2144378328253196" ESTIMABLE="YES" MEAN_1="-16.2" MEAN_2="-11.4" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="769" SD_1="22.46" SD_2="22.22" SE="0.10560120995501471" STUDY_ID="STD-Bogan-2006" TOTAL_1="176" TOTAL_2="185" WEIGHT="6.998722316254111"/>
<CONT_DATA CI_END="0.006352555871046328" CI_START="-0.4108195955186231" EFFECT_SIZE="-0.2022335198237884" ESTIMABLE="YES" MEAN_1="-12.8" MEAN_2="-9.0" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="754" SD_1="18.7" SD_2="18.8" SE="0.10642342274660915" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="177" TOTAL_2="178" WEIGHT="6.934419773150153"/>
<CONT_DATA CI_END="0.27523880928444056" CI_START="-0.1953165740588687" EFFECT_SIZE="0.039961117612785924" ESTIMABLE="YES" MEAN_1="-11.25" MEAN_2="-12.14" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="757" SD_1="23.74" SD_2="20.44" SE="0.12004184440504777" STUDY_ID="STD-GSK-2006" TOTAL_1="144" TOTAL_2="134" WEIGHT="5.964873662713504"/>
<CONT_DATA CI_END="-0.15023216214706833" CI_START="-0.5963339009699391" EFFECT_SIZE="-0.37328303155850373" ESTIMABLE="YES" MEAN_1="-19.8" MEAN_2="-12.3" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="756" SD_1="21.3" SD_2="18.83" SE="0.11380355515245799" STUDY_ID="STD-GSK-2007" TOTAL_1="150" TOTAL_2="165" WEIGHT="6.387290235614443"/>
<CONT_DATA CI_END="0.15247095797955224" CI_START="-1.1595142816570208" EFFECT_SIZE="-0.5035216618387343" ESTIMABLE="YES" MEAN_1="-26.3" MEAN_2="-14.1" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="772" SD_1="22.81" SD_2="24.62" SE="0.3346962622745482" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.0994789906750708"/>
<CONT_DATA CI_END="-0.04134372468137473" CI_START="-0.521588859677615" EFFECT_SIZE="-0.28146629217949487" ESTIMABLE="YES" MEAN_1="-15.44" MEAN_2="-9.1" MODIFIED="2010-03-11 17:08:22 +0000" MODIFIED_BY="[Empty name]" ORDER="765" SD_1="22.97" SD_2="21.4" SE="0.12251376524883942" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" WEIGHT="5.807029022718643"/>
<CONT_DATA CI_END="0.09528354093034438" CI_START="-0.3201086775603478" EFFECT_SIZE="-0.11241256831500168" ESTIMABLE="YES" MEAN_1="-18.1" MEAN_2="-15.4" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="762" SD_1="24.06" SD_2="23.88" SE="0.10596934988786859" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" WEIGHT="6.969846196696985"/>
<CONT_DATA CI_END="-0.17870864235887038" CI_START="-0.5757592811597243" EFFECT_SIZE="-0.37723396175929735" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-1.3" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="758" SD_1="3.1" SD_2="2.7" SE="0.10129028949836291" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" WEIGHT="7.347290160681349"/>
<CONT_DATA CI_END="0.3167314869365693" CI_START="-0.9309373883978281" EFFECT_SIZE="-0.30710295073062943" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-2.3" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="773" SD_1="4.1" SD_2="2.8" SE="0.318288724990829" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.2075932338267115"/>
<CONT_DATA CI_END="-0.24481528899128663" CI_START="-0.7001529151704156" EFFECT_SIZE="-0.47248410208085106" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.5" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="766" SD_1="1.3" SD_2="1.2" SE="0.11615969216035957" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="115" WEIGHT="6.223591467605658"/>
<CONT_DATA CI_END="0.07383545814660011" CI_START="-0.5462288325643339" EFFECT_SIZE="-0.23619668720886686" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.6" MODIFIED="2010-03-11 17:04:55 +0000" MODIFIED_BY="[Empty name]" ORDER="763" SD_1="2.97" SD_2="2.9" SE="0.15818257263957958" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="4.027390542415514"/>
<CONT_DATA CI_END="0.45269341880730085" CI_START="-0.5798951589122643" EFFECT_SIZE="-0.06360087005248174" ESTIMABLE="YES" MEAN_1="-10.1" MEAN_2="-9.0" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="770" SD_1="15.8" SD_2="19.7" SE="0.2634202939096055" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="1.7079061626722685"/>
<CONT_DATA CI_END="0.511340221669817" CI_START="-0.872461509179009" EFFECT_SIZE="-0.18056064375459602" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.2" MODIFIED="2010-03-11 17:06:03 +0000" MODIFIED_BY="[Empty name]" ORDER="768" SD_1="2.9" SD_2="2.4" SE="0.3530171323973495" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.9947464536795825"/>
<CONT_DATA CI_END="0.03614635839976188" CI_START="-0.4425466793009884" EFFECT_SIZE="-0.20320016045061326" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="-4.9" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="755" SD_1="22.85" SD_2="19.04" SE="0.12211781478553174" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="130" WEIGHT="5.831960652402027"/>
<CONT_DATA CI_END="-0.0013417984094976076" CI_START="-0.4768719096240942" EFFECT_SIZE="-0.2391068540167959" ESTIMABLE="YES" MEAN_1="-9.94" MEAN_2="-5.2" MODIFIED="2010-03-11 17:07:02 +0000" MODIFIED_BY="[Empty name]" ORDER="759" SD_1="20.32" SD_2="18.5" SE="0.12131093095728222" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="221" TOTAL_2="99" WEIGHT="5.883180507020713"/>
<CONT_DATA CI_END="-0.051623098203539164" CI_START="-0.5484415501761857" EFFECT_SIZE="-0.3000323241898624" ESTIMABLE="YES" MEAN_1="-11.5" MEAN_2="-5.6" MODIFIED="2010-02-15 13:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="753" SD_1="19.15" SD_2="20.03" SE="0.12674172992245955" STUDY_ID="STD-Walters-2004" TOTAL_1="123" TOTAL_2="129" WEIGHT="5.54894040094856"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.303958172661737" CI_END="-0.16986258272601362" CI_START="-0.31205084012034817" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2409567114231809" ESTIMABLE="YES" I2="29.338504961056557" I2_Q="22.94068200614614" ID="CMP-001.20" MODIFIED="2010-12-06 12:40:20 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.10239709000484576" P_Q="0.26827394417875683" P_Z="3.077088974997813E-11" Q="5.19080638673578" RANDOM="YES" SCALE="1.5" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.007648154081257162" TOTALS="YES" TOTAL_1="2846" TOTAL_2="2119" UNITS="" WEIGHT="100.0" Z="6.642833731521108">
<NAME>Medication subgroups: change in daytime tiredness</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3167314869365693" CI_START="-0.9309373883978281" DF="0" EFFECT_SIZE="-0.30710295073062943" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.01" MODIFIED="2010-04-14 11:44:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3346166953739167" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.207593233826712" Z="0.9648565174260513">
<NAME>Cabergoline</NAME>
<CONT_DATA CI_END="0.3167314869365693" CI_START="-0.9309373883978281" EFFECT_SIZE="-0.30710295073062943" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-2.3" MODIFIED="2010-02-15 13:40:42 +0000" MODIFIED_BY="[Empty name]" ORDER="858" SD_1="4.1" SD_2="2.8" SE="0.318288724990829" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.207593233826712"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.557479951530142" CI_END="-0.19445372933572308" CI_START="-0.7369584877388802" DF="1" EFFECT_SIZE="-0.46570610853730166" ESTIMABLE="YES" I2="35.79371605923064" ID="CMP-001.20.02" MODIFIED="2010-03-11 17:03:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21203462624494485" P_Z="7.654064809416504E-4" STUDIES="2" TAU2="0.013999806073449627" TOTAL_1="254" TOTAL_2="130" WEIGHT="8.27525346599" Z="3.365010853730056">
<NAME>Lisuride</NAME>
<CONT_DATA CI_END="-0.28206369049232705" CI_START="-0.9691661121764319" EFFECT_SIZE="-0.6256149013343795" ESTIMABLE="YES" MEAN_1="-2.45" MEAN_2="-0.4" MODIFIED="2010-03-11 17:03:39 +0000" MODIFIED_BY="[Empty name]" ORDER="859" SD_1="3.29" SD_2="3.2" SE="0.1752844509143742" STUDY_ID="STD-Axxonis-2005" TOTAL_1="102" TOTAL_2="51" WEIGHT="3.4288452199860697"/>
<CONT_DATA CI_END="-0.07222879033855395" CI_START="-0.6196265836512516" EFFECT_SIZE="-0.34592768699490273" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.9" MODIFIED="2010-02-15 13:40:50 +0000" MODIFIED_BY="[Empty name]" ORDER="860" SD_1="3.3" SD_2="2.9" SE="0.13964486021949932" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="79" WEIGHT="4.84640824600393"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.086884776066528" CI_END="-0.03960354565951399" CI_START="-0.4674073134483099" DF="3" EFFECT_SIZE="-0.2535054295539119" ESTIMABLE="YES" I2="75.17970878699566" ID="CMP-001.20.03" MODIFIED="2010-04-14 11:44:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.00709139340054421" P_Z="0.020187332345662383" STUDIES="4" TAU2="0.03577803824520687" TOTAL_1="764" TOTAL_2="647" WEIGHT="27.034735567088603" Z="2.3228477597528814">
<NAME>Pramipexole</NAME>
<CONT_DATA CI_END="0.25743137650381215" CI_START="-0.18087908144564485" EFFECT_SIZE="0.038276147529083634" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.8" MODIFIED="2010-02-15 13:41:04 +0000" MODIFIED_BY="[Empty name]" ORDER="862" SD_1="2.4" SD_2="2.8" SE="0.11181594697831031" STUDY_ID="STD-BI-2009" TOTAL_1="161" TOTAL_2="159" WEIGHT="6.529434165651441"/>
<CONT_DATA CI_END="0.006352555871046328" CI_START="-0.4108195955186231" EFFECT_SIZE="-0.2022335198237884" ESTIMABLE="YES" MEAN_1="-12.8" MEAN_2="-9.0" MODIFIED="2010-02-15 13:41:04 +0000" MODIFIED_BY="[Empty name]" ORDER="861" SD_1="18.7" SD_2="18.8" SE="0.10642342274660915" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="177" TOTAL_2="178" WEIGHT="6.934419773150154"/>
<CONT_DATA CI_END="-0.17870864235887038" CI_START="-0.5757592811597243" EFFECT_SIZE="-0.37723396175929735" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-1.3" MODIFIED="2010-02-17 09:34:37 +0000" MODIFIED_BY="[Empty name]" ORDER="863" SD_1="3.1" SD_2="2.7" SE="0.10129028949836291" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="195" WEIGHT="7.347290160681352"/>
<CONT_DATA CI_END="-0.24481528899128663" CI_START="-0.7001529151704156" EFFECT_SIZE="-0.47248410208085106" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.5" MODIFIED="2010-02-17 09:34:38 +0000" MODIFIED_BY="[Empty name]" ORDER="864" SD_1="1.3" SD_2="1.2" SE="0.11615969216035957" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="115" WEIGHT="6.223591467605659"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.877935362148975" CI_END="-0.1013559883739648" CI_START="-0.2837020178725717" DF="8" EFFECT_SIZE="-0.19252900312326826" ESTIMABLE="YES" I2="9.888958708711115" ID="CMP-001.20.04" MODIFIED="2010-04-14 11:45:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.35269774363037687" P_Z="3.490764235183754E-5" STUDIES="9" TAU2="0.0019338946191431027" TOTAL_1="1151" TOTAL_2="1035" WEIGHT="45.062165044587964" Z="4.138833328464531">
<NAME>Ropinirole</NAME>
<CONT_DATA CI_END="0.28392265590120086" CI_START="-0.8091292700756145" EFFECT_SIZE="-0.26260330708720686" ESTIMABLE="YES" MEAN_1="-12.4" MEAN_2="-7.8" MODIFIED="2010-02-17 09:54:23 +0000" MODIFIED_BY="[Empty name]" ORDER="865" SD_1="17.86" SD_2="16.57" SE="0.27884490087539093" STUDY_ID="STD-Allen-2004" TOTAL_1="27" TOTAL_2="25" WEIGHT="1.5406359600805524"/>
<CONT_DATA CI_END="0.16867445895417904" CI_START="-0.38880091677821754" EFFECT_SIZE="-0.11006322891201926" ESTIMABLE="YES" MEAN_1="-11.1" MEAN_2="-9.0" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="870" SD_1="18.9" SD_2="19.4" SE="0.14221571930139817" STUDY_ID="STD-Benes-2010" TOTAL_1="198" TOTAL_2="66" WEIGHT="4.720416629202708"/>
<CONT_DATA CI_END="-0.007463264589638141" CI_START="-0.4214124010610011" EFFECT_SIZE="-0.2144378328253196" ESTIMABLE="YES" MEAN_1="-16.2" MEAN_2="-11.4" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="867" SD_1="22.46" SD_2="22.22" SE="0.10560120995501471" STUDY_ID="STD-Bogan-2006" TOTAL_1="176" TOTAL_2="185" WEIGHT="6.998722316254113"/>
<CONT_DATA CI_END="0.27523880928444056" CI_START="-0.1953165740588687" EFFECT_SIZE="0.039961117612785924" ESTIMABLE="YES" MEAN_1="-11.25" MEAN_2="-12.14" MODIFIED="2010-02-17 09:54:10 +0000" MODIFIED_BY="[Empty name]" ORDER="868" SD_1="23.74" SD_2="20.44" SE="0.12004184440504777" STUDY_ID="STD-GSK-2006" TOTAL_1="144" TOTAL_2="134" WEIGHT="5.964873662713505"/>
<CONT_DATA CI_END="-0.15023216214706833" CI_START="-0.5963339009699391" EFFECT_SIZE="-0.37328303155850373" ESTIMABLE="YES" MEAN_1="-19.8" MEAN_2="-12.3" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="866" SD_1="21.3" SD_2="18.83" SE="0.11380355515245799" STUDY_ID="STD-GSK-2007" TOTAL_1="150" TOTAL_2="165" WEIGHT="6.387290235614445"/>
<CONT_DATA CI_END="0.15247095797955224" CI_START="-1.1595142816570208" EFFECT_SIZE="-0.5035216618387343" ESTIMABLE="YES" MEAN_1="-26.3" MEAN_2="-14.1" MODIFIED="2010-02-17 09:54:22 +0000" MODIFIED_BY="[Empty name]" ORDER="869" SD_1="22.81" SD_2="24.62" SE="0.3346962622745482" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.0994789906750708"/>
<CONT_DATA CI_END="0.09528354093034438" CI_START="-0.3201086775603478" EFFECT_SIZE="-0.11241256831500168" ESTIMABLE="YES" MEAN_1="-18.1" MEAN_2="-15.4" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="871" SD_1="24.06" SD_2="23.88" SE="0.10596934988786859" STUDY_ID="STD-Kushida-2008" TOTAL_1="174" TOTAL_2="183" WEIGHT="6.969846196696988"/>
<CONT_DATA CI_END="0.03614635839976188" CI_START="-0.4425466793009884" EFFECT_SIZE="-0.20320016045061326" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="-4.9" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="872" SD_1="22.85" SD_2="19.04" SE="0.12211781478553174" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="140" TOTAL_2="130" WEIGHT="5.831960652402028"/>
<CONT_DATA CI_END="-0.051623098203539164" CI_START="-0.5484415501761857" EFFECT_SIZE="-0.3000323241898624" ESTIMABLE="YES" MEAN_1="-11.5" MEAN_2="-5.6" MODIFIED="2010-02-15 13:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="873" SD_1="19.15" SD_2="20.03" SE="0.12674172992245955" STUDY_ID="STD-Walters-2004" TOTAL_1="123" TOTAL_2="129" WEIGHT="5.5489404009485614"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5908516961803111" CI_END="-0.09796830948177088" CI_START="-0.3772683196633362" DF="4" EFFECT_SIZE="-0.23761831457255353" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.05" MODIFIED="2010-04-14 11:45:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9640748563789157" P_Z="8.53201113286627E-4" STUDIES="5" TAU2="0.0" TOTAL_1="657" TOTAL_2="287" WEIGHT="18.42025268850672" Z="3.3349324858710894">
<NAME>Rotigotine</NAME>
<CONT_DATA CI_END="-0.04134372468137473" CI_START="-0.521588859677615" EFFECT_SIZE="-0.28146629217949487" ESTIMABLE="YES" MEAN_1="-15.44" MEAN_2="-9.1" MODIFIED="2010-03-11 17:08:00 +0000" MODIFIED_BY="[Empty name]" ORDER="876" SD_1="22.97" SD_2="21.4" SE="0.12251376524883942" STUDY_ID="STD-Hening-2010" TOTAL_1="205" TOTAL_2="100" WEIGHT="5.807029022718644"/>
<CONT_DATA CI_END="0.07383545814660011" CI_START="-0.5462288325643339" EFFECT_SIZE="-0.23619668720886686" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.6" MODIFIED="2010-03-11 17:05:05 +0000" MODIFIED_BY="[Empty name]" ORDER="874" SD_1="2.97" SD_2="2.9" SE="0.15818257263957958" STUDY_ID="STD-Oertel-2008" TOTAL_1="166" TOTAL_2="53" WEIGHT="4.027390542415515"/>
<CONT_DATA CI_END="0.45269341880730085" CI_START="-0.5798951589122643" EFFECT_SIZE="-0.06360087005248174" ESTIMABLE="YES" MEAN_1="-10.1" MEAN_2="-9.0" MODIFIED="2010-02-15 13:41:41 +0000" MODIFIED_BY="[Empty name]" ORDER="877" SD_1="15.8" SD_2="19.7" SE="0.2634202939096055" STUDY_ID="STD-Oertel-2010" TOTAL_1="46" TOTAL_2="21" WEIGHT="1.7079061626722687"/>
<CONT_DATA CI_END="0.511340221669817" CI_START="-0.872461509179009" EFFECT_SIZE="-0.18056064375459602" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.2" MODIFIED="2010-03-11 17:05:54 +0000" MODIFIED_BY="[Empty name]" ORDER="878" SD_1="2.9" SD_2="2.4" SE="0.3530171323973495" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.9947464536795825"/>
<CONT_DATA CI_END="-0.0013417984094976076" CI_START="-0.4768719096240942" EFFECT_SIZE="-0.2391068540167959" ESTIMABLE="YES" MEAN_1="-9.94" MEAN_2="-5.2" MODIFIED="2010-03-11 17:07:26 +0000" MODIFIED_BY="[Empty name]" ORDER="875" SD_1="20.32" SD_2="18.5" SE="0.12131093095728222" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="221" TOTAL_2="99" WEIGHT="5.883180507020714"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="115.19823454566134" CI_END="-4.739084163740582" CI_START="-6.740265777158731" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_SIZE="-5.739674970449657" ESTIMABLE="YES" I2="74.82600309425297" I2_Q="90.03688019128558" ID="CMP-001.21" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-10 14:39:34 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="3.164357664786621E-12" P_Q="0.0015342638686011156" P_Z="2.5095965862811557E-29" Q="10.037016709618726" RANDOM="YES" SCALE="20.63" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.231672195038064" TOTALS="YES" TOTAL_1="1600" TOTAL_2="1780" WEIGHT="100.00000000000001" Z="11.242913836123401">
<NAME>Subgroup analysis: Effect of randomisation on change on IRLS</NAME>
<GROUP_LABEL_1>Favours dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.896017510264295" CI_END="-1.2394462282900722" CI_START="-5.834553434282997" DF="3" EFFECT_SIZE="-3.5369998312865345" ESTIMABLE="YES" I2="66.27704479517294" ID="CMP-001.21.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03070584382461672" P_Z="0.002550432074409457" STUDIES="4" TAU2="3.3830290316210068" TOTAL_1="175" TOTAL_2="184" WEIGHT="13.914433626792874" Z="3.0172929474222716">
<NAME>Randomisation unclear</NAME>
<IV_DATA CI_END="0.050364344694653784" CI_START="-3.8303643446946536" EFFECT_SIZE="-1.89" ESTIMABLE="YES" ESTIMATE="-1.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="531" SE="0.99" STUDY_ID="STD-BI-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.195669919636068"/>
<IV_DATA CI_END="1.0511470572738797" CI_START="-4.71114705727388" EFFECT_SIZE="-1.83" ESTIMABLE="YES" ESTIMATE="-1.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="528" SE="1.47" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5255043926180725"/>
<IV_DATA CI_END="-4.251300122978649" CI_START="-15.14869987702135" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="530" SE="2.78" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.010987697763853"/>
<IV_DATA CI_END="-2.1500360154599463" CI_START="-6.069963984540054" EFFECT_SIZE="-4.11" ESTIMABLE="YES" ESTIMATE="-4.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="529" SE="1.0" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="4.182271616774881"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="96.26520032577831" CI_END="-4.996970861142816" CI_START="-7.140008922276702" DF="25" EFFECT_SIZE="-6.068489891709759" ESTIMABLE="YES" I2="74.03007533834072" ID="CMP-001.21.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.649775954211009E-10" P_Z="1.2523397334716142E-28" STUDIES="26" TAU2="5.137895863221159" TOTAL_1="1425" TOTAL_2="1596" WEIGHT="86.08556637320714" Z="11.100149683765627">
<NAME>Randomisation clear</NAME>
<IV_DATA CI_END="-5.996504804988441" CI_START="-17.40349519501156" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="544" SE="2.91" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.9024072353402006"/>
<IV_DATA CI_END="2.75912724877091" CI_START="-5.1591272487709094" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="539" SE="2.02" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.798791203556212"/>
<IV_DATA CI_END="-4.785668069219298" CI_START="-12.194331930780702" EFFECT_SIZE="-8.49" ESTIMABLE="YES" ESTIMATE="-8.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="535" SE="1.89" STUDY_ID="STD-Axxonis-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.960383931906161"/>
<IV_DATA CI_END="-4.79925330288072" CI_START="-10.60074669711928" EFFECT_SIZE="-7.7" ESTIMABLE="YES" ESTIMATE="-7.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="541" SE="1.48" STUDY_ID="STD-Axxonis-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.511491812728084"/>
<IV_DATA CI_END="-1.3816554638083165" CI_START="-7.418344536191684" EFFECT_SIZE="-4.4" ESTIMABLE="YES" ESTIMATE="-4.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SE="1.54" STUDY_ID="STD-Benes-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.427806486181236"/>
<IV_DATA CI_END="-0.7224381763875423" CI_START="-4.877561823612457" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="542" SE="1.06" STUDY_ID="STD-BI-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.100933043702123"/>
<IV_DATA CI_END="-2.034030613140954" CI_START="-5.365969386859046" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="548" SE="0.85" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="192" WEIGHT="4.377190462861027"/>
<IV_DATA CI_END="-1.8596356553053461" CI_START="-5.740364344694654" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="551" SE="0.99" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" WEIGHT="4.195669919636068"/>
<IV_DATA CI_END="-5.010090038649865" CI_START="-14.809909961350137" EFFECT_SIZE="-9.91" ESTIMABLE="YES" ESTIMATE="-9.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="536" SE="2.5" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" WEIGHT="2.269925957093266"/>
<IV_DATA CI_END="-4.086432774068551" CI_START="-7.653567225931449" EFFECT_SIZE="-5.87" ESTIMABLE="YES" ESTIMATE="-5.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="554" SE="0.91" STUDY_ID="STD-GSK-2007" TOTAL_1="181" TOTAL_2="193" WEIGHT="4.300911801221466"/>
<IV_DATA CI_END="0.8074987965575522" CI_START="-10.207498796557552" EFFECT_SIZE="-4.7" ESTIMABLE="YES" ESTIMATE="-4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="533" SE="2.81" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.9852984466171526"/>
<IV_DATA CI_END="-0.38323889669674127" CI_START="-4.616761103303259" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="534" SE="1.08" STUDY_ID="STD-GSK-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.07349979054087"/>
<IV_DATA CI_END="-2.941237095923744" CI_START="-6.978762904076255" EFFECT_SIZE="-4.96" ESTIMABLE="YES" ESTIMATE="-4.96" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="538" SE="1.03" STUDY_ID="STD-Hening-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.141795268857502"/>
<IV_DATA CI_END="-4.159635655305346" CI_START="-8.040364344694654" EFFECT_SIZE="-6.1" ESTIMABLE="YES" ESTIMATE="-6.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SE="0.99" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="196" WEIGHT="4.195669919636068"/>
<IV_DATA CI_END="-6.213328935346606" CI_START="-20.246671064653395" EFFECT_SIZE="-13.23" ESTIMABLE="YES" ESTIMATE="-13.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="540" SE="3.58" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.44406258267951"/>
<IV_DATA CI_END="-4.483238896696741" CI_START="-8.71676110330326" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="552" SE="1.08" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" WEIGHT="4.07349979054087"/>
<IV_DATA CI_END="-3.7612551036537165" CI_START="-9.758744896346283" EFFECT_SIZE="-6.76" ESTIMABLE="YES" ESTIMATE="-6.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="545" SE="1.53" STUDY_ID="STD-Oertel-2008" TOTAL_1="0" TOTAL_2="53" WEIGHT="3.4417031723290052"/>
<IV_DATA CI_END="-1.5824921995774606" CI_START="-11.617507800422539" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="549" SE="2.56" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.2114504709807203"/>
<IV_DATA CI_END="-6.488861946591106" CI_START="-13.231138053408893" EFFECT_SIZE="-9.86" ESTIMABLE="YES" ESTIMATE="-9.86" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="555" SE="1.72" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.182211966598152"/>
<IV_DATA CI_END="-6.577278513702681" CI_START="-15.12272148629732" EFFECT_SIZE="-10.85" ESTIMABLE="YES" ESTIMATE="-10.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="537" SE="2.18" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.610412388574836"/>
<IV_DATA CI_END="-6.696504804988442" CI_START="-18.103495195011558" EFFECT_SIZE="-12.4" ESTIMABLE="YES" ESTIMATE="-12.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="553" SE="2.91" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.9024072353402006"/>
<IV_DATA CI_END="-8.603256904426713" CI_START="-14.796743095573285" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="543" SE="1.58" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="51" WEIGHT="3.3724511221681914"/>
<IV_DATA CI_END="-0.991237095923744" CI_START="-5.028762904076256" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SE="1.03" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" WEIGHT="4.141795268857502"/>
<IV_DATA CI_END="-4.842456184117516" CI_START="-10.957543815882484" EFFECT_SIZE="-7.9" ESTIMABLE="YES" ESTIMATE="-7.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="550" SE="1.56" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="0" TOTAL_2="114" WEIGHT="3.4000809212259813"/>
<IV_DATA CI_END="-0.40283853654214186" CI_START="-4.597161463457859" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SE="1.07" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.087234481032539"/>
<IV_DATA CI_END="-1.9860414177789378" CI_START="-6.493958582221063" EFFECT_SIZE="-4.24" ESTIMABLE="YES" ESTIMATE="-4.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="532" SE="1.15" STUDY_ID="STD-Winkelman-2006" TOTAL_1="0" TOTAL_2="85" WEIGHT="3.976481693002202"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="115.19823454566135" CI_END="-4.739084163740584" CI_START="-6.740265777158731" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_SIZE="-5.7396749704496575" ESTIMABLE="YES" I2="74.82600309425295" I2_Q="92.93778239354384" ID="CMP-001.22" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:39 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="3.1651348209038588E-12" P_Q="1.6791607287813815E-4" P_Z="2.5095965862810475E-29" Q="14.159858216289138" RANDOM="YES" SCALE="20.63" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.231672195038064" TOTALS="YES" TOTAL_1="1600" TOTAL_2="1780" WEIGHT="100.0" Z="11.242913836123405">
<NAME>Subgroup analysis: Effect of study origin on change on IRLS</NAME>
<GROUP_LABEL_1>Favours dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="72.50979130608859" CI_END="-5.44912377630604" CI_START="-8.31172159101396" DF="17" EFFECT_SIZE="-6.88042268366" ESTIMABLE="YES" I2="76.5548904585352" ID="CMP-001.22.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.939431778680728E-9" P_Z="4.435128540758441E-21" STUDIES="18" TAU2="6.689588604259148" TOTAL_1="816" TOTAL_2="901" WEIGHT="58.25651752138942" Z="9.42177807102252">
<NAME>Europe</NAME>
<IV_DATA CI_END="-4.785668069219298" CI_START="-12.194331930780702" EFFECT_SIZE="-8.49" ESTIMABLE="YES" ESTIMATE="-8.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="570" SE="1.89" STUDY_ID="STD-Axxonis-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.96038393190616"/>
<IV_DATA CI_END="-4.79925330288072" CI_START="-10.60074669711928" EFFECT_SIZE="-7.7" ESTIMABLE="YES" ESTIMATE="-7.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="565" SE="1.48" STUDY_ID="STD-Axxonis-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.511491812728083"/>
<IV_DATA CI_END="-1.3816554638083165" CI_START="-7.418344536191684" EFFECT_SIZE="-4.4" ESTIMABLE="YES" ESTIMATE="-4.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="562" SE="1.54" STUDY_ID="STD-Benes-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.427806486181235"/>
<IV_DATA CI_END="-0.7224381763875423" CI_START="-4.877561823612457" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="573" SE="1.06" STUDY_ID="STD-BI-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.100933043702121"/>
<IV_DATA CI_END="-1.8596356553053461" CI_START="-5.740364344694654" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="566" SE="0.99" STUDY_ID="STD-Ferini_x002d_Strambi-2008" TOTAL_1="178" TOTAL_2="179" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-0.38323889669674127" CI_START="-4.616761103303259" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="568" SE="1.08" STUDY_ID="STD-GSK-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.073499790540868"/>
<IV_DATA CI_END="-4.251300122978649" CI_START="-15.14869987702135" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="564" SE="2.78" STUDY_ID="STD-Inoue-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.010987697763852"/>
<IV_DATA CI_END="-4.159635655305346" CI_START="-8.040364344694654" EFFECT_SIZE="-6.1" ESTIMABLE="YES" ESTIMATE="-6.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="571" SE="0.99" STUDY_ID="STD-Montagna-2010" TOTAL_1="202" TOTAL_2="196" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-6.213328935346606" CI_START="-20.246671064653395" EFFECT_SIZE="-13.23" ESTIMABLE="YES" ESTIMATE="-13.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="559" SE="3.58" STUDY_ID="STD-Oertel-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.4440625826795095"/>
<IV_DATA CI_END="-4.483238896696741" CI_START="-8.71676110330326" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="574" SE="1.08" STUDY_ID="STD-Oertel-2007" TOTAL_1="224" TOTAL_2="114" WEIGHT="4.073499790540868"/>
<IV_DATA CI_END="-3.7612551036537165" CI_START="-9.758744896346283" EFFECT_SIZE="-6.76" ESTIMABLE="YES" ESTIMATE="-6.76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="560" SE="1.53" STUDY_ID="STD-Oertel-2008" TOTAL_1="0" TOTAL_2="53" WEIGHT="3.4417031723290044"/>
<IV_DATA CI_END="-1.5824921995774606" CI_START="-11.617507800422539" EFFECT_SIZE="-6.6" ESTIMABLE="YES" ESTIMATE="-6.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="563" SE="2.56" STUDY_ID="STD-Oertel-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.21145047098072"/>
<IV_DATA CI_END="-6.488861946591106" CI_START="-13.231138053408893" EFFECT_SIZE="-9.86" ESTIMABLE="YES" ESTIMATE="-9.86" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="567" SE="1.72" STUDY_ID="STD-Partinen-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.182211966598151"/>
<IV_DATA CI_END="-6.577278513702681" CI_START="-15.12272148629732" EFFECT_SIZE="-10.85" ESTIMABLE="YES" ESTIMATE="-10.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="572" SE="2.18" STUDY_ID="STD-Stiasny_x002d_Kolster-2004a" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.610412388574835"/>
<IV_DATA CI_END="-6.696504804988442" CI_START="-18.103495195011558" EFFECT_SIZE="-12.4" ESTIMABLE="YES" ESTIMATE="-12.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="558" SE="2.91" STUDY_ID="STD-Stiasny_x002d_Kolster-2004b" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.9024072353402002"/>
<IV_DATA CI_END="-8.603256904426713" CI_START="-14.796743095573285" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="561" SE="1.58" STUDY_ID="STD-Trenkwalder-2004a" TOTAL_1="46" TOTAL_2="51" WEIGHT="3.3724511221681905"/>
<IV_DATA CI_END="-0.991237095923744" CI_START="-5.028762904076256" EFFECT_SIZE="-3.01" ESTIMABLE="YES" ESTIMATE="-3.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="575" SE="1.03" STUDY_ID="STD-Trenkwalder-2004b" TOTAL_1="146" TOTAL_2="138" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-4.842456184117516" CI_START="-10.957543815882484" EFFECT_SIZE="-7.9" ESTIMABLE="YES" ESTIMATE="-7.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="569" SE="1.56" STUDY_ID="STD-Trenkwalder-2008" TOTAL_1="0" TOTAL_2="114" WEIGHT="3.4000809212259804"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="28.528585023283622" CI_END="-2.948698303624694" CI_START="-5.314382208899827" DF="11" EFFECT_SIZE="-4.1315402562622605" ESTIMABLE="YES" I2="61.44218161881375" ID="CMP-001.22.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-11 14:49:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0026850032959371273" P_Z="7.597304629126787E-12" STUDIES="12" TAU2="2.3892749837920113" TOTAL_1="784" TOTAL_2="879" WEIGHT="41.74348247861058" Z="6.845944282661589">
<NAME>Other origin</NAME>
<IV_DATA CI_END="-5.996504804988441" CI_START="-17.40349519501156" EFFECT_SIZE="-11.7" ESTIMABLE="YES" ESTIMATE="-11.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="587" SE="2.91" STUDY_ID="STD-Adler-2004" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.9024072353402002"/>
<IV_DATA CI_END="2.75912724877091" CI_START="-5.1591272487709094" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="581" SE="2.02" STUDY_ID="STD-Allen-2004" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.7987912035562115"/>
<IV_DATA CI_END="0.050364344694653784" CI_START="-3.8303643446946536" EFFECT_SIZE="-1.89" ESTIMABLE="YES" ESTIMATE="-1.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="586" SE="0.99" STUDY_ID="STD-BI-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.195669919636067"/>
<IV_DATA CI_END="-2.034030613140954" CI_START="-5.365969386859046" EFFECT_SIZE="-3.7" ESTIMABLE="YES" ESTIMATE="-3.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="580" SE="0.85" STUDY_ID="STD-Bogan-2006" TOTAL_1="187" TOTAL_2="192" WEIGHT="4.377190462861026"/>
<IV_DATA CI_END="1.0511470572738797" CI_START="-4.71114705727388" EFFECT_SIZE="-1.83" ESTIMABLE="YES" ESTIMATE="-1.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="577" SE="1.47" STUDY_ID="STD-Garcia_x002d_Borreguero-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5255043926180716"/>
<IV_DATA CI_END="-5.010090038649865" CI_START="-14.809909961350137" EFFECT_SIZE="-9.91" ESTIMABLE="YES" ESTIMATE="-9.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="582" SE="2.5" STUDY_ID="STD-GSK-2005" TOTAL_1="37" TOTAL_2="17" WEIGHT="2.2699259570932653"/>
<IV_DATA CI_END="-4.086432774068551" CI_START="-7.653567225931449" EFFECT_SIZE="-5.87" ESTIMABLE="YES" ESTIMATE="-5.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.91" STUDY_ID="STD-GSK-2007" TOTAL_1="181" TOTAL_2="193" WEIGHT="4.300911801221465"/>
<IV_DATA CI_END="0.8074987965575522" CI_START="-10.207498796557552" EFFECT_SIZE="-4.7" ESTIMABLE="YES" ESTIMATE="-4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="585" SE="2.81" STUDY_ID="STD-GSK-2008" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.985298446617152"/>
<IV_DATA CI_END="-2.941237095923744" CI_START="-6.978762904076255" EFFECT_SIZE="-4.96" ESTIMABLE="YES" ESTIMATE="-4.96" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="584" SE="1.03" STUDY_ID="STD-Hening-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.141795268857501"/>
<IV_DATA CI_END="-2.1500360154599463" CI_START="-6.069963984540054" EFFECT_SIZE="-4.11" ESTIMABLE="YES" ESTIMATE="-4.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="579" SE="1.0" STUDY_ID="STD-Kushida-2008" TOTAL_1="175" TOTAL_2="184" WEIGHT="4.18227161677488"/>
<IV_DATA CI_END="-0.40283853654214186" CI_START="-4.597161463457859" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="576" SE="1.07" STUDY_ID="STD-Walters-2004" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.087234481032538"/>
<IV_DATA CI_END="-1.9860414177789378" CI_START="-6.493958582221063" EFFECT_SIZE="-4.24" ESTIMABLE="YES" ESTIMATE="-4.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="583" SE="1.15" STUDY_ID="STD-Winkelman-2006" TOTAL_1="0" TOTAL_2="85" WEIGHT="3.976481693002201"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-01 14:08:29 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Active trials: dopamine agonists versus levodopa</NAME>
<CONT_OUTCOME CHI2="2.233597109977393" CI_END="-2.098387419982116" CI_START="-8.39943234904382" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.248909884512968" ESTIMABLE="YES" I2="55.22916843270265" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-05-10 14:45:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1350392369614305" P_Q="1.0" P_Z="0.0010931470596973925" Q="0.0" RANDOM="YES" SCALE="10.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.0254814613276624" TOTALS="YES" TOTAL_1="206" TOTAL_2="216" UNITS="" WEIGHT="100.0" Z="3.265386756502199">
<NAME>Change on IRLS</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5986965282361081" CI_START="-6.998696528236108" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-4.0" MODIFIED="2010-03-04 11:30:54 +0000" MODIFIED_BY="[Empty name]" ORDER="867" SD_1="9.5" SD_2="7.5" SE="1.938146087479026" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" WEIGHT="38.0993992594269"/>
<CONT_DATA CI_END="-4.409336586017076" CI_START="-8.61066341398292" EFFECT_SIZE="-6.509999999999998" ESTIMABLE="YES" MEAN_1="-16.06" MEAN_2="-9.55" MODIFIED="2010-03-04 11:30:54 +0000" MODIFIED_BY="[Empty name]" ORDER="866" SD_1="10.17" SD_2="9.68" SE="1.0717867422833716" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="167" TOTAL_2="177" WEIGHT="61.900600740573104"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7133965377495467E-32" CI_END="1.48398625096223" CI_START="-9.083986250962228" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7999999999999994" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-11-30 11:09:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.1586826470528002" Q="0.0" RANDOM="YES" SCALE="9.373062586236202" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="1.409515995598196">
<NAME>Change in periodic limb movements in sleep</NAME>
<GROUP_LABEL_1>Pramipexole</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pramipexole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4839862509622295" CI_START="-9.08398625096223" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="-11.5" MEAN_2="-7.7" MODIFIED="2010-03-04 11:31:16 +0000" MODIFIED_BY="[Empty name]" ORDER="868" SD_1="13.9" SD_2="9.5" SE="2.6959608914457807" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9379474053902612" CI_END="3.010319609145786" CI_START="0.9632592974024213" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7028559397854244" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.47861260759371127" LOG_CI_START="-0.016256790473714613" LOG_EFFECT_SIZE="0.2311779085599983" METHOD="MH" MODIFIED="2010-11-30 15:02:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3328064372469005" P_Q="0.0" P_Z="0.06707193053511988" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="257" WEIGHT="100.0" Z="1.8311917308621124">
<NAME>Number of dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.916774175142308" CI_START="0.014223223195330906" EFFECT_SIZE="0.3561253561253561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9502077679055764" LOG_CI_START="-1.8470019748211117" LOG_EFFECT_SIZE="-0.4483971034577677" MODIFIED="2010-03-03 09:29:55 +0000" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="1.6430948492891952" STUDY_ID="STD-BI-2006" TOTAL_1="58" TOTAL_2="63" VAR="2.6997606837606836" WEIGHT="3.129904832759249"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-03 09:29:59 +0000" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="0.0" STUDY_ID="STD-Staedt-1997" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.195475352328949" CI_START="1.0040028188416563" EFFECT_SIZE="1.791163382072473" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.5045354720523693" LOG_CI_START="0.0017349321373453031" LOG_EFFECT_SIZE="0.25313520209485735" MODIFIED="2010-03-03 09:30:00 +0000" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.29534752604889825" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="178" TOTAL_2="183" VAR="0.08723016114320463" WEIGHT="96.87009516724075"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.777112176699071" CI_END="1.5634819109832847" CI_START="0.9088817037856478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1920654776867452" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="134" I2="43.728932078026276" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.1940928609511376" LOG_CI_START="-0.04149263904027737" LOG_EFFECT_SIZE="0.07630011095543006" METHOD="MH" MODIFIED="2010-05-10 14:48:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.18250446363798345" P_Q="0.0" P_Z="0.20423990017589022" Q="0.0" RANDOM="YES" SCALE="11.34" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02163401058888538" TOTALS="YES" TOTAL_1="206" TOTAL_2="216" WEIGHT="100.0" Z="1.2695642940206646">
<NAME>Responder rates on CGI-I</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4811859049319558" CI_START="0.6093090657931017" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.17060957062058654" LOG_CI_START="-0.21516236004289102" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2009-12-04 10:52:49 +0000" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="0.2266043416735812" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" VAR="0.051349527665317134" WEIGHT="26.23900746420771"/>
<DICH_DATA CI_END="1.4701714946324924" CI_START="1.1359664118009256" EFFECT_SIZE="1.2923101166088875" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="114" LOG_CI_END="0.16736799789676313" LOG_CI_START="0.0553654903669285" LOG_EFFECT_SIZE="0.11136674413184583" MODIFIED="2010-01-27 14:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.0657908273443787" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="167" TOTAL_2="177" VAR="0.004328432962657848" WEIGHT="73.76099253579228"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.08927316279654762" CI_START="-1.3492731627965484" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6300000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-05-10 14:54:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0860337277858108" Q="0.0" RANDOM="YES" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="177" UNITS="" WEIGHT="100.0" Z="1.7167014899588313">
<NAME>Change in self rated quality of sleep</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08927316279654762" CI_START="-1.3492731627965484" EFFECT_SIZE="-0.6300000000000003" ESTIMABLE="YES" MEAN_1="-3.43" MEAN_2="-2.8" MODIFIED="2010-04-13 15:00:38 +0100" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="3.45" SD_2="3.35" SE="0.3669828468635561" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="167" TOTAL_2="177" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.619099835585503E-31" CI_END="-2.6463365014583258" CI_START="-8.433663498541671" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.539999999999998" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-05-10 14:43:57 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="1.7514546442648764E-4" Q="0.0" RANDOM="YES" SCALE="10.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="164" UNITS="" WEIGHT="100.0" Z="3.7524060692696763">
<NAME>Change in quality of life</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.6463365014583267" CI_START="-8.433663498541671" EFFECT_SIZE="-5.539999999999999" ESTIMABLE="YES" MEAN_1="-15.92" MEAN_2="-10.38" MODIFIED="2010-04-13 15:02:26 +0100" MODIFIED_BY="[Empty name]" ORDER="448" SD_1="13.91" SD_2="12.08" SE="1.476386056767635" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="150" TOTAL_2="164" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.430975152407606" CI_END="19.00361749672345" CI_START="0.43415569851794644" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.8723733790469925" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="141" I2="63.17420087784088" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.2788362803909208" LOG_CI_START="-0.36235449426434163" LOG_EFFECT_SIZE="0.4582408930632895" METHOD="MH" MODIFIED="2010-11-30 11:02:23 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.06617287664401705" P_Q="0.0" P_Z="0.2737389720956114" Q="0.0" RANDOM="YES" SCALE="156.34" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.7631979799434148" TOTALS="YES" TOTAL_1="228" TOTAL_2="233" WEIGHT="99.99999999999999" Z="1.0944926824075945">
<NAME>Number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.22342344401358" CI_START="0.012836070821955842" EFFECT_SIZE="0.32489451476793246" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.9150526537109057" LOG_CI_START="-1.8915678953861497" LOG_EFFECT_SIZE="-0.48825762083762203" MODIFIED="2010-11-30 11:02:23 +0000" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="1.6486228035353918" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" VAR="2.717957148336895" WEIGHT="20.739742483493696"/>
<DICH_DATA CI_END="308.00023297748066" CI_START="2.3088005623784826" EFFECT_SIZE="26.666666666666668" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="2.488551045009522" LOG_CI_START="0.3633864195350401" LOG_EFFECT_SIZE="1.4259687322722812" MODIFIED="2009-10-07 13:12:39 +0100" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="1.248332220738267" STUDY_ID="STD-Staedt-1997" TOTAL_1="11" TOTAL_2="11" VAR="1.5583333333333333" WEIGHT="27.980468833044313"/>
<DICH_DATA CI_END="3.1751570375100355" CI_START="1.3312431200210628" EFFECT_SIZE="2.055944055944056" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="99" LOG_CI_END="0.5017652095768119" LOG_CI_START="0.12425737631737897" LOG_EFFECT_SIZE="0.31301129294709545" MODIFIED="2009-10-07 13:13:23 +0100" MODIFIED_BY="[Empty name]" ORDER="399" O_E="0.0" SE="0.22174996995050344" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="178" TOTAL_2="183" VAR="0.049173049173049176" WEIGHT="51.27978868346198"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9539629960319572" CI_START="-0.4139629960319572" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2010-05-10 14:44:53 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.43910121664675483" Q="0.0" RANDOM="YES" SCALE="2.39" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="177" UNITS="" WEIGHT="100.0" Z="0.7737118512199291">
<NAME>Change in daytime tiredness</NAME>
<GROUP_LABEL_1>Dopamine agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Levodopa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9539629960319572" CI_START="-0.4139629960319572" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="-1.16" MEAN_2="-1.43" MODIFIED="2009-10-07 13:59:39 +0100" MODIFIED_BY="[Empty name]" ORDER="447" SD_1="3.4" SD_2="3.05" SE="0.34896712461400825" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="167" TOTAL_2="177" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Active trials: lisuride vs. ropinirole</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3000271496272324" CI_START="-5.699972850372768" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.029423934728647346" Q="0.0" RANDOM="YES" SCALE="1.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="78" UNITS="" WEIGHT="100.0" Z="2.1777596588826307">
<NAME>Change on IRLS</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3000271496272324" CI_START="-5.699972850372768" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-14.6" MEAN_2="-11.6" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1048" SD_1="10.95" SD_2="9.3" SE="1.3775624815914012" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.418871597080442" CI_START="0.9981858128170475" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.53125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.8074586881570653" LOG_CI_START="-7.886070395776356E-4" LOG_EFFECT_SIZE="0.4033350405587438" METHOD="MH" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.05044874548907668" Q="0.0" RANDOM="YES" SCALE="5.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="78" WEIGHT="100.0" Z="1.9561393100754132">
<NAME>Number of dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.418871597080442" CI_START="0.9981858128170475" EFFECT_SIZE="2.53125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" LOG_CI_END="0.8074586881570653" LOG_CI_START="-7.886070395776356E-4" LOG_EFFECT_SIZE="0.4033350405587438" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1049" O_E="0.0" SE="0.47476846208714474" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="78" VAR="0.2254050925925926" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.15767081523079" CI_START="0.8239490600259253" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9766584766584766" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.06358508490720555" LOG_CI_START="-0.08409963737266753" LOG_EFFECT_SIZE="-0.010257276232730969" METHOD="MH" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7854265799027637" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="75" WEIGHT="100.0" Z="0.2722541869636735">
<NAME>Responders on CGI-I</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ropinirole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lisuride</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.15767081523079" CI_START="0.8239490600259253" EFFECT_SIZE="0.9766584766584766" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="55" LOG_CI_END="0.06358508490720555" LOG_CI_START="-0.08409963737266753" LOG_EFFECT_SIZE="-0.010257276232730969" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1050" O_E="0.0" SE="0.086750736918363" STUDY_ID="STD-Axxonis-2008" TOTAL_1="148" TOTAL_2="75" VAR="0.007525690355879031" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1493499558652296" CI_START="-0.7493499558652302" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6796750970204481" Q="0.0" RANDOM="YES" SCALE="4.053620246695907" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="78" UNITS="" WEIGHT="100.0" Z="0.4129065309227841">
<NAME>Change in self-rated quality of sleep</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1493499558652296" CI_START="-0.7493499558652302" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.4" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1051" SD_1="3.8" SD_2="3.3" SE="0.4843711228132666" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8835716907099957" CI_START="-8.116428309290004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.014735077739393351" Q="0.0" RANDOM="YES" SCALE="17.75651261557923" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="78" UNITS="" WEIGHT="100.0" Z="2.438825597005074">
<NAME>Change in quality of life</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8835716907099957" CI_START="-8.116428309290004" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-14.8" MEAN_2="-10.3" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1052" SD_1="13.9" SD_2="12.9" SE="1.8451503894030346" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8362948200753675E-31" CI_END="1.5227032971782088" CI_START="0.42784408035631194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8071428571428572" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="60" I2="100.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.18261528813482056" LOG_CI_START="-0.36871447252445716" LOG_EFFECT_SIZE="-0.09304959219481829" METHOD="MH" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.5082416468455087" Q="0.0" RANDOM="YES" SCALE="2.4219119248102885" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="78" WEIGHT="100.0" Z="0.6615781062132446">
<NAME>Number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5227032971782086" CI_START="0.42784408035631194" EFFECT_SIZE="0.8071428571428572" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="60" LOG_CI_END="0.18261528813482047" LOG_CI_START="-0.36871447252445716" LOG_EFFECT_SIZE="-0.09304959219481829" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1053" O_E="0.0" SE="0.32385383053758976" STUDY_ID="STD-Axxonis-2008" TOTAL_1="155" TOTAL_2="78" VAR="0.10488130355386992" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3829127364551206" CI_START="-1.3829127364551206" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.26702400707863594" Q="0.0" RANDOM="YES" SCALE="12.200360925542757" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="78" UNITS="" WEIGHT="99.99999999999999" Z="1.1099420721968944">
<NAME>Change in daytime tiredness</NAME>
<GROUP_LABEL_1>Lisuride</GROUP_LABEL_1>
<GROUP_LABEL_2>Ropinirole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lisuride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ropinirole</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3829127364551206" CI_START="-1.3829127364551206" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.5" MODIFIED="2011-01-12 13:49:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1054" SD_1="3.3" SD_2="3.2" SE="0.45047395942957297" STUDY_ID="STD-Axxonis-2008" TOTAL_1="152" TOTAL_2="78" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-01-11 13:15:01 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-12-01 09:59:22 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-12-01 09:59:22 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVIAAAVeCAIAAACsOiTQAAA47UlEQVR42u3dvY4UyZ6/8ZJwMDAw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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-12-06 09:06:30 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.2 Medication subgroups: change on IRLS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq0AAARwCAMAAAD38p1SAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-05-11 14:49:24 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.4 Medication subgroups: change in periodic limb movements in sleep.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAAMwCAMAAAAXvVgfAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-01-11 13:14:41 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.6 Medication subgroups: change in sleep efficiency.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAALwCAMAAAByckdHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2011-01-11 13:14:41 +0000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.8 Medication subgroups: number of dropouts due to adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv0AAAUwCAMAAADnyRrCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2011-01-11 13:14:39 +0000" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.10" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.10 Medication subgroups: responder rates on CGI-I.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv0AAARgCAMAAABNMBmBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2011-01-11 13:15:01 +0000" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.12" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.12 Medication subgroups: change in self-rated quality of sleep.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAx0AAANQCAMAAAB6gfITAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2011-01-11 13:15:01 +0000" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.14" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.14 Medication subgroups: change in quality of life.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxEAAAMACAMAAABsMxpqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2011-01-11 13:15:01 +0000" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.02" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Dopamine agonists versus placebo, outcome: 1.2 Medication subgroups: change on IRLS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAVZklEQVR42u2dfWwb533HH8qWjrKsl8yxt6CxaoSyHdlO0Lhu02aQ
58LtWqhsYCdbO2TB/siK7I8i2T8Duj+aYI1XJEM2YKiBGdmADujapv1jSLCxars1my2idbLGzUq7
YmRbaCarSeEXmJJiiUdK1u6VPFJ3JI+8o453nw99fDmSifjc977P7/nd8xKTBID3dFEEgLAAYUG0
2dzoB2Vlk/QH7YmQJVmLz5R72dgnE7CBS2HJknEnWXbIptKMNyWUBZ5XhZJMaUJzwpKqHEzRUqVH
IS5wWRVKslnjVSkMoKXgvTrGAvCiKqSOgzYG79ZmIC1CqFsVyuuqvOoYqzKzIFvqSgCFmJ0U5AaS
nbLU6E6gKnRVC6Ir8CPGkhraBcRYNZqCna6Ylc0c6SA5lqSg33U4oxzozko3dApZDjTCgvDGWJJM
IA5+BO9SJH4lUBUCwgKIjLBWONAIyw/IY7WdWL04PRTX/8i841iAsAAiLixqQoQFCAsg4sIij4Ww
fIE8VtshjwU4FiAsQFgRgJoQYQHCAoi4sMhjISxfII/VdshjAY4FCAsQVgSgJkRYgLAAIi4s8lgI
yxfIY7Ud8liAYwHCAoQVAagJEVa7WcohAoTlg66W+5dQAcJqtlXo9Ebm/GUhLSMD74lAuuFWbMvu
S05+NSQyw1f29iIEHMstNy9Ky1lnXYnC7H3TeYRAe8mtX8VFZqmWXynbzlWEgGO59KsLiiddFraW
pOwvbUCM5davVE/64Ja4zbvLPTnNs/J9CIGq0F18JYSiKzH8f3tsWoQjvYVp9f0FdIVjuWJk/jea
XymbvMXGzP7ixXuf+/TQXVfNxqM1P3Hv20LZSNl77FjhWCs19t4jegy1NqWLZmFK7j9o+FVcvBnL
znz+rt8evGq8tohvNBvTNvDWseTyajqdLLGV0bWef+5R/OpeLY+VTx+dGJ/o/2RRbRFKqo9975lp
RT+bzdeFXtO4Rt5W9iv6uoRCvGwVhmVtZ8VzMo//Ylb8Us9jpacmZsTM2I+VJmJGEoVZIT79jPIZ
tReg/rqnW9yMn1cT8TFt/yjrHHpbFYZl8a81kRVrj3/jd+7XXs33K34lEmKxoMRXZuz11ZeF4ljm
6x/97ztKO1Exrqz+XfThrWOVnEtBv+u0OnC3dlN8R/GeF9/Td2bFjH57SxRL+atT6meU+Ep//YXn
1celvPY9dQNf0g1Sp1aLo7rfZI1H/VcmROJkQr2XxJDyqzSP+tkTv1HeHzH9y9yKB4zvE2P54lgd
S1b3m9Gs1XckMZNQ/GpifJ8QWwrn1fzWp17U3t+y94qR75rVH5fN7yMQb1uFFp/qSMdaEXoeqvJa
zZnFcSXKGn9tTM3CL6/2ZvaUMqPL0zutniVtRRl+VoUd3R605qH0UToPvKVGWK+NF8XKaPb+7Fc/
dUfp8735aSF+UTCvHe5BGD45VoenHnav6Xko87Qx+2MtyDOjUnz9+wr5r+184pGvJLh2iLBqVYWj
We12qcKxnN839yX+5AvizZ5dd6ALhNVQjLVOWLYxmBZ5yfgVwmpcaA04llEjTg/jVwirlRhM9Sw6
L/hGNId/mXkujj/C8lhZXAukKvQhxgIcyxOo83AsHAvHAkBYgLC8h5oQYTUPEzAgLD+Y/9E8hxNh
ec653oHT3Y6tQtf/ubUx44ZEmiMs6Yb508fWuiaOxO3f3e267/pYurxBdIV17r575oT4b9lQ1sLU
zv4Bq2NVR++ZkS11HCtW3iCyVeH8nKToSvy+uKZF8b/aev2uyTM1gvlb+6U6M48etmwQVWGd6x06
/XPlsfi5t9R5GNL/pvZtH0s7Kkudt6HOzKOTSnylbUgkHMLKv/xQ8aFNLr/z3qnFsXf/Uwndi8eG
8mLhqD5+UC6UPlFZEy7tz+QOiemayjqcjqW1DYmEQlgXnrw8N/3SH59wlZNKa+MF5R/nxbVX5+Ni
yhw/uOjgV5I2fnDnxVr/k0nLBh0vrPzfHHtm9sB9/3jxopsA62hiXHGo8cXC1cHD27URz9rriVmH
+CqTG7pf2Q6sEmNFRVh9ex5RH+Kf/TsXXyrNyfDGt+aHhDbiWb/tL7cKLR8vz9tQIMbyj2BdRXvw
2DPa44Hvu/hSQr+dTOQf366+Hkgvaq/39ZQ+Yh01oc7bINS5R/fUGo0TSxs3JBIGYcnGcRz5Rnfj
X1IcSp336qmTj+4w5JlWX+8bL5ZNzfoztxTOJxRn28Uor+gISzKuoPQ/8S+Nf0lxKG3eq313Gjvi
YuHBj+6Tik5f6F1ereNXEDJhPf233ZocbruaPMGYk+HB8vWcgdpf6M1fGEZX/hKwSzonJp4+sLv/
mz94ad3qNto8xqNr9vMYm3MyAMJy4O6j+dnJF55bX43t1scuZ+mzh7A8ZUQfu0xn0A6hY64VtjR2
eYUDjbAcUGpBbU7RpmBcIcJy1IY273qT+UrmEkVYThjzIFfvZgQFwvIjxjrXNcwxpFXoOfOnBxb+
oMhRDCAd3XqP1RxBAVSFTfrVq0fWxG1pjjgLx/KSc4pfKQ8fP32l7keZbQbHatyv5r6kZbXiH5ev
1vsseSyC90bJd/3kE+bJke8r4lgIy7MW4Z2/qz3Jnf3wDj+rworFoqFBNtkWuby6au5fDerJ/sK/
PvqnL/21ENf6v15PV+J2CzX+zb5jf34KoXgSY8mSJAV/8cviEfn0vLg6mKurq1aaKLfeyR3at4xQ
PKsKzSow0AnSK78czzegqxa4OZBTR/4UyZVFplWosvNgfslXXd1S14jO5MQKuTKPhKUZVfDXhN5x
e6iRjzXbH+tm3BiD2Etl6JJOXxO6sSqq2bWdpZy+5qrI9SAVTxwrZEszNdsfa8u7il/NKrr6NYN6
PAneLbqK+AIC+VuqZ8XRlTfpBhHkuKq9VW3fvCjgVx6mGzbesRRpb7thhnobR35VoKtQCWvr+5WP
EIZ0QwC4UfUICCtwwTsHGmH5Af2xiLF8ibHoj4VjEWMhLABHglxHyEYeK9y/khgLgKoQEFYbII+F
sHyBPBYxlj+ORfSOYwHCai+ZHIcLYXnP0gf6l5r9LjUhwnLU1fKQkBgrg7B80FUm14OyOoUOqSQy
54U2vm863+CQ5IWpwocGaBUirAb8Sh3ft3O1oc/n01snZhbOfNKc3ajZcYUQ8qpQG488q61f2RDp
KTHz1MzYhDkwnnneEZYtQ/eL3CF1Hed8QwNm5o/qq67KBQ4wwqpJb+GK6luN6aq8SvQiBxhh1VHW
3gu5QwcaHOCXOGmsE32ls5ooCGtDlDWXb3TgqJRQ3GpiXMxw8ZlWYV1cTH02cEZxq/GJ8YfppIiw
POWBN7RVoveY6QbyWAjLEwaE9NiDo+V17MljtR36Y0G0g3dAWAGHfl0Iq4KRlZXdytbMwAhrTdhK
vy4Io7Bi2prQraam6NeFsKrIGutCt6wr+nUhLCujxrrQzbQKS/HV+ctGvy4Ovb8Erx2eGdni5FjZ
UcWzmslJmd9x268LOt6xFl7/9c+NYz+95ORYWozVTN8q8ztu+3VB02yqZ1ltWVYu/3v3Hj/48J99
+7aiq3tOff7vv2b3oavizuvXla2Jc8FcVu6Fkydy95zKPD+UZyLkSFSFao9PMfPUa2O3tb7t9j3b
db+KtfQ/6i1Mu+jXBR1eFc5PGT0+88uHDmVyh+572y62vrRZv7V0+rjq1wUdLqys2X9qUYl/tNh6
2rf/l5t+XdDhVWHioxNa/6nE7MfUNpuy+ZgNYEnLDXSsNi+lI5l91Pfo7bbLCx57CvNjBcOx1K4y
7ewuM5Be1Pqp7+sv9Gh+5XVdRX+sYAir7V2wHvgfpU148rXxoii+Lc8ueB4DZemP1W6Csth497sz
+3rU8MeXxbbo6BcUYcn6sr0bZmEIC8cCaLhVCOCHsFi2F/xpFcqdH1YRYwWxKpSkcEVWDLUPTvBe
HcTjWEDwDggLEFbImiiAsABhAURHWPTHQli+QB6r7ZDHAhwLEBYgrAhATYiwAGEBRFxY5LEQli+Q
x2o75LEAxwKEBQgrAlATRkhY8lZZ1jYOAueyp7wvaRvCwrE6t1XIgY6OsLZVPfoJeay2s3F5rHbO
OkIei6oQEBZAxIVFTRglYRl5LI4BwTsAVWFFq5ADjbD8gDwWVaE/jkX0jmMBwgKItrCoCREWICyA
iAuLPBbC8gXyWG2HPBbgWND5wqLTAfghrJDpipqQqhDCLCw6YYGflYRs3rEmNHjhWKZhSeq6hVII
Fi8kj9V2bPNYmlOFabFxHCsYVaFElAW0CqGThBUuw6ImxLEAYQFEXFj0x0JYvkAeq+3QHwtwLEBY
gLAiADUhwgKEBRBxYZHHQli+QB6r7ZDHAhwLEBYgrAhATYiwAGEBRFxY5LEQli+Qx2o75LEAxwKE
BQgrAlATIixAWAARFxZ5LITlC+Sx2g55LMCxAGEBwooA1IQUOXQEeuit3Fvnq0VY4ImySqKyaeGR
x4LWkeSICos8lh9aqpmJioawsgiBViEgLIBoC4u2rx9BllTRRKTIwVMcVoeLxkVoCEhVKCsE8tRo
kpXA/CUiKn+JQ4wVgjUKrZDHCoZjha76I48VkPaSHLblv6Dd2K+wKlkuMoaBTascab+RGnAsyfIY
nGqxlb9kc2D+EhHWv6Sx4B3Aj+CdcgE/gneJ4B38CN4BfHEsa50oiWBkH4xO1kGw0oD4eWBKxFYl
m+v96Wp/eWnjmx+y9Q/a+AMqB0Lewfhj7FXS5SI1QbM6QASnRKTGW4XBA111Wol0dcyJAR1ln5uD
HaAKrluGrFUoBcawUFVHxntdVITgRzuiZoLUHEJNHiuIlXNQSsReJWTeYUNahQAICxAWICwAhAUI
CxAWAMIChAUICwBhwYbT6BDhpHqXKr9KUXTggWMpSkqldHUBeOhYhmGpVqXbVdJ4qf0TQlddyvyA
/k8YOwHHcvasSrtKqvoxRKVoR1NThaWZH8DnEFZts6qUVqrq0fYbRh1KKVMV2kwIIhk6SWou5I5U
shznM9NIqJHqxliSowU1Uadp9WGq5n8XwoDcbKswWZl4KIks6ZCZ0O+T5CWIseo5jyaSlOk/qYpX
xifsPoC0osm6wRRuRnwlU065UuQUtaqwfozlLjaPYppqaa0PJfnqWNEks18sDlEMdWTDRWjXfrU/
k+tfphyaC97lMpRRpV9JonBZ9MxTErWpMykIec1qv5Iyw0MiM7y10EthNOFY22waehWXdOolS5Mi
lNcIFb9SdCWGZ8V0vlQsyWTS7vfbllRkLpw6ONYNyTa14KoFGMLmoulXyrZzNR8v/8x1JZMKczG0
4FjCTld6esE8P5PJso8lNYfS7svOppmW9VMhia+MLT5ta+nGT05WPbOWQUhKo7kYy9GEkuVN/2d9
tc7ZKj/V6SRETvcr7XHE3tKTpYsP654lU815f/iFJZz6y5Qu44S6Ouxb/JXiVbOarsSuPkvUlKpd
CUawOnSfeW8mGA2L9Q8tm56V2dNX6eJNlyDCsli6W0sKzRnbW5jWY6xd1qs6qci3apoP3lPJctsn
6dSeTob/NO3dez536FAmf0drPzT8puXgWNtulLeysoyWoX7tWevAYO4tv2HZI6q/Gwpl5aer/Mqw
LGsBOZyZqdCVhjPeXoRORsLlb4m+qBfBOtbJppawFgbchqR0wkJY9YV1dSi3A6FAc8JyDt6vvf6T
Ia7hg9cx1tWhpaGu7z80SBFVkV+cGunpj1MQtR1rU3WzcFXfce1bL28Ta1985x+ep9AqeH145x/u
OnLi+osUhY1s6laFVwcf3648fGLkp3kKzcr16yIhEicntl2jLGrS5RBfGXH73eJsuc0nHBJ7td4L
Wz34WzMT42ImMSO2LRi/uqo/ll1HtKSI3gQWXfZ+ddhoD8aP5Cs+YduWjlADe1EkxieULSEmpsxf
r5KsVx4phKXGV/OlUSjxh/M/rTIns99RqauRvtM8f0NdXFkxY97W9dnWfrulPJJV+0LWOc29sLoH
H9heflV881plmJWsPEHNPkbGxcRUKtSlpsZXCaHfqnWl/faUWF8exj5jZ+jLSMfmWmFxuTd+u5yP
uHZsrZaxl8fYR+E8vCJmnjopZiYUx3rMGmHa1HRh75zmXlhicPns/u1Goubc3JG19QXmWERhF9eH
dLdS46z+slzcXcZJRlZYYrD734U+VODc3N2DNieeY0mG/aSM3/iOEWPdGbeea25+dzSMyz7dUPxc
z2k1sorNfenDziecfV/ScJ+Q2x/T4qyRNz7WijFFdzBF8aGz/9FdjL1ajq9KoYRRFaaS1iiiRmes
sCnr/al07LGqSzrW/ljJ1PrysDpaNLpj1ejd0PXK8VeOcKmweSLVgcbFNEa3d+TvRlfNikpEvXNa
rY5+eS7hQ7OOxfxY0N6qsPvZi5dHDjzNnCrgYbpBiO9+ZPeXz365sDlGEVWwNla6URhNxFgv/+Al
zavefPq/CLSsjKVVdcXMZ+AuxvrgB35W1F+e+KvVUjOnZjunYgaMEDtWrEJdjTcAK0sldGXUYIz1
xX2PGs+OrT2rP0nVL44otK8Pq5qajJnPjDJpQCdRSz7Yx1h/udd8dvCH1WdezQmxQt8va1JTV+mZ
pVyEZVKsqrnDojhNlr1jHT5gPiue6V7n6DUmxLKdJCtUjjWp3WRp8nDa1o6SxpqNKecJsyIxTZa9
sIb/yVRWd1HYhhJOE2KFvV/WZCwdS6uaismWn1tVMKkKtUVzmix7YR18xXz2vQvPVhZKtCbEqhFj
SaJe8JmMaBnVENZXPvLdP9Ke5J883lQQGtpzsxy3T8bqtO+qZhKLWDjv0B9r7uvPnV8Wy688+e3j
tU61ZI0TMZwn5OHKCL6OBTUwaXm0HEvMXuwTPywe/czxb9pEUDUmxAp9v6zJw6VbrCLGquyfZikL
p/ILeb+sFi9CJ5m4CGxl08KycvQ5At8cC8BeNiwrB21sFQL4I6zdK+aNIgIPhbUmsuo2Sm828FRY
MTGqbtlSB1L7VfmsDcTm3oSQ4pBuyJqeVdpTs9sRWQdozLFGTc9abz/Jyo5GVavzmTNCiQgu0Qf1
HUuNr7K2MVZVRyNR1dlI359KpiK4RB/UF5YaX2m3ikjJ6Gtk7WgU+SVqwYMYq5FwXH+vemIfKkKE
pcdY2Zix2WmnVkejlK2QsDOCdzPGqpnHStbaZaw6R9YBx1rH5c3adsn2fduORhULGGrTRaWitkQf
WKN0r3o30OiLNPRugA5zLMCxcCzYqFYhAMIChAUIC6AF1idAZQoFWidGdgGoCgFhAcICQFiAsABh
ASAsQFiAsAAQFiAsQFgACAsQFiAsAE/4fyzbbvUWgg5+AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-30 15:02:37 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-04-08 16:00:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-08 16:00:26 +0100" MODIFIED_BY="[Empty name]">Central (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 14:46:29 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AF dopamin* agonist*</LI>
<LI>AF cabergolin*</LI>
<LI>AF pergolid*</LI>
<LI>AF bromocriptin*</LI>
<LI>AF Alpha-Dihydroergocryptin*</LI>
<LI>AF pramipexol*</LI>
<LI>AF ropinirol*</LI>
<LI>AF rotigotin*</LI>
<LI>AF apomorphin*</LI>
<LI>AF piribedil*</LI>
<LI>AF lisurid*</LI>
<LI>AF talipexol*</LI>
<LI>or/1-12</LI>
<LI>AF &#8220;rls&#8221;</LI>
<LI>AF &#8220;restless leg*&#8220;</LI>
<LI>14 or 15</LI>
<LI>13 and 16</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-11-30 15:00:17 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-30 15:00:17 +0000" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 15:06:14 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>TX dopamin* agonist*</LI>
<LI>TX cabergolin*</LI>
<LI>TX pergolid*</LI>
<LI>TX bromocriptin*</LI>
<LI>TX Alpha-Dihydroergocryptin*</LI>
<LI>TX pramipexol*</LI>
<LI>TX ropinirol*</LI>
<LI>TX rotigotin*</LI>
<LI>TX apomorphin*</LI>
<LI>TX piribedil*</LI>
<LI>TX lisurid*</LI>
<LI>TX talipexol*</LI>
<LI>or/1-12</LI>
<LI>AF &#8220;rls&#8221;</LI>
<LI>AF &#8220;restless leg*&#8220;</LI>
<LI>14 or 15</LI>
<LI>13 and 16</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-11-30 15:00:26 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-11-30 15:00:26 +0000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-06-17 15:23:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>(random* or factorial* or crossover* or "cross over*" or placebo* or (doubl* adj blind*) or (singl* adj blind*) or assign* or allocat* or volunteer*).mp</LI>
<LI>Randomized Controlled Trial/</LI>
<LI>(l-dopa or levodopa* or ldopa or "l dopa").mp</LI>
<LI>Levodopa/</LI>
<LI>(rls or "restless leg*").mp</LI>
<LI>Restless Legs Syndrome/</LI>
<LI>(1 or 2) and (3 or 4) and (5 or 6)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-11-30 15:00:34 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-11-30 15:00:34 +0000" MODIFIED_BY="[Empty name]">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-08 15:59:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>randomized.ab.</LI>
<LI>placebo.ab.</LI>
<LI>drug therapy.fs.</LI>
<LI>randomly.ab.</LI>
<LI>trial.ab.</LI>
<LI>groups.ab.</LI>
<LI>or/ 1-8</LI>
<LI>humans.sh.</LI>
<LI>9 and 10</LI>
<LI>AF dopamin* agonist*</LI>
<LI>AF cabergolin*</LI>
<LI>AF pergolid*</LI>
<LI>AF bromocriptin*</LI>
<LI>AF Alpha-Dihydroergocryptin*</LI>
<LI>AF pramipexol*</LI>
<LI>AF ropinirol*</LI>
<LI>AF rotigotin*</LI>
<LI>AF apomorphin*</LI>
<LI>AF piribedil*</LI>
<LI>AF lisurid*</LI>
<LI>AF talipexol*</LI>
<LI>or/12-23</LI>
<LI>AF rls</LI>
<LI>AF restless leg*</LI>
<LI>25 or 26</LI>
<LI>11 and 24 and 27</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-11-30 15:00:51 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-11-30 15:00:51 +0000" MODIFIED_BY="[Empty name]">PsycINFO (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-06-17 14:16:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>TX dopamin* agonist*</LI>
<LI>TX cabergolin*</LI>
<LI>TX pergolid*</LI>
<LI>TX bromocriptin*</LI>
<LI>TX Alpha-Dihydroergocryptin*</LI>
<LI>TX pramipexol*</LI>
<LI>TX ropinirol*</LI>
<LI>TX rotigotin*</LI>
<LI>TX apomorphin*</LI>
<LI>TX piribedil*</LI>
<LI>TX lisurid*</LI>
<LI>TX talipexol*</LI>
<LI>or/1-12</LI>
<LI>TX &#8220;rls&#8221;</LI>
<LI>TX &#8220;restless leg*&#8220;</LI>
<LI>14 or 15</LI>
<LI>13 and 16</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2010-11-30 15:01:30 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-03-23 10:11:29 +0000" MODIFIED_BY="[Empty name]">Univariable meta-regressions</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-30 15:01:30 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="4">
<TR>
<TD>
<P>
<B>Explanatory variable</B>
</P>
</TD>
<TD>
<P>
<B>Coefficient (B)</B>
</P>
</TD>
<TD>
<P>
<B>95% confidence interval</B>
</P>
</TD>
<TD>
<P>
<B>Statistical significance</B>
</P>
</TD>
<TD>
<P>
<B>Proportion of heterogeneity explained (R²)</B>
</P>
</TD>
<TD>
<P>
<B>Interpretation</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of sites</P>
</TD>
<TD>
<P>0.097</P>
</TD>
<TD>
<P>0.05 to 0.15</P>
</TD>
<TD>
<P>0.001</P>
</TD>
<TD>
<P>0.42</P>
</TD>
<TD>
<P>Studies with more investigating sites result in lower IRLS treatment effects than studies with less investigating sites.</P>
</TD>
</TR>
<TR>
<TD>
<P>Duration of treatment</P>
</TD>
<TD>
<P>0.023</P>
</TD>
<TD>
<P>0.003 to 0.042</P>
</TD>
<TD>
<P>0.027</P>
</TD>
<TD>
<P>0.15</P>
</TD>
<TD>
<P>Studies with longer treatment duration show lower IRLS treatment effects than studies with shorter treatment duration.</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline severity on the IRLS</P>
</TD>
<TD>
<P>-0.42</P>
</TD>
<TD>
<P>-0.96 to 0.11</P>
</TD>
<TD>
<P>0.12</P>
</TD>
<TD>
<P>0.06</P>
</TD>
<TD>
<P>Baseline severity has no influence on treatment effect.</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2010-11-30 15:02:37 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2010-03-23 10:52:57 +0000" MODIFIED_BY="[Empty name]">Mutivariable meta-regression</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-30 15:02:37 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="4">
<TR>
<TD>
<P>
<B>Explanatory variable</B>
</P>
</TD>
<TD>
<P>
<B>Coefficient (B)</B>
</P>
</TD>
<TD>
<P>
<B>95% confidence interval</B>
</P>
</TD>
<TD>
<P>
<B>Statistical significance</B>
</P>
</TD>
<TD>
<P>
<B>Proportion of heterogeneity explained (R²)</B>
</P>
</TD>
<TD>
<P>
<B>Interpretation</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of sites</P>
</TD>
<TD>
<P>0.097</P>
</TD>
<TD>
<P>0.04 to 0.15</P>
</TD>
<TD>
<P>0.001</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Studies with more investigating sites result in lower IRLS treatment effects than studies with less investigating sites.</P>
</TD>
</TR>
<TR>
<TD>
<P>Duration of treatment</P>
</TD>
<TD>
<P>0.006</P>
</TD>
<TD>
<P>-0.01 to 0.024</P>
</TD>
<TD>
<P>0.429</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Studies with differing treatment duration have no differential influence on IRLS treatment effects.</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline severity on the IRLS</P>
</TD>
<TD>
<P>-0.346</P>
</TD>
<TD>
<P>-0.75 to 0.059</P>
</TD>
<TD>
<P>0.091</P>
</TD>
<TD>
<P>0.56</P>
</TD>
<TD>
<P>More severe baseline severity scores on the IRLS in tendency lead to larger treatment effects on the IRLS.</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>